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Abstract
Patients deserve their medicines on time every time. Regulators safeguard public health
by ensuring availability of safe, effective, high-quality medicines. Pharmaceutical
companies must continually improve and innovate to deliver such medicines. In spite of
these patient-centric objectives, drug shortages have continued to grow as a global
public health concern. The drug shortage problem has existed for decades though there
has been no shortage of effort, recommendations, papers, and expectations to resolve it.
During the ongoing COVID-19 pandemic even exceptional measures were rapidly
implemented to prevent shortages, yet no long-term solutions have been found.
This research hypothesis was that due to the high global regulatory complexity of
making post-approval changes (PACs), pharmaceutical companies are slow in
implementing new knowledge to continually improve and innovate their products and
processes – even when this reduces risk to patients or improves the state-of-control.
This results in sub-optimal operations, and eventually drug shortages.
To date, most efforts and solutions to tackle drug shortages by the industry or regulatory
authorities have been from their individual respective perspectives. This research
concluded that no one stakeholder can solve this ‘wicked problem’, and that its
resolution lies in practical standard solutions collaboratively developed and globally
implemented across the pharmaceutical industry and its regulatory authorities.
This research explored how an enhanced science and risk basis which considers current
product and process knowledge within the framework of an effective Pharmaceutical
Quality System (PQS) – could provide a clear pathway to overcome the global
regulatory complexity, accelerate continual improvement and innovation, and help
reduce drug shortages. It proposed that any PAC which can be demonstrated to not
increase risk to product quality or patient safety should be implemented immediately
within the construct of an effective PQS, without requiring prior regulatory approval;
such changes would still remain under regulatory oversight through routine inspections
that assess effectiveness of a company’s PQS.
The research resulted in the development of standard practical solutions for the
pharmaceutical sector - to enable regulatory flexibility, faster decision-making and
implementation of PACs by allowing more changes to be managed in the PQS without
requiring prior-approval. The research also defined what constitutes an effective PQS
for PAC management, and how companies could demonstrate this during inspections,
thereby shifting the regulatory oversight from review of individual PACs by assessors,
to evaluation of the PQS effectiveness for PAC management by inspectors.
A portion of this research occurred during the COVID-19 pandemic. Given the
pandemic is still ongoing, it did not assess implications or consequences of the “new
normal” state that will emerge post-pandemic. However, the thesis touches on
anticipatory considerations and poses relevant questions on how faster risk-based
decision-making and collaborative models that emerged during the pandemic could and
should continue as part of the “new normal”.
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Thesis Overview
This thesis submitted for the purpose of a PhD comprises of six parts across ten chapters
that summarise the purpose, findings and key contributions from this research study.
Important findings, unified pharmaceutical industry positions, and standard solutions
resulting from this research study have been published by the researcher in various peerreviewed journals. In order to improve readability of the work, these publications are
discussed as appropriate and referenced throughout this thesis.
The following section provides the reader with an orientation of the six-part structure of
this research thesis: The activities featured across the six parts were not in all cases
conducted sequentially as the research study was iterative in nature.
Part One lays the foundation for this research study: Exploring the context of a
problem resulting from global regulatory complexity that presents a barrier to continual
improvement and innovation in the pharmaceutical sector (the term used throughout
this thesis to refer collectively to pharmaceutical companies and regulatory authorities),
which eventually contributes to the ‘wicked problem’ of drug shortages.
Part Two frames drug shortages as a global problem: Exploring what makes drug
shortages global in nature and the detrimental consequences especially for patients.
Given this context, why a response and the resulting solutions must also be global.
Part Three examines the pharmaceutical regulatory landscape: Exploring the vision
and position of key pharmaceutical regulatory authorities (henceforth referred to as
regulatory authorities throughout this thesis) on the global problem of drug shortages
established in Part Two.
Part Four provides an overview on how the researcher brought the
pharmaceutical industry together to create deeper awareness and understanding of
current state challenges in assuring a reliable supply of safe, effective, high-quality
medicines for patients, due to inadequate continual improvement and innovation.

1

Part Five focuses on the development of practical, standard, global solutions that
facilitate effective delivery of medicines to patients. These solutions are a result of
ongoing collaborative work within the pharmaceutical industry through the 1VQ for
PAC Initiative (established during this research), with ongoing input from regulators.
Part Six brings the research study to a close with a review of the outputs,
outcomes, and impact of this research with recommendations for future research. It
also articulates key learnings and opportunities brought forward by the pandemic.
Table 1 provides a summary of the six parts and corresponding chapters in this thesis.
Table 1: Thesis Overview
Part

Chapters

Part One: Research Study
Foundations

• Chapter 1: Research Introduction and Context
• Chapter 2: Literature Review
• Chapter 3: Research Design, Methodology, and Methods

Part Two: Recognition of
Drug Shortages as a Global
Problem and the Need for
Global Solutions

• Chapter 4: A ‘Wicked Problem’ – Drug Shortages in the
Context of Inadequate Continual Improvement and Innovation
• Chapter 5: Responding to the ‘Wicked Problem’

Part Three: Exploring and
Contributing to Regulatory
Authorities’ Positions in
Context of the Research

• Chapter 6: Exploring and Contributing to Regulatory
Authorities’ Positions

Part Four: Unifying the
Pharmaceutical Industry

• Chapter 7: The Importance of Bringing the Pharmaceutical
Industry Together

Part Five: Practical
Science and Risk-Based
Solutions

• Chapter 8: Standard Solutions for the Pharmaceutical Sector

Part Six: Outcomes and
Impact, Conclusions, and
Opportunities for Future
Research

• Chapter 9: Outputs, Outcomes, and Impacts of Research
Study
• Chapter 10: Research Conclusions and Opportunities for
Future Research
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Part One: Research Study Foundation
Part One lays the foundation for this research. It explores the context of a problem
resulting from global regulatory complexity that presents a barrier to continual
improvement and innovation in the pharmaceutical sector, which eventually contributes
to the ‘wicked problem’ of drug shortages. This part is predominantly comprised of the
foundational elements of pharmaceutical product quality, specifically:
•

a Pharmaceutical Quality System (PQS)

•

Quality Risk Management (QRM)

•

Knowledge Management (KM)

It also considers the researcher’s prior body of work which served as the starting point
and continued throughout this research. It includes the following:
•

Introduction, background and context for the research study (Chapter 1).

•

A review of literature and guidance which provide the background for an
effective PQS, QRM, KM, and their application to enable science and risk-based
decision-making in relation to drug shortages and PAC management. It
additionally highlights deficiencies in literature published thus far, some of
which is being addressed by outputs from this research study (e.g., practical
guidance and standard solutions for pharmaceutical companies on how to
perform risk-based assessment of PACs), and some that still need to be
addressed beyond this study (Chapter 2).

•

An overview of the research design, methodology and methods used (Chapter
3).
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Research Introduction and Context
Patients deserve to receive every dose of every medicine they need, every single day.
They place their trust in regulators and pharmaceutical companies to provide them with
a reliable supply of safe, effective, high-quality medicines. However, quality defects
and drug shortages have been a constant struggle for patients, and these challenges have
also impacted those in the sector including manufacturers and regulatory authorities.
In 2015, Dr Janet Woodcock, the then Center 1 for Drug Evaluation and Research
(CDER) director at the United States (US) regulatory authority, Food and Drug
Administration (FDA) and one of the most respected and outspoken international
regulators, led the establishment of a new Office of Pharmaceutical Quality (OPQ), to
present One Quality Voice in addressing the following pharmaceutical quality problems:
1. High occurrence of product recalls and product defects
2. Alarming shortages of critical medicines, many due to outdated equipment,
aging facilities, and lack of effective quality management systems
3. A burdensome regulatory framework that requires manufacturers to submit postapproval supplements as they strive for process optimisation (partly because of
the current practice of “locking in” an applicant’s manufacturing process before
it is fully optimised)
4. Current regulatory review and inspection practices that tend to treat all products
equally, without considering specific risk to consumer or individual product
failure modes
5. The fact that FDA only gets limited information about current state of
pharmaceutical quality with no formal means for quality surveillance except
through inspections, where inspection findings are not a reliable predictor of the
state of quality
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The US spelling of the word ‘Centre’ is being used throughout this thesis when referring to the US FDA
Center for Drug Evaluation and Research to be consistent with its US origin

4

6. The fact that inspections are not well-connected to knowledge gained from
product reviews, and product reviews are based on pre-marketing data instead of
the conditions under which the product is manufactured during commercial
production (FDA, 2015)
In 2019, in an FDA Voices article titled ‘To Help Reduce Drug Shortages, We Need
Manufactures to Sell Quality – Not Just Medicine’ (Woodcock, 2019), Dr Woodcock
identified a critical element to quality in pharmaceutical manufacturing as:
‘the ability to reliably make the product in sufficient quantities and with
sufficient speed to ensure that supply consistently meets demand over sustained
periods of time. This is especially true in the pharmaceutical industry, where the
product is often life-sustaining — and ongoing access is critical.’
In 2012, the researcher also set about exploring this topic of drug shortages through her
activities as a member of the Parenteral Drug Association (PDA). PDA, a leading global
provider of science, technology and regulatory information, is a non-profit international
professional association of more than 10,000 individual member scientists with an
interest in the fields of pharmaceutical, biological, and device manufacturing and
quality (PDA, 2021). PDA creates awareness and understanding of important issues
facing the pharmaceutical and biopharmaceutical community; it therefore, provided the
researcher a useful industry platform to discuss this topic.
Specifically focusing on risk-based applications to prevent and manage drug shortages,
the researcher led a PDA Drug Shortage Task Force between 2012-2015, the output of
which was published as PDA Technical Report 68, Risk-Based Approach for Prevention
and Management of Drug Shortages (Ramnarine et al., 2014). A key insight the
researcher gained during the development of Technical Report 68 was that a
contributing factor to manufacturing issues, quality defects, and drug shortages was the
slow pace of adoption of new technologies and a reluctance to continuously improve
within the pharmaceutical manufacturing sector. The researcher suggested that solving
the continual improvement and innovation challenge could help address the drug
shortage problem and benefit patients. In this context, it is useful at this point to
consider how medicines are approved prior to marketing to patients.
Medicines are developed by pharmaceutical companies and applications are submitted
to regulatory authorities (as regulatory filings) for approval, prior to putting any
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medicine into commerce and making it available for patients in a country or region.
Once a medicine has been approved by a regulatory authority and launched (i.e., made
available to patients) within a country or region, any change that is made to the product
post-approval, or which affects its manufacturing facilities, manufacturing processes,
raw materials, analytical methods, or any third-party suppliers, is called a post-approval
change (PAC). Continuous improvement by definition, requires that changes be made,
and today, when a PAC is needed, most must be submitted as a regulatory filing for
approval by assessors at each of the regulatory authorities that approved the initial
product application.
This process, while appearing to be relatively straightforward from a regulator’s
perspective, typically proves to be a great challenge from a pharmaceutical company’s
perspective, who may have their products on sale in several countries and regulatory
jurisdictions. This means that companies need a PAC to be approved by all those
countries before it can be implemented, and this can often take several years. In order to
focus on this conundrum, and advance the insights gained during the development of
PDA Technical Report 68, the researcher in 2016, formed a PAC-specific Task Force
within PDA, called Post-Approval Change: Innovation for Availability of Medicines
(PAC iAMSM) Task Force. The outputs of this Task Force are discussed in Chapter
Seven, section 7.1.
Figure 1.1, developed by the researcher and Dr Anders Vinther in 2019, for the first
time articulated in visual format the view of a single PAC from a regulatory authority’s
perspective versus that from a pharmaceutical company’s perspective, where the PAC
requires approval sometimes in 100+ countries.
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Figure 1.1: Post-Approval Change View for a Regulatory Authority vs. a
Pharmaceutical Company
In reality, a pharmaceutical company may be managing several hundred PACs at any
given time; consequently, their perspective of this is better depicted in figure 1.2 below:

Figure 1.2: Reality of Many Concurrent PACs for a Pharmaceutical Company
These two graphical illustrations have become widely used and referenced by both
pharmaceutical companies and regulators, as they served to raise awareness, educate
each stakeholder segment on the implications of the problem, and bring a common
understanding of the problem to the pharmaceutical industry and regulatory authorities
alike.
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In 2019, the researcher and Vinther met with Dr Woodcock to discuss PACs and the
significant challenge with continual improvement and innovation in a global
environment. At this meeting the researcher shared the images above, outlined the
current complexities with global PAC management and raised the question of how the
pharmaceutical industry could build trust with regulators so that more changes could be
managed within a company’s PQS and without requiring prior-approval from the
regulator?
Upon seeing the two graphics on the current state (Figures 1.1 and 1.2), Dr Woodcock
acknowledged a serious problem existed and that neither regulatory authorities nor
pharmaceutical companies were working together as they could and should, to
collectively and globally address this issue. She noted that the current ways of
addressing this topic through different pharmaceutical industry associations and
volunteer-based activities, albeit well-intentioned, were not making sufficient progress
in addressing the problem. To resolve this, she specifically asked the researcher and
Vinther to unite Senior Quality Leaders in the industry (as they are the accountable
owners of product quality-related decisions and the PQS within their companies), with a
view to developing standard pharmaceutical industry solutions for PAC management.
At the time (2017-2018), the researcher was enrolled at the Stanford Graduate School of
Business in a Corporate LEAD Innovation Certificate Program, which focused on
design thinking and the innovation process, building business models and organization
design for innovation, overcoming resistance to change, critical thinking, and
negotiation strategies. The program equipped the researcher on methodologies and tools
to engage, accelerate and disrupt for meaningful, impactful change.
Taking the learning from the LEAD program, building on Dr Woodcock’s vision of
One Quality Voice for regulators, and with the aim to unify senior leaders in the
pharmaceutical industry, in 2018 the researcher transitioned the volunteer-based PDA
PAC iAMSM Task Force into a One-Voice-of-Quality for PAC (1VQ for PAC) Initiative
for the industry, sponsored by the Chief Quality Officers (CQOs) of the top 25 global
pharmaceutical companies. This was the first time that Senior Quality Leaders in the
industry united to speak with one voice in addressing this challenge. And to unite
regulators globally on this topic as well, Dr Woodcock set in motion mechanisms
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whereby assessors and inspectors could come together in their respective circles to find
solutions; details of these are discussed in Chapter Six.
Dr Woodcock and the researcher are not alone in their desire to ensure the reliable
supply of safe, effective, high-quality medicines to patients. The International Council
for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use
(ICH), an international non-profit association that brings together regulatory authorities
and the pharmaceutical industry, aims to:
“achieve greater harmonisation worldwide to ensure that safe, effective, and
high-quality medicines are developed and registered in the most resourceefficient manner.” (ICH, 2021)
For well over 15 years, ICH has consistently developed and established guidances such
as ICH Q9 Quality Risk Management (ICH, 2005c), ICH Q10, Pharmaceutical Quality
System (ICH, 2008), and the latest one, ICH Q12 Technical and Regulatory
Considerations for Pharmaceutical Product Lifecycle Management (ICH, 2019), yet the
objective of reliable supply of safe, effective, high-quality medicines for patients, has
yet to be accomplished. Numerous new and revised regulations, papers and positions
advocating for QRM, KM and continual improvement have been developed, yet the
issue of drug shortages persists.
This research seeks to explore why this is the case, why in spite of the existence of ICH
Q9, Q10 and more recently Q12, drug shortages still persist, and how ‘slow’ continual
improvement and innovation in the pharmaceutical sector might be contributing to the
growing problem of drug shortages. Specifically, the research focuses on how an
effective PQS and a science and risk-based approach could transform PAC
management, enabling timely implementation of changes (i.e., continual improvement)
which would enhance and improve pharmaceutical manufacturing.
The researcher proposes that a company which demonstrates it has an effective PQS and
which applies science and risk-based assessments to PACs, should be able to implement
certain PACs without regulatory prior-approval where it determines no or minimal
impact of the change to product quality or patient safety. Such changes could still be
reviewed by inspectors during their inspections of companies to ensure that the
company’s PQS was indeed effective in handling these PACs. In other words, while the
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regulatory oversight would shift from the assessors’ 2 review and approval of each PAC
to the inspectors’ 3 evaluation of the overall effectiveness of a company’s PQS in
managing these PACs, there would still be regulatory oversight; it however, would be in
a manner that would facilitate faster continual improvement and innovation.
The study first explored the global complexity associated with continual improvement
and innovation within the pharmaceutical industry, and the barriers that existed. It
examined why this was such a significant challenge, and, as the study progressed, it
became evident that addressing the problem required collaborative work across a broad
and diverse stakeholder community, including pharmaceutical companies, regulatory
authorities, policy makers, healthcare providers, patient care and advocacy groups,
governments, and society as a whole.
The research plan was designed to examine the problem primarily through the lens of
the frontline stakeholders, pharmaceutical companies and their regulators. It excluded
the exploration of policies or policy makers, legislation or legislators, healthcare
providers, patient care and advocacy groups, governments and society at large.
Nevertheless, the study reaffirmed the interconnectedness within these aspects and their
implications for public health, pharmaceutical regulations, and a marketing
authorisation holder’s (MAH) ability to reliably supply medicines to patients.
This chapter outlines the overall context, intent, scope and objectives of this research
study. It introduces the researcher and lays out the researcher’s pre-study work that led
to undertaking this research.

Background
Pre-research study work on this topic was initiated in 2012 as part of the researcher’s
pharmaceutical industry affiliation; this was 6+ years before this research was registered
for a PhD with the Technological University (TU) Dublin, and although that prior work
by the researcher had not been organised under a formal study, some of it was extended
and deepened via this research study with TU Dublin. It provided an important
2

Assessors are those who review and approve product regulatory submissions at a regulatory authority.
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Inspectors are those who inspect pharmaceutical companies, including their PQS.
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foundation for the research undertaken in this PhD. Key elements of the prior work
were specifically relevant to certain aspects of this study and are discussed within the
appropriate chapters of this thesis. An overall summary is also provided in Appendix I.
Figure 1.3, developed by the researcher, illustrates the interconnectedness between:
1. The ultimate objective of ensuring an uninterrupted reliable supply of safe,
effective, high-quality medicines to patients and the stakeholder community
involved in accomplishing this objective (shown in the top stratum of the figure)
2. The foundational regulatory framework and expectations laid out by ICH in its
guidances:
a. ICH Q12 on product lifecycle management (shown in the middle
stratum), and
b. ICH Q9 and Q10 that provide the foundational bases for Q12 in relation
to QRM, KM and PQS (shown in the bottom stratum of the figure)

Figure 1.3: Connecting Risk, Knowledge and Lifecycle Management (within an
Effective PQS) to Deliver Value for Patients
The researcher’s aims for this study were to:
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•

Explore the challenge and root cause of slow continual improvement and
innovation in the pharmaceutical sector

•

Assess how a science and risk basis and timely KM, within the construct of an
effective PQS, might be a suitable lever in addressing the challenge

•

Use the findings to design practical standard solutions for the pharmaceutical
industry that, when implemented, would accelerate continual improvement and
innovation, making a meaningful contribution towards reducing drug shortages
and improving the timely availability of medicines for patients globally

Research Context – Framing the Problem to be
Addressed
The problem this research seeks to address has several facets, but at the heart of it is the
premise this chapter opens with, that:
‘Patients deserve to receive every dose of every medicine they need, every single
day.’
As described in the introduction, there is a gap between what patients deserve and what
they get. This research specifically seeks to explore ways to address this gap. To set the
context, the problem will be discussed under the following headings:
•

The burden of high global complexity with respect to PACs

•

The potential link of this burden to drug shortages

•

The PQS as a potential means to reduce this burden

1.2.1 The Burden of High Global Complexity
The globalisation of pharmaceutical manufacturing and supply has continued to evolve
over the last few decades. It is an unavoidable reality primarily resulting from
geopolitical, economic, business and supply chain factors to list a few. From a patient’s
perspective the complexity it introduces is not ideal. This research acknowledges the
high global complexity but does not attempt to reduce it; rather it addresses what the
pharmaceutical sector (as a key stakeholder) could do to reduce the burden it leads to.
Post-Approval Changes
Pharmaceutical companies have become increasingly global in the manufacturing and
marketing of their products. Before a product can be marketed in any country, it must be
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approved by the regulatory authority in that country or region to ensure that it meets
their regulatory and legal expectations. A globally marketed product can often be
distributed in as many as 100+ countries, and, as such, it needs to be approved by the
regulatory authority of each of those 100+ countries, or within their regions. Once a
product has been approved by the regulatory authority and launched within a country or
region, most changes made post-approval to the product, its manufacturing facilities,
manufacturing processes, raw materials, analytical methods, or any third-party suppliers
- known as post-approval changes, or PACs, must also be approved by the same
regulatory authorities that approved the initial product application.
During the commercial life of a product, PACs are inevitable as new knowledge and
experience with the product is gained. PACs are needed to maintain a state of control
and drive continual improvement. Reasons for PACs include (but are not limited to):
•

upgrades to aging equipment and facilities

•

supplier changes

•

implementation of new regulatory requirements

•

improvements needed to raw materials

•

changes to manufacturing processes (e.g., to improve consistency, reduce
variability, improve yields etc.)

•

addition of new sites or equipment to increase manufacturing capacity

•

addressing quality issues, manufacturing issues and/or compliance gaps

•

responding to signals and trends (e.g., from product quality reviews, corrective
and preventative actions (CAPAs), operational reviews, management reviews)

As this research progressed, a number of standard solutions for PAC management
(based on the premise of reduced regulatory complexity and an increased use of the
PQS, supported by QRM and KM) were developed. A total of 13 PAC examples were
selected and evaluated within the context of those standard solutions, and that work
directly led to a number of industry 1VQ for PAC position papers. Those examples and
position papers are discussed in Chapter Eight, section 8.6 of this thesis.
Today many PACs require a regulatory filing and an individual approval by each
country where the product is marketed before the changes can be implemented. To
illustrate the scale involved, a global vaccine company is known to submit up to 8000
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PACs in a year that need either approval by (or at least a notification to) the regulatory
authority in each country their products are marketed in, prior to PAC implementation.
In discussions with multiple companies, it was noted that greater than 99% of such
PACs submitted to regulatory authorities were approved. This raised a logical question:
if >99% of submitted PACs were approved by the regulatory authorities, could
a company not make decisions on some of these PACs without having to submit
and wait for regulatory authorities from each of the 100+ countries to approve
them?
The issue is not as much that 100+ countries must approve a PAC, but that obtaining
approval from all these countries takes a very long time, and this introduces complexity
and risk. Global approval for a single PAC can often takes years (sometimes 5+ years)
because of the varying timelines and requirements (that add significant workload for
PAC submissions) across the regulatory authorities in each of these countries. Until the
time a PAC has been approved and implemented in all relevant countries, a company
must maintain and produce product in both the pre-change and post-change state for
each country, in order to be compliant with each country’s regulatory expectations. This
means that a company has to maintain inventory of product manufactured both by the
pre-change and post-change state, and ensure that the post-change state product is only
sent to those countries that have already approved the change; countries that have not
yet approved the change must receive product manufactured by the pre-change state.
For a company, replicating this pre-change and post-change state across 8000 PACs a
year across its product portfolio very quickly results in a product inventory comprised
of hundreds of versions of the same product, pre-change and post-change state. This
leads to highly complex and challenging product inventory and supply logistics which
present numerous opportunities in daily manufacturing and supply operations for
potentially serious errors due to multiple versions of a process or product being in place
at the same time. The risk is that an unapproved version of the product gets supplied to
a country that has not yet approved and given the clearance for the related PAC, or that
a country has approved a PAC related version yet receives the pre-change version of the
product.
But arguably, the more important issue is that such massive global complexity has
severely hindered and disincentivised continual improvement, innovation, and the
timely implementation of knowledge gained during commercial operations in
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pharmaceutical companies - even when doing so can result in a reduction of risk to
product quality or patient safety, accelerate product and process improvements, or close
compliance gaps. On the contrary, this current global PAC complexity has created the
opposite undesired effect: a disincentive to pursue continual improvement, innovation
and meaningful change in favour of the current state and status quo. Pharmaceutical
companies that maintain status quo may even have a financial advantage over
companies that continually improve and innovate, because the cumulative global cost of
filing a PAC and maintaining a complex inventory of multiple product versions during
the long transition state until a PAC is approved globally, is a heavy burden for many
companies. It can rapidly outweigh the long-term benefits of continual improvement
and innovation. This can eventually result in drug shortages and impact public health,
because of a company’s failure to upgrade its aging facilities, equipment, processes,
materials and methods. It can also eventually impact the viability of a product and
perhaps the company. This has been evident in several instances of aging facilities and
equipment, where companies had not upgraded their older equipment and facilities, and
were ultimately unable to meet cGMP and regulatory expectations, let alone continually
improve. Innovation typically precedes regulation change. As Peter Drucker stated:
“The enterprise that does not innovate, inevitably ages and declines. And in a
period of rapid change such as the present entrepreneurial period, the decline
will be fast.”(Drucker, 1993)
The Common Technical Document (CTD)
For regulatory review and approval, all Quality, Safety and Efficacy information for a
product is assembled in a common format called a Common Technical Document
(CTD). The CTD is organised into five modules - Module 1 is region-specific, while
Modules 2, 3, 4 and 5 are intended to be common for all regions (ICH M4, 2000). At its
first approval, a product is typically approved for one indication and it has one
registered manufacturing process, as submitted to regulatory authorities in the CTD
format. During its commercial life, the product may remain the same, the indication
may remain unchanged – yet, due to the many PACs necessary during the commercial
life of the product, the company has to maintain different inventories associated with
each PAC until the PAC has been approved across all countries. This significantly
lowers a company’s ability to respond to a change in demand signals for a specific
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product version, eventually resulting in shortages even when acceptable product
versions are available and a shortage could in theory be entirely avoided.
Example from a Global Vaccine Manufacturer’s Perspective
Currently, from a regulatory perspective, individual PACs are essentially treated the
same across all companies, in that, the level of product and process knowledge, and the
effectiveness of the company’s PQS in managing PACs, are generally not taken into
account by regulators when regulating those PACs. In addition, the same PAC may
sometimes receive varying approval decisions from different regulatory authorities,
even though the science and risk-based assessment for the PAC remains exactly the
same for each country that it is submitted to. Figure 1.4 is a real example from a global
vaccine company that illustrates the global PAC complexity for a single PAC. This is
not an uncommon scenario – it is experienced by most global companies with products
marketed in multiple countries. The example shows that different decisions are being
made for the same PAC even though the risk to product quality or patient safety remains
unchanged. Additionally, there is limited transparency (for a company from a regulatory
authority, and between regulatory authorities) on the process and considerations
regulatory authorities use in making these PAC decisions.

22 countries
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Manufacturing
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changes
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138 countries
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19 are different
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Figure 1.4: Global PAC Complexity for One Change – An Example from One
Pharmaceutical Company
As discussed in the introduction to this chapter, in January 2019 the researcher and
Vinther met with Dr Woodcock, Head of CDER at the US FDA (hereafter referred to as
FDA) and senior leaders from her staff, including Dr Ashley Boam, Rapporteur for the
ICH Q12 guidance that was in development at the time. The meeting was to discuss
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PACs and the significant challenge with continual improvement and innovation in a
global environment. At this meeting the researcher and Vinther laid out the current
complexities with global PAC management and raised the question of how the
pharmaceutical industry could build trust with regulators so that more changes could be
managed within a company’s PQS.
Dr Woodcock acknowledged the gravity of the problem and that neither regulatory
authorities nor pharmaceutical companies were working together as they could and
should to collectively reduce this global complexity. This discussion catalysed two
significant actions:
1. Establishment of a pharmaceutical industry 1VQ for PAC Initiative in 2019
2. Launch of a strategic initiative in 2021 by the International Coalition of
Medicines Regulatory Authorities (ICMRA), a strategic coordinating, advocacy
and leadership entity of regulatory authorities, on a global Product Quality
Knowledge Management System (PQKMS) that would enable:
“more extensive mutual reliance among regulators through work to harmonize
specific data expectations for sponsors and standards for review among
regulators, so that regulators can be assured of the comparability of the
assessments and related determinations of other regulatory authorities on whom
they intend to rely.”(ICMRA, 2021)
Further details and outcomes from this January 2019 meeting, the 1VQ for PAC
Initiative, and the ICMRA strategic PQKMS initiative are described in Chapter Six and
Chapter Seven of this thesis.

1.2.2 The Potential Link of the Global Complexity
Burden to Drug Shortages
Drug shortages are a global problem; they are not localised to certain countries or
regions, and therefore, local solutions cannot sustainably resolve this problem. In spite
of appreciable advancements in regulations and technologies since the beginning of the
21st century, which are discussed in detail in Chapter Two of this thesis, the problem of
drug shortages has continued to worsen. The researcher contends that:
the enormous complexity associated with global PAC management delays
resolution of cGMP compliance or quality issues and continual improvement to
such an extent, that it potentially contributes to exacerbating the issue of drug
shortages.
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This linkage between undesirably slow continual improvement and innovation and drug
shortages was first suggested and described as what is termed a ‘wicked problem’ by
Vinther in an article in the PDA Letter (Vinther, 2016). The concept of a ‘wicked
problem’ is defined and explained in Chapter Four of this thesis. The current situation is
contrary to what every stakeholder wants, in spite of the best intentions and
commitment to provide a reliable supply of safe, effective, high-quality medicines to
patients.
A regulatory framework that supports the availability of safe, effective, high-quality
medicines for patients is a vital component within the pharmaceutical environment.
However, the increased globalisation of the pharmaceutical industry at the same time as
increased regionalisation of regulatory frameworks, along with the complexity added by
increasing and varying submission documentation requirements, have contributed to a
state of dysfunction, and is hindering this very objective. Though more World Health
Organisation (WHO) countries have strengthened their regulatory systems in
accordance with the World Health Assembly’s (WHA) direction given in WHA67.20,
Regulatory System Strengthening for Medical Products (World Health Assesmbly,
2014), this has had the unintended consequence of every country adding often countryspecific requirements. This has had the impact of further increasing the PAC processing
times in these countries, and aggravating the regulatory complexity problem.
All of this global complexity causes a significant time lag between the acquisition of
new knowledge about products and their manufacturing processes, and the
implementation of such new knowledge into daily operations. Regulatory oversight,
designed to safeguard public health, has, on account of this global complexity,
paradoxically and unintentionally contributed to a loss in the state of control and to
challenges with product availability. The increased global burden of PAC management
and the resulting complexity in product lifecycle management are potentially
compounding the drug shortage problem.
Several regulatory authorities have identified that most drug shortages are caused by
manufacturing and/or quality issues (European Commission, 2012). The researcher
explored this specific aspect in her discussions with pharmaceutical companies, both in
her pre-research work and through the 1VQ for PAC Initiative focus groups (described
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in Chapter Seven of this thesis). In applying the Five Whys technique, a simple and
effective approach to systematic problem-solving (Serrat, 2017), in her inquiry, the
following responses were noted:
•

Why do you have a drug shortage?
o because of manufacturing and/or quality issues

•

Why do you have manufacturing and/or quality issue?
o because facilities or equipment are aging, or processes and methods
haven’t been brought up-to-date

•

Why have aging equipment, processes or methods not been updated?
o because the global regulatory complexity is too high and a PAC takes a
long time or significant effort, making it easier to maintain status quo

This link between global regulatory complexity being an aggravating factor for the lack
of continual improvement and that in turn contributing to drug shortages is noted in a
research conducted by the Economist Intelligence Unit (EIU) (EIU, 2018), and is
explored in further detail in Chapter Four and Chapter Five of this thesis.

1.2.3 The Pharmaceutical Quality System (PQS) as
a Means to Reduce the Burden of Global Complexity
The Pharmaceutical Quality System (PQS)
In 2005, ICH recognised the need for a guideline describing a:
“modern quality system to establish and maintain a state of control that can
ensure the realisation of a quality drug product and facilitate continual
improvement over the lifecycle of a drug product.” (ICH, 2005b)
The PQS model as envisaged by ICH was intended to augment current Good
Manufacturing Practices (cGMPs) and reflect the concepts of a Quality Management
System (QMS) defined by the International Organisation for Standardisation (ISO), an
independent, non-governmental international organisation. Even back in 2005, the
perceived problem with regional differences in regulatory requirements was that they
could lead to varying interpretations and potential divergence, resulting in:
•
•
•

“fragmented or fundamentally divergent approaches to quality systems
delays in the availability of medicines to patients around the world
delays in the implementation of innovation and continual improvement for
existing products due to different expectations
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•
•

delays in the launch of new products, and
different approaches to compliance inspections.” (ICH, 2005b)

The ICH Q10 Concept Paper envisioned the encouragement of science and risk-based
approaches to quality decisions, facilitation of innovation and continual improvement
throughout the entire product lifecycle, and demonstration of pharmaceutical industry
and regulatory commitment to robust quality systems and technical innovation, along
with assurance of consistent availability of medicines.
Consistent with that Concept Paper, ICH Q10, Pharmaceutical Quality System, was
approved in 2008 (ICH, 2008). It established a comprehensive PQS model across the
product lifecycle (pharmaceutical development, technology transfer, commercial
manufacturing and product discontinuation) with three specific objectives:
1. Achieve product realisation
2. Establish and maintain a state of control, and
3. Facilitate continual improvement
The PQS model identified four PQS elements (Process Performance and Product
Quality Monitoring System (PPPQMS), CAPA System, Change Management System
and Management Review), along with two enablers (KM and QRM), as depicted in
Figure 1.5.
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Figure 1.5: Pharmaceutical Quality System per ICH Q10
ICH Q10 clearly stated that:
“regulatory approaches for a specific product or manufacturing facility should
be commensurate with the level of product and process understanding, the
results of quality risk management and the effectiveness of the PQS.” (ICH,
2008)
Annex 1 of ICH Q10 described potential opportunities to enhance science and riskbased regulatory approaches. It indicated that demonstration of an:
“effective PQS and product and process understanding, including the use of
quality risk management principles” presented an opportunity to “optimise
science and risk based post-approval change processes to maximise benefits
from innovation and continual improvement.” (ICH, 2008)
In spite of ICH Q10 providing a detailed framework for an effective PQS in 2008, over
a decade later its vision and value have yet to be realised in the pharmaceutical sector.
Continued product recalls, manufacturing, quality and supply chain issues, and
increasing drug shortages provide clear evidence that management of risks based on
operational knowledge and an effective PQS is still lagging. Evidence of these issues
are presented in Chapter Two of this thesis. Mature risk and knowledge bases that are
key for making a PQS effective are still in early implementation maturity, as researched
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and expounded upon by TU Dublin’s Pharmaceutical Regulatory Science Team (PRST
researchers) Dr Kelly Waldron (Waldron, 2017) and Dr Ghada Haddad (Haddad, 2019)
with respect to QRM, and by Dr Martin Lipa with respect to KM (Lipa, 2021). The
researcher asserts that, without effective use of QRM and KM to manage products,
processes and systems within the PQS framework, the PQS cannot be effective; and
without an effective PQS, it is not possible to optimise PAC processes “to maximise
benefits from continual improvement and innovation” to quote from ICH Q10.
Additionally, until July 2021 (with the publication of the PIC/S Recommendation Paper
titled How to Evaluate and Demonstrate the Effectiveness of a Pharmaceutical Quality
System in Relation to Risk-Based Change Management (PIC/S, 2021)), there was no
further practical guidance published on how to demonstrate the effectiveness of a PQS,
and this area has remained challenging.
Drug shortages as a ‘wicked problem’
A ‘wicked problem’ is multi-faceted and highly complex and it is explored in more
detail in Chapter Two and Chapter Four of this thesis. It offers the possibility of being
explored from various perspectives as follows:
•

It could be explored for global regulatory complexity where the problem is
assessed from the lens of different regulatory expectations by country or region,
and how these might contribute to the growing challenge of slow and prolonged
PAC management.

•

It could also be assessed from the perspective of regulatory authority
assessors, who may not have visibility of a company’s PQS, how it is
performing, or how its effectiveness is demonstrated and monitored. This likely
limits their ability to integrate, in their decision-making, considerations related
to the company’s latest product and process knowledge or the strength of their
PQS in ensuring good risk-based decision-making. These assessors also do not
have visibility to how assessors in other countries might have assessed a
particular PAC submission; this is of relevance because the assessment of a PAC
should be based on science, knowledge and data which does not vary by
country.

•

Alternately, it could be assessed from the perspective of regulatory authority
inspectors, who are typically not involved in the review and approval of PACs,
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but have visibility into, and an understanding of, how effective a company’s
PQS is for managing PACs, and how strong (or weak) their KM and QRM
systems are.
•

It could be assessed for the potential value that would be realised across the
pharmaceutical sector if the interactions and exchange between regulatory
assessors and inspectors were improved, whereby the regulatory oversight is
shifted from assessors reviewing each PAC application to inspectors verifying
the effectiveness of the PQS in managing PACs.

•

It could be assessed from a pharmaceutical company’s perspective in relation
to the challenges encountered and the solutions that the pharmaceutical industry
could develop and commit to implementing, even without expecting global
regulatory convergence, harmonisation, reliance, or improved interactions
between assessors and inspectors.

•

It could also be assessed from the perspective of hospitals and pharmacies that
experience the frontline impact of drug shortages when issues with
manufacturing, quality, supply and distribution prevent the availability of
medicines. Possibly getting earlier visibility from these stakeholders on potential
shortages or weak nodes in their warehouse, distribution and supply networks
could contribute to useful solutions

•

It could be explored from the perspective of reforming policies, legislation and
legal frameworks globally to significantly reduce the burden associated with
changes and mobilise the pharmaceutical sector towards accelerated continual
improvement and innovation. An example of this is the recent work that the
European Commission initiated in 2020 to revise the EU variations legislation.

•

Finally, and most importantly, this wicked problem could be assessed from the
perspective of impact to patient, for example, shortage instances where a patient
might have to switch to an alternative medicine (where one is available) or even
have to go without. Any barrier that impedes the timely and reliable availability
of quality medicines, manufactured and tested with state-of-the-art technology,
is simply unacceptable.

How do all of the stakeholders who desire to serve and meet the needs of patients, end
up in a collective state of dysfunction that detracts from this very objective? Regardless
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of the lens that this issue is viewed through, one aspect is certain - all stakeholders
involved – pharmaceutical companies, regulators, distributors, policy makers,
legislators, healthcare providers, hospitals, and pharmacies - must work together to
ensure that patients are never deprived of their medicines. They are the sub-parts of a
holistic system that is intended to serve public health needs in the best possible manner.
The researcher made a noteworthy observation during the early stages of this study:
not only do these stakeholder groups not work with each other towards
collaborative solutions, they also often do not work together within their
respective groups to design and implement standard solutions.
This early insight emerged as a red thread that became increasingly evident and
irrefutable as the research study progressed.
Given the enormous breadth of this research topic, framing the problem clearly was
challenging, yet essential, in order to develop a defined scope for the research with
specific attainable outcomes. It also provided a useful basis for the research hypothesis.
These are laid out below in section 1.3.

Research Hypothesis, Scope, Objectives and
Expected Benefits
The research study was developed with the underlying objective:
to accelerate continual improvement and innovation, and reduce global
complexity through science and risk-based transformation of PAC
management – so that the pharmaceutical sector can ensure the uninterrupted
delivery of safe, effective, high-quality medicines to patients.
Per the problem framing provided in section 1.2, the research hypothesis focused on
three core points:
1. The high global regulatory complexity, as described in section 1.2.1,
incentivises the pharmaceutical sector to maintain a status quo rather than
continually improve and innovate their operations and technologies
2. Without effective use of QRM and KM to manage the lifecycle of products,
processes and systems within the PQS, the PQS cannot be effective; and without
an effective PQS, it is not possible to “optimise science and risk-based postapproval change processes to maximise benefits from continual improvement
and innovation” per ICH Q10 Annex 1
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3. Without continual improvement and innovation, the pharmaceutical sector
cannot sustainably ensure the timely and uninterrupted delivery of high-quality
medicines to patients
Although all stakeholders - including regulators, pharmaceutical companies and patients
- desire an uninterrupted supply of high-quality medicines and all favour innovation and
continual improvement in pharmaceutical manufacturing, these objectives remain
unaccomplished, and the problem unsolved. While some progress has been made, it is
the researcher’s belief that there is still insufficient awareness of and therefore, a lack of
mutual understanding and agreement on what the exact problem is. The global nature of
the pharmaceutical product supply chain diminishes the value of local regulations that
do not address global needs, and the solutions designed by one stakeholder in isolation
of their implications for other stakeholders remains ineffective.
This research study explored the implications of global complexity in implementing
continual improvement and innovation. It was designed to then use the findings to
develop solutions that could be implemented across the global pharmaceutical sector,
with the ultimate goal of benefitting patients by ensuring timely and reliable supply of
safe, effective, high-quality medicines.
The researcher proposed that science and risk-based applications, utilising the latest
product and process knowledge within the framework of an effective PQS to assess
individual PACs, could enable companies to overcome existing barriers to proactive
continual improvement and innovation. It was postulated that this, in turn, should help
reduce potential drug shortages in the global environment. It was proposed throughout
this study that in order to realise the regulatory flexibility envisioned in ICH Q10,
Annex 1, any PAC that could be demonstrated via a current knowledge-based risk
assessment to reduce risk to patients should be implemented immediately within the
structure of an effective PQS, and without requiring prior-approval. This approach fully
recognises the need for regulators to maintain their oversight of how pharmaceutical
companies manage such PACs; such oversight is already provided for via the GMP
inspection and market surveillance programs that regulators throughout the world
currently operate. The oversight would simply shift from the assessors to the inspectors,
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At the outset of this research, there was no guidance available on what constitutes an
effective PQS or how might a pharmaceutical company demonstrate the effectiveness of
its PQS for the management of PACs. This research, therefore, also explored how to
demonstrate effective management of PACs within the PQS.
The study also sought to explore how to enable alignment, common understanding and
mutual appreciation between regulators and the pharmaceutical industry of the
challenges they each encounter in effective PAC management. This was essential to
activate collaborative discussions and the development of standard practical solutions
that could be deemed acceptable by both stakeholder communities. It was also
anticipated that such standard solutions, when implemented, would instil confidence
among regulators in a company’s ability to effectively manage and implement PACs
within the framework of their PQS, without the need for prior regulatory approval.
Furthermore, it was envisaged that the results produced from this research and its jointly
designed practical solutions could be transformational in facilitating the availability of
medicines and catalysing technical innovation in the pharmaceutical sector, while also
facilitating the following outcomes and benefits:
•

Reducing the burden for both pharmaceutical companies and regulators by
o Enabling faster and more timely implementation of knowledge
o Simplifying product supply and inventory logistics due to PACs
o Enabling regulators to focus their resources on high impact, high value
activities while deprioritising low risk PACs, based on sound product
and process understanding, robust QRM, KM, and an effective PQS

•

Developing standard solutions that facilitate harmonisation globally across the
pharmaceutical industry and which lead to increased harmonisation across
regulatory agencies

•

Reducing the time lag between when new knowledge is gained during the
commercial life of a product and when it is actually implemented to drive
continual improvement

•

Building trust with regulatory agencies that can ultimately provide powerful
mechanisms and incentives for both pharmaceutical companies and regulators to
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downgrade PACs from prior-approval to notification, or even simply to manage
them only within the PQS
•

Ensuring patients receive value from the best innovations in a timely manner

The overall outcome of this research is a set of methodologies and practical standard
solutions which can facilitate a transformational shift in PAC implementation timelines
and a significant reduction in PACs requiring prior-approval.

Why an Overarching Framework of a PQS,
QRM, and KM?
It must be noted that pharmaceutical companies cannot decide the regulatory outcomes
for individual PACs – this is the responsibility of regulatory authorities. At the same
time, regulators cannot decide on the innovation and continual improvement decisions
that companies must make based on their evolving product and process knowledge. The
pharmaceutical industry also cannot create mutual reliance between regulatory
authorities or reduce the complexity of the global regulatory landscape. Even so, the
concept of mutual regulatory reliance started to emerge as a topic of substantive
relevance during the course of this research. Mutual reliance in a PAC context means
that, when one regulatory authority has assessed a PAC or a company’s PQS, other
regulatory authorities may rely on and accept their conclusions (and approval or
rejection) of a company’s PAC. This would speed up the approval timelines for PACs,
improve consistency in approval decisions across countries, and save resources both for
companies and regulators by eliminating redundancies in PAC reviews and approvals.
The World Health Organisation (WHO) is a United Nations agency that connects
nations, partners and people to promote health, keep the world safe and serve the
vulnerable – so everyone, everywhere can attain the highest level of health. The WHO,
through its Working Document QAS/20.851, Good Reliance Practices in Regulatory
Decision-Making: High Level Principles and Recommendations (WHO, 2020), has in
recent years been encouraging reliance between regulatory authorities; however, the
desired state is still far from realisation. Solutions that enable mutual reliance and
reduce regulatory complexity are still needed; however, these are not directly within the
scope of this research study, which is focused specifically on science and risk-based
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solutions that pharmaceutical companies can implement to support management of
additional PACs within their PQS.
These aspects related to the role of assessors in evaluating a PAC versus inspectors in
evaluating a company’s PQS for, especially change management. This is a topic that is
both within and also outside the sphere of control of a pharmaceutical company, and
while PACs may have a local scope, there can also be international interaction
opportunities for regulatory authorities with regard to those same PACs. This is
illustrated in Figure 1.6 below as developed by the researcher:

Figure 1.6: Roles and Interactions for Regulatory Authorities and
Pharmaceutical Companies
As laid out in the research hypothesis in section 1.3 and as envisaged by ICH Q10
Annex 1, sound science and risk bases (i.e., mature QRM), utilisation of the latest
product and process knowledge (i.e., mature KM), and an effective PQS are anchors to
maximise continual improvement and innovation. The responsibility of developing
methodologies and solutions which demonstrate effective QRM per ICH Q9, Quality
Risk Management (ICH, 2005c), KM, and an overall PQS that is capable of effectively
managing PACs, must start with pharmaceutical companies as a first step. This could
then be followed by exchanges with regulators to build trust in the solutions proposed
by the pharmaceutical industry, as well as increased transparency from regulatory
assessors to companies with regard to their decision-making criteria and processes for
PAC assessments. It could eventually result in opportunities for assessors to provide
increased transparency to each other with regard to their PAC assessment work and
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their decision-making, to help drive regulatory convergence, mutual reliance and a
reduction of global regulatory complexity.
This research therefore probed into appraising where and how QRM and KM
applications could be implemented for PAC management and how one could
demonstrate the capability of the PQS in effectively managing PACs, such that priorapproval by individual regulatory authorities would be necessary only for higher risk
changes. This research also intended to translate high-level concepts and guidance in
this area into practical, standardised, implementable solutions.
The product and process knowledge that a company gains during the commercial life of
a product continues to grow throughout the product’s life. A company’s PQS should
provide a structured framework to capture and manage such growing knowledge. At the
same time, the QRM system employed by the company should enable the utilisation of
this knowledge to drive risk reduction and continual improvement. It is not always
possible to update product filings with the latest knowledge in as timely a manner as is
possible to update and maintain that knowledge within the company’s PQS. This creates
a lag in the knowledge for a product that resides within the company’s PQS versus what
is documented and registered in product filings with regulatory authorities, as illustrated
in Figure 1.7, developed by the researcher:
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Figure 1.7: Managing Product Knowledge in the PQS vs. Regulatory Filings
This results in a missed opportunity for regulatory authority assessors to utilise the latest
product and process knowledge while making their PAC regulatory categorisation and
approval decisions.
The research hypothesis propounds that QRM could provide a desired framework that
utilises the latest product and process knowledge (which is captured in the company’s
PQS) to identify, assess and adequately control risks associated with a proposed PAC,
such that PACs presenting a lower risk to product quality and/or patient safety relative
to the current state could be managed within the PQS or as notifications to regulatory
authorities, without requiring regulatory approval prior to implementation of the
change. Figure 1.8, developed by the researcher, illustrates such a framework – one that
is based on QRM and KM within the construct of an effective PQS, and is consistent
with the expectations of ICH Q10.
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Figure 1.8: QRM and KM as Enablers for Effective Management of PACs in the
PQS
Reading the figure left to right, new knowledge that is acquired during the commercial
life of a product should get documented within the PQS. When a PAC is needed, the
latest knowledge relevant to that PAC, as captured within the company’s PQS, should
be utilised to perform a risk assessment on the PAC. The needed controls identified in
the risk assessment should be implemented through the PQS. The risk level of a PAC
identified by the risk assessment should help answer the question: ‘Can the change be
managed within the PQS only’? If yes, then the change should not require a regulatory
prior-approval submission, and instead regulatory oversight will transfer to the inspector
when inspecting the PQS. If no, then the change must be submitted to regulatory
authorities for assessor review and prior-approval.
This research claims that application of such an approach could reduce the number of
PACs that need prior-approval regulatory submission. To facilitate this the 1VQ for
PAC Initiative developed standard science and risk-based solutions during 2019-2021
that companies could apply to facilitate management of more PACs within the PQS; at
the same time, the solutions provided standards for inspectors to audit the PQS against.
The impact and level of reduction that could be achieved by applying the standard
solutions resulting directly from this research, and those identified as additional
31

opportunities, are discussed later in Chapter Ten, section 10.3 of this thesis, and
depicted in Figure 10.1.
Returning to the premise at the centre of this study, patients deserve to receive every
dose of every medicine they need, every single day. They place their trust in regulators
and pharmaceutical companies for reliable supply of safe, effective, high-quality
medicines. This research led to the proposal of a clear and practical path to realise the
promise of ICH Q10 and maximise benefits for patients, depicted in Figure 1.9 below
as:
1. Current state as starting point: risk for a PAC remains the same, yet there are
different submission requirements and approval timelines across different
countries and regions
2. As a first improvement milestone: companies consistently start performing
risk assessments for individual PACs, utilising the latest product and process
knowledge relevant for those PACs
3. As the next improvement milestone: risk-based decision-making by regulators
takes into account the company-specific product and process knowledge and
effectiveness of their PQS to acceptably manage PACs without extensive
regulatory approvals, leading to reduced reporting category for PACs that do not
increase risk to product quality or safety
4. The final milestone: consistency in risk-based decision making for PACs across
countries and regions, with convergence and eventually reliance, all resulting in
faster global implementation of PACs
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Figure 1.9: Realising the Promise of ICH Q10 for Patients

Overall Research Progression, Outcomes and
Timelines
Though this thesis is laid out in six distinct parts, these were not sequential in the order
they were executed, but rather iterative with several components being interconnected
and occurring in parallel. The approach taken for the study was necessary in order to
gather input, develop a position or a draft solution, solicit feedback from multiple
stakeholder communities through various focus groups, interviews, conference
presentations or discussion sessions, adjudicate and incorporate such input, update and
re-socialise for ratification or endorsement prior to publishing as a standard solution.
While it is acknowledged that solving ‘wicked problems’ requires collaborations across
various stakeholders and that no one stakeholder group can singularly resolve such
complex issues, Figure 1.10 summarises the specific contributions the researcher made
towards addressing this ‘wicked problem’ and the high-level study timeline:
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Figure 1.10: Research Outputs Progression and Timelines
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For each of the activities numbered in Figure 1.10, the papers published and proposals
submitted to regulatory authorities are supplied.
•

The pre-research publications that were foundational for this research are
discussed in Chapter Five and Chapter Seven of this thesis

•

The publications resulting from this research are discussed in Chapter Eight of
this thesis

•

Specific proposals and contributions made to various regulatory authorities are
discussed in Chapter Six of this thesis.

This chapter has introduced the research study, its context and background, framed the
problem being addressed, and outlined the key contributions from the researcher in
terms of inputs into, and outputs from, this research study.
The next chapter provides the literature review conducted in order to explore published
data and insights of relevance for this study.
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Literature Review
Throughout the research study a literature search and review on the topics of global
regulatory complexity, PAC management, and product lifecycle management, in
addition to drug shortages, QRM, KM and PQS within the pharmaceutical sector was
carried out. Additionally, the researcher wished to understand foundational elements of
Quality Systems that are relevant to any customer-oriented industry. Therefore,
characteristics of a QMS per the ISO 9000 series quality systems framework, which is
applicable to a broad range of industries beyond the pharmaceutical industry, and which
actually formed the basis for the ICH Q10 PQS model were also reviewed. Though
there are other examples of ‘wicked problems’, such as climate change, poverty, world
hunger, etc., the review of this topic focused on a seminal paper in 1973 by Rittel and
Weber (Rittel and Webber, 1973), because it describes characteristics that are relevant
for any ‘wicked problem’. Beyond this seminal paper; a deep literature review into
other ‘wicked problems’ was not deemed necessary for this study, given the highly
unique nature of each wicked problem and the very restrictive (if any) ability to draw
common lessons or parallelisms in solving them.
The literature search also revealed some deficiencies, in that there is very little
published on global pharmaceutical regulatory complexity, PAC management or their
linkage to drug shortages. This lack of literature did not come as a surprise to the
researcher and further confirmed the need for this research. Some literature found on
these topics was published by other stakeholders such as the Economist Intelligence
Unit (EIU), which is reviewed in Chapter Four of this thesis, but not much by the
pharmaceutical industry. Thus far, there is also no published guidance for assessors on
how to perform PAC assessments; and until publication of a recent PIC/S guidance in
July 2021 (PIC/S, 2021), there has been limited to no guidance for the pharmaceutical
industry or inspectors on how to demonstrate or assess effectiveness of a PQS
specifically for PACs. Indeed, much of the published literature directly relating to the
global pharmaceutical regulatory complexity and PAC management was driven by the
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researcher, either prior to or during the course of this study, and as such the researcher
cites this work throughout the thesis.
Figure 2.1 lays out in broad heading the topics for which literature was reviewed, and it
includes a mapping of the applicable thesis chapters or sections where they are
discussed. The colour-coding shown in the figure indicates whether the literature
reviewed was specific to the pharmaceutical sector, whether it applied to other
industries, or whether it was applicable to even larger problems related to social policy
or public good.

Figure 2.1: Scope of Literature Review
While the body of guidance and published literature is rich on risk management in other
industries, as well as on QRM in the pharmaceutical sector, and on QMSs in general, it
was found that not much has been published on linking enhanced science and risk-based
approaches to PAC management beyond ICH Q10, Pharmaceutical Quality System
(ICH, 2008), ICH Q12, Technical and Regulatory Considerations for Pharmaceutical
Product Lifecycle Management (ICH, 2019), and the researcher’s prior and current body
of work (described throughout this thesis).
It was also found that extensive published literature exists for KM in other industries,
but it is far less for the pharmaceutical sector, especially when compared to QRM
literature. There is even less published on the practical application of enhanced science
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and risk-based approaches for high complexity, multi-faceted topics such as drug
shortages, and on the resulting expected optimisation of regulatory approaches to enable
continual improvement and innovation within the pharmaceutical industry.
Recent PRST doctoral theses from Dr Martin Lipa (Lipa, 2021) and Dr Paige Kane
(Kane, 2018) provide thorough reviews of the published literature on knowledge
management. Similarly, the PRST doctoral theses from Dr Ghada Haddad (Haddad,
2019), Dr Kelly Waldron (Waldron, 2017), and Dr Kevin O’Donnell (O’Donnell, 2007)
provide detailed literature reviews on QRM in the pharmaceutical sector. Though
conducted over a decade ago, the comprehensive literature review of risk management
by Dr O’Donnell is noteworthy, as it covers risk management in the aeronautics and
nuclear power generation industries and compares it to practice in the pharmaceutical
industry. Finally Dr Nuala Calnan’s doctoral thesis (Calnan, 2014) focused on a review
of ICH Q8, Q9, Q10 and Q11, with an emphasis on QMSs and the importance of
shifting from compliance-based quality to excellence-based quality. In lieu of
conducting another independent literature review into QRM and KM, the researcher
opted to review the insights from these PRST doctoral theses and build upon them.
This review was supplemented by the researcher’s 10+ years of deep practical first-hand
experience with QRM and KM as part of her pharmaceutical industry affiliation and
work. Figures 2.2 and 2.3 below depict key aspects of the researcher’s career,
leadership, training and influencing experience in the pharmaceutical sector. It includes
her role and involvement in establishing a QRM program at her company of
employment, her activities in training and advancing risk-based application both for the
company and broader for the pharmaceutical sector, leading up to her pre-study work on
drug shortages and eventually this research study into PAC management; further details
on the researcher’s prior-experience are provided in Appendix I of this thesis.
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Figure 2.2: Summary of Researcher’s Career, Leadership and Influencing
Experience
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Figure 2.3: Researcher’s Experience with Training Regulators and the
Pharmaceutical Industry
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The literature review for this research focused on a review of QMSs in a broader
context beyond the pharmaceutical sector, literature relevant to describing the global
regulatory landscape in the context of drug shortages, and the application of enhanced
science and risk-based approaches to PAC management. Given that the literature on
these topics was more finite, and to allow for more integrative understanding,
topic-specific literature reviews are embedded within the specific chapters of this
thesis as per Figure 2.1 above. A general overview of literature on QMSs and
applicable ICH guidelines that form the basis of this research are provided in this
chapter, with topic-specific aspects integrated into other relevant chapters.
Furthermore, it is useful to provide a brief overview and context of the pharmaceutical
sector relevant for this research. For the scope of this study, the term ‘pharmaceutical
sector’ is comprised of three primary stakeholders - pharmaceutical industry, regulatory
agencies (regulatory authorities that have legal authority to regulate the pharmaceutical
industry in their respective countries) and academia (where direct collaborations with
the pharmaceutical industry or regulators enable advancement of patient-focused work).
The pharmaceutical sector landscape, with key enterprises that participated in,
contributed to, and are referenced throughout this research study, is depicted in Figure
2.4 (modified with permission from the original figure developed by Dr Martin Lipa for
PRST (PRST, 2021). The figure serves as a useful ‘quick reference guide’ to these
entities as mentioned throughout this thesis.
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Figure 2.4: Pharmaceutical Sector Landscape Relevant for Research4

4

Descriptions for 1VQ for PAC, PDA, ISPE, EFPIA, IFPMA, PRST and ICH, are taken from their respective About pages (1VQ, 2021; EFPIA, 2021; ICH, 2021; IFPMA, 2021; ISPE, 2021; PDA,
2021; PRST, 2021)
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As a large part of this research study is based on ICH guidelines, it is useful to provide a
brief overview of ICH. The International Council for Harmonisation of Technical
Requirements for Pharmaceuticals for Human Use (ICH) is an international non-profit
association that brings together regulatory authorities and the pharmaceutical industry
to:
“achieve greater harmonisation worldwide to ensure that safe, effective, and highquality medicines are developed and registered in the most resource-efficient
manner” (ICH, 2021).
ICH brings experts from regulatory authorities and industry together to develop
guidelines through a process of scientific consensus. ICH guidelines fall in the
following four categories (ICH, 2021):
1. Quality (Q): “Harmonisation achievements in the Quality area include pivotal
milestones such as the conduct of stability studies, defining relevant thresholds
for impurities testing and a more flexible approach to pharmaceutical quality
based on Good Manufacturing Practice (GMP) risk management.”
2. Safety (S): “ICH has produced a comprehensive set of safety Guidelines to
uncover potential risks like carcinogenicity, genotoxicity and reprotoxicity. A
recent breakthrough has been a non-clinical testing strategy for assessing the
QT interval prolongation liability: the single most important cause of drug
withdrawals in recent years.”
3. Efficacy (E): “The work carried out by ICH under the Efficacy heading is
concerned with the design, conduct, safety and reporting of clinical trials. It also
covers novel types of medicines derived from biotechnological processes and the
use of pharmacogenetics/genomics techniques to produce better targeted
medicines.”
4. Multi-disciplinary (M): “Those are the cross-cutting topics which do not fit
uniquely into one of the Quality, Safety and Efficacy categories. It includes the
ICH medical terminology (MedDRA), the Common Technical Document (CTD)
and the development of Electronic Standards for the Transfer of Regulatory
Information (ESTRI).”
The order of literature review presented in the sections below, starts with the topic
broadest in scope i.e., wicked problems, and progresses to more specific topics with
direct implications for this study as follows:
•

Wicked Problems

•

Drug Shortages

•

Quality Management Systems

•

ICH Q10, Pharmaceutical Quality System

•

ICH Q12, Technical and Regulatory Considerations for Pharmaceutical
Product Lifecycle Management
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It is noteworthy that throughout the literature review, the importance and relevance of
global considerations provided a useful basis given the global nature and implications of
this research topic.

Wicked Problems
A ‘wicked problem’ was defined in the literature for the first time in 1973, by Rittel and
Webber as ‘a problem highly resistant to solutions’ (Rittel and Webber, 1973). They
identified that wicked problems are highly complex, stubborn problems that cannot be
well-defined, do not have easily defined solutions, and cannot be solved by any one
group of people. Addressing wicked problems must be based on systems thinking,
seeking to answer two primary questions within the context of ever-evolving social
complexities – “What do the systems do?” and “What should these systems do?”. The
concept of systems thinking and its relevance and application for this research study is
expanded upon in Chapter Three, section 3.2.1 of this thesis. Examples of wicked
problems include climate change, obesity, poverty, hunger, sustainability and,
biodiversity loss. Rittel and Webber stated that:
“one of the most intractable problems is that of defining problems (of knowing
what distinguishes an observed condition from a desired condition) and of
locating problems (finding where in the complex causal networks the trouble
really lies). In turn, and equally intractable, is the problem of identifying the
actions that might effectively narrow the gap between what-is and what-oughtto-be.” (Rittel and Webber, 1973)
This statement essentially summaries the core challenge of this research topic. As
described in Chapter One, section 1.2 of this thesis, the task of framing the problem, its
scope, the research hypothesis, and exploring possible solutions, was not a simple
undertaking. Not only is the gap between what-is and what-ought-to-be difficult to
articulate, equally - if not more difficult - is the task of conclusively determining
whether or not a set of solutions has narrowed that gap. Considering the findings from
this research, this aspect of the ‘wicked problem’ has been expounded upon in the
concluding Chapter Ten of this thesis.
Rittel and Webber identified ten features that are characteristic of all ‘wicked
problems’, irrespective of how diverse and distinct they might be from each other. The
researcher developed Figure 2.5 below for a visual depiction of these characteristics.
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Figure 2.5: Characteristics of a Wicked Problem (Rittel and Webber, 1973)
Some parties have identified the COVID-19 pandemic as a ‘wicked problem’ (Kerr and
Glantz, 2020), since it is presenting many of the typical characteristics and societal
complexities. This may be proved to be the case, but given that vaccines have been
bending the curve and the world is still in a state of pandemic, it might be too soon to
conclude this.
In 2016, Vinther asserted that drug shortage is a ‘wicked problem’, because it presents
all the characteristics of a ‘wicked problem’ as outlined by Rittel and Webber (Vinther,
2016). Chapter Four, section 4.1of this thesis specifically discusses why drug shortage
can be considered a ‘wicked problem’.
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Drug Shortages
Chapter One of this thesis framed the problem and laid out the hypothesis that there is a
connection between drug shortages and inadequate continual improvement and
innovation due to the global complexity for PAC management, even if a direct
correlation is difficult to make. There is an extensive body of information and data
published on drug shortages, including each country having their own database for the
tracking and notification of drug shortages. For the purpose and scope of this research,
it wasn’t deemed necessary to do a detailed literature review on drug shortages broadly,
but rather a targeted search was performed to find any literature published linking drug
shortages to slow innovation or global regulatory complexity.
Most literature on drug shortages centres on it being a multi-causal issue, with the
causes ranging across a wide variety of economic, business and manufacturing or
supply chain factors as shown in Figure 2.6 (Birgli®, 2013).

Figure 2.6: An overview of the Causes of Drug Shortages (Birgli®, 2013)
Regulators such as the European Medicines Agency (EMA) and FDA have identified
manufacturing or product quality issues as a prominent cause of drug shortages; one
example of this is given in FDA’s 2019 Drug Shortages Report, which shows that 62%
of shortages between 2013-2017 were as a result of manufacturing or quality issues
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(EMA, 2012; FDA, 2019). The researcher contends after applying the Five Whys
technique, as described in Chapter One, section 1.2.2 of this thesis, that the inability to
make changes (to fix issues) due to the global complexity, is as an appreciable
disincentivising factor.
Researcher’s Prior-Work on Drug Shortages: Resulting in the Publication of PDA
Technical Report 68
Prior to initiating this research study, the researcher identified that taking a science and
risk-based approach was necessary to address drug shortages. In 2012, the researcher
was instrumental in forming and leading a PDA Drug Shortage Task Force. The
researcher chartered and set up the Task Force, identified suitable participants
comprising of industry experts and regulators, and held multiple working sessions to
develop the scope, objectives and deliverables of the Task Force. The Task Force
comprised of seven experienced members drawn from the pharmaceutical companies
and regulatory agency listed in Table 2.1 below:
Table 2.1: Composition of PDA Drug Shortage Task Force
Participants
Amgen
Concordia ValSource
G-CON Inc.
Genentech
Health Products Regulatory Authority (HPRA)
Merck Sharp & Dohme
Sanofi Pasteur

The Task Force met regularly over 18 months with a view to developing strategies for
managing drug shortages. These concepts, strategies and a Risk Triage model for drug
shortages were published by PDA in 2014 as Technical Report 68, Risk-Based
Approach for Prevention and Management of Drug Shortages (Ramnarine et al., 2014).
This work initiated a review into how aging facilities and equipment could result in
manufacturing and quality issues which could then lead to drug shortages. The research
explored barriers that pharmaceutical companies encounter in proposing and making
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changes to upgrade aging facilities, equipment, methods and processes. A specific
barrier that the researcher identified during the course of this pre-research study was the
global regulatory complexity that is associated with implementing PACs. The
researcher found that this barrier created a disincentive for pharmaceutical companies
and prevented them from implementing the latest technology or making continual
improvements that could in fact reduce manufacturing and quality issues, and ultimately
prevent resulting drug shortages. The researcher identified an interesting paradox:
while continual improvement and innovation could reduce risk to drug
shortages, the enormous global complexity with PAC management delays
resolution of compliance or quality issues and continual improvement to such an
extent, that it potentially contributes to exacerbating the issue of drug shortages.
Though published as a PDA Technical Report and as work conducted by the Task
Force, the thought leadership and core concepts including the Risk Triage model and
the Drug Shortage Prevention and Response Plan were original contributions from the
researcher.
This prior work by the researcher on risk-based application for drug shortages was
instrumental in instigating this research study, and as such will be referred to throughout
this thesis; details of Technical Report 68 are described in Chapter Five, section 5.3.4 of
this thesis. For ease of reading, it will be referred to as PDA Technical Report 68
hereon, and a citation is not deemed necessary for each reference instance in this thesis.
Regulators’ Focus on Drug Shortages
The FDA in 2019 published a report on drug shortages (that was updated in 2020) on
root causes and potential solutions (FDA, 2019). It identified economic forces as the
overarching root cause. The report also found three additional major root causes:
1. Lack of incentives to produce less profitable drugs
2. Market does not recognise and reward manufacturers for mature Quality
Management Systems
3. Logistical and regulatory challenges make it difficult for the market to recover
after a disruption
Root causes #2 and #3 are directly relevant to this research. This FDA report was the
first time that a regulatory authority had acknowledged the link between the regulatory
complexity and a lack of utilising an effective PQS to prevent shortages.
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The report identified regulatory complexity being a factor contributing to drug
shortages, specifically stating:
“Many drug manufacturers supplying the U.S. market are in fact global
operations that also supply other regions. Making post-approval changes to
update manufacturing operations generally requires that they seek approval not
only from FDA but the regulators in the other markets. According to industry
observers, many post-approval changes to regulatory filings require priorapproval by the regulatory authority of every country individually, and this
can be over 100 countries for globally marketed products. The global
approvals for changes can often take years because of varying requirements
and timelines across different regulatory authorities, and this creates
disincentives for timely improvements to manufacturing operations that could
reduce the risk of drug shortages.” (FDA, 2019)
The bold text regarding discussion with industry observers reflected precisely the
dialogue the researcher and Vinther had had with FDA in January 2019, that is
discussed in Chapter Six, section 6.1.2 of this thesis, indicating their direct impact and
influence on this report.
The report’s recommendations to address the second and third root causes were to:
•

Create a rating system to incentivise drug manufacturers to invest in achieving
Quality Management System maturity

•

Promote sustainable private sector contracts – whereby contracting practices by
payers, purchasers and global purchasing organisations (GPOs) recognised and
rewarded manufacturers for mature quality management

In addition to the recommendations, the report also identified several FDA initiatives to
prevent and mitigate shortages, with one of them being the adoption and
implementation of ICH Q12 (FDA, 2019).
The EMA has also undertaken extensive activities as described in Chapter Five, sections
5.2.1, 5.3.1, 5.3.3 and 5.3.5 to address drug shortages; however, these have not drawn
any linkages between global regulatory complexity or PAC management and drug
shortages. Therefore, they are not included as part of literature review in this chapter.
Part Two of this thesis, Chapter Four and Chapter Five further delve into specific
responses and literature from various regulatory authorities (FDA, EMA, WHO) and the
pharmaceutical industry on drug shortages within the context of this study.
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Quality Management Systems, ISO 9001:2015 –
Basis for the Pharmaceutical Quality System
Having focused on the ‘wicked problem’ and how drug shortages can be classified as
such, with one cause of them being manufacturing and quality issues, this section
reviews literature pertinent to QMSs.
ISO is an independent, non-governmental international organisation, with 164 national
standards bodies as its members. ISO develops voluntary, consensus-based market
relevant International Standards that support innovation and provide solutions to global
challenges (ISO, 2021). These International Standards cover a broad range of industries
and technologies including food, agriculture, pharmaceutical, healthcare, to ensure that
products and services are safe, reliable and of good quality, and to help facilitate
international trade. Since 1947 when it was established, ISO has published over 23,056
International Standards.
ISO 9000:2015 describes universally applicable fundamental concepts, principles and
vocabulary for QMSs (ISO, 2015a). It can be adopted by any organisation that wants to
implement a QMS to consistently provide products and services conforming to their
requirements.
ISO 9001:2015 provides requirements for a QMS that an organisation can use to
demonstrate its ability to consistently provide products and services that meet customer
needs and applicable regulatory requirements, and which enable improvement of the
system through a process approach and the application of risk-based thinking (ISO,
2015b). It applies the following seven principles to establish the right quality culture:
1. Customer focus
2. Leadership
3. People engagement
4. Process approach
5. Improvement
6. Evidence-based decision-making
7. Relationship management
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An integrated QMS is a set of policies, processes and procedures required for planning
and execution in the core business areas of an organisation to meet customer
requirements. Operating within a QMS framework allows a company to produce highquality end product and meet customer requirements.

ICH Q10, Pharmaceutical Quality System - for
Product Lifecycle Management
ICH Q10, developed in 2005 describes a QMS model specifically for the
pharmaceutical sector; it is referred to as the Pharmaceutical Quality System (PQS). It is
based on the ISO QMS and its seven principles as described in section 2.3. The right
quality culture foundation is essential for the PQS, as expected in a QMS framework.
Chapter One, section 1.2.3 of this thesis provides the context of why a PQS foundation,
as described in ICH Q10, is an important basis for this research. It also describes why
the need for a PQS was recognised in 2005 (ICH, 2005b), the key objectives, and
principles of the ICH Q10 PQS framework, and why the model could be useful to
implement throughout the product lifecycle in order to enhance quality and availability
of medicines.
ICH Q10 establishes QRM and KM as enablers for science and risk-based decisionmaking in relation to product quality, and accomplishment of the PQS objectives of
achieving product realisation, establishing and maintaining a state of control, and
facilitating continual improvement.
Compliance with cGMPs remains a baseline expectation. In line with ISO quality and
QMS concepts, ICH Q10 clearly states expectations for continual improvement and
innovation. As a result of this and other ICH quality guidelines, continual improvement
expectations have made their way into the cGMPs such as Chapter 1 of the European
Union (EU) GMP Guide which states that:
“continual improvement is facilitated through implementation of quality
improvements appropriate to the current level of process and product
understanding.” (EudraLex, 2012)
It also requires periodic management review to identify continual improvement
opportunities for products, processes and the overall PQS.
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The Final ICH Q10 Business Plan, approved in November 2005 envisioned the
following potential benefits for a PQS:
•
•
•
•
•

“Improved process performance
A reduction in the costs of internal failures (rejects, reworks, reprocessing and
investigations) as the quality systems guideline drives improvement
A reduction in the costs of holding duplicate stock and operating multiple
processes as improvements and changes are made more effectively across all
regions
A reduction in the costs of preparing / reviewing certain regulatory submissions
Enhanced assurance of consistent availability of medicines to the patient.”

If only a small percentage of these costs could be avoided, then substantial saving of
resources by industry and regulators will be realised and the benefits of this project
will greatly exceed the costs.” (ICH, 2005a)
15+ years since these envisioned benefits were laid out in the ICH Q10 Business Plan,
there is abundant evidence (e.g., regarding sub-optimal process performance, failures
and their costs, inventory costs, operating multiple versions of a process, drug
shortages, effort and cost for preparing and reviewing regulatory submissions etc.), that
the pharmaceutical sector (industry and regulators) are yet to realise these benefits. This
research study instigated an inquiry for the researcher as to why, in spite of having a
PQS model in place, have none of these benefits been achieved?
As the researcher took a deeper look into the ISO quality concepts that form the basis of
ICH Q10, the evolution of a QMS from end product testing to early detection and
prevention, and further to designing in quality into products, it led her to examine the
two specific ICH Q10 objectives - maintaining a state of control and facilitating
continual improvement, and whether or not these objectives might be perceived as
contradictory was explored, specifically:
how to maintain control while continually improving?
The research dissected the different elements of the PQS and explored how both
reactive triggers and proactive signals throughout the lifecycle of a product could (and
should) be managed within the PQS, and solutions to manage these were developed.
The specifics of the solutions developed are covered in Chapter Eight of this thesis. The
researcher and O’Donnell published their insights in a peer-reviewed paper in the
Journal of Validation Technology, titled “Continual Improvement While Maintaining A
State of Control: A Concealed Paradox or a Mutual Interdependence” (Ramnarine et
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al., 2019). That paper concluded that the two objectives of maintaining a state of
control and facilitating continual improvement may seem to present an inherent
paradox, but are in fact mutually interdependent, since a state of control cannot be
maintained without continual improvement and implementation of new knowledge
gained throughout the lifecycle of a product. It also concluded that the PQS, as laid out
in ICH Q10, provides a holistic model to accomplish both of those objectives
effectively in a systematic, transparent and structured manner.
In regards to regulatory approaches, ICH Q10 clearly states:
“Regulatory approaches for a specific product or manufacturing facility should
be commensurate with the level of product and process understanding, the
results of quality risk management, and the effectiveness of the
pharmaceutical quality system. When implemented, the effectiveness of the
pharmaceutical quality system can normally be evaluated during a regulatory
inspection at the manufacturing site.” (ICH, 2008)
This explicitly implies that regulatory approaches may vary and the effectiveness of the
PQS, including QRM application can be assessed during inspections. This eventually
became the guiding vision for the recently published PIC/S Recommendation Paper on
How to Evaluate and Demonstrate the Effectiveness of a Pharmaceutical Quality
System in Relation to Risk-Based Change Management (PIC/S, 2021). The researcher
played a key role in the development of this guiding document which is described
further in Chapter Eight, section 8.4 of this thesis. A related area of particular relevance
and application to this research includes evaluating the impact of proposed changes by
pharmaceutical companies and regulators, and determining what is important to
communicate between regulatory assessors and inspectors in order to facilitate and
ensure better management and control of risks to product quality and patient safety in
the context of PACs.
ICH Q10, in its Annex 1 identifies, Potential Opportunities to Enhance Science and
Risk Based Regulatory Approaches; it opens the possibility of using enhanced science
and risk-based regulatory approaches based on the level of product and process
understanding, application of QRM, and effectiveness of the PQS. The opportunities
include optimisation of PAC processes through science and risk-based approaches to:
“maximise benefits from innovation and continual improvement.” (ICH, 2008)
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Though ICH Q10 has been in place since 2008, these potential opportunities for
advancing continual improvement and innovation have not been realised to any
meaningful extent by the pharmaceutical sector.
The researcher hypothesises that this is because there has been no guidance available on
what is meant by the following:
1. an enhanced science and risk-based approach
2. an effective PQS and
3. how to demonstrate effectiveness of both in order to gain regulatory flexibility
and allow more PACs to be managed in the PQS without prior regulatory
approval
This is the core premise of the study, the expected outcome being a transformational
shift in the ability of the pharmaceutical sector to reap the benefits laid out in ICH Q10
i.e., assure availability of safe, effective, high-quality medicines in a timely manner with
reduced burden for both pharmaceutical companies and regulatory authorities. The
context and framework needed to achieve this are already provided through ICH Q9 and
Q10. The recently published (July 2021) PIC/S Recommendation Paper has been a first
significant step in providing practical guidance on how to demonstrate effectiveness
specifically for the change management system (PIC/S, 2021). Similar practical
implementation guidance on the other elements of the PQS namely, Management
Review, CAPA, and PPPQMS is also needed.
ICH Q10 does not address the concept of mutual reliance, where regulatory authorities
can benefit from leveraging each other’s assessments. Through this research and its
resulting solutions, it is anticipated that regulators could potentially move one step
further in their journey towards harmonisation, convergence and ultimately mutual
reliance, especially in relation to review and approval of PAC submissions.

2.4.1 QRM and KM – The PQS Enablers are Integral
for Transforming PAC Management
ICH Q10, Pharmaceutical Quality System, describes QRM and KM as enablers in
achieving the objectives of a PQS, and “providing the means for science and risk based
decisions related to product quality” (ICH, 2008). ICH Q9, Quality Risk Management
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published in November 2005, provided a structured framework, process, principles and
tools for application of QRM throughout the lifecycle of a product – starting from
product development, through technology transfer, commercial manufacturing and
product discontinuation (ICH, 2005c). Since the publication of ICH Q9, QRM
expectations have been increasingly integrated across the GMPs in many countries, and
the application of QRM is an expectation across many regulatory authorities. However,
no parallel guidance providing a structured framework for KM currently exists, and
there is sufficient evidence that KM implementation and maturity have been lagging
more so than QRM in the pharmaceutical sector, as also noted by Kane and Lipa in their
respective doctoral theses (Kane, 2018; Lipa, 2021).
QRM and KM are both necessary for facilitating practical science-based decisionmaking, with the PQS providing clear documentation and transparency to such risk and
science-based decisions. They are also intended to improve the effectiveness and
consistency of product quality and patient safety related risk-based decisions, by both
industry and regulatory authorities across the entire lifecycle of a product. However, in
spite of the clear PQS (in ICH Q10) and QRM (in ICH Q9) frameworks, and significant
efforts to implement QRM, both pharmaceutical companies and regulatory authorities
have yet to realise the full potential and value of science and risk-based decision
making, stated in ICH Q9 as:
“effective quality risk management can facilitate better and more informed
decisions, can provide regulators with greater assurance of a company’s ability
to deal with potential risks, and level of direct regulatory oversight. In addition,
quality risk management can facilitate better use of resources by all parties.”
(ICH, 2005c)
This was most recently referred to by ICH, when, in its published concept paper of
November 2020 which described a planned 2020-2022 revision of its ICH Q9 Quality
Risk Management guideline, it stated that:
“the benefits of QRM, as envisaged by ICH Q9, have not yet been fully
realized.”
and it indicated that product availability risks and risk-based decision-making, two areas
of direct relevance to this research work, were areas in need of improvement (ICH,
2020).
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So why is this the case? The researcher hypothesises that even though ICH Q9 and Q10
collectively discuss that QRM and KM can improve risk-based decisions, there has been
insufficient attention or clarity on what good risk-based decision-making looks like and
how it might be achieved. This is also supported by the aforementioned ICH Q9(R1)
2020 Concept Paper.
Utilisation of these enablers should begin early in development and continue all through
the product lifecycle, incorporating new knowledge that continues to grow through the
commercial life of the product to drive risk reduction and continuous improvement.
This is essentially the basis for ongoing product lifecycle management, including PAC
management – hence its relevance to this research.
Lipa’s research explored the integration of QRM and KM and resulted in a very useful
risk knowledge infinity cycle (RKI) (Lipa, O’Donnell and Greene, 2020). This cycle
shown in Figure 2.7 below is a continuous cycle where knowledge flows to inform risk
and an understanding of risk informs new knowledge. Lipa et. al. further published case
studies demonstrating how to utilise the RKI cycle for specific instances across the
product lifecycle (Lipa et al., 2021). Application of the RKI cycle for PAC management
to drive continual improvement and innovation as another application area is further
described in Chapter Nine, section 9.1.4 of this thesis.

Figure 2.7: The RKI Cycle Applies Throughout the Product Lifecycle (Lipa,
O’Donnell and Greene, 2020)
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The risk - knowledge relationship as demonstrated by Lipa’s work, can be applied to
any QRM activity across the product lifecycle. This holds true even for PAC
management. The better the knowledge and understanding base from the
pharmaceutical development phase of a product’s lifecycle, the more effective it is to
continue to build the experience space from this base, as the product progresses into its
commercial life. A strong product development knowledge base also improves the level
of rigor and quality of the risk assessments that are needed to manage the product and
its control strategy, including PACs, throughout the product lifecycle. Higher product
and process understanding are expected to drive risk reduction, which in turn can
activate flexible regulatory approaches. Such flexible regulatory approaches can
facilitate risk-based regulatory decisions for reviews and inspections, enable process
improvements with reduced regulatory oversight, and reduce the number of postapproval submissions that may be required. Enhanced product and process
understanding is essential to gain this regulatory flexibility.
Connecting back to the ISO quality concepts and evidence-based decision-making, one
of the seven principles, evidence-based decision making, a science and risk bases
becomes fundamental to:
1. evidence-based decision-making related to product quality and patient safety
2. an effective PQS
3. the right quality culture and mindset
ICH Q9 refers to, but was deemed to not adequately address QRM application for the
management of product availability (i.e., drug shortage) risks. There was evidence
through the continuing global drug shortages problem that such risks, when not well
managed, ultimately impact patients. The strategic importance of an increased emphasis
on managing product availability risks, through risk-based drug shortage prevention and
response plans, can be linked directly to protection of public health by serving the
interests of patients well.
In July 2017, Dr Kevin O’Donnell initiated the development of a proposal to revise ICH
Q9 to address the topic of risk-based decision making and QRM application for product
availability risks (along with two other points, not directly related to this research). The
proposal recognised that when ICH Q9 was published in November 2005, ICH Q10 had
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not yet been in place, therefore the concepts of QRM and KM as being enablers of the
PQS and as means to drive continual improvement and innovation, had not been fully
articulated. The final ICH Q9 revision proposal was endorsed by ICH in October 2020
with Dr O Donnell appointed as the Rapporteur (ICH, 2020).

2.4.2 Demonstrating Pharmaceutical Quality
System Effectiveness and Driving Continual
Improvement: Evidence-based Risk Reduction
The research explored how risk-based decision-making might be improved in the
pharmaceutical industry in order to understand what the barriers to innovation are, and
how they may be overcome. Through 15 years of active and practical experience with
implementing QRM in the industry, the researcher learnt that risk-based decisionmaking was indeed weak, and that the link between the initial steps in the QRM process
i.e., planning and performing the risk assessment using various methods and tools, and
the subsequent decision-making steps, was either broken or often subjective and
passive. Therefore, the QRM and the PQS frameworks as envisioned in ICH Q9 and
ICH Q10 were still far from full implementation and realisation.
The researcher, together with O’Donnell, explored this area and it was part of the
preliminary body of work leading up to this study. The resulting peer-reviewed
publication “Demonstrating Pharmaceutical Quality System Effectiveness and Driving
Continual Improvement: Evidence-based Risk Reduction” described that there is not a
well-established link between product and process knowledge (which is dynamic and
continues to evolve during the lifecycle of a product) and control strategies, such that it
can lead to continual improvement and innovation (Ramnarine and O’Donnell, 2018).
The paper presented how evidence-based risk reduction could be the mechanism to
establish this link in utilising the latest product and process knowledge to not only
ensure that the control strategy is robust and effective, but to also drive continual
improvement and innovation. The basis for evidence based-risk reduction are data that
are related to the effectiveness of risk-based mitigating controls; such data can also be
derived from assessments of the robustness of controls when testing at the edges of
failure, and when performing worst-case validation studies etc. Controls that did not
lend well towards data-based assessments of their effectiveness e.g., procedural or
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training controls, tended to be more difficult to generate risk-reduction evidence for.
The authors concluded that the only way to achieve regulatory relief and flexibility (as
envisioned in ICH Q10 and eventually carried into ICH Q12) in PAC management was
to utilise enhanced science and risk-based approaches and make this transparent within
the construct of an effective PQS that is capable of assuring a state of control and
enabling continual improvement.
Building on the importance of evidence basis described in that paper, the researcher
asserts that when data-based evidence is provided to show that a PAC (which results in
process improvement, continual improvement or innovation) could reduce current risks
to product quality and/or patient safety, this should serve to build trust with regulators
and facilitate confidence among regulators such that regulatory flexibility can be
provided to companies for faster implementation of such PACs. It would form the basis
for companies demonstrating to regulators that their risk-based decision-making
processes were sound, based on objective evidence, and backed by science and data.
Additionally, it could also be a mechanism to determine where companies and
regulators should focus their resources. Could all of this be achieved through qualitative
or subjective assessments, was a question posed. Possibly, but not in a rigorous manner
that engendered confidence and trust in the risk-based decision-making process and the
resulting decisions. Without this, it would not be possible to realise the vision of ICH
Q9, Q10 and Q12.
Other industries, such as aerospace and nuclear power generation, have been well-ahead
of the pharmaceutical industry with regard to established risk-based decision-making
processes; while it is not the subject of this research, the paper proposed that there was
merit for the pharmaceutical industry in leveraging the learnings from these other
industries. It also proposed specific areas to look into to improve evidence-based risk
reduction and decision-making in the pharmaceutical industry.
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ICH Q12, Technical and Regulatory
Considerations for Pharmaceutical Product
Lifecycle Management
In September 2014, the ICH Steering Committee endorsed a Concept Paper for a
guideline that:
“will provide a framework to facilitate the management of post-approval
Chemistry, Manufacturing and Controls (CMC) changes in a more predictable
and efficient manner across the product lifecycle. Adoption of this guideline will
promote innovation and continual improvement, and strengthen quality
assurance and reliable supply of product, including proactive planning of supply
chain adjustments. It will allow regulators (assessors and inspectors) to better
understand, and have more confidence and trust in a firm’s Pharmaceutical
Quality System (PQS) for management of post-approval CMC change.” (ICH,
2014)
This ICH Q12 Concept Paper acknowledged that absence of harmonised approaches for
technical and regulatory aspects for product lifecycle management impeded innovation
and continual improvement in the pharmaceutical industry. It recognised that though
ICH Q8 through ICH Q11 focused well on product development stages, there wasn’t
adequate guidance on utilisation of science and risk-based assessments for product
lifecycle management throughout the commercial life of a product. Further, though ICH
Q10 laid out the framework for all elements of the PQS, the ICH Q12 Concept Paper
emphasized the need to develop further details on the change management system such
that it enabled transparent, harmonised understanding with regulators (inspectors and
assessors) and their confidence and trust in a company’s capabilities to effectively
utilise the latest product and process knowledge to implement changes, and justify the
desired operational and regulatory flexibility that was being sought by companies.
Implementation of harmonised change management could facilitate more transparency
and efficiency for both regulators and pharmaceutical companies, thereby improving
supply reliability and product availability. It further anticipated one of the benefits being
mitigation of drug shortages related to manufacturing and quality problems through
strategic management and use of science and risk-based approaches for PACs.
The vision, expectations and resulting benefits identified by the ICH Q12 Concept
Paper, aligned completely with the researcher’s work including the PAC iAMSM Task
Force’s charter she was co-leading at the time. A component of the researcher’s work
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and the Task Force’s charter was to provide active input including draft content to the
ICH Q12 Expert Working Group (EWG) and contribute towards the development of the
ICH Q12 guideline. This also included providing practical recommendations and realworld examples from the pharmaceutical industry to facilitate development and
implementation of ICH Q12.
In order to achieve this, the researcher in her capacity as co-lead of the PAC iAMSM
Task Force, influenced and contributed to ICH Q12, by developing and proposing draft
text to the ICH Q12 Expert Working Group (EWG) for:
•

product lifecycle management including a template for a product lifecycle
management (PLCM) plan

•

vision of an effective PQS for PACs

•

change management considerations for PACs

Published in November 2019, ICH Q12 is the latest finalised ICH quality guideline; it
provides a framework for managing PACs more efficiently and predictably, such that
continual improvement and innovation, as expected by ICH Q10, can be promoted
(ICH, 2019). ICH Q12 expands on the flexible regulatory approaches for post-approval
CMC changes that have been referred to in ICH Q10 Annex 1. It brings alignment on
terminologies such as established conditions, product lifecycle management; provides a
series of regulatory tools and enablers; and it describes how these can be used to
integrate the latest product and process knowledge, understanding of risks, and the
framework of an effective PQS to determine the appropriate regulatory reporting
categorisation for a PAC, and to allow more PACs to be managed within the company’s
PQS with reduced regulatory oversight. The concepts and tools provided in ICH Q12
have a strong underlying construct of risk and knowledge basis, and include the
following:
•

A risk-based decision tree for categorisation of PACs

•

Established Conditions (ECs)

•

Post-approval change management protocol (PACMP)

•

Product lifecycle management (PLCM) document

•

PQS and change management
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•

Structured approach for frequent PACs without the need for prior regulatory
approval

•

Stability data approaches to support the evaluation of CMC changes

The ICH Q12 guidance has been in place for under two years, so it remains to be seen
what its level of adoption and value delivery will be in terms of accelerating continual
improvement and innovation through faster PAC management.
This research expanded specifically on how to apply the ICH Q12 concepts and tools
for the risk-based categorisation of PACs, PQS and change management. It delved into
how increased collaboration between regulatory assessors and inspectors was essential
for the successful implementation of ICH Q12.
For categorisation of PACs, the ICH Q12 guideline described a risk-based approach that
utilised current product and process knowledge to determine the level of risk associated
with a change. Moderate to low-risk changes could be managed via a regulatory
notification and did not require prior-approval by regulatory authorities. Changes that
did not require regulatory reporting via prior-approval or notification could be
documented and managed only within the PQS, and verified by inspectors during
routine inspections. This was a useful step in the direction of regulatory flexibility – it
set out a path for easing the regulatory burden for those companies which merit it,
whilst still affording oversight by regulators. However, it should be noted that, for
countries which do not have notification pathways within their regulatory framework,
the current state of requiring prior-approval would likely continue.
The guideline defined Established Conditions (ECs) as:
“legally binding information considered necessary to assure product quality.
As a consequence, any change to ECs necessitates a submission to the
regulatory authority.” (ICH, 2019)
It described how to identify ECs based on product and process understanding. A
decision-tree with a step-wise approach to identify ECs and reporting categories for
changes to them were provided. A change to an EC requires reporting to regulatory
authorities (either as a prior-approval submission or a notification, depending on the risk
level). For changes to non-ECs, no reporting is required, and such changes may be
managed solely within the company’s PQS.
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An effective PQS per ICH Q10 was considered necessary for use of the ICH Q12 tools.
The guideline illustrated the connection between change management and knowledge
management, and how this could be linked to the regulatory process for the
management and reporting of changes to ECs. Appendix 2 in ICH Q12 provided twelve
change management principles for effective PAC management, including - proper
change planning, utilisation of existing product and process knowledge, application of
science-based risk management for assessment of risks associated with a change and
identification of appropriate risk controls, determination of data required to implement
the change, ensuring appropriate regulatory submission, adequate implementation
planning for the change, verification of effectiveness post-implementation, and
documentation of new knowledge post-implementation.
The guideline highlighted the importance of collaboration and effective communication
between regulatory assessors, who reviewed the PAC filings, and inspectors who
inspect the effectiveness of the PQS at manufacturing sites. PQS gaps found by
inspectors could be used by assessors in their review and decision-making for PACs.
Similarly, inspectors being aware of the latest product lifecycle management
information from a filing, could be useful during inspections, in order to assess whether
the company’s PQS is adequate, capable and effective in managing a product through
its commercial life in the context of PACs.
Finally, the ICH Q12 annexes provide examples of identifying ECs for manufacturing
processes and analytical procedures, PACMPs and a PLCM document.
ICH Q12 training is still under development. Implementation of ICH Q12 first requires
the implementation of ICH Q8(R2), Q9, Q10 and Q11. Therefore, these ICH quality
guidelines have built upon each other and are interconnected, in that companies cannot
realise the value of ICH Q12 unless the preceding guidelines have been wellimplemented.
ICH Q12 does not specify how a company’s risk-based decision-making process,
utilising the latest product and process knowledge, could be integrated into its change
management system, or how the decision-making by a company utilising these concepts
from a PQS perspective could be integrated with decision-making by regulators from a
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regulatory CMC perspective. This research, therefore, explored opportunities on both of
these aspects such that mutually integrative decision-making by pharmaceutical
companies and regulators in relation to PAC management could result in the desired
state of faster and more timely continual improvement and innovation.

Literature Published by the Researcher Prior
to Initiating the Research Study
The researcher’s experience with QRM, PQS, drug shortage management, and PAC
management, spanned over 16+ years; details of this experience and related literature
are depicted above in Figures 2.2 and 2.3, and described in Appendix I, but are not
included in this chapter. Key publications from that body of work that directly relate to
this research such as PDA Technical Report 68, are described in this thesis while others
are provided as supporting evidence for this research. These draw the link between the
researcher’s journey towards this research study, starting with her initial body of work
in QRM, its evolution into the specific application of QRM in addressing the problem of
drug shortages, and from there towards product lifecycle management and PAC
management, the topic of this research.

Literature Review Summary
The literature review provided in this chapter was built both on broader reviews
conducted through several PRST doctoral dissertations on QRM, KM and PQS, and on
a targeted review specifically for drug shortages; it explored published data and
insights, linking limited continual improvement and innovation to drug shortages. With
regard to the latter point, very little has been published to date, and not unexpectedly so,
because of the high complexity and challenge associated with drawing such a
correlation. The literature review further confirmed how little progress has been
possible, not only because of the complexity of this ‘wicked problem’, in spite of good
intent and significant effort, but also that QRM, KM and PQS maturity are a long way
from the state desired (when compared with other mature industries such as nuclear or
aerospace) that is necessary to achieve the objectives and value proposition laid out by
this research study. It also reaffirms the importance of tackling this problem, whilst
acknowledging that this will be a long journey.
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The next chapter presents the research design, methodology and methods utilised for
this study and the researcher’s perspective based on her prior work and practical
application experience.
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Research Design, Methodology, and
Methods
This chapter describes the research design, methodologies and methods utilised for this
research study. As mentioned in Chapter One and Chapter Two, and described in
Appendix I of this thesis, the pre-research body of work conducted by the researcher,
coupled with her direct pharmaceutical industry experience with managing PACs,
building Quality Systems and being a QRM expert, lent a pragmatic insider’s
perspective to the work. It also permitted a real-life, bona fide and attestable worldview
to be applied to the research. This chapter also outlines the methodology and methods
used for the specific research questions, as well as the research ethics, confidentiality
and privacy considerations.

The Researcher’s Worldview
The researcher’s direct experience in the pharmaceutical industry coupled with her 6+
year prior pre-research work that eventually led to this research study, served to
formulate the researcher’s philosophical worldview assumptions in the context of this
research. Creswell and Creswell introduced the term ‘worldview’ (Creswell and
Creswell, 2020) in lieu of ‘paradigm’ defined by Guba as “a basic set of beliefs that
guide action” (Guba, 1990). These worldviews or paradigms also guide disciplined
inquiry by a researcher (also known as research methodology).
In developing the research problem and research hypothesis, the researcher needed to
probe her own beliefs and philosophical assumptions. The researcher’s broader
philosophical belief and sense of purpose is one rooted in the bottom-line importance of
serving the needs of, and bringing value to, others through everyday actions.
Specifically, within the pharmaceutical sector, this philosophical belief has directly
translated into actions that serve the needs of patients and public health, current and
future.
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Extensive literature has been published on various inquiry paradigms with three specific
ones of particular relevance noted by Guba (Guba, 1990):
1. Ontological: What is the nature of the “knowable”? Or what is the nature of
“reality”?
2. Epistemological: What is the nature of the relationship between the knower (the
inquirer) and the known (or knowable)?
3. Methodological: How should the inquirer go about finding knowledge?
For the purpose of this research, and guided by her philosophical beliefs and personal
experiences, the researcher based her ontological reality on works and practical actions
that result in benefiting and serving patients’ needs and improving public health. From
an epistemological perspective, the researcher holds the belief that the current state of
public health is not being served well, as objectively and subjectively evidenced by the
ongoing issue of drug shortages and the slow pace of continual improvement and
innovation during lifecycle management of commercial pharmaceutical products. If
continual improvement could be accelerated, it would not only reduce drug shortages,
but advance innovation that could reduce risks to patients (e.g., improved control
systems).
Creswell highlighted four worldviews that have been discussed widely in published
literature; these are shown in Table 3.1 below (Creswell and Creswell, 2020):
Table 3.1: Four Worldviews (Creswell and Creswell, 2020)

Postpositivism
•
•
•
•

Constructivism

Determination
Reductionism
Empirical observation and
measurement
Theory verification

•
•
•
•

Transformative
•
•
•
•

Understanding
Multiple participant meetings
Social and historical construction
Theory generation

Pragmatism
•
•
•
•

Political
Power- and justice-oriented
Collaborative
Change-oriented
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Consequences of action
Problem-centered
Pluralistic
Real-world practice oriented

Worldview Basis for Research Inquiries –
Pragmatism, Transformative and Systems Thinking
During the initial course of this research and through the exploration of the ‘wicked
problem’, two worldviews were found to be primarily applicable – pragmatism and
transformative, with constructivism having a secondary relevance in relation to viewing
the complexity of a ‘wicked problem’ from the perspective of the different stakeholder
groups. These are expanded upon below:
•

Pragmatism: For Phases 1 (Problem Definition), 2 (Exploring the ‘Wicked
Problem’ and Regulatory Authorities’ Positions) and 3 (Bringing the
Pharmaceutical Industry Together – to establish the 1VQ for PAC Initiative) of
the research study, the researcher most associated with the worldview of
pragmatism with a secondary component of constructivism.
Given the high complexity of a ‘wicked problem’, the researcher needed to be
open to highly divergent and sometimes conflicting viewpoints. This was
entirely expected for a ‘wicked problem’, as described in Chapter Four, section
4.2 of this thesis, namely that every problem is unique and difficult to clearly
define, whereby not all stakeholders’ views fully aligned on the problem or its
solutions. The pragmatism worldview afforded the researcher the flexibility of
utilising mixed methods to investigate the ‘what’ and the ‘how’ for the problem,
based on the intended consequences. This research study necessitated the use of
mixed methods, whereby multiple methods, specific aspects from different
worldviews, including a range of related assumptions, and a mix of qualitative
and quantitative data could be considered to seek a reality-based understanding
of the research problem and sharpen the research questions.
Instead of looking at the problem from the narrow view of any single
stakeholder group, the research study intended to explore the views of two of
them – the pharmaceutical industry and regulatory authorities. A commonality
for these two stakeholder groups is that their work and decisions are supposed to
be science and data-based. Therefore, if they align on a standard science-based
global approach, it could transform PAC management and reduce drug
shortages.
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The study did not delve into the detailed views of healthcare providers, policy
makers, governments or legislators, but acknowledged that each stakeholder’s
perception of the ‘wicked problem’, and therefore its solutions, may not be the
same, given that their relative realities may vary. (This is where a
constructivisim worldview would become important, especially if one were to
expand the exploration of this problem to the interfaces, touchpoints,
interconnectedness or interdependencies across all these communities. This,
however, was not within the scope of this research, hence the secondary
relevance of a constructivism worldview.)
•

Transformative: For Phases 4 (Exploring and Developing Practical Science and
Risk-Based Solutions) and 5 (Application to Specific PAC Example Case
Studies) of this research study, the transformative worldview was most relevant,
as envisioned by the overarching goal of this research:
to accelerate continual improvement and innovation, and reduce global
complexity through science and risk-based transformation of PAC
management – so that the pharmaceutical sector can ensure
uninterrupted delivery of safe, effective, high-quality medicines to
patients.
The ‘wicked’ nature of this problem, with its characteristic high level of
complexity, multi-causal, multi-factorial, multi-stakeholder interfaces, and
interconnectedness, where every problem is a symptom of another problem,
meant that an incremental approach to finding its solutions would not suffice. A
transformative worldview whereby systems thinking as described further below
must be applied, emerged as being necessary to address the problem. The
transformative nature of this research enabled the researcher to:
a) raise consciousness and awareness of the global problem
b) articulate impact to patients
c) provide a voice for contributing participants at a senior leadership
level where decisions are made
d) establish a unified voice for reform, change and transform PAC
management for the ultimate benefit of patients
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e) work collaboratively across different stakeholders and geographies in
the pharmaceutical sector to iteratively define the problem and the
development of the resulting standard solutions, and
f) think differently than what had been done for almost decades with
limited to no results (in terms of overcoming the global regulatory
complexity for PAC management)
•

Systems Thinking: During the course of the research, particularly when
developing the standard solutions in Phase 4 (Exploring and Developing
Practical Science and Risk-Based Solutions), evaluating approaches for piloting
and implementing those solutions, and for Phase 6 (Impacts and Future
Opportunities), an unexpected new worldview emerged for the researcher, that
of ‘systems thinking’. Even though this research did not deeply explore the
sociological, geopolitical, behavioural or cultural contexts of the research
problem, a combination of the transformative, pragmatist and systems thinking
worldviews provided the optimal space for this research to acknowledge the
relevance and importance of these contexts in addressing the ‘wicked problem’.

Given the value and significance of the systems thinking that emerged for the
research questions investigated in this study, the next section expands on what
systems thinking is, why it was important for this research topic, and how it was
applied during this work.

3.2.1 Systems Thinking Worldview
Systems thinking is simply:
the ability or skill to perform problem solving in complex systems (Wikepedia,
2021).
A system is:
“a group of interacting interdependent parts that form a complex
whole.”(Montuori, 2011)
In other words, a system is an entity with interrelated and interdependent parts; it is
more than the sum of its parts (subsystems) - it is an ecosystem, where every subsystem
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depends on every other subsystem, either directly or indirectly; therefore, an awareness
and understanding of the boundaries of those parts is of fundamental importance.
The concept of systems thinking goes back to the ancient Mayan and Egyptian times;
the term ‘general systems theory’ was coined in the 1940 by Ludwig von Bertalanffy
who developed a new approach to study living systems (Von Bertalanffy, Braziller and
York, 1968). It encompasses an approach to inquiry that is not limited to one discipline,
and proposes a new way of thinking about the world, focusing on interconnected,
interdependent, dynamic systems, rather than parts that can be isolated from the whole
(Montuori, 2011).
Systems inquiry, as a worldview, was initially not part of the researcher’s study design,
but with the exploration of the characteristics of a ‘wicked problem’, and while
designing standard solutions for operational implementation by pharmaceutical
companies and their acceptance by regulators, systems inquiry and systems thinking
emerged as an important basis to examine the problem. This was so that the design of
solutions could address multiple subparts of the system as connected and part of a
whole, as opposed to isolated, independent, self-contained entities. It became
increasingly clear that changing one part of the system affected other parts of the whole
system. So, although not consciously planned within the study design, systems thinking
was applied in designing the standard solutions, where instead of identifying what other
stakeholders needed to change, the exploration of the problem and the design of the
solutions considered what would work across stakeholder groups. An example of this is
transparency for both pharmaceutical companies and regulatory authorities on how
decisions are made for PACs.
Beyond this, the considerations also needed to further extend to the individuals working
as a part of the system, as they are components of the system too, and therefore, they
contribute to its outcomes. Systems thinking is intended to drive user-centred processes
and solutions, in this case, the end user being the patients who expect and deserve their
medicines to be on time, every time.
While the scope of this research was primarily limited to the pharmaceutical sector, the
researcher acknowledges that these are only two subsystems within the whole which
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involves many other organisations and stakeholders, as described in Chapter One,
section 1.2.3 of this thesis. However, if these two subsystems could collaborate and
agree on solutions, it would result in a meaningful impact in advancing innovation and
continual improvement in the pharmaceutical industry, and reducing drug shortages.
The general modus operandi in the pharmaceutical sector has remained that, regulatory
authorities establish expectations and requirements primarily at a national or regional
level, as guidance for industry that then must be implemented by those companies.
Calnan in her thesis reviewed and researched how decades of emphasising compliance
as a means to achieve quality might have limited continual improvement and innovation
in the pharmaceutical industry and beyond complying with the cGMPs, the
pharmaceutical sector (both industry and regulatory authorities) must adopt mainstream
quality management standards and principles (Calnan, 2014). This was indeed the intent
of the ICH Q10 PQS model, but thus far, the ISO 9001 quality management-based
concepts that ICH Q10 has been based on, have not been realised; this has been a
divergence for the pharmaceutical industry from other ISO managed non-pharma
industries that have also implemented QMSs.
Many regulatory authorities have a practice of inviting feedback on draft regulatory
guidances before they are finalised and brought into force. Beyond this practice, over
the last few years, some regulatory authorities and organisations such as FDA, PIC/S
and WHO, have started inviting more collaboration with the industry through pilot
projects. These have related to the implementation of tools and concepts, such as PQS
maturity assessments, inspection protocols, established conditions, etc.
An interesting insight the researcher gained during the course of the study was that,
there have been very limited, if any, collaborative proposals made by the
pharmaceutical industry to regulatory authorities or vice-versa, and there is also no
guidance for regulators that can facilitate harmonisation across assessors on PAC
assessment and decision-making. A systems worldview propounds that, involved
individuals or stakeholder groups must constantly be aware of and understand the
boundaries between their respective subsystems, and design solutions that are not linear
in addressing only their individual parts, but the whole. It is contrary to the conventional
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tendency to reinforce organisational boundaries through structures, systems, policies,
etc.
John Atkinson, a systems thinker and thought leader, states that:
“messy complex problems are just too hard for individuals to comprehend, so
we parcel it up into packets of problem we can understand and manage and tell
ourselves that we have done a good and right thing.” (Atkinson, 2018)
Systems thinking challenges the notion and assumption that, the way we run an
organisation – be it a regulatory authority, pharmaceutical company, government,
legislative or policy-making body, hospital, distribution channel, or country - is how it
should be run to serve its purpose and be of value to society, that each stakeholder must
design and own their solutions within their respective organisational accountabilities,
and that our control or even influence is limited beyond our own organisation’s primary
and maybe, secondary boundaries that interface with another organisation. This research
study design intended to first facilitate the pharmaceutical industry looking inwards to
determine what they could do to contribute towards solving the problem, and then
collaborate with regulatory authorities to enable joint application of the resulting
solutions.
Organisations certainly manage relationships with other organisations they need to
interface with, but this is typically linear and within their positional power and
hierarchies; however, in a systems world, power is dispersed, the relevance of traditional
positional authorities must be diminished and set aside in order to connect, collaborate
and jointly solve issues for the collective good of the society. Current organisational
setups, systems and ways of working tend to inherently push back on complex
challenges and usually try to band-aid fix them, which usually adds more complexity or
bureaucracy. The global complexity with respect to increasing local and regional
requirements is an example of this, and yet drug shortages continue.
Therefore, several system scientists such as Atkinson and Myron Rogers have asserted
that ‘wicked problems’ are addressed by asking questions and not following standard
operating procedures. The questions include:
•

“Who are the 'we' who have a collective interest and energy for addressing the
problem we face?
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•
•

What do we individually and collectively know about what is going on in order
that we might make more sense of what we are trying to do?
How well do we connect to each other so that we might have the opportunity to
decide where to place our efforts?” (Atkinson, 2018)

To address these questions, it is critical to have the same level of awareness and a
common understanding of a problem and its implications, before it can be solved. The
ability to work with multiple perspectives, value insights and knowledge offered by
each of those perspectives, but not at the exclusion of others, and to harness the
collective power of the sub-parts of a whole living system to co-create solutions is the
fundamental basis of systems leadership (Atkinson, 2018). As new connections form
between stakeholders, new patterns, relationship formats and interaction pathways
emerge, and transformative solutions that once could not be conceived, become
possible. At the same time this might challenge existing ways of finding coherence, and
even lead to the collapse of conventional or traditional ways of working.
With these new insights related to systems thinking, even though it might seem atypical
(relative to conventional ways of working in the pharmaceutical sector), the researcher
decided to develop use case studies for the developed solutions while the research study
was still ongoing. It was considered imperative, given the iterative nature of this
research and the multiple perspectives involved, that the solutions be developed through
active collaborative dialogue and input-gathering, from both pharmaceutical companies
and regulators, even as the research study was in progress. Exchange between regulators
and pharmaceutical companies for the development and implementation of these
standard solutions formed an integral component of the systems approach used in this
research study. The researcher posits that this exchange was paramount, not only for
calibration and alignment between the pharmaceutical industry and its regulators on a
common understanding of the problem, but also in the interpretation and acceptability
of the solutions. Therefore, this research aimed to facilitate such exchange between the
pharmaceutical industry and regulatory authorities. The exchange also served a valuable
means for pharmaceutical companies to build credibility and trust with regulators.
A systems thinking approach to working across organisational boundaries to address the
issues of mutual concern (i.e., slow continual improvement and innovation contributing
to drug shortages), was imperative. It was considered key for testing and gaining
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adoption of the solutions within the pharmaceutical industry, and their acceptance by
regulators. To wait for completion of this PhD, before the solutions were made available
for testing and adoption, would have been a missed opportunity in advancing this topic
with a sense of urgency. TU Dublin, through this research, intends to make an
invaluable academic contribution to a current, real and growing global problem for the
pharmaceutical industry, its regulators, and ultimately the patients who rely on
medicines.
With this framing of the researcher’s pragmatic, transformative and systems worldview
for this study, the next section elaborates on the insider’s perspective that the researcher
brough to this body of work.

The Researcher’s Insider Perspective
As stated in Chapter One and Chapter Two of this thesis, the researcher had been
employed in the pharmaceutical industry for 20+ years and, prior to registering for this
research, undertook activities as part of her pharmaceutical industry affiliation which
served to provide an important pre-research foundation to this study. The researcher’s
high-level career experience informing this research and her prior registration preresearch work are provided in Appendix I of this thesis.
The researcher acquired over 15+ years of practical QMS and QRM application
experience for the pharmaceutical development, technology transfer and commercial
manufacturing

phases

of

a

product

lifecycle,

across

the

medical

device,

biopharmaceutical and pharmaceutical sectors. She also managed global validation and
change management processes, in addition to establishing a QRM program with
policies, procedures, tools and training for her company, and facilitated risk
assessments. Outside her company, she provided QRM training sessions and held QRM
application workshops for the industry and regulators. Additionally, in her position of
leading a Global Analytical Science and Technology function and managing QC
operations within her pharmaceutical company of employment, the researcher also
acquired direct first-hand experience with operational aspects of product and process
knowledge management, PAC management, regulatory submissions and the associated
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quality, operational, regulatory and supply processes. All of this experience is
summarised in Appendix I of this thesis.
Given the researcher’s employment in a pharmaceutical company and the deep
experience she gained with QRM, QMS, PAC management and product lifecycle
management, the researcher acknowledges having an insider’s and a practitioner’s
perspective when undertaking this research, thereby making some of this study insider’s
research. The term ‘insider research’ is used to describe research projects, where the
researcher has a direct involvement or connection with the research setting (Robson,
2002), or “insider research is that which is conducted within a social group,
organization or culture of which the researcher is also a member.” (Greene, 2014). An
article by Rooney on the validity of insider research is also useful in this context
(Rooney, 2005).
A researcher’s insider perspective has advantages (pros) and disadvantages (cons);
Greene categorised them as follows (Greene, 2014) and Lipa summarised them
succinctly in his PhD thesis as given below (Lipa, 2021):
•

•

“Pros (advantages):
o Knowledge: Insider researchers often do not have to worry about
orienting themselves with the research environment and/or participants;
they can ask more meaningful questions and better understand the
history and practicality of the research topic.
o Interaction: Insider researchers are more familiar with the group under
study, know how to approach individuals, and are more likely to engage
in discussing issues.
o Access: Insider researchers will know how to gain access and may have
existing contacts within the group under study.
Cons (disadvantages):
o Too subjective: Insider researchers risk having narrow perceptions due
to familiarity and normalisation with the group under study, thus
impacting the ability of the researcher to be objective. In addition, there
is increased risk of assumptions based on prior knowledge and/or
experience.
o Biased: Insider researchers risk bias as the researcher may be
considered too close to the group under study. This bias may influence
study methodology, design, and/or results. Insider researchers must not
fear bias, but must be aware of the potential for bias and take steps to
mitigate it.”
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Specific to this study, the advantages that the researcher’s insider’s perspective lent to
this research included the following:
•

Understanding and knowledge of the vision, expectations, along with the
operationalisation experience, of QRM, PQS and PAC concepts, which
expedited the researcher’s ability to probe further with targeted inquiries

•

Access to a broad network of Operations, Quality and Regulatory Affairs
practitioners in pharmaceutical companies, and to assessors and inspectors in
different regulatory authorities

•

Familiarity and knowledge of risk management and QMSs within and beyond
the pharmaceutical sector

•

Familiarity and deep application and practical operational experience with
QRM, KM, PQS, drug shortages, and PAC management

•

Understanding what approaches had been tried with limited success, and seeking
alternate ways to design the research queries, such as exploring it from the
perspective of a ‘wicked problem’ and systems thinking

It should be noted though that, while still remaining employed in the pharmaceutical
industry, when the researcher started this research study, she was no longer in a role that
involved QMS, QRM or PAC management; instead, she did this research while holding
a position in product CMC development (i.e., prior to product commercialisation), with
no direct involvement in PAC management for commercial products. This allowed her
to have a degree of separation by no longer being active or connected within the
community directly responsible for PAC or PQS management within her company of
employment, or with regulators on PAC submissions, or PQS inspections. Additionally,
being mindful of the potential risk of bias and subjectivity, the researcher mitigated
these through the following means:
•

Utilising a mixed methods approach that incorporated both qualitative and
quantitative data as described in section 3.5

•

Gathering diverse insights and even divergent viewpoints from multiple and
varied stakeholder groups, i.e., Operations, Quality, Regulatory stakeholders
from the industry (those involved in direct execution as well as senior leaders),
regulatory authorities’ assessors and inspectors from a broad range of countries

77

or regions (those involved in direct execution as well as senior leaders), and
academia
•

Utilising a variety of channels to gather data, i.e., conferences, presentations,
focus group sessions, workshops, surveys, interviews, dialogues

•

Utilising an iterative approach to gather input, develop solutions, socialise for
feedback (with each solution being reviewed by 250 - 400 people across the
pharmaceutical sector), collect and adjudicate comments, refine the solutions
before finalisation and publication as peer-reviewed papers. This approach was
particularly important and useful in mitigating the risk of ‘group think’, limiting
bias and promoting further objectivity

In spite of having an insider’s perspective, the researcher approached this study from
neither the pharmaceutical industry nor a regulatory authorities’ viewpoint. The
researcher’s interest for this topic was entirely driven by her broader philosophical
beliefs, purpose and commitment to serve the needs of patients and public health by
creating a space for stakeholders to explore solutions together as opposed to unilaterally
or independent of each other. It was this interest and passion that motivated her to take
on an outsider’s view and utilise the neutral and broader academic research space to
pursue this topic. As such, her pre-research and research work on all aspects of this
topic since 2012 have been independent of the researcher’s employer. Through the
course of the research, she further realised the tremendous value in exploring this
complex ‘wicked problem’ as an academic researcher, as opposed to trying to solve it as
a pharmaceutical industry professional. The researcher’s employer did not influence any
aspect of this research or the researcher’s perspectives, research methods or the results
generated herein.

A Brief History of the Research Questions
The original research proposal for this study was developed utilising the insights gained
from the pre-research work undertaken by the researcher as described in Chapter Two
and Appendix I of this thesis. The research proposal included in the research application
and registration package submitted to TU Dublin was based on the following research
hypotheses:
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1. The increasing complexity of the global regulatory framework for managing
PACs is hindering the objectives of product realization, maintaining a state of
control and driving continual improvement to ensure that safe, high-quality
products are available to patients – it causes a significant time gap between new
knowledge gained for products and processes, and its implementation into daily
operations. Because of this global complexity, companies prefer to maintain
status quo rather than continually improving and innovating their operations;
this eventually results in drug shortages
2. A second hypothesis is - although regulators, industry and patients alike desire
an uninterrupted supply of high-quality products, and all favour innovation and
continual improvement - local solutions, or solutions designed by one
stakeholder population independently, will not resolve this problem
These hypotheses guided the researcher’s literature review and her initial discussions
with various stakeholders in the pharmaceutical industry, regulatory authorities and
academia, specifically TU Dublin PRST members. As work per the research plan
progressed, the overarching goal of the research further solidified to the following:
To accelerate continual improvement and innovation, and reduce global
complexity through science and risk-based transformation of PAC
management – so that the pharmaceutical sector can ensure an uninterrupted
delivery of safe, effective, high-quality medicines to patients.
The research hypotheses were also further refined as follows:
1. The high global regulatory complexity in relation to PAC management
incentivises the pharmaceutical sector to maintain status quo rather than
continually improve and innovate their operations and technologies
2. Without the effective use of QRM and KM to manage the lifecycle of products,
processes and systems within the PQS, the PQS cannot be effective; and without
an effective PQS, it is not possible to “optimise science and risk-based postapproval change processes to maximise benefits from continual improvement
and innovation” in accordance with ICH Q10 Annex 1
3. Without

continual

improvement

and

innovation

post-approval,

the

pharmaceutical sector cannot sustainably ensure the timely and uninterrupted
delivery of safe, effective, high-quality medicines to patients
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The following concepts and associated inquiries were then derived from these
hypotheses:
Concept 1: Drug shortages are a ‘wicked problem’ and the global complexity
associated with PAC management further aggravates this problem.
Associated Queries:
•

What is a ‘wicked problem’ and what are its characteristics?

•

What characteristics make drug shortages a ‘wicked problem’?

•

Why are continual improvement and innovation relevant for drug shortages?

•

What makes the global regulatory landscape complex?

•

Why does the complexity of the global regulatory landscape matter?

Concept 2: A science, risk and knowledge bases within the framework of an effective
PQS are essential for continual improvement and innovation. However, beyond the
high-level concepts stated in ICH Q10 and Q9, there has been little to no practical
guidance on how companies can actually demonstrate the effectiveness of a PQS or on
the application of risk-based application of QRM principles for PAC management.
Associated Queries:
•

What is the relevance of a QRM, KM and PQS framework for PAC
management? Why are they integral for transforming PAC management?

•

What could effective science and risk-based PAC management look like? How
could it be achieved?

•

What is meant by an effective PQS? How could it be demonstrated?

•

How could a science, risk and knowledge bases and an effective PQS facilitate
faster continual improvement and innovation and how could it contribute to
reducing drug shortages?

A third concept that wasn’t envisioned as part of the research plan but that started
emerging towards the later part of this research study linked back to a fundamental
question reflecting on why ICH Q10 and Q9 had had a lack of success in reducing
defects and facilitating continual improvement. Even though ICH Q10 had laid out 16+
years ago a clear quality system model with the following envisioned benefits, why has
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there been limited to no realisation of these benefits; in fact, for some of these, the
situation has worsened?
•
•
•
•
•

“Improved process performance
A reduction in the costs of internal failures (rejects, reworks, reprocessing and
investigations) as the quality systems guideline drives improvement
A reduction in the costs of holding duplicate stock and operating multiple
processes as improvements and changes are made more effectively across all
regions
A reduction in the costs of preparing / reviewing certain regulatory submission.
Enhanced assurance of consistent availability of medicines to the patient.”

This third concept that emerged was as follows:
Concept 3: The concepts laid out in ICH Q9, Q10 and Q12 are not, by themselves,
sufficient for realisation of the desired state and its expected benefits. Standard practical
solutions that are developed in a unified manner by a stakeholder group at a senior
leadership (decision-makers) level, to ensure that they can be implemented in
collaborative and consistent ways within and across stakeholder segments, are the
missing components for success and realisation of the desired state. Associated queries
that might be worth looking into for future research could include the following:
Associated Queries:
•

Even though it was based on the ISO 9001 QMS framework, could the
establishment of a separate ICH Q10 PQS model specifically for pharmaceutical
companies, have inadvertently moved the pharmaceutical sector away from
standardising on concepts and solutions (such as those expected by ISO)?

•

How could standard solutions (such as those resulting from this research study)
and standard certifications of an effective PQS (such as ISO certification of a
company’s QMS system), leap-frog achievement of the vision laid out in the
ICH guidances?

Indeed, the medical device industry has a long history of using and getting certified
against ISO standards such as ISO 13485, Medical Devices – Quality Management
Systems – Requirements for Regulatory Purposes and ISO 14971, Medical Devices –
Application of Risk Management to Medical Devices. In Europe, products sold in the
European Economic Area (EEA) and the European Union (EU) are certified with a CE
mark, an EU Declaration for Conformity to relevant European product directives. It’s
81

worth the pharmaceutical industry considering the adoption of similar harmonised ISO
or CE mark certifications that could drive standardisation of the PQS and realisation of
its envisioned value.
Based on these hypotheses, concepts and associated queries, two final research
questions crystallised; these were as follows:
•

Research Question 1 (RQ1): How can an effective PQS, coupled with product
and process understanding, including QRM, be used to “optimise science and
risk based post-approval change processes to maximise benefits from innovation
and continual improvement”?

•

Research Question 2 (RQ2): How can the pharmaceutical industry be unified
to develop and implement standard practical solutions, in collaboration with
regulatory authorities, for “effective risk-based PAC management within the
PQS”?

Research Study Design, Methodology, and
Methods
Based on the underlying worldview and research questions discussed in the prior
sections, and the insights gained during the course of the research, a mixed methods
approach was determined to be the most suitable research methodology for this study
design. And given the iterative nature of this study, it was determined that a
transformative mixed methods strategy of inquiry would be optimal, as it would allow
the use of both concurrent and sequential exploratory and explanatory qualitative and
quantitative research techniques.
Section 3.4 above describes the qualitative research queries associated with each of the
concepts explored in this study. Given the complexity of the research topic and
consideration of the multi-stakeholder perspectives, the two central research questions
RQ1 and RQ2 were intentionally designed to be broad in their inquiry so as to explore
the complex set of factors surrounding the central phenomenon of drug shortages as a
‘wicked problem’. It was also important to not be limited by the current state, to
presume certain outcomes, or be exclusionary of potentially interconnected viewpoints.
As emphasized in section 3.2.1 above, seeking holistic, interconnected system solutions
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meant that a quantitative design for the inquiries would not provide the appropriate
initial starting point.
Qualitative methods:
Literature review served as the starting qualitative method for this study. As described
in Chapter Two of this thesis, the researcher determined where an abundant literature
basis for this study was available, and where deficiencies existed in published literature,
including the deficiencies that literature resulting from this research study was
alleviating (e.g., the link between global regulatory complexity and inadequate
continual improvement contributing to drug shortages, or demonstrating effectiveness
of the PQS for PAC management).
The mixed qualitative and quantitative strategy of inquiry led the researcher to select
focus groups as the predominant and overarching qualitative and quantitative research
methodology, combined with surveys where deeper quantitative exploration on a
specific aspect was deemed important. The focus group methodology served a threefold purpose in the research study design:
1. To collect practical experiential data, insights, feedback and to facilitate an
iterative review of study deliverables including the design of practical standard
solutions suitable for implementation
2. To generate discussion among participants (from different stakeholder groups)
to surface commonalities and divergent perspectives, to get to aligned
understanding, and to generate unified positions among and between stakeholder
groups on certain topics, such as the standard solutions developed via the 1VQ
for PAC Initiative. This, as described above in section 3.2.1, is at the core of
systems thinking
3. To serve as a communication means in raising awareness and garnering support,
to the extent of creating accountability and ownership of the solutions in order to
ensure their practical implementation and achievement of the desired state
A combination of structured and semi-structured (i.e., open and informal though with
defined objectives) focus groups, and unstructured (formal or informal) philosophical
dialogues with key opinion leaders (KOLs) such as Senior Regulatory Authority
Leaders or Senior Quality Leaders, all moderated or co-moderated by the researcher,
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provided a balanced approach - the unstructured philosophical dialogues or semistructured focus groups provided the appropriate flexibility and space that permitted
participants to voice their genuine, unfiltered perspectives, while the structured focus
groups facilitated the iterative development of the standard solutions that resulted from
this research, or probed into specific topics in order to gain semi-quantitative or
quantitative data. All of the structured and semi-structured focus groups were
conducted with clear objectives, agendas and expected outcomes from each session. The
main difference between the structured and semi-structured focus groups was the level
of open-ended discussion space that was provided for exploratory vs. explanatory
topics. These structured or semi-structured focus groups are described in Chapter Seven
of this thesis. The unstructured philosophical dialogues occurred all through this study
(such as with FDA, PIC/S and KOLs), and these are described in various chapters of the
thesis as relevant to the context and content of those chapters.
Peer review of the standard solutions resulting from this research and their endorsement
by Senior Quality Leaders or regulatory authorities’ bodies such as PIC/S was a crucial
extension of the focus groups methodology. It resulted in each of the resulting standard
solutions being reviewed and commented on by 300-500 expert stakeholders for their
iterative development before they were finalised and published; these stakeholders
being the implementers, users or decision-makers for the solutions.
An unanticipated benefit of the focus groups and peer review methodology was that it
resulted in creating a new stakeholder community through the 1VQ for PAC Initiative,
the Senior Quality Leaders in the pharmaceutical industry. This group was unified via
this research for the first time in realising the significance and public health relevance of
a topic that has been discussed for close to 20 years, yet has remained unsolved.
Quantitative methods:
Surveys were used to collect both quantitative and qualitative data on specific research
questions at various points in the study. They were either administered concurrently
with a qualitative inquiry, or sequentially, after exploration of a broader qualitative
question. Survey conduct and survey results obtained and published during the preresearch work and this research study are described in various chapters of the thesis.
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The structured focus groups also served a second purpose of gathering quantitative
data where this was deemed useful in querying specific aspects of the research questions
or when probing for insights that resulted from the qualitative focus groups or
philosophical dialogues. Some examples of where a structured focus group served a
quantitative data collection purpose included voting on, and prioritising, PAC examples
for development of 1VQ for PAC position papers, assessing the maturity of a company’s
change management system against the PIC/S Recommendation Paper (both described
in Chapter Eight of this thesis), and gathering data from the CQOs on ICH Q10 benefits
realisation.
Table 3.2 below summarises the research design, methodology and methods used to
address the two research questions through each of the research phases as depicted in
Figure 1.10 in Chapter One of this thesis:
Table 3.2: Research Design, Methodology, and Methods Used
Research Phase

Methodology

Phase 0: Pre-research

Phase 1: Problem definition
Phase 2: Exploring the
‘Wicked Problem’ and
Regulatory Authorities
Positions
Phase 3: Bringing the
Pharmaceutical Industry
Together – to establish 1VQ
for PACs

Concurrent and
sequential mixed
methods (Qualitative
and Quantitative)

Systems thinking-based
design

Phase 4: Exploring and
Developing Practical Science
and Risk-Based Solutions
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Methods
•
•
•
•
•
•
•
•

Philosophical dialogues
Semi-structured focus groups
Surveys
Peer reviews
Literature review
Surveys
Philosophical dialogues
Semi-structured focus groups

• Literature review
• Philosophical dialogue
• Semi-structured focus groups
• Philosophical dialogue
• Surveys
• Semi-structured and structured
focus groups
• Peer review
• Philosophical dialogue
• Semi-structured and structured
focus groups (for iterative
solutions design)
• Peer review

• Philosophical dialogue
• Surveys
• Semi-structured and structured
focus groups
• Peer review
• Case studies
Suggested: transformative mixed
methods that facilitate co-creation of
systems-based solutions and new
ways of working across
stakeholders’ and subsystems

Phase 5: Application to
Specific PAC Example Case
Studies

Phase 6: Impacts and Future
Opportunities

After identification of the initial research methodology, the researcher applied for ethics
approval from the TU Dublin Research Ethics and Integrity Committee, as discussed in
the next section.

Research Ethics and Privacy
Research ethics and Integrity was approved, and all research activities were conducted
in accordance with TU Dublin's Code of Conduct for Ensuring Excellence in Research
Integrity (TU Dublin, no date).
Specifically, the researcher:
•

Requested the senior-most Heads of Quality, the CQOs, in global
pharmaceutical companies to identify participants for the focus group sessions
held during the course of this study. As participants were selected and informed
by their senior management to represent their respective companies in the focus
group sessions, no additional consent forms were deemed necessary.

•

The researcher did not (and will not) have any power over any of the involved
research subjects, each of whom was selected by their respective pharmaceutical
companies and agreed voluntarily to participate. The researcher did not have any
influence over who the CQOs selected to represent their companies in the focus
groups.

•

Agendas with topics for discussion were disclosed in advance of the focus group
sessions and any information captured from those sessions, which included
outputs, outcomes, decisions and agreements were sent to all participants for
their review and comments prior to finalisation; these were additionally sent to
the CQOs of the 1VQ for PAC member companies.
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•

Any publications that contained content developed or contributed through the
focus group sessions were reviewed by all participants, their companies, and
endorsed by the CQOs for those companies prior to publication.

•

All electronic information for this study, including participant information and
company information, were captured on a non-shared computer, handled and
stored in a secure, password-protected location, with the password being
encrypted and known only to the researcher. No recording devices were used.

•

Though actively employed by Genentech/Roche, a private pharmaceutical
company, neither the researcher nor her employer had any financial interest or
material benefits resulting from this research study. There were no direct or
indirect conflicts of interest, as the research intended to contribute to improving
public health and the pharmaceutical sector as a whole.

The researcher also undertook formal Research Integrity Training sponsored by TU
Dublin and received competency-based certificates for the domains of Natural and
Physical Sciences and Biomedical Sciences. Those modules train researchers on their
responsibilities and on how to handle complex issues that can arise while planning,
conducting, and reporting on their research.
Part Two of this thesis, Chapter Four and Chapter Five, investigate drug shortages as a
global ‘wicked problem’ and examine the responses to it from the pharmaceutical
sector. This sets the stage for the next part, Part Three, which explores the positions of
various regulatory authorities on the topic of this research.

87

Part Two: Recognition of Drug Shortages
as a Global Problem and the Need for
Global Solutions
Part Two frames drug shortages as a global problem, by exploring what makes it
global, its detrimental consequences especially for patients, and therefore, why a
response to it, and the resulting solutions must be global. It includes the following:
•

An investigation into the term ‘wicked problem’, and what makes drug
shortages a ‘wicked problem’ specifically through the lens of post-approval
changes and in the context of insufficient continual improvement and innovation
(Chapter 4).

•

How regulatory authorities and the pharmaceutical industry have responded to
this ‘wicked problem’ thus far (Chapter 5).
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A ‘Wicked Problem’ – Drug Shortages in
the Context of Inadequate Continual
Improvement and Innovation
Medical and pharmaceutical science continue to make incredible advances in
discovering, developing and launching new therapies for unmet medical needs, and
transform patient survival and quality of life. Delivering safe, effective, high-quality
products to patients remains paramount – therefore both regulators and pharmaceutical
companies must continue to strive for high standards to safeguard public health.
However, drug shortages have continued to become a growing global problem (Gray
and Manasse, 2012; WHO, 2016c) resulting from a complex set of potential causes
related to economic, business, manufacturing, quality, supply chain issues and
increasing regulatory complexity (Birgli®, 2013; EAHP, 2018; AESGP et al., 2019;
ASHP, 2021). Many of these causes might even be the first of the causes (and not the
ultimate root cause) if a Five Whys technique (Serrat, 2017) were to be applied as
described in Chapter One, section 1.2.2 of this thesis Drug shortages have increased in
frequency, severity and duration (Van Roey and Haxaire, 2008; WHO, 2016d; EAHP,
2018; EIU, 2018). Per the EAHP survey across 38 countries, the latest data from 2018
on the average duration of shortages in Europe was 2.2 months, with the maximum
shortage duration reported being 13.2 months; in 2014 the survey showed that the
maximum shortage duration had been 9.3 months. The 2018 survey also documented
many examples of shortages up to 1 year, 2 years, 3 years or even longer, and it
provided other statistically significant evidence that the problem of shortages has been
increasing (EAHP, 2018). Over the last decade, regulators, legislators, healthcare
providers and the pharmaceutical industry have made many efforts to ensure the
uninterrupted supply of safe and efficacious products to patients; however, these efforts
have not been effective in preventing drug shortages as can be seen by the continued
high number of shortages at the pharmacy and/or patient level (EAHP, 2018; ASHP,
2021). ASHP provides data on national shortages in the US from January 2001 through
June 2021 shown in Figure 4.1, and while the shortages reduced from 267 in 2011 to
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166 in 2019 and to 129 in 2020 (ASHP, 2021), it is still premature to conclude this as
evidence of a sustainable downward trend. A downward trend would still not be good
enough for patients; the objective should be close to zero drug shortages.

Figure 4.1: National Drug Shortages in the US (January 2001 – June 2021)
(ASHP, 2021)
ICH Q9, Quality Risk Management, defines patient harm as:
“Damage to health, including the damage that can occur from loss of product
quality or availability.”(ICH, 2005c)
It is not sufficient only to make safe, effective, high-quality medicines - being able to
sustain a reliable, uninterrupted and timely supply of these medicines is equally
fundamental to patient care. While the researcher does not have any data to corroborate,
her opinion is that in the event of shortages, patients likely have to switch to an alternate
if one is available in their country (alternatives are not available for many life-saving or
life-sustaining drugs), or have to go without.
Timely and sustained availability of medicines to meet the needs of patients is expected
by all regulatory authorities, and is also required by legislation in many countries, such
as Europe’s Article 81 of Directive 2001/83/EC which states that:
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“The holder of a marketing authorisation for a medicinal product and the
distributors of the said medicinal product actually placed on the market in a
Member State shall, within the limits of their responsibilities, ensure
appropriate and continued supplies of that medicinal product to pharmacies and
persons authorised to supply Medicinal products so that the needs of patients in
the Member State in question are covered.” (European Commission, 2001)
However, in spite of significant efforts from regulators, legislators and the
pharmaceutical industry, the global issue of drug shortages has yet to be resolved. The
researcher contends that this is likely because solutions are still sought for mostly at a
local or regional level and still inclined towards more oversight of or requirements for
the industry, as opposed to seeking new, alternate and collaborative ways where
stakeholders come together with a systems-based mindset to jointly solve a problem.
This chapter provides a brief background on drug shortages and its context and
relevance for this research study.

Exploring a ‘Wicked Problem’
In the 21st century healthcare environment, patients should expect that medicines have
the right level of quality, and that they are safe, effective and available. Yet there are an
increasing number of stock-outs for medicines, mostly antimicrobial agents, preventive
medicines (vaccines), and oncology medicines, including critical medicines (EAHP,
2018). In the US, shortages for sterile injectables have remained high, ranging from 3973% of injectable and non-injectable medicines (ASHP, 2021). Though there is no
harmonised definition or classification for critical medicines, as the importance of a
product may vary by country based on factors such as availability of alternate
medicines, disease situation, national control programs, etc., the EMA identified two
criteria for defining a product as critical: therapeutic use (i.e., it is integral for treatment
or prevention of life-threatening or irreversibly progressive disease or without which
public health would be severely harmed) and availability (of alternatives) (EMA, 2016).
As the researcher explored the topic of drug shortages in depth, it became evident that it
is a highly complex issue that could not be solved only by pharmaceutical companies
and regulators; indeed, even defining the problem and its scope was difficult due to the
many interdependencies it had across economic, business, supply chain, policy,
regulatory and legislative considerations.
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In 2016, Vinther in an article published in the PDA Letter contended that drug shortage
is a ‘wicked problem’ (Vinther, 2016). This led to the researcher exploring the
definition and examples of a ‘wicked problem’, including learnings from other ‘wicked
problems’ that could be leveraged to solve the drug shortage situation.
As noted earlier, a ‘wicked problem’ was first defined as a problem highly resistant to
solutions, by Rittel and Webber in 1973 (Rittel and Webber, 1973). These are highly
complex problems that cannot be well-defined, do not have easily defined solutions, and
cannot be solved by any one group of people. Examples of wicked problems include
climate change, obesity, poverty, hunger, sustainability and, biodiversity loss.
With the increasing dialogue across the healthcare sector on pricing and access
(Birgli®, 2013; Woodcock and Wosinska, 2013; Stomberg, 2016; WHO, 2016c) for the
healthcare sector, and recognising that the problem is highly complex and highly
resistant to solutions, the researcher asserts that affordable global access to medicines is
indeed a ‘wicked problem’. This chapter describes the characteristics that make drug
shortages a ‘wicked problem’, and why in spite of sincere and focused efforts by
different stakeholder groups, it has yet to be resolved. It also expands on the complexity
of stakeholder groups and where collaborative and complementary efforts might be
essential. Finally, it delves into the global regulatory complexity that exists and
discusses how this might be an aggravating factor in addressing the ‘wicked problem’ of
shortages. This component of the research set the foundation and led to a deeper
exploration into one of the many contributing factors to drug shortages - namely the
global complexity and long lead times for continual improvement and innovation in the
manufacturing, testing and supply of products to patients. Indeed, it was found that this
complexity eventually, even if indirectly, resulted in the unintended and undesired
consequence of drug shortages.
During the course of this research the COVID-19 pandemic presented an unexpected
serious crisis that challenged pharmaceutical companies and regulators alike in making
life-saving decisions for patients in unprecedented ways. The global impact of COVID19 has demonstrated that diseases know no borders, and solutions to fight such diseases
must be global. Opportunities to learn from and adopt new ways of working have
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emerged from the crisis; these should be integrated into transforming how patient needs
are met post-pandemic, by making products available with the highest sense of urgency.

The Characteristics of Drug Shortage that Make
it a ‘Wicked Problem
Drug shortages present all the characteristics of a ‘wicked problem’ that Rittel and
Webber articulated as depicted in Figure 2.5, Chapter Two of this thesis, and as first
described by Vinther in an article in 2016 (Vinther, 2016). The following aspects make
drug shortage a ‘wicked problem’:
•

Every problem is unique and is difficult to clearly define:
For drug shortages: in spite of attempts by EMA and WHO (WHO, 2016d), there is
still not a single unified definition of a shortage that could be agreed upon by all
stakeholders. WHO identified at least fifty-six known definitions of shortages depending on what aspect of the supply chain they addressed (e.g. at the
manufacturing level, distribution centre level, pharmacy level, or patient level), or
based on timeframes or durations, or varying levels of specificity, or
interchangeable terms (e.g., shortage, unavailability, disruption of supply,
interruption of supply etc.), or based on the demand side of the system (e.g., at
healthcare facilities) (WHO, 2016d). The criticality and patient impact of a shortage
varies, and therefore the level of risk, nature of solutions, and attention to resolution
could vary broadly. Stakeholders may agree on the nature of the problem and the
importance of addressing it, but they may not always all agree on how to solve it.
This is evident through the extensive and ongoing discussions on drug shortages that
have taken place over the years as described in Chapter Five of this thesis.

•

Often

the

problem

is

multi-causal

with

interdependencies

and

interconnectedness:
For drug shortages: the causes can range across economic (e.g., price cuts, spend
reductions, reference pricing, payment delays, tendering), business (e.g., reduced
product introductions, parallel distribution, tight payment terms, market access and
withdrawals, market quotas) and manufacturing and supply chain (e.g.,
manufacturing or quality issues, just-in-time supply chain, legislation change,
channel strategy) (Birgli®, 2013; AESGP et al., 2019). Often the cause-effect
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relationship is difficult to determine or demonstrate and every drug shortage
situation can be considered a symptom of another problem. It is also possible to
explain the drug shortage problem and its causes in many different ways, sometimes
such that different stakeholders have a different understanding of the problem, its
causes, and possible solutions. Each shortage event is different and can present a
unique set of causal events with varying interdependencies in each country or
region, and therefore may need to be dealt with differently with different
stakeholder

groups,

in

different

countries.

Additionally,

there

is

an

interconnectedness across various issues and causal events which makes each
stakeholder view their understanding of the problem and its solution as the correct
one, based on the objectives of their organisation. The pharmaceutical industry (via
the 1VQ for PAC Initiative) has stated that the global regulatory complexity
associated with medicines is a key contributing cause for drug shortages (Vinther
and Ramnarine, 2019a), while regulators often take the position of manufacturing
and quality issues as a key cause for shortages (EMA, 2012; FDA, 2019). Each
stakeholder tends to see and act to solve the problem in a linear manner from their
own perspective.
•

The problem has multiple stakeholders, cannot be solved by any one group:
Solving a wicked problem is rarely the responsibility of one stakeholder. Often the
stakeholders are dispersed with conflicting agendas such that getting to a shared
understanding of the problem itself becomes difficult.
For drug shortages: manufacturers, MAHs, regulators, suppliers, wholesalers,
distributors, hospitals, pharmacies, patient advocacy groups, and policy makers all
play a role, depending on the nature and extent of the shortage. Addressing the issue
of shortages therefore, must cut across a range of organisational and disciplinary
boundaries. Often adequate communication channels do not exist between and
across all these stakeholder groups, making it extremely hard to coordinate, design
and implement joint, collaborative or integrated solutions. The need to work across
stakeholders has been recognised, for instance by WHO (WHO, 2016c) EMA
(EMA, 2013, 2015a, 2018) and the Economist (Boshnakova, Karnad and Pannelay,
2017). Though the various stakeholders have attempted to address the problem of
shortages, most have assessed it either only locally or regionally, from their specific
perspective (e.g., regulators within their jurisdiction, pharmaceutical companies
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from an industry viewpoint, or supply chain players from their perspective), or with
a subset of other stakeholder groups (EMA, 2018; AESGP et al., 2019). In spite of
the various EMA multi-stakeholder workshops, the opportunities to design joint
solutions did not materialise to the extent needed, as evidenced by the continued
efforts to solve the shortage issue. With the EMA Drug Shortage Inter-Association
Task Force’s body of work, described in Chapter Five, section 5.3.3 of this thesis,
the collaboration was limited to pharmaceutical industry association groups; it did
not extend to joint solutions with the other stakeholder segments and therefore, in
the researcher’s opinion, fell short of what was truly needed to address this ‘wicked
problem’. Additional attempts should be made to set up multi-disciplinary, crossstakeholder efforts similar to the ones EMA (EMA, 2013, 2015a, 2018) and WHO
(WHO, 2016d) attempted, but broader, bolder, more inclusive, innovative and
disruptive in its scope and vision. To this end, instead of discussing what other
stakeholder groups could do the 1VQ for PAC Initiative co-led by the researcher and
described in Chapter Seven of this thesis, focused on actions the pharmaceutical
industry could take without waiting for other stakeholders to do their part.
•

The problem is often not stable:
For drug shortages: managing through a shortage situation can be highly dynamic
and sometimes unpredictable, making it difficult if not impossible at times, to lay
out a clear, well-structured plan in advance, based on past learnings and
experiences. Even where a plan may have been put in place proactively, the
researcher’s experience has been that it was typically not straightforward to execute
as designed, because of the diversity of the causes, implications, and varying
potential solutions for each shortage situation. Additionally, because every shortage
situation was often unique with typically no precedents, prior experience with a
previous shortage offered little value if any, in resolving a new shortage event.
Opportunities to learn by trial-and-error tend to be limited at best, making any
solution a ‘one-shot’ operation, as termed by Rittel and Webber. This became
particularly evident with the COVID-19 pandemic where exceptional processes such
as EU’s Exceptional Change Management Process (ECMP) or FDA’s Emergency
Use Authorization (EUA), described later in Chapter Ten, section 10.1.1 of this
thesis, had to be put in place or activated as the regulatory frameworks for PAC
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management were not agile enough to adapt to sudden changes in medicine
demands.
•

No clear solution to the problem:
For drug shortages: this problem has existed for 15+ years and has been
acknowledged as a growing issue for almost as long. If a simple solution were
obvious and possible, it would have been implemented already. It is clear that given
each shortage problem can be unique, a solution that could resolve a shortage in one
situation might not work in another; hence the term ‘one-shot operation’ used by
Rittel and Weber, meaning there is no opportunity to learn by trial-and-error.
Depending on the causal events, criticality, level of impact, local requirements,
possible mitigating or aggravating factors, the solutions for a shortage may vary
greatly. Solutions are not right or wrong, rather they are better or worse; and the
determination of better or worse becomes a judgment call that is based on the
perspective of one stakeholder versus another. There is usually no ultimate or
immediate test of the ‘goodness’ or ‘effectiveness’ of a solution for the wicked
problem of shortages. In fact, it is usually impossible to find a single solution for a
‘wicked problem’ like shortages, that meets the needs of all stakeholders. The
problem must be addressed globally, but the solutions are unlikely to be global, in
terms of ‘one size fits all’. It can also take a long time to determine whether a
solution has made things better or not. There is no way to know if a solution is final
and therefore, the search for a solution cannot stop (also called by Rittel and Webber
as the ‘no stopping rule’ (Rittel and Webber, 1973)). Given these challenges, the
effort to find solutions needs to be elevated to another level and systems thinking
needs to be applied, as has been initiated by this research including the 1VQ for
PAC Initiative described in Chapter Seven of this thesis.

•

Attempts to address the problem often leads to unforeseen consequences: Each
solution can have ramifications that may extend beyond the anticipated or foreseen
implications. Some consequences may be irreversible and may even manifest over
an extended period of time.
For drug shortages: the supply chain is global but supply management and
oversight at the regulatory authority level is still national. An example is legislation
or regulatory requirements being set by each country or region to deal with the issue
of shortages within their specific scope – this has led to an exponential increase in
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regulatory complexity for global pharmaceutical companies which then struggle to
meet and comply with all local and regional expectations that vary greatly by
country or region, in order to make product available. Solving a drug shortage in
one country might lead to issues in other countries. The unintended consequences of
a regulation being put in place might not be recognised until years later. As another
example, the EU variations regulations while well-intended and clear in their
objectives, caused a significant discord and challenge during the development of
ICH Q12, Technical and Regulatory Considerations for Pharmaceutical Product
Lifecycle Management. After extensive discussions, an allowance for regional
requirements had to be included in the published ICH Q12 guidance as follows,
leading to a widespread concern that the guidance would not help reduce the global
regulatory complexity to the extent needed:
“Use of Q12 tools is not intended to change the responsibilities for the holder of
the referenced information, the MAH or the regulatory authority. For example,
the holder of the referenced information has a responsibility to report relevant
drug substance changes to the MAH referencing their submission, so that the
MAH can assess the impact of the change and report any related changes to the
approved MAA, as necessary and per regional requirements.” (ICH, 2019)
Significant resources and effort within the supply chain and regulatory functions in
a pharmaceutical company need to be dedicated simply to navigate and manage
through the complexity presented by implementation of local and regional solutions,
without adequate consideration of the global impact. The complexity has become
severely constraining for manufacturing and supply chain operations (Vaccines
Europe, 2016). Instead of improving the availability of medicines, it has been
getting in the way of making products available, as evidenced by the conflict
between the initial draft of ICH Q12 and the EU variations regulations. With the EU
variations regulations being legally binding, the ICH Q12 language had to be
modified in order to avoid being contradictory to those regulations.
•

The problem is socially complex:
For drug shortages: beyond the direct implications for patients, the multi-causal
nature and multi-dimensional impacts associated with shortages, makes it a problem
that affects society’s overall well-being. Because the players involved are so widely
dispersed, and because society’s infrastructural or organisational elements are not
designed for those players to come together in solving the issue in a collaborative or
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integrative manner, the problem is socially complex and difficult to handle in spite
of all stakeholders desiring to invest in solving the problem. An example is related
to the distribution of COVID-19 vaccines – according to Our World in Data, that
focuses on research and data to make progress against the world’s largest
problems, as of 9-September-2021, 41.3% of the world population has received at
least one dose of a COVID-19 vaccine, but only 1.9% of people in low-income
countries have received at least one dose of a vaccine (Our World in Data, 2021).
Effective inclusion and involvement of patients and patient advocacy groups in
solving the drug shortage problem is further needed.
•

Solutions to the problem involve changing behaviours:
Traditional ways of working or solving a problem most often do not work for
wicked problems. Seeking alternate, new and often transformative ways of working
is often necessary.
For drug shortages: working beyond and across organisational boundaries, with a
systems thinking worldview is essential to solve this problem as described in
Chapter Three, section 3.2.1 of this thesis. Innovative, adaptive and flexible models
are needed that require everyone involved in managing shortages to change their
mindset and behaviours. This also includes having the willingness and courage to
cross organisational and disciplinary boundaries, establish processes, resourcing,
infrastructure and tools that are capable of cutting across and beyond local or
regional requirements, and giving up local or regional practices for the sake of the
greater global good. This requires building trust, transparency, and establishing or
opening up communication channels between stakeholder groups where they might
not exist. As an illustration, when patients in a country such as Vietnam or Kenya
are impacted by a shortage, stakeholders in other countries such as the US or
Germany would need to care and work with them to make the medicine available to
patients in Vietnam and Kenya, just as much as they would to make it available to
patients in their own countries. For behaviours to change, the solutions need to be
driven and owned by those whose behaviours must change. This is not an easy
mindset barrier to overcome, and tools beyond the traditional ones of legislation,
regulations, local policies etc., are needed to drive such cooperative behavioural
changes.

•

The problem can be resistant even to policy solutions:
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For drug shortages: the problem is global, but in the current state, policy
approaches are typically national or regional. The supply chain will likely always be
driven by economic and geopolitical factors. It is important for governments and
policy makers to recognise and advocate the need for policy changes first at a
country or regional level and then at the global level. Short-term solutions are less
likely and commitment must be made towards longer-term strategies and sustained
efforts, in spite of uncertainties and the inability to prove effectiveness of any
actions taken in the short to medium term. A good and recent example is the
PQKMS strategic initiative launched by ICMRA as mentioned in Chapter One,
section 1.2,1 and described in Chapter Six, section 6.5 of this thesis. Policy makers
also need to be open to taking learnings from others, and adopting innovative
measures that others might have implemented. Failures in policies should be viewed
as learning points resulting in a willingness to learn, adapt and try something
different.
As described above, drug shortages demonstrate the characteristics of a ‘wicked
problem’, thus one should not expect this global issue and ‘wicked problem’ to be
solved in the near-term no matter how intensive the efforts and investment might be. It
is for this reason, in spite of the right intent and efforts from various regulatory
authorities such as EMA, FDA, WHO and the pharmaceutical industry, society and
patients as a whole have continued to struggle with unreliable medicines’ access.
Dialogue, shared understanding, collaboration and shared commitment from all
stakeholders are essential to addressing the ‘wicked problem’ of shortages and
achieving the common objective of ensuring reliable and sustainable availability of
medicines for patients.

Relevance of Drug Shortages to this Research
Study
Most pharmaceutical companies have been challenged with managing drug shortages,
many of which may be due to causes beyond the scope and control of the MAH
(Birgli®, 2013; AESGP et al., 2019). It is the researcher’s belief that drug shortages due
to manufacturing and/or quality issues can and should be proactively anticipated and
prevented by manufacturers and MAHs. In general, drug shortage management has
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primarily been reactive in that, companies and regulators do not typically have drug
shortage plans and therefore deal with shortage crises as and when they arise. This
severely limits the options that might be availed of to mitigate a shortage situation,
simply because of time pressures, a lack of visibility, poor communications and timely
access to all stakeholders and solutions that might be possible to resolve a shortage.
Several parallels can be drawn between drug shortage prevention planning and business
continuity planning, and between drug shortage response planning and crisis
management planning – drug shortage prevention planning would enable the prevention
and reduction of shortages, and also lead to better and faster response in the event of a
shortage, with quicker recovery to normal state.
The researcher proposes that an underlying premise to make this possible is for
companies to effectively use and apply QRM as intended by ICH Q9, to proactively
identify, assess and control risks in their manufacturing and supply operations before
the risks materialise and impact a company’s ability to reliably supply products to
patients. Furthermore, the researcher asserts that QRM and KM must be the
foundational basis for such shortage prevention and response planning. The limited
guidance in ICH Q9 on addressing product availability issues, resulted in Dr Kevin
O’Donnell developing in 2018 a proposal to revise ICH Q9 in order to expand on the
importance of using QRM to address product availability risks among other topics
(ICH, 2020). An ICH Q9 EWG with O’Donnell as the Rapporteur is currently working
on this revision to ICH Q9.
As stated in Chapter Two, section 2.2 of this thesis, from 2012-2014, the researcher led
the development and publication of PDA Technical Report 68, which is further
described in Chapter Five, section 5.3.4 of this thesis. That Technical Report identified
aging (or obsolete) facilities, equipment and technology as one of the causes of drug
shortages, because older assets may not be able to meet current standards and
performance expectations to deliver the required product quality attributes, or simply
because they breakdown often leading to quality issues. Continual improvement and
upgrades to facilities, equipment, processes and methods lower the risk of failures and
their resulting quality issues. The Technical Report emphasized the importance of
continual improvement and innovation as essential for lifecycle management. It also
acknowledged that continual improvement can be slow with very limited or no
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incentive for companies to innovate and improve because of the global regulatory
complexity for the approval of changes, even when they reduce potential risks to
product quality, patient safety and drug shortages.
As a follow-on to the work on PDA Technical Report 68, the researcher explored the
current global PAC landscape and what could be done to expedite PACs even though
regulatory processes may take a long time to harmonise. In the report, the researcher
articulated ways that companies could use enhanced and prospective science and riskbased approaches for specific types of changes to expedite approval and implementation
of PACs. It was further proposed that a company’s PQS should be used to manage more
changes in order to implement changes faster to mitigate the risks of drug shortages
caused by aging facilities, equipment and processes.
All of this formed the basis for this research study into the use of an enhanced science
and risk-based approach and an effective PQS for the management of PACs. The
subsequent parts of this thesis present the researcher’s view on why regulatory
authorities and the pharmaceutical industry need to develop standard solutions in this
area and the interactions that are important between these two stakeholder groups.
Those standard solutions when implemented, should result in more effective and more
timely PAC management in order to ensure reliable and timely supply of quality
medicines to patients.

Complexity of the Global Regulatory Landscape
and Why it Matters?
The global regulatory landscape has continued to become increasingly diverse and
complex over the past 15 years, with regulatory authorities further developing their
national and regional regulatory frameworks, becoming more advanced in their
requirements, and increasing their level of expectations from MAHs. Getting a PAC
approved globally by all countries where a product is filed takes a long time, sometimes
several years. The regulatory framework for PAC management is simply not capable of
reacting with agility to implement changes that enable continual improvement and
innovation even where such changes can reduce risks to patients. In general, the
increased rigor and scrutiny is well-intentioned and justified given the diversity and
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complexity of pharmaceutical advances, and the range of maturity in quality mindset,
systems and processes that regulatory authorities usually experience across the
pharmaceutical industry. This causes them to have to sometimes establish requirements
or regulations that are aimed at the lowest common denominator as opposed to ones that
reflect more advanced positions. An example of this is animal testing being required in
China to release every batch of product even when better test methods might already be
a part of the product control system.
A useful research study which illustrates this complexity was carried out by the
Economist Intelligence Unit (EIU); it is discussed in section 4.4.1 below, giving some
understanding of the current regulatory landscape, and the implications it might present
in the context of drug shortages and PACs.

4.4.1 Economist Intelligence Unit (EIU) Drugs
Shortages Research
In 2017, the EIU published a report on Cancer Medicines Shortages in Europe
(Boshnakova et al., 2017). The EIU, established in 1946, helps businesses and
organisations understand how the world is changing, what risks and opportunities are
present, and how to manage them. EIU Healthcare does this through customised and
evidence-based research, market intelligence and analysis to help healthcare
organisations deliver better value products and services, and manage sustainably and
successfully for the future.
This independent research by the EIU on cancer medicines shortages in Europe,
commissioned by the European Society for Medical Oncology (ESMO), explored
current European policy and regulatory frameworks for medicines supply. It resulted in
EIU making six policy recommendations for countries in Europe to prevent and manage
cancer medicines’ shortages. These recommendations were in line with FDA and
EMA’s work on drug shortages and were as follows (Boshnakova et al., 2017):
1. Introduce legislation for early notification requirements for medicines shortages
2. Establish strategic plans for medicines shortages
3. Develop catalogues of shortages
4. Develop essential medicines lists and assess the risks for shortages
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5. Introduce incentives for production infrastructure improvements
6. Establish procurement models designed to prevent medicines shortages
They published an additional research report in 2017 titled Addressing Medicine
Shortages in Europe (Boshnakova, Karnad and Pannelay, 2017) that was supported by
Medicines for Europe. Development of policies that ensure maintenance of fair
economic conditions was noted as key for reduction of shortages. It also emphasized the
importance of all stakeholders – competent authorities, manufacturers, wholesalers,
parallel distributors, pharmacists, clinicians and patients, in together creating a shared
vision and taking collective actions to address the problem of drug shortages. The
research involved interviews across this broad segment of stakeholders, including the
generic and innovative pharmaceutical industry representatives, and patient groups. The
research identified several actions that reiterated the importance of having a common
definition of medicine shortages, implementing early notification requirements, and
establishing a system that promotes transparency of shortages at a national level. One of
the actions it specifically identified was “Enhance the efficiency of regulatory
procedures and implement fast-track processes to mitigate acute medicine shortages.”
However, it was interesting that the topic of global regulatory complexity did not
feature in the EIU research.
Global regulatory complexity had started to emerge as a topic worthy of deeper
exploration in the context of the researcher’s drug shortages work with the PDA PAC
iAMSM Task Force, as described in Chapter Seven, section 7.1 of this thesis. The
researcher was keen to understand why it did not feature anywhere in the EIU report,
whether the EIU had researched the topic of global regulatory complexity as part of
their work, and if so, what were its findings. To this end, the researcher and Vinther
contacted the authors of the EIU report, Anelia Boshnakova (Senior Information
Specialist and the main project researcher), Annie Pannelay (Principal for Healthcare
and senior advisor for the project) and Aditi Karnad (Senior Healthcare Analyst) to
understand the scope and extent of their work. EIU acknowledged that since their scope
was focused on the EU, which has a common regulatory framework for all companies in
the EU, they had not delved much into the topic of global regulatory complexity. EIU
also acknowledged the high complexity and multi-faceted nature of the drug shortages
problem, true to the characteristics of a ‘wicked problem’, and they agreed to research
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the link between global regulatory complexity and drug shortages, as a new and
independent segment of their work on drug shortages.
The researcher and Vinther developed a proposal for PDA to commission the EIU to
perform an independent research study into global regulatory complexity, and that study
was initiated in late 2017, continuing through the first half of 2018. The hypothesis for
that research was that:
Complex regulatory processes that are long and can vary greatly between
countries, can result in long lead times to implement variations, thereby creating
numerous challenges for sustaining the supply of medicines.
The objective of the study was to explore the link between complexity and diversity of
regulatory requirements for PACs and drug shortages. The EIU research included a
literature review and interviews with representatives from academia, industry,
regulatory authorities, international organisations and non-governmental organisations.
It assessed the current global regulatory landscape and varying regulatory requirements,
the state of regulatory harmonisation and convergence initiatives, hurdles to achieving
regulatory change around shortages, and opportunities to improve regulatory
harmonisation and convergence. The published report (EIU, 2018) listed the following
six key findings:
1. Medicines and vaccines shortages are a global problem affecting rich and poor
countries alike
2. Causes for shortages are complex, multi-faceted and not well-understood
3. The study found little evidence for the existence of a direct correlation between
the global complexity of regulatory requirements for post approval changes and
shortages; however, it indicated that the complexity could be an aggravating
factor that delays or hinders mitigation actions
4. There is a universal agreement that regulatory convergence and harmonisation
are beneficial to all stakeholders
5. Trust and strong political will are required for harmonisation and convergence
initiatives to succeed
6. Finding a permanent solution for shortages is critical for achieving global health
goals
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These EIU findings were not entirely unexpected given drug shortages are a ‘wicked
problem’ and therefore, it is difficult to draw a direct cause-effect correlation between
global complexity for PACs and drug shortages. The position of various regulatory
authorities and the complexity of the global regulatory landscape is discussed in
Chapter Six of this thesis.

Drug Shortages through the Lens of PostApproval Changes
The EIU research, as discussed in section 4.4.1, resulted in the report Medicine and
Vaccine Shortages: What is the Role of Global Regulatory Complexity for Post
Approval Changes? (EIU, 2018). The research reiterated that there is considerable
regulatory variance, with different countries and regions having their own requirements,
classification systems, reporting categories and processes for review and approval of
PACs. This results in manufacturers having to submit multiple applications, to different
countries or regions for a single PAC, even when the data and scientific basis for the
PAC remains unchanged. Sometimes, different countries require submission of different
data and scientific requirements for the same PAC in some cases, and this can even
mean, for example, additional animal studies or clinical trials (Vaccines Europe, 2016).
It is difficult to explain logically why some countries can accept and approve a PAC
without additional studies or trials, while others require them, even though the risk of
the PAC to product quality and/or patient safety remains essentially unchanged,
irrespective of the country.
The EIU research study (EIU, 2018) included a comparison of approval timelines in
different countries, and found it ranged from 30-90 days for a major change in the
European Union (Lokesh, Gupta and Belagoankar, 2015) to 730 days in South Africa
(Chorley, 2014). The study found that such varying requirements and approval timelines
contribute to making the global regulatory processes highly inefficient, and result in
complex, time-consuming, difficult to manage PAC processes for manufacturers
(Vaccines Europe, 2016). It can also significantly increase challenges when trying to
mitigate a shortage as varying regulatory timescales and complexities increase approval
lead times.
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The EIU report noted that the global complexity increases the risk of errors, can result
in non-compliance with regulatory requirements, and presents a barrier to innovation
and continual improvement, while also increasing the burden on MAHs in terms of
time, resources and costs to develop and submit multiple applications for each country
for the same change. Therefore, while solving the global regulatory complexity by itself
will likely not eliminate drug shortages, it can address and simplify several issues that
directly or indirectly contribute to drug shortages.
The focus of this PhD research study is not as much to solve the problem of a lack of
global regulatory harmonisation or convergence, as it is to explore even in the current
complex global environment, the actions that pharmaceutical companies and regulators
could take to reduce the drug shortage problem through unified leadership-sponsored
science and risk-based approaches, as described in Part Four of this thesis.
This chapter described what makes drug shortages a ‘wicked problem’ and it expanded
on the available evidence which reinforces this assertion. The next chapter then shifts
the focus for the remainder of this thesis to what then has been done, what is in
progress, and what can be done even further to address this ‘wicked problem’.
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Responding to the ‘Wicked Problem’
A patient’s reality due to a drug shortage underscores the fact that, while improving
patient care through medical advances and assuring high quality medicinal products are
important, being able to sustain reliable, uninterrupted and timely supply at all times, is
even more fundamental to patient care and protection. As discussed previously in
Chapter Two, section 2.2 of this thesis, the causes of drug shortages are varied and
regulators have been particularly emphatic that drug shortages caused by manufacturing
and quality issues are common and must be addressed. The researcher proposes that by
exploring in detail why manufacturing and quality issues occur, clear evidence would
emerge indicating that these issues are often exacerbated by 3 key factors, namely:
•

a lack of investment in current technologies and facility upgrades

•

insufficient proactive end-to-end supply chain risk management

•

regulatory hurdles to PACs that limit innovation

Investing in state-of-the-art technologies and facilities, building resilience into the
supply chain, and improving interactions between the pharmaceutical industry and
regulators, are key elements to ensuring reliable supply of safe, effective, high-quality
medicines to patients.
The urgency to address these key elements and develop sustainable solutions has
resulted in increased collaboration opportunities and much-needed dialogue between
regulators, legislators, healthcare providers and the pharmaceutical industry over the
last 5-7 years. The common unifying objective has been preventing drug shortages to
ensure uninterrupted supply of safe, effective, high-quality products to patients. To
achieve this, all stakeholders must explore and develop solutions that will serve the best
interests of patients, and bring patient care to a reliable, sustainable and improved state.
It is not an easy challenge to overcome, but for patients, this a non-negotiable especially
in the case of life-saving, life-sustaining, or medically necessary products.
This research study focuses specifically on the relationship between the pharmaceutical
industry and its regulators, with particular emphasis on developing solutions which can
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be implemented by the pharmaceutical industry. Thus, this chapter describes the
response from regulatory authorities and pharmaceutical companies to the concerning
increase in the ‘wicked problem’ of drug shortages. PDA Technical Report 68 being
fundamental for the exploration of the topic, is also discussed in this chapter.
Before embarking on the details of research-related activities, it is first useful to explore
the role of regulatory authorities in the context of drug shortages and their relevant
activities thus far in responding to drug shortages.

The Role of Regulatory Authorities in the
Context of Drug Shortages
Less than10 years ago, neither the investigation and management of drug shortages nor
addressing product supply issues were a core or routine activity for many regulatory
authorities. Typically, the primary responsibilities of many regulatory authorities
focused on the licensing of medicines, the inspection of manufacturers, MAHs, and
wholesalers, carrying out pharmacovigilance activities, etc. Their responsibilities did
not generally extend to the management of product supplies, nor to resolving supply
shortages. Consequently, the legislation and regulatory processes for drug shortagerelated work was underdeveloped or in some cases, not existent. With the increased
occurrence of drug shortages within the last decade, the role and involvement of
regulatory authorities in resolving and responding to shortages has become more
prominent, given that the primary objective of regulatory authorities is to protect
patients by ensuring the availability of safe, effective, high-quality medicines.
This increase in drug shortages and product supply issues highlighted the importance of
early interactions between a pharmaceutical company and relevant regulatory
authorities when shortage issues arise or are likely to arise. In instances where a
potential supply disruption may have patient impact (e.g., for life-saving, life-sustaining
or medically necessary products), regulatory authorities must be involved as early as
possible in the various aspects of drug shortage management and response activities. In
many countries, it is a regulatory and/or legal requirement that regulatory authorities are
notified by a MAH of a potential drug shortage as soon as one becomes apparent; some
regulatory authorities even go to the extent of specifying the notification timelines.
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Some relevant GMP requirements are provided in the EU directives (European
Commission, 2001), the EU GMPs (EudraLex Vol. 4, 2021), and US FDASIA laws
(FDASIA, 2012).
Early and timely notifications have had a positive impact in reducing shortages, by
enabling manufacturers and regulatory authorities to jointly take steps to reduce supply
disruption (FDA, 2011; European Commission, 2012; EMA, 2019). As identified by the
researcher in PDA Technical Report 68, because the primary goal of regulatory
authorities is the protection of patient health, they should be actively involved in any of
the following for management of a drug shortage issue:
•

Providing oversight of how a company is managing a particular shortage
situation

•

Reaching out to other manufacturers that produce the same or alternate products
to ask them to increase the supply of their product to mitigate the shortage issue

•

Working

across

various

stakeholder

groups

i.e.,

patients,

healthcare

professionals, government agencies that purchase medicines etc., in order to
coordinate actions and responses to a shortage. A pharmaceutical company
usually may not have direct access to or any authority over these stakeholder
groups, and this is where a regulatory authority can play a significant role
•

Ensuring that a company has identified adequate corrective actions to not only
mitigate the shortage at hand, but also prevent a similar recurrence in the future

•

Contributing and enabling an environment and processes that ensure robust
supply chains capable of preventing and rapidly responding to drug shortages

The researcher’s experience is that regulatory authorities typically take a risk-based
approach to addressing shortages that may have an impact on patients in the near or
longer-term. Not all shortages impact patients; many may have no impact at all, and
there is usually no need for regulatory authorities to become involved in those.
Notwithstanding this, regulatory authorities and the pharmaceutical industry both have
an interest in understanding the causes of drug shortages, and proactively identifying
and taking preventive actions.
Identification of which shortage issues may impact patients and which may not, requires
careful analysis on a case-by-case basis; additionally, the situation and its mitigating
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actions may vary from country to country. Robust risk assessments based on current
knowledge of manufacturing and supply processes, understanding of the root or
aggravating cause(s) behind a specific shortage issue, and active and timely dialogue
with regulatory authorities can facilitate risk-based evaluations and decision-making by
the pharmaceutical company and the applicable regulatory authority. These can also
help activate collaborations across appropriate stakeholder groups to quickly resolve a
shortage situation and minimise impact to patients.

Regulators’ Response to Drug Shortages:
Overview of EMA, FDA and WHO Activities
This section reviews at a high level, the activities (primarily prior to the COVID-19
pandemic) that key regulatory authorities such as EMA, FDA and WHO initiated over
the last 10 years as the issue of drug shortages increased. Since this research study was
scoped for the pre-pandemic state and because the pandemic is still ongoing with
learnings, continuing to emerge, regulatory authorities’ responses to mitigate drug
shortages during the COVID-19 pandemic are not included in this section.
Nevertheless, key insights gained thus far from the pandemic in context of regulatory
flexibility provided by regulatory authorities for PAC management to mitigate drug
shortage of COVID-19 medicines, is indicative of progress in the science and risk-based
direction this is being advanced by this research including the 1VQ for PAC Initiative;
therefore, the pandemic-related learnings and insights are discussed in Chapter Ten,
sections 10.1 and 10.2 of this thesis.

5.2.1 EMA Activities
In November 2012, EMA published an EMA Reflection Paper (EMA, 2012) on
medicinal product supply shortages caused by manufacturing or GMP compliance
problems and an Implementation plan 2012-2015 (EMA, 2015b). The Reflection Paper
focused on lessons learned, and identified 10 short- and 3 mid-term actions that could
be taken for the management and minimisation of supply shortages arising from
manufacturing problems and quality defects. The short-term actions included
establishing a catalogue of Centrally Authorised Products (CAPs) requiring
coordination at an EU level, maintaining a public catalogue of current CAP shortages,
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assisting the EU regulatory authorities known as National Competent Authorities
(NCAs) with dealing with certain shortages at the EU level, establishing a procedure for
handling shortages due to quality defects and manufacturing problems, clarifying
reporting requirements for supply restrictions, information sharing on best practices and
risk management strategies, and raising awareness and stimulating industry response
towards improvement. The mid-term actions focused on better and proactive risk
management by MAHs and facilitating a risk-benefit evaluation in the event of a
shortage; the latter was intended to balance between the potential risk of a product
defect versus risk to product availability. The Implementation Plan detailed the
expected deliverables and owners for implementation of the aforementioned short- and
medium-term actions. Two of the outcomes of the EMA Reflection Paper and its
Implementation Plan were that relevant stakeholders were brought together and a Call
to Action was issued to pharmaceutical industry associations. The Call to Action
resulted in the establishment of a pharmaceutical industry Inter-Association Task
Force, which comprised of representatives from the pharmaceutical industry
professional associations and trade associations. The researcher was invited to be a core
member of this Task Force because she was leading the PDA Drug Shortage Task Force
and because of her QRM and risk-based application experience and together with
Vinther, she represented PDA on the Inter-Association Task Force. The composition of
this Inter-Association Task Force, its charter, and the body of work commenced and
completed is elaborated upon in section 5.3.1.

5.2.2 FDA Activities
During the period January 2010 to September 2011, FDA had successfully prevented
137 drug shortages (FDA, 2011); however, prescription drug shortages continued to
threaten the health and safety of the American public. On 31-October-2011, President
Obama signed an Executive Order (The White House, 2011) directing the FDA to:
•
•

“take steps that will help to prevent and reduce current and future disruptions in
the supply of lifesaving medicines.”
“use all appropriate administrative tools including authority to interpret and
administer the reporting requirements in 21 U.S.C. 356c, to require drug
manufacturers to provide adequate advance notice of manufacturing
discontinuances that could lead to shortages of drugs that are life supporting or
life sustaining, or that prevent debilitating disease.”
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•

•

“take steps to expand its current efforts to expedite its regulatory reviews,
including reviews of new drug suppliers, manufacturing sites, and
manufacturing changes, whenever it determines that expedited review would
help to avoid or mitigate existing or potential drug shortages. In prioritizing and
allocating its limited resources, the FDA should consider both the severity of the
shortage and the importance of the affected drug to public health.”
“communicate to the Department of Justice (DOJ) any findings that shortages
have led market participants to stockpile the affected drugs or sell them at
exorbitant prices.”

In conjunction with the Executive Order, the FDA also accelerated its focus and efforts
on addressing drug shortages in the US. In 2011, it published a comprehensive review
on its approach to managing drug shortages, A Review of FDA’s Approach to Medical
Product Shortages (FDA, 2011). The report concluded that drug shortages were a
complex problem resulting from interconnected economic, legal, regulatory, policy and
clinical factors. It also described the actions FDA was taking to prevent drug shortages
before they occurred, in addition to actions it was taking in response to drug shortages
once they had occurred. It further provided recommendations on immediate and longerterm actions to improve FDA’s internal processes to prevent and mitigate shortages.
Activities working with manufacturers to prevent and mitigate shortages by each of the
FDA’s divisions were elaborated upon in the report.
The impact of early notification to FDA of a potential supply disruption was noted to be
key as stated by FDA Commissioner Dr Margaret Hamburg in May 2012:
“Early notification to FDA of potential disruptions in drug supply has made a
huge difference in our efforts – and the numbers really tell the story. Since
reaching out to industry, there has been a six-fold increase in early notifications
from manufacturers. Also, in that six-month timeframe, we have been able to
prevent 128 drug shortages, and we’re seeing fewer numbers of shortages occur
– 42 new drugs in shortage reported in 2012, compared to 90 new shortages at
this time last year.” (Mulcahy, 2012)
Title X of the Food and Drug Administration Safety and Innovation Act (FDASIA) was
enacted in July 2012 to address the issue of drug shortages (FDASIA, 2012),
emphasising the high priority that FDA was placing on resolving the drug shortage
issue. It expanded the FDA’s authorities and strengthened its ability to advance and
safeguard public health by giving FDA the authority to:
•

collect user fees from pharmaceutical companies to fund reviews of innovator
drugs, medical devices, generic drugs and biosimilars
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•

promote innovation to speed patient access to safe and effective products

•

increase stakeholder involvement in FDA processes, and

•

enhance the safety of the drug supply chain

FDASIA also amended section 506C of the Federal Food, Drug, and Cosmetic Act,
requiring manufacturers to notify FDA of a discontinuance or interruption in production
of life-saving, life-sustaining drugs, or drugs used in the prevention or treatment of a
debilitating disease or condition. FDASIA directed FDA to establish a task force on
drug shortages that would develop and submit a Strategic Plan to FDA to enhance
FDA’s response to preventing and mitigating drug shortages.
In early 2014, FDA provided an annual report to Congress on drug shortages in the
calendar year 2013, describing the seven requirements that helped them prevent 140
shortages in the first three quarters of 2013 (FDA, 2014). One of those requirements
related to identifying the number of instances in which FDA had exercised regulatory
flexibility and discretion in order to prevent or alleviate a drug shortage. Another
requirement related to reporting the number of manufacturers that had submitted a
notification to the Secretary under section 506C(a) during the calendar year.
FDA also published its FDA Drug Shortages Strategic Plan for Preventing and
Mitigating Drug Shortages (FDA, 2013). That plan identified two central goals with
specific tasks under each. The first goal was to strengthen FDA’s mitigation response to
imminent or existing shortages, and the second was to develop and implement longterm shortage prevention strategies by focusing on the root causes of shortages. It
identified actions for external stakeholders also, which included exploring incentives to
encourage high-quality manufacturing, better use of manufacturing quality data to make
purchasing decisions, ensuring redundant manufacturing capacity and capabilities, and
minimising gray market activities (i.e., trade of goods by entities unrelated to the
original product manufacturer, through distribution channels unintended by the original
manufacturer).

5.2.3 WHO Activities
The sixty-ninth World Health Assembly Resolution (WHA69.25) in 2014:
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“urged member states to develop strategies to forecast, avert or reduce drug
shortages”, and “called upon manufacturers, wholesalers, global, and regional
procurement agencies and other relevant stakeholders to contribute to global
efforts to address the challenges of medicines and vaccines shortages, including
through participation in notification systems.” (WHO, 2016a)
This resulted in the recognition of a need to develop standard definitions of shortages, to
help align stakeholders on key terms. It also resulted in specific actions to support
Member States in addressing the global challenges of shortages through the
development of a notification system, including mechanisms to better detect and
understand the causes of shortages. Two draft definitions resulted from working groups,
and were reported to the WHO Executive Board as part of the progress on WHA69.25 –
one definition focused on the supply aspects and the other on the demand aspects of the
overall supply chain as follows:
“On the supply side:
A “shortage” occurs when the supply of medicines, health products and
vaccines identified as essential by the health system is considered to be
insufficient to meet public health and patient needs. This definition refers only to
products that have already been approved and marketed, in order to avoid
conflicts with research and development agendas.
On the demand side:
A “shortage” will occur when demand exceeds supply at any point in the supply
chain and may ultimately create a “stockout” at the point of appropriate service
delivery to the patient if the cause of the shortage cannot be resolved in a timely
manner relative to the clinical needs of the patient.”(WHO, 2016d)
Even though it was agreed that the draft definitions would be used by the WHO
secretariat for work going forward, it was acknowledged that adapting to and
implementing the definitions would be challenging since the context across various
shortages is often complex – another recognition of shortages being a ‘wicked problem’
as described in Chapter Four of this thesis.
It is important to note that, thus far, based on a detailed review of the activities initiated
by EMA, FDA or WHO, the researcher found that none of them focused on
understanding and addressing the impact of slow continual improvement and
innovation in the pharmaceutical industry in the context of drug shortages.
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Industry’s Response to Drug Shortages:
Researcher’s Involvement
Most pharmaceutical companies have been challenged with addressing the growing
problem of drug shortages, causes of which have become increasingly complex over the
past 10 years. Most shortages are addressed by the companies and regulators from each
impacted country, on a case-by-case basis, and often this is not until a product is already
in an impending shortage situation. With the increased concern and focus from
regulatory authorities such as FDA and EMA, and the requirement and expectations of
early notifications of shortages to the relevant regulatory authorities, pharmaceutical
companies started to focus their attention on ways to systematically reduce shortages.
One of the challenges companies faced is that there were no consistent processes or
communication mechanisms to regulatory authorities in place that met the expectations
of all countries for managing drug shortages. While common discussions across
countries started improving the situation through the focused efforts of WHO and EMA,
a position of global harmonisation in this area was not achieved and is still far from
realisation.
The researcher has been involved in various PQS and QRM related topics since 2003,
details of which are described in Appendix I. In particular PDA provided the researcher
with a mechanism to connect with the pharmaceutical industry and regulators to bring
them together to advance the interactions, dialogue and practical applications of ICH
Q8, Q9, Q10, Q11 and Q12. With the heightened global focus on reducing drug
shortages, starting in 2012, the researcher was also instrumental in forming and leading
a PDA Drug Shortage Task Force for the development of PDA Technical Report 68, as
stated in Chapter Two, section 2.2 of this thesis; in this leadership role, she also
represented PDA on the EMA’s Inter-Association Task Force, formed in 2013, details
of which are provided in section 5.3.3 and 5.3.4. In addition to the finalised model
published in PDA’s Technical Report 68, the researcher also developed templates, tools
and training material designed to support the implementation and use of the model by
pharmaceutical companies.
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5.3.1 Interactions with European Medicines
Agency (EMA)
This section describes the researcher’s interactions and involvement with the EMA and
the work carried out by the researcher as part of the EMA-sanctioned Drug Shortages
Inter-Association Task Force, as co-lead and PDA’s representative on the activities
scoped within the Task Force’s charter.
As noted earlier, in 2012, the EMA published a Reflection Paper on Medicinal Product
Supply Shortages caused by Manufacturing/Good Manufacturing Practice Compliance
Problems (EMA, 2012) and an associated implementation plan (EMA, 2015b). These
were intended to raise public awareness of the challenges with drug shortages and to
implement short and mid-term actions over 3 years. Per one of the short-term actions in
this Reflection Paper, in October 2013, EMA organised a public workshop with
stakeholders (EMA and NCAs, pharmaceutical industry, patient and healthcare
representatives) at their London EMA headquarters. The researcher participated in the
workshop representing PDA as the lead for PDA’s Drug Shortage Task Force. At that
workshop, EMA requested the pharmaceutical industry via various pharmaceutical
industry associations to provide an integrated action plan with solutions for managing
drug shortages caused by manufacturing, quality and/or GMP compliance issues. They
additionally requested the pharmaceutical industry associations to propose ways to
improve communications related to supply issues to authorities.
A Drug Shortage Inter-Association Task Force was sanctioned by EMA in November
2013 to address this call from EMA. Membership of the Task Force included the
pharmaceutical industry associations that represented a broad section of innovator,
generic & biosimilar, plasma protein pharmaceutical and biopharmaceutical companies
- PDA, International Society for Pharmaceutical Engineering (ISPE), European
Federation of Pharmaceutical Industries and Associations (EFPIA), European Generic
and Biosimilar Medicines Association (EGA), Plasma Protein Therapeutics Association
(PPTA) and AESGP (Association of the European Self-Medication Industry). The
researcher with Vinther represented PDA on this EMA sanctioned Inter-Association
Task Force, co-leading the deliverable on risk-based drug shortage prevention at the
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product level. The work from this Task Force including the researcher-led deliverable is
described in sections 5.3.3 and 5.3.4.

5.3.2 Researcher-Led PDA’s Activities on Drug
Shortages
As part of the pre-research foundational work, described in Appendix I, the researcher
led a PDA Commenting Team that provided feedback to FDA in March 2013 on its
FDA Drug Shortages Strategic Plan (FDA, 2013). In June 2013, the researcher via a
PDA meeting with FDA on the topic of drug shortages, shared progress on the
development of PDA Technical Report 68 and the risk-based concept and model being
developed by the researcher for the prevention and management of drug shortages was
presented. The researcher and her PDA colleagues also informed FDA of PDA’s plan to
hold a workshop on Drug Shortages in September 2014 that would be chaired by the
researcher. The FDA supported the development of such a risk-based approach, the use
of a workshop to get input on it, and it indicated that it looked forward to seeing the
risk-based framework published and implemented by pharmaceutical companies.
The researcher presented on risk-based application specifically for the management of
drug shortages at the September 2013 PDA/FDA Joint Regulatory Conference, and this
helped raise awareness of the growing global challenges with drug shortages and
initiated an ongoing dialogue within the pharmaceutical industry on the proactive role
that pharmaceutical companies must play to prevent drug shortages. In that presentation
the initial thinking on a structured application of QRM and KM concepts to address the
problem of drug shortages was presented. In addition, the researcher presented an early
draft of the risk-based triage approach focused at the product level, which the PDA
Drug Shortage Task Force, led by the researcher had started developing in 2012. As
discussed in section 5.3.4, the Risk Triage model eventually became the solution
delivered to EMA via its Drug Shortage Inter-Association Task Force.
Throughout 2013-2014, the researcher continued to raise awareness of the need to apply
QRM and KM principles and concepts to the problem of drug shortages; she continued
to socialise and encourage dialogue between stakeholders and regulators, while at the
same time working on the development of the Risk Triage model. This comprised of
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presentations and discussions led by the researcher at PDA’s Annual Conference in
2014, the PDA QRM Interest Group, Drug Shortage workshops, and publications (all of
which are noted in Appendix I). The researcher used all these channels to gather input
and refine the Risk Triage model for publication in Technical Report 68.
PDA Drug Shortage Workshop
Specifically, the 10-11-September-2014 PDA Drug Shortage Workshop held in
Washington DC, was chaired by the researcher. This workshop brought together the
pharmaceutical industry and regulatory authority participants, including global
regulatory senior personnel from FDA and EMA, along with senior leaders from global
pharmaceutical companies and pharmaceutical industry associations, who shared their
insights, experiences and lessons learned. The objectives of the workshop were to
explore:
•

the application of risk and knowledge management in the prevention of, and
response to, drug shortages

•

incentives for manufacturers to build in proactive end-to-end controls and good
practices in their manufacturing processes and supply chains such as:
o redundant capacity and new technology
o more transparency and linkages to supply planning
o manufacturing site metrics and quality standards for potential
manufacturing partners, purchasers and prescribers
o focusing on root causes and solutions related to manufacturing, product
quality and supply continuity

Highlights of the workshop are given below:
Capt. Valerie Jensen (FDA), who led the Drug Shortages Team at FDA (CDER),
presented progress on FDA’s strategic plan for drug shortages, reviewing drug
shortages statistics and offering FDA’s perspective on the causes of drug shortages.
These included the lack of manufacturing redundancy and flexibility, complexity in
manufacturing processes, and the lack of technology improvements and innovation.
Jensen described specific tactics FDA used to prevent and mitigate shortages, such as
using regulatory discretion to allow manufacturers with low-risk quality issues to
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continue production of medically necessary drugs, or requesting other companies to
ramp up production. In particular Jensen reported that:
‘Some shortages have been ongoing for a long period; FDA encourages
companies to submit applications for these products.’
Dr Sabine Haubenreisser (EMA), EMA’s liaison at FDA, presented the European
perspective, highlighting the complexity of the drug shortages issue and the need for
multi-disciplinary teams to resolve it. According to Haubenreisser, most drug shortages
in Europe fell under the remit of national authorities, with EMA getting involved in
shortages for CAPs or when coordination across national agencies was needed. EMA’s
actions included consultation with its scientific committees, discussions with heads of
national medicines agencies, and a Call to Action public workshop with stakeholders
(13-October-2013), as discussed in section 5.2.1. She encouraged the pharmaceutical
industry to perform proactive risk management and to improve communications with
regulatory authorities; she encouraged pharmaceutical industry associations to continue
their work on developing and sharing methodologies for the assessment, communication
and mitigation of drug shortages.
In addition to the regulatory presentations, the workshop featured presentations of
work-in-progress by different pharmaceutical industry associations (EFPIA, ISPE,
PDA), in particular their work on the possible root causes of shortages, of which two
were highlighted: aging facilities or equipment, as presented by Maik Jornitz (GCon) and regulatory hurdles for PAC management, as presented by Anders Vinther
(Sanofi). Finally, two generic product companies, represented by Share Ernst
(Hospira) and Andreas Brutsche (Sandoz), illustrated how they addressed and
mitigated drug shortages within their own companies. Hospira, which had a long history
with drug shortages, shared that they had implemented a proactive approach to
resolving and preventing drug shortages, forming strong partnerships with government
agencies and pharmaceutical groups, and taking a risk-based approach to managing
their supply chains and strengthening their manufacturing operations network. After
facing drug shortage issues, Sandoz took a three-tiered approach to remediation which
included business continuity planning, rigorous governance processes, and a cultural
change in mindset and behaviours to achieve a sustainable quality culture.
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In addition, the workshop included multiple breakouts on manufacturing risk
identification and mitigation, supply chain risk identification and mitigation, barriers
and incentives for new technologies and innovation to mitigate risks of drug shortages
in aging facilities. The breakout sessions and panel discussions generated extensive
dialogue on potential solutions, and these formed a part of the researcher’s continued
development of the risk-based triage model and exploration into how slow PAC
processes led to inadequate continual improvement, innovation, thus contributing to
potential drug shortages.

5.3.3 EMA Drug Shortages Inter-Association Task
Force
The rest of this chapter focuses on the work of the EMA Drug Shortages InterAssociation Task Force, established in November 2013. While each pharmaceutical
industry association that participated in the Task Force already had several ongoing
activities, the joint Drug Shortages Inter-Association Task Force served to coordinate
the unique perspectives and solutions from all of the associations involved. The
organisations focused on the scientific and technical elements of restrictions in supply
due to quality and manufacturing issues including root causes, risks, prevention and
control throughout the supply chain that fell within the scope of responsibilities of a
manufacturer and/or MAH. Economic and business-related root causes and supply
interruptions by other players in the supply chain though also likely causal factors, were
out of scope of this team’s deliverables.
The Task Force took a three-phased approach, as follows, for their work:
•

Phase 1: Each association would finalise their deliverables according to their
individual milestones and timelines.

•

Phase 2: The joint team would develop a plan to be presented to EMA before
the end of January 2014 that would include a series of proposals based on results
from the existing activities (Phase 1). It would also recommend new activities
which were considered worthy of further evaluation against the goal of reducing
drug shortages caused by manufacturing and/or quality issues.

•

Phase 3: EMA would review the proposals and determine which of the
proposals they would support and be further engaged in advancing. The
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associations, through the joint team, would share plans and collaborate as
relevant to ensure that significant areas of drug shortages were covered. During
Phase 3 the associations would also deliver conference sessions, meetings,
workshops, etc. with interested parties and publications detailing progress and
requesting feedback.
The goal for the joint team was, by October 2014, it would deliver to EMA a series of
reports (white papers, best practices), presentations, training materials, etc., that could
assist both pharmaceutical companies and regulators in addressing drug shortages. The
next part of this chapter focuses on the deliverables for each of the associations as part
of the Inter-Association Task Force’s charter, which were performed complementarily
and collaboratively under two workstreams, as follows:
1. The first workstream involved the individual member-based associations of
PDA and ISPE, who were chartered to deliver a proposal and a plan to EMA to
address the prevention of drug shortages due to manufacturing and quality
issues. The researcher co-led the PDA team that was a part of this Drug Shortage
Inter-Association Task Force.
2. The second workstream under the remit of the pharmaceutical industry trade
associations EFPIA, EGA, PPTA, and AESGP, was chartered to address
communication principles and a reporting framework between the MAH and
regulatory authorities.
The complementary solutions developed by the various pharmaceutical industry
associations were intended to:
•

enable a shift from reactive to proactive prevention of shortages at a root causebased system level (ISPE) and a risk-based prevention plan at a product level
(PDA)

•

address harmonised communication principles to regulatory authorities for
manufacturing and quality issues-driven supply disruptions (EFPIA, EGA,
PPTA, AESGP)

A summary of the solutions developed and the recommendations from the Interassociation Task Force was published in a report that was provided to EMA in
December 2014 (EMA Drug Shortages Inter-Association Task Force, 2014a).
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ISPE developed a holistic system-based Drug Shortages Prevention Plan (DSPP) that
described a framework based on six dimensions – corporate quality culture, robust
quality system, metrics, business continuity planning, communication with authorities
and building capability (ISPE, 2014). The intent was for companies to use the DSPP at a
system level to look holistically across their entire supply chain and identify potential
gaps and an appropriate action plan.
EFPIA, EGA, AESGP and PPTA developed Quality and Manufacturing Driven
Supply Disruptions: Industry Communication Principles to Authorities (EMA Drug
Shortages Inter-Association Task Force, 2014b) to enable transparency and
predictability in the management of drug shortages by:
1. Harmonising definition of a meaningful disruption to supply
2. Harmonising reporting content with initial categorisation based on PDA’s Risk
Triage model (described in PDA Technical Report No. 68)
3. Harmonising timepoint and recipient of the information at NCAs and EMA
PDA’s response to the EMA Inter-Association Task Force revolved around the work
carried out by the researcher for the development of Technical Report 68. The next
section of this chapter will take a deeper look into this.

5.3.4 PDA Technical Report 68: Risk-Based
Approach for Prevention and Management of Drug
Shortages
PDA’s deliverable as part of the EMA Inter-Association Task Force was Technical
Report No. 68. It provided an easy step-by-step guide to proactively identify and
manage drug shortage risks caused by manufacturing and quality issues in the end-toend product value chain. The PDA Technical Report provided a practical structured
approach consisting of:
1. A holistic risk-based framework at a product level for the prevention and
management of drug shortages caused by manufacturing and quality issues.
2. A Risk Triage model that could be used to assess drug shortage risks and
implement appropriate controls in the end-to-end value chain for manufacturing
and distribution of a product.
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3. Templates for developing a Drug Shortage Risk Register and a Drug Shortage
Prevention and Response Plan at a product level, especially for products
classified as being at risk level A (based on their therapeutic use and the
availability of alternative treatments).
The framework provided in the report also supports and enables MAHs to meet the
requirements of Section 506C of the Federal Food, Drug and Cosmetic Act and Article
13 of the EU GMP Directive 2003/94/EC, which obliges them to notify relevant
regulatory authorities in a timely manner in the event of a meaningful disruption or
potential drug shortage.
PDA Technical Report 68 also described management responsibilities and expectations
related to prevention, management and notification of drug shortages to regulatory
authorities. In addition, it provided ways for pharmaceutical companies to engage more
proactively with regulatory authorities through use of PAC management plans and
harmonised global change protocols, to expedite the review and approval of PACs by
multiple regulatory authorities. The report claimed that such protocols could also be
helpful for companies to address the risk of drug shortages due to aging facilities,
processes and analytical technologies by modernising their facilities and implementing
new technologies (equipment, processes, and analytics).
As the risk to patients from a potential drug shortage increases, the level of rigor, effort,
and cross-functional collaboration within an organisation to address the risk should also
increase. This effort should be coupled with effective and timely communication
between the MAH and regulatory authorities to proactively manage drug shortage risks.
The Technical Report leveraged the guidance developed by EFPIA, EGA, AESPG and
PPTA for communications between MAHs and regulatory authorities.
A high-level overview of this risk-based approach for the prevention and management
of drug shortages was first published in April 2014 in a PDA Letter article (Ramnarine,
Roenninger and Vinther, 2014). This also served as a means for the researcher to
socialise and invite feedback on the risk-based approach from the broader
pharmaceutical industry community.
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The holistic Risk Triage model developed by the researcher at a product level for
prevention and management of drug shortages caused by manufacturing and quality
issues, included a step-wise assessment approach that started with product
categorisation, identification and assessment of drug shortage risks, development of a
Drug Shortage Risk Register, and finally a Drug Shortage Prevention and Response
Plan:
•

Categorising each product by criticality based on its indication and patient needs

•

Establishing a Drug Shortage Risk Register (a single source of information on
risks that can result in drug shortages) by proactively identifying and assessing
risks (to quality, compliance, and supply) that could lead to a shortage

•

Ensuring timely reduction and management of risks by completing risk control
actions defined in the risk control plan, based on criticality

•

Establishing a Drug Shortage Prevention and Response Plan, with a particular
focus on medically necessary, life-supporting or life-sustaining products.
Communication of these plans with regulatory authorities would improve
response and recovery times from a shortage, when one did occur

The Risk Triage model and the Drug Shortage Prevention and Response Plan is applied
at a product level and is depicted in Figures 5.1 and 5.2; both are described in detail in
PDA Technical Report 68.
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Figure 5.1: Risk Triage Model: Categorisation, Patient Impact and End-to-End
Controls (Ramnarine et al., 2014)

Figure 5.2: Drug Shortage Prevention and Response Plan for a Product
(Ramnarine et al., 2014)
Use and Benefits of the Product Level Risk-Based Prevention Triage Model
The Risk Triage model is a practical risk-based application targeted to be used in the
case of drug shortages caused by manufacturing and quality issues. There is evidence
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that it, as well as PDA Technical Report 68 in general, has been viewed as an important
part of the solution to drug shortages. For example, EMA and several NCAs have
actively advocated its use by both pharmaceutical companies and regulatory authorities.
In July 2019, EMA issued a Guidance on Detection and Notification of Shortages of
Medicinal Products for Marketing Authorisation Holders (MAHs) in the Union (EEA)
(EMA, 2019); this advised MAHs to utilise PDA’s Technical Report 68. It has also
been cited by EMA in its public presentations on medicines shortages (Houÿez, 2015).
In 2021, the Expert Working Group assigned to the revision of ICH Q9, Quality Risk
Management, communicated to the PDA the value that the Technical Report 68
presented to its work on product availability risks, and it requested a copy of the report
for the EWG to use, as it developed new guidance in relation to the management of such
risks. The ICH Q9(R1) Rapporteur for the revision work confirmed to the researcher in
2021 that the EWG also intended to make use of the Technical Report when training
materials were developed in the latter half of 2021 and in early 2022 to support the
revisions made to the guideline. He indicated that the value of the Technical Report was
also one reason why the EWG had identified the PDA as a key, non-ICH member
stakeholder that would be invited in mid-2021 to send suggested case studies and other
training materials to the EWG for consideration by the EWG in relation to product
availability risks and other QRM-related topics. That invitation was communicated to
the researcher and to the President of the PDA by the ICH Q9(R1) Rapporteur on 6August-2021.
Use and Benefits for Regulators (including Inspectors): PDA Technical Report 68
can be used by regulators to enable the following:
•

A shift from reactive to proactive management of drug shortage risks in
alignment with the principles of ICH Q9, Quality Risk Management and ICH
Q10, Pharmaceutical Quality System

•

Ensure that the QRM policy and procedures at companies make provision for
the proactive management of product availability (drug shortage) risks

•

Raise awareness and reinforce the application of the risk-based concepts, tools
and templates at a product level
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•

Bring attention to the importance of training activities and the need for training
resources, especially for companies that are in more of a reactive state related to
the management of shortage risks

•

Leverage relevant elements of the Drug Shortage Risk Register (especially for
medically necessary, life-saving or life-supporting products) to engage in
proactive dialogue and partnership with companies on management of drug
shortage risks

Use and Benefits for Pharmaceutical Industry: Companies should have robust QRM
and KM systems to both prevent (proactive) and respond (reactive) to drug shortages.
Practical application by a pharmaceutical company of the risk-based triage model at a
product level, including the Risk Triage tool and its templates, will allow companies to
be more proactive in identifying potential drug shortage risks in their manufacturing and
supply chain operations. Being proactive will enable better control of identified risks,
the prevention of shortages, and the ability to respond and quickly recover in the event
of a shortage. The Drug Shortage Prevention and Response Plan also offered a
mechanism to share potential shortage information proactively with regulatory
authorities and collaborate with them in developing a suitable communication and
response plan in the event of a drug shortage.

5.3.5 EMA’s Response to the Drug Shortages InterAssociation Task Force Solutions
EMA, EU NCAs and FDA have been supportive and have encouraged use of the
solutions developed by the Inter-association Task Force; EMA advised MAHs to utilise
the PDA and ISPE solutions in their shortages guidance issued in 2019 (EMA, 2019).
PDA Technical Report 68, the Risk Triage tool, and templates for Drug Shortage Risk
Register and Drug Shortage Prevention and Response Plan, were made available for
free and can be downloaded by anyone for use at www.pda.org/drugshortage. The
Technical Report and its templates facilitate and encourage companies to engage in a
more proactive dialogue with regulatory authorities on this topic.
Progress on the Drug Shortages Inter-Association Task Force’s work was presented by
the representatives from each of the associations, to EMA and the EU Inspectors
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Working Party at periodic intervals. The researcher presented for PDA. Upon
completion of the set of solutions by the Associations, a final report was prepared and
submitted to the EMA (EMA Drug Shortages Inter-Association Task Force, 2014a).
The EMA received all the solutions very positively, as evidenced by EMA referencing
them in its 2019 guidance (EMA, 2019) on medicines shortage; EMA acknowledged
that the combined body of work was very informative, and that it would integrate them
into its next steps of continued work on the topic of drug shortages. EMA also agreed to
make the solutions available on the EMA website with recommendations that NCAs
post them online as well.
The PDA Risk Triage model was recommended by EMA for implementation by MAHs
and use by NCAs for the proactive identification and management of shortages, and the
timely communication and collaboration with regulatory authorities.
Additional dialogue has continued within the European Commission, EMA and EU
Member States on further actions to address this problem of drug shortages. Awareness
of the global complexity for PACs, its impact on continual improvement and
innovation, and its connection with drug shortages, has gradually started entering the
dialogue since 2020. Though these discussions are still in their infancy, as expected, this
research study has served to increase awareness and has activated a better understanding
of the challenges presented by slow PAC timelines.
From this point forward, the thesis focuses on addressing transformation of PAC
management through science and risk-based approaches within the framework of an
effective PQS.
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Part Three: Exploring and Contributing to
Regulatory Authorities’ Positions in Context of
the Research
Part Three explores the regulatory landscape and the vision and position of key
regulatory authorities on the global problem laid out in Part Two. Regulatory
Authorities are one of the primary stakeholders in relation to this problem and for the
design and implementation of solutions. Therefore, this part of the research study was
essential in exploring and determining key aspects that must be addressed from the
perspective of regulatory authorities.
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Exploring and Contributing to Regulatory
Authorities’ Positions
In parallel with the activities around bringing the pharmaceutical industry together, as
described later in Part Four, the researcher sought opportunities to solicit the opinions of
one of the other key stakeholder groups in the drug shortage crisis, those of the
regulators. Improved public health requires reliable availability of quality drugs.
Continual improvement requires the continued implementation of new knowledge and it
is essential for achieving product realisation and maintaining a state of control.
Continual improvement is desired and expected, yet it can take years to implement new
knowledge in daily operations in a large part due to the global regulatory complexity.
The activities from this point forward in the research were initiated at the request of the
FDA - to unify the pharmaceutical industry and bring its senior Quality leaders together
on the topic of PAC management and accelerating continual improvement and
innovation in the pharmaceutical industry. This required the researcher to also further
explore the position of other regulatory authorities, given the challenges with drug
shortages and the fact that continual improvement and innovation are global issues and
not confined only to the US.
This chapter describes the exploration activities conducted by the researcher with regard
to regulatory authorities, starting with the FDA and then the Pharmaceutical Inspection
Cooperation Scheme (PIC/S), the European Commission (EC), WHO, and the
International Coalition of Medicines Regulatory Agencies (ICMRA). The chapter also
lays out the aspects where the researcher specifically provided input into, and
influenced the development of, certain regulatory authority positions, strategies and
guidances.
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US Food and Drug Administration
This section describes the activities conducted by the researcher with the FDA within
the context of the FDA’s 21st Century Initiative and its components that were relevant
for the topic of this research.

6.1.1 Context of FDA’s 21st Century Initiative
In 2004, the FDA published its final report on pharmaceutical quality for the 21st
century (FDA, 2004), which laid out a vision to modernise pharmaceutical
manufacturing and enhance product quality.
The FDA’s vision for the 21st century was launched before ICH Q8, ICH Q9 or ICH
Q10 were published. The development of ICH Q8 and ICH Q9 had only just begun and
the report stated FDA’s interest to actively participate in the development of those
guidances. Dr Woodcock, Head of CDER at the FDA, stated that the realisation of this
21st century vision would result in:
“a maximally efficient, agile, flexible manufacturing sector that reliably
produces high-quality drug products without extensive regulatory oversight.”
(FDA, 2004)
The objectives of this 21st Century Initiative by the FDA included the following:
• “Encourage the early adoption of new technological advances by the
pharmaceutical industry
• Facilitate industry application of modern quality management techniques,
including implementation of quality systems approaches, to all aspects of
pharmaceutical production and quality assurance
• Encourage implementation of risk-based approaches that focus both industry
and Agency attention on critical areas
• Ensure that regulatory review, compliance, and inspection policies are based on
state-of-the-art pharmaceutical science
• Enhance the consistency and coordination of FDA's drug quality regulatory
programs, in part, by further integrating enhanced quality systems approaches
into the Agency’s business processes and regulatory policies concerning review
and inspection activities.” (FDA, 2004)
With a key public health focus, this initiative by FDA was intended to shift the current
CMC review assessment system from a compliance-based approach to a new risk-based
pharmaceutical quality assessment system, in order to provide a scientific framework
that would enable mitigation of risks while facilitating continuous improvement and
innovation in pharmaceutical manufacturing. This new assessment system was expected
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to reduce the regulatory burden and enable manufacturers to improve their efforts
towards continuous improvement and process optimisation. These progressive science
and risk-based expectations from FDA laid out prior to the ICH Q8, 9, 10 made their
way into these ICH guidances a few years later. Regardless the shift from a compliancebased to more science and risk-based assessments that enable technological
advancement, state-of-the-art pharmaceutical science, and application of modern QMS
concepts, has been discouragingly slow. Pharmaceutical companies have advanced
implementation of the ICH Q10 PQS model, yet comparable progress in the integration
of enhanced quality systems approaches into regulatory authorities’ processes and
policies for reviews and inspections as envisioned by FDA, has not been made.
The report also articulated FDA’s intent to increase its collaboration with international
health and regulatory partners through multilateral and international forums such as ICH
and PIC/S, in order to harmonise pharmaceutical quality standards and requirements as
much as possible. FDA has indeed driven several activities in this regard, an example
being the latest ICMRA strategic initiative on PQKMS, described in section 6.5
(ICMRA, 2021).
In regards to risk-based regulatory oversight, the report stated that the intensity of FDA
oversight should be based on the degree of a manufacturer's product and process
understanding and the robustness of the quality system controlling its processes, among
other factors, such as criticality to product safety and public health. This implied that
complex or less understood processes (from a manufacturing or quality attribute
perspective) might require higher regulatory oversight, whilst process changes for welldefined and well-understood processes could be managed under a company’s change
control procedures. This eventually became a part of ICH Q10 Annex 1. Though the
report discussed risk-based approaches within a quality system framework, it did not
provide details of how a risk-based change management system might work.
Regardless, the risk-based approach that was suggested was intended to reduce the
frequency and/or scope of inspections, by focusing inspections on areas that had highest
public health impact. FDA’s hope was that these science and risk-based regulatory
oversight approaches would provide positive incentives for pharmaceutical companies
to implement effective quality systems, and that they would result in facilitating
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continual improvement in manufacturing along with improving the availability of
medicines for patients, while increasing product quality and process efficiency.
In regards to FDA’s science-based policies and standards to facilitate continuous
improvements, the report described the use of comparability protocols. In 2003, FDA
established a ‘Changes Without Prior Review Working Group’ to identify options for
performing a systematic risk-based review of post-approval manufacturing changes, and
to establish a mechanism for regulatory relief through the use of comparability
protocols. A comparability protocol predefined a comprehensive change evaluation plan
that included specific tests and studies, analytical procedures, and acceptance criteria in
order to demonstrate that there was no adverse effect of a CMC PAC on the safety or
effectiveness of the drug product. The use of a comparability protocol could allow an
applicant to implement a CMC change without waiting for prior-approval from FDA,
and, therefore, to allow distribution of a product sooner than would be possible without
the use of such a protocol. It was also envisaged that a comparability protocol would
provide a means to facilitate process improvements and/or process optimisation which,
in some cases, could even prevent and/or mitigate a supply disruption or shortage
situation.

6.1.2 Exploring FDA’s Position
The researcher believed that the vision and expectation that FDA had communicated in
2004 through their 21st Century Initiative, even prior to ICH Q8, Q9 and Q10 being
published, was a step in the right direction. Yet, forward progress in delivering against
the vision and objectives of that initiative had been very slow; the pharmaceutical
industry and its regulators were still a long way from achieving the value for patients as
envisaged by the 21st Century Initiative by the time this PhD research commenced,
despite the strong intent and commitment of all stakeholders. This was evidenced by the
fact that innovation and continual improvements still were taking years to implement in
many cases even after the availability of tools such as comparability protocols.
The researcher established the PDA PAC iAMSM Task Force, which recognised that the
pharmaceutical industry had a more active role to play if realisation of FDA’s 21st
Century Initiative was to occur, and if the concepts and objectives of ICH Q8, Q9 and
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Q10 were to be realised at a practical level. Thus, the researcher led the Task Force
through several conferences and workshop discussion sessions, which involved
colleagues from various pharmaceutical companies as well as regulators. For example,
in August 2018, the Task Force invited representatives from 13 global companies for a
workshop hosted at the PDA Headquarters in Bethesda, to explore what pharmaceutical
companies could do to contribute towards solving the problem of global PAC
management complexity that was stifling innovation.
A significant outcome of that workshop was the agreement of its participants that Senior
Quality Leaders within the pharmaceutical industry could (and should) speak with one
voice, to create an industry-wide common approach to comprehensive PAC
management. It was agreed that the Quality Leaders could:
•

Emphasize the role of QRM for PACs

•

Agree on a common understanding of what is meant by ‘an effective PQS for
PACs’, since there has been no guidance, clarity or alignment across the
industry and/or regulatory authorities on what an effective PQS is and how it
might be demonstrated

•

Drive the implementation of this ‘effective PQS for PACs’ within their
respective companies

•

Raise awareness about the role that reduced regulatory burden could play in
achieving the objective of uninterrupted availability of high-quality medicines
for patients

It was acknowledged that, while companies’ representatives can participate in active
dialogue about PACs, they generally did not have control or authority over deciding
regulatory outcomes for individual PACs, for creating mutual reliance among
regulators, or for reducing the level of global regulatory complexity that was associated
with many PACs. This complexity is described in Figure 6.1, which was developed by
the researcher and Vinther; it illustrates that while companies have a direct role to play
along the Science axis, they cannot influence the Reliance axis, which in this context
means that, if one regulatory authority has assessed a PAC or a company’s PQS, other
regulatory authorities could place reliance on and accept that regulatory authority’s
conclusions (of acceptance or rejection about the PAC or the PQS). Companies cannot
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of course influence how much mutual reliance is in place between regulatory authorities
– and this is as it should be. Even along the Science axis, after companies complete a
science and risk-based assessment of a PAC, regulatory authorities still have the final
decision on whether or not a prior-approval submission is needed. Therefore, making a
meaningful difference will require both the pharmaceutical industry and regulatory
authorities to work together and advance both axes, so that the global complexity
associated with PACs could be overcome to a significant extent. This became an
important component of the activities undertaken by the 1VQ for PAC Initiative and is
described in Chapter Seven and Chapter Eight of this thesis.
1 change
Fewer
submissions
Fewer
approvals

Fewer
submissions
Many
approvals

+
Company’s
product/process
knowledge

Science

Regulatory risk
based approaches

+
Effective PQS
One change
Many
submissions
Many approvals

Reliance

Many
submissions
Fewer
approvals

Figure 6.1: Pharmaceutical Industry and Regulatory Authorities Working
Together
Prior to August 2018, the focus of ICH Q12 development was mainly on regulatory
CMC aspects. Little attention was given to the practical realities of quality operations
during the commercial phase of a medicinal product, where a lack of continual
improvement and innovation created significant challenges, or to the role an effective
PQS could play in reducing the number of PACs that need regulatory prior-approval. To
address this, at the workshop in August 2018, the pharmaceutical industry came
together to speak with one voice – and a One-Voice-of-Quality (1VQ) for PAC
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Initiative was born. This initiative had the researcher as its co-lead, and it had the
purpose of putting a strong focus on the importance of implementing new knowledge to
continually improve and innovate faster and contribute to reducing drug shortages.
From the very beginning, the 1VQ for PAC Initiative decided not to focus on the
Reliance axis or what regulatory authorities could do; it instead focused on what the
pharmaceutical industry could do to drive better science and risk-based decision-making
for PACs and ensure an effective PQS within their companies. A second 1VQ for PAC
workshop was held in November 2018, also hosted at the PDA Headquarters in
Bethesda. At it, the 1VQ for PAC Initiative planned to develop practical solutions to
address PAC complexity, by standardising the approach to PAC management across the
pharmaceutical industry. Details of all the focus group sessions conducted under the
1VQ for PAC Initiative are discussed in Chapter Seven, section 7.3 of this thesis.
One of the topics mooted at the 1VQ for PAC focus group sessions was initiating a
proactive discussion with FDA to get the regulators’ input into the 1VQ for PAC
activities. In order to do this, after the November 2018 session, the researcher and
Vinther reached out to Dr Janet Woodcock (Head of CDER at FDA), requesting a
meeting with her to discuss PAC management. In January 2019, at the CDER office in
Bethesda, senior FDA leaders including Dr Woodcock, accompanied by Dr Ashley
Boam (Rapporteur for the ICH Q12 EWG) and other senior FDA leaders, met with the
researcher and Vinther. The objective of the meeting was to explore FDA’s interest and
position on the topic of this research - the ‘wicked problem’ of the lack of continual
improvement and innovation leading to drug shortages in a global environment.
Highlights from the August 2018 and November 2018 1VQ for PAC workshops with the
15+ global pharmaceutical companies were presented to Dr Woodcock and her FDA
colleagues in January 2019. The need and the decision to establish a one-voice-ofquality within the pharmaceutical industry in solving this challenge was emphasized.
The FDA concurred stating that, in order for FDA to enter into productive discussions
on this topic, senior leaders in the pharmaceutical industry had to put forward unified
positions and standard solutions that could be implemented consistently and that were
applied to actual PAC examples. It was also emphasized at the meeting that all
attendees at the most recent 1VQ for PAC workshop had unanimously agreed that the
documentation requirements and the level of global complexity that were associated
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with PACs and product lifecycle management had increased exponentially over the past
decade. It was stated that the current situation was considered to be unsustainable, and
this was why the 1VQ for PAC Initiative had made the decision to take practical actions
to improve the handling of PACs, such as through a standardised risk-based approach
across the pharmaceutical industry for PAC management, and align on what aspects of
the PQS are essential specifically for the effective management of PACs. There was
also an agreement at the November 2018 1VQ for PAC workshop to align on practical
PAC examples that, at that time required prior-approval from regulatory authorities, but
which could more reasonably be managed within the company’s PQS only, or as a
notification to the regulatory authorities, instead of a prior-approval submission.
It is useful to consider the framework of the FDA’s 21st Century Initiative that relate to
science and risk-based regulatory oversight approaches and tools; these include
comparability protocols, ICH Q8’s product and process understanding through Quality
by Design principles, ICH Q9’s systematic QRM framework, and ICH Q10’s holistic
PQS model. FDA laid out the desired state and the approaches to achieve that state, yet
the literature does not indicate or give evidence that the continual implementation of
new knowledge that is gained constantly during daily commercial operations has
resulted in the extent of continual improvement that was envisaged by the FDA’s 21st
Century Initiative. It is apparent that these approaches are yet to be fully implemented
within the quality and regulatory processes in pharmaceutical companies and regulatory
authorities.
PACs only allow filing and implementation of smaller discrete segments of this
knowledge, as opposed to the timely implementation of the entire body of relevant
knowledge gained from routine operations. Even implementation of these discrete PACs
in all countries where the product is marketed can take up to several years, as shown in
Figures 1.1 and 1.2 in Chapter One of this thesis. So, the current reality in
pharmaceutical manufacturing is far from the state desired in all these well-intentioned
initiatives and guidances.
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6.1.3 Examples Presented to FDA on Practical
Operational Challenges with PAC Complexity
In the January 2019 meeting with senior FDA leaders, the researcher highlighted that
every day, operational Quality leaders face the risk of drug shortages and cGMP
compliance issues, while not being able to continually improve and innovate in a timely
manner due to the extent of global PAC complexity, and the lack of utilisation of
science and risk-based approaches when managing PACs. Examples of the enormous
PAC logistical complexities that companies live with every day were presented at the
meeting, highlighting that the current state in fact introduced risks to a state of control
and product availability, which was quite contrary to the desired state for patients. Two
of these examples shared are given below:
Example 1
In relation to a pentavalent vaccine manufactured by a pharmaceutical company, 83
batches of the same product (same end product specifications and indication) had been
produced using 55 different versions of the manufacturing process within a year. This
need to continue to operate so many different versions of a manufacturing process was
due to the fact that multiple PACs were under assessment at various regulatory
authorities, with varying approval timelines in different countries. This required the
company to keep multiple batches in inventory, reflecting the different manufacturing
process versions, even though all versions produced an end product that met exactly the
same product specifications. This greatly increased the risk of errors, such as the risk of
sending a batch manufactured via one process version to a country that hadn’t yet
approved the PAC for that process, or worse, having the product available in inventory
but not being able to supply it to a country as a result of regulatory requirements. This
resulted in drug shortages, simply because the PAC for the process that was used to
produce that batch had not yet been approved by the regulatory authority of that specific
country (even though it had been approved and found acceptable by many other
countries).
Example 2
Another example that related to the researcher’s direct experience concerned the
implementation of a state-of-the-art analytical method with a higher level of sensitivity
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than the currently used and approved method. This new analytical method delivered
improved testing capabilities, increased innovation, higher speed in product testing and
faster batch release decision-making, thus making the product available to patients
faster. However, the necessary regulatory approvals for this analytical test method
change took almost ten years from the first to last regulatory authority approval. During
this period, while submissions of the PAC for approval were being made to each of the
relevant countries, the company had to dual test batches of the product, using both the
old and new test methods, because the new method had not been approved in all
countries. This resulted in an increased dual testing burden and cost on the QC labs, and
it introduced compliance risks, such as addressing differences in test results by the two
methods, even though equivalency had been demonstrated for both methods. It also
presented challenges in determining how to investigate and manage instances where
testing by one method met specifications, but where testing with the other method
resulted in an out-of-specification result.
It is also noteworthy that, by the time a new technology is finally implemented in all
relevant countries, it is highly likely that another technology upgrade has become
available in the interim, and the cycle to implement that upgraded technology needs to
start all over again, even while the previous ‘new’ technology is still in the process of
being implemented across all countries. This is exactly what happened in the
researcher’s experience with this particular example, where the company was
implementing a new technology - before it had been fully implemented in all countries,
an upgrade of the technology was available, and a whole new PAC cycle had to be
initiated, even as the previous one was still in progress. The logistical complications that
this led to in the testing, release and inventory management of product increased
exponentially and it was extremely challenging to manage for QC labs, QA personnel,
and supply chain planners.
The question that such real-life examples raised for the researcher was:
Given the addition of this enormous complexity with inventory, daily operations
management, and long lead-time challenge associated with implementing a new
method or technology, why would any company want to invest in taking on this
significant effort and the burden of implementing a new technology, improving
and innovating, even when it greatly improved the current state, reduced risks
and improved product availability for patients?
139

It is the researcher’s position that the global regulatory complexity for PACs is a
significant reason why companies do not have the incentive or motivation to continually
improve and innovate; instead, they choose to continue to operate with aging, suboptimal processes, methods, equipment and technologies that can lead to manufacturing
and quality issues and eventually supply challenges. It in fact, works against continual
improvement, in contradiction to what all regulatory authorities want and have stated as
an expectation in their regulations. The activation energy to overcome the global PAC
complexity hurdle is daunting for any company, and even if indirect, it is possible that
there is a link between this inertia to improve and drug shortages.
The researcher made the case to the FDA, that a significant shift from years to months
(or weeks) was needed in the time it takes from when new knowledge is acquired in
daily operations to when it is implemented; this desired shift is depicted in Figure 6.2.
New knowledge

New knowledge

GAINED

IMPLEMENTED
from YEARS

Faster regulatory approval
Less countries approving
Less PACs requiring prior approval
New knowledge

GAINED
to

MONTHS or WEEKS

New knowledge

IMPLEMENTED

Figure 6.2: A Significant Shift is Needed in Implementation of Improvements
Based on New Knowledge Gained
Indeed, these challenges were also in the minds of FDA, where as noted in FDA
Pharmaceutical Quality Oversight: One Quality Voice:
“the number of post-approval supplements received for review has increased
over the past decade, in part owing to our current practice of “locking in” an
applicant’s manufacturing process before it is fully optimized. A burdensome
regulatory framework requires manufacturers to submit supplements as they
strive for process optimization.” (FDA, 2015)
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In this context, it is also noteworthy that new knowledge is gained mostly during the
commercial phase as the number of batches manufactured during the development
phase is limited. Related to this, another real-life situation discussed in Example 3
below was presented by the researcher during the January 2019 meeting with FDA.
Example 3
A major global vaccine company submitted approximately 8000 PACs in a year, either
for prior-approval or via notification mechanisms. This high number of PACs is not
atypical for a global pharmaceutical company that has many commercial products each
potentially registered in 100+ countries. Of these 8000 changes, more than 99% were
approved by the regulatory authorities for implementation; this raised the question:
If >99% of the submitted PACs were approved, what could be done through use
of a risk-based approach, to reduce the number of changes that had to be
submitted to regulatory authorities, such that only the higher risk changes
needed to be reviewed for prior-approval?
Continual improvement and innovation require increased risk tolerance; thus, one
ponders would it be possible, without compromising product quality and/or patient
safety by implementing the concepts of ICH Q9 and ICH Q10, that only higher risk
changes might need prior-approval by regulatory authorities? Then, with fewer PACs
requiring prior-approval, coupled with faster regulatory approvals and fewer countries
needing to approve each PAC, the global PAC complexity hurdle could be markedly
reduced.
In addition to discussing the current complexities with global PAC management and
presenting examples that challenge companies in their daily operational work, the
researcher and her co-lead discussed with FDA during the January 2019 meeting, ways
that pharmaceutical companies could build trust with regulators, so that more changes
could be managed in the PQS without requiring prior-approval. This raised the question
- what does a pharmaceutical company need to do to be trusted to make PAC decisions
in the future without obtaining prior-approval of those PACs which today require that?
The researcher inquired if the FDA would be interested and willing to work with the
1VQ for PAC Initiative in piloting a shift for several PAC examples, where they were
moved from being prior-approval changes to notifications, or to only being managed
within a company’s PQS. This involved moving towards the vision of science and risk141

based approaches that enabled continual improvement and innovation, and it was in line
with the FDA’s 21st century vision as described in 2004 and as documented in ICH Q10
Annex 1. The FDA agreed that the current state of complexity could not continue and
that a change was essential. They stated that instead of multiple conversations with
different industry associations, unified positions and solutions from the pharmaceutical
industry would be essential in gaining alignment between companies and regulators.
The FDA also emphasized that given the global nature of the problem, other regulatory
authorities needed to be included in the discussion. Outcomes of the meeting with FDA
are described in section 6.1.5.
In order to fully understand the PAC management landscape and the role of different
stakeholders, it is useful to understand the current role of regulatory inspectors in
assessing the effectiveness of a company’s PQS, and becoming more integral for faster
PAC management.

6.1.4 The Role of Inspectors in PAC Management
Within each regulatory authority, regulatory assessors (sometimes also known as
reviewers) are responsible for the review and approval of regulatory submissions made
by pharmaceutical companies for new products or for PACs to existing commercial
products. Regulatory authorities also have regulatory inspectors who are responsible for
inspecting (mainly through on-site visits), the quality systems and processes within
companies to ensure that they are compliant with regulatory requirements and with the
approved regulatory filing for a product. This is to assure that the product manufactured,
tested and released by the company has the right quality, efficacy and safety attributes.
Currently, regulatory inspectors do not usually get involved in evaluating submissions
for PACs - this is generally the role of regulatory assessors. Similarly, regulatory
assessors do not usually get involved in evaluating the quality system and its related
processes within a company - this is the role of regulatory inspectors. In some instances,
assessors may also be inspectors during pre-approval inspections for a product, but in
general, the assessor and inspector roles are distinct and separate within most regulatory
authorities. There are typically quite limited interactions between regulatory assessors
and inspectors within regulatory authorities. This clear distinction of responsibilities
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between regulatory assessors and inspectors, coupled with the limited interactions
between the two, while understandable, does result in a sub-optimal situation. This is
because each has only a partial and limited understanding of the extent of process
knowledge, systems and processes that support the maintenance of a state of control and
continual improvement of the manufacturing, testing, release and distribution of a
product.
Though PIC/S, which has an excellent knowledge base through its global network of
regulatory inspectors, was an observer in the ICH Q12 EWG, there had been very
limited detailed discussions on the valuable role that inspectors can (and should) play in
assessing the effectiveness of a company’s PQS. There is a greater opportunity where
inspectors can contribute towards the decision-making on whether or not a particular
PAC may be managed within a company’s PQS without requiring prior-approval from
regulatory assessors.
ICH Q12 states that, while regulatory assessment and inspection should be maintained
as complementary and independent activities, timely knowledge and information
exchange between assessors and inspectors can facilitate regulatory oversight of product
lifecycle management and even reduce submission burdens for the MAH. If a company
fails an inspection for critical PQS aspects, that can impact its ability to take advantage
of the flexibility offered by ICH Q10 Annex 1 or the ICH Q12 tools. On the other hand,
if a company has an effective PQS and can demonstrate during inspections that its PQS
is being used to make, document and implement decisions in a manner that assures
product quality and patient safety, the company should be allowed reduced reporting for
certain PACs, as described by ICH Q10 Annex 1 and ICH Q12. Therefore, inspectors
indeed have an important role to play in realising the vision of both of these ICH
guidances, even though they do not review and approve specific PACs, which remains
the role of assessors.
Towards this end, in September 2018, the researcher had made a proposal to the PIC/S
QRM Expert Circle, asking if they would be interested in a collaboration to:
1. Review a pilot on a standard risk-based approach to PACs developed and
implemented by companies
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2. Have a dialogue with the 1VQ for PAC Initiative team on what constitutes an
effective PQS and how it could be assessed during inspections
This proposal is discussed in section 6.2.1 below. PIC/S responded that they would take
this collaboration into consideration. Details on the resulting interactions between the
researcher and PIC/S since 2018 are described further in this chapter in section 6.2.
Finally, at the meeting with Dr Woodcock and the senior FDA leaders, the researcher
raised this topic and presented the proposal made to the PIC/S QRM Expert Circle. The
outcome of this, and all the other dialogue presented above, is summarised in section
6.1.5.

6.1.5 Outcomes of the Meeting with Dr Woodcock
and FDA
The discussions with, and the position of, the FDA were encouraging in validating the
need for this research. Dr Woodcock and the FDA senior leaders appreciated the global
complexity associated with PACs and they acknowledged that no one stakeholder group
could resolve this situation through their own solutions; so, they agreed on the urgent
need for collaborative solutions to the ‘wicked problem’ of continual improvement,
innovation and shortages. This was further confirmation that solving the ‘wicked
problem’ needed a multi-stakeholder approach and holistic systems thinking.
Furthermore, the FDA agreed that the current regulatory approval effort being put in by
both companies and regulators, was not proportional to the value gained for the patient
from the existing regulatory reviews of PACs (this was related to the discussion on the
example of greater than 99% of 8000 PACs submitted per year by a company and
approved by regulatory authorities; similar percentages were reported by multiple
vaccine companies through the 1VQ for PAC focus groups). The dialogue highlighted
the importance and value of using better science and risk-based approaches to enable
regulatory resources and oversight to focus on a subset of these PACs – those that
represented higher risks to product quality, safety and public health.
The FDA leaders agreed that, in addition to regulatory risk-based guidances, a
company’s demonstrated product and process knowledge and an effective PQS should
be leveraged for PAC categorisation. They suggested that, in order to lower the
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activation energy needed to overcome the global complexity hurdle, companies needed
to demonstrate their application of product and process knowledge in their risk-based
decision-making in daily operations. In addition, companies needed to demonstrate that
they had an effective PQS framework that is utilised appropriately to maintain a state of
control, document their risk-based decisions for PACs, and ensure management
accountability as described in ICH Q10. In their experience, FDA had not seen
companies do this well, and they stated that companies demonstrating a deep
understanding of their product and processes, and using an effective PQS, was
fundamental in gaining trust with regulators.
The FDA recognised that these challenges cannot be solved independently by
pharmaceutical companies or their regulators, but that both together needed to find a
way to drastically reduce the gap between knowledge gain and knowledge
implementation in daily operations. FDA also supported the thinking that an effective
PQS was essential for successful implementation of the concepts and tools that ICH
Q12 was developing. This required the involvement of both assessors and inspectors,
and active interactions between them.
The proposal to PIC/S, described further in this chapter, was well-received by Dr
Woodcock and FDA, and they supported the development of practical application PAC
examples to be used as a means to improve the dialogue between assessors and
inspectors on what an effective PQS may look like, and how it might be leveraged in the
regulatory decision-making for PACs.
FDA also expressed that they would be keen and open to hosting and utilising a
consortium of regulators from different countries to pilot a joint review (or even a
reliance conversation) for PAC assessments and approval. They were willing to help
activate the dialogue with regulatory authorities from different countries to come
together and work more closely for approval of PACs. As resulting from and committed
to at the end of the January 2019 meeting with the researcher and Vinther, the FDA
subsequently activated this discussion in 2020 via ICMRA, which is further elaborated
upon in section 6.5.
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The FDA was very positive on the industry’s 1VQ for PAC Initiative and underscored
the importance of operational Quality leaders engaging in developing and implementing
global solutions in this area. They were encouraged to see the pharmaceutical industry
working on standardisation through the 1VQ for PAC Initiative, and they expressed a
desire to see more of this happening. They strongly encouraged the researcher and
Vinther to get involvement, sponsorship and support from senior management within
pharmaceutical companies.
One suggestion the FDA made was that the 1VQ for PAC Initiative should work
towards bringing clarity and alignment on how to demonstrate an effective management
of PACs within the PQS. To achieve this, FDA indicated it was open to a discussion
with Quality heads from pharmaceutical companies on what is an effective PQS and
how it could be used for PACs (both from an assessor and inspector perspective). Its
goal was to see these elements of an ‘Effective PQS for PACs’ integrated into the
quality culture tools that were in development and under discussion by organisations
such as PDA, ISPE, St. Gallen University et. al.., at the time. FDA indicated that it
wanted to see practical examples of PACs that could be managed using an effective
PQS and a standard risk-based approach. However, before they committed to
participation in further discussions with pharmaceutical companies on such examples,
they asked for a Concept Paper (which was subsequently delivered by the researcher
and Vinther via the 1VQ for PAC Initiative) to outline:
•

The pharmaceutical industry’s role in the topic of PAC management, and
advancing continual improvement and innovation, since ownership for product
quality resides with a company

•

What aspects would be included in a practical pilot implementation e.g.,
standard risk-based approach, how to demonstrate an effective PQS, etc.

•

Expectations from FDA and other regulatory authorities for the pilot

•

Expected decision and outcomes from the pilot. e.g., FDA accepts the approach,
examples etc., for PAC management and could consider participation in specific
pilots with the pharmaceutical industry or other regulatory authorities

In general, FDA was supportive of the 1VQ for PAC Initiative publishing some of the
solutions (e.g., standard risk-based approaches, how to demonstrate an effective PQS)
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as industry standards – and could consider endorsing those solutions for use by their
assessors.
When asked by the researcher and Vinther if the FDA would be willing to jointly
partner on such a Concept Paper, they responded that a partnership only with FDA
would not be useful in resolving this global issue. FDA indicated that it was open and
interested in reviewing and providing feedback on the Concept Paper (which they did
once the Concept Paper was developed and before it was finalised and endorsed by the
CQOs), but asked that it be a pharmaceutical industry Concept Paper with sponsorship
and commitment from senior management of pharmaceutical companies. FDA also
offered to continue the dialogue on this topic and to facilitate ongoing and new solution
opportunities being discussed with the 1VQ for PAC Initiative team and with other
regulatory authorities.
As the 1VQ for PAC Initiative has progressed, the researcher and Vinther continued
their interactions with FDA, providing updates on progress, seeking feedback, and
exchanging on opportunities to advance solutions that could improve the current state
and better enable continual improvement, innovation and the mitigation of shortages.
Details of these interactions and 1VQ for PAC solutions are discussed in Chapter Seven
and Chapter Eight of this thesis.

6.1.6 FDA ICH Q12 Implementation Guidance and
Feedback from the 1VQ for PAC Initiative
In May 2021, the FDA issued a draft guidance for the industry on ICH Q12
implementation considerations for FDA-regulated products (FDA, 2021). The guidance
clarifies how the ICH Q12 tools and enablers can be implemented within the US
regulatory system. The FDA solicited comments on the draft guidance by July 2021.
The researcher and Vinther developed draft comments on the guidance and solicited
further input from the 1VQ for PAC Initiative team. The comments were finalised and
sent to the CQOs sponsoring the 1VQ for PAC Initiative for review, input and
endorsement.

147

The overall position and comment submitted by the 1VQ for PAC Initiative was that the
clear and comprehensive guidance was welcomed by the pharmaceutical industry
especially in relation to the science and risk-based assessment of individual PACs and
the ability to manage more PACs within the PQS only, by applying the principles of
ICH Q10 and ICH Q9. Several suggestions were provided, such as referencing the
published PIC/S Recommendation Paper on “How to Evaluate and Demonstrate
Effectiveness of a Pharmaceutical Quality System in Relation to Risk-Based Change
Management”, emphasising the importance of interactions between assessors and
inspectors in realising ICH Q12, and the vision of regulatory flexibility through
utilisation of an effective PQS.

The Pharmaceutical Inspection Cooperation
Scheme (PIC/S)
PIC/S is a non-binding informal cooperation agreement between 53 participating
regulatory authorities on GMPs for human and veterinary medicinal products. PIC/S
was established in 1995 as an extension of the Pharmaceutical Inspection Convention
(PIC) that was founded in 1970 by the European Free Trade Association (EFTA). PIC
was founded with the goals to advance mutual recognition of inspections, harmonisation
of GMP requirements, achieve uniformity of inspection systems, training of inspection,
exchange of information and mutual confidence and trust.
After 1993 it was not possible to add new members to PIC, because, under EU law, only
the European Commission could authorise signing agreements with other countries, and
expansion of PIC was not possible until the European Commission became a member of
PIC. Therefore, in November 1995 it was decided to develop PIC/S. PIC and PIC/S
would operate in parallel; so, since November 2004, PIC/S is officially registered as an
Association under Swiss Law with the “Registre du Commerce” (Trade Registry) of the
Canton of Geneva (http://rc.ge.ch/). Its official name is “Pharmaceutical Inspection Cooperation Scheme - Association de Droit Suisse”.
PIC/S’ mission is to:
“lead the international development, implementation and maintenance of
harmonised Good Manufacturing Practice (GMP) standards and quality
systems of inspectorates in the field of medicinal products.” (PIC/S, 1995)
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This is achieved through harmonised GMP standards and guidance documents, training
Competent Authorities, particularly GMP inspectors, assessing or reassessing GMP
inspectorates, and facilitating cooperation and networking between Competent
Authorities and international organisations. Before any regulatory authority becomes a
member (or as officially known, a Participating Authority) of PIC/S, they are assessed
for equivalence in relation to their GMP guidance and legislation. The number of
participating authorities in PIC/S has increased from 10 when it started, to 53 as of
2020.
PIC/S is one of the few regulatory organisations that achieves harmonisation of GMPs
and inspections at a global level through Expert Circles, Working Groups, training of
inspectors, and joint visits programme. The PIC/S organisational setup includes an
overall PIC/S Committee of Representatives from the Participating Authorities, which
supervises seven sub-committees on various topics (PIC/S, 2020). The PIC/S
Committee is the decision-making body, and decisions are made unanimously. One of
the seven sub-committees is the Sub-Committee on Expert Circles (SCEC), which
reviews the composition, functioning, activities and mandates of all the PIC/S Expert
Circles. The Executive Bureau steers the PIC/S organisation between meetings, and the
Secretariat supports the Committee, Sub-Committees, Executive Bureau and the
Participating Authorities in executing their responsibilities.
PIC/S is the only global organisation that deals exclusively with GMP. In addition to
having Participating Authorities as members, PIC/S also interacts with other
pharmaceutical industry and professional organisations, such as ICH, International
Federation of Pharmaceutical Manufacturers’ Association (IFPMA), PDA, ISPE, etc.,
such as soliciting input and comments during the development of PIC/S documents.
With the increasing globalisation of both the pharmaceutical industry and regulatory
requirements, PIC/S’ role has become increasingly important and valuable in
internationally harmonising GMP and regulatory requirements, inspecting for and
evaluating GMP compliance, licensing manufacturing sites, and increasing information
exchange between regulatory authorities. The primary mechanism that PIC/S uses to
drive GMP harmonisation is through its own GMP Guide, as well as its related guidance
documents, Q&As, recommendation papers and aide-memoir documents for the
pharmaceutical industry, inspectorates and inspectors. PIC/S’ global harmonisation
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work has provided direct benefits not only to the participating regulatory authorities, but
also to the pharmaceutical industry, through reduced duplication of inspections,
enhanced market access, export facilitation and in general, higher confidence in
medicines manufactured in countries where the regulatory authority is a participating
PIC/S authority.

6.2.1 Discussions with PIC/S QRM Expert Circle
Per the PIC/S organisational structure, PIC/S Expert Circles facilitate discussions and
exchange of ideas and experiences on specific topics among inspectors, which can result
in draft guidance, recommendations, and training events. One of the eight current PIC/S
Expert Circles with is the QRM Expert Circle, chaired by Dr Kevin O’Donnell from the
HPRA in Ireland. It was established in 2007 and has developed QRM implementation
models for inspectorates, guidance documents and basic and advanced training
programmes for inspectors on how to inspect and assess QRM implementation at
pharmaceutical companies.
Prior to embarking on this specific inquiry, the researcher primarily interacted with the
PIC/S QRM Expert Circle for PIC/S in relation to QRM training activities, as noted in
Appendix I of this thesis. Further interactions with PIC/S occurred for the development
of one of the solutions in scope of this research study, described in Chapter Eight,
section 8.4 of this thesis.
As described in Appendix I, the researcher had thus far participated as a trainer in three
advanced PIC/S QRM training workshops for GMP inspectors since 2015, being the
only trainer invited from a pharmaceutical company to these inspector-only training
sessions. PIC/S workshops are typically closed to pharmaceutical industry participation,
and the researcher was invited in her capacity as a QRM expert and not as a
pharmaceutical industry representative. Each training event were attended by 70-80
inspectors per session from almost all PIC/S member countries and WHO. This
inspector training aspect of the researcher’s activities with PIC/S is not being further
elaborated upon in this thesis as they were not directly related to this research study.
The PAC management related interactions with PIC/S are the most relevant, and are
described further in the next section.
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6.2.2 Initiating Activities with PIC/S QRM Expert
Circle on Advancing Role of Inspectors in
Transforming PAC Management, September 2018
At the third PIC/S QRM advanced training event, which was held in Taiwan in
September 2018, the researcher was invited to join the QRM Expert Circle closed
session to discuss the further development of the Expert Circle QRM training
programmes for GMP inspectors. At this closed session, the researcher was given time
on the agenda to specifically present on the topic of utilisation of risk-based approaches
to improve PAC management. The researcher presented a proposal for a possible
collaboration with the PIC/S QRM Expert Circle, on how the pharmaceutical industry
might be incentivised to continually improve their processes and products and thus
reduce risks to patients. This led to a discussion on ways to reduce PAC complexity and
increase innovation by pharmaceutical companies.
It was suggested by the researcher, based on her PAC work conducted to date, that a
risk-based approach and an effective PQS could provide a means to manage more PACs
in the PQS without requiring prior-regulatory approval. The concept of using PAC risk
assessments as part of regulatory submissions in order to reduce review redundancies by
each regulatory agency involved was explored. In addition, it was proposed that datadriven risk assessments could also be used to demonstrate when a PAC does not
increase risk to product quality and/or patient safety and therefore, could be
implemented faster through the PQS only, without a regulatory prior-approval
submission; this would also facilitate the timely implementation of new product and
process knowledge. The researcher suggested that practical application of this proposal
would involve performing a structured and standard risk assessment for each PAC, and
the shift that could be expected in risk-based decision-making for PACs was presented
in a diagram developed by the researcher, as shown in Figure 6.3.
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Regulators decide if they
accept the conclusions of the
PAC risk assessment and
assess PQS effectiveness

Company submits same
PAC risk assessment to
each country

• Same RA submitted to all countries
can improve consistency and speed
of PAC decisions by regulators
• Enable discussion and alignment on
risk decisions between countries
• Reliance on PQS effectiveness
assessment by inspectors

• Today we do not perform PAC RAs
• If performed, not structured/
positioned effectively (as a
company and as an industry)
• Integration of current knowledge,
scientific and data basis for RAs is
key

Figure 6.3: Standard PAC Risk Assessment Submitted to Each Country
The left-hand side of the diagram depicts the current situation, which results in
individual submissions to regulatory bodies globally. The right-hand side presents a
situation where one risk assessment for each change is reviewed by all regulatory
authorities, who could in turn each use this to determine if they accept the conclusions
of the PAC risk assessment, and also, whether or not they could rely on the
effectiveness of the company’s PQS to be satisfied that no prior-approval for the PAC is
required.
The researcher proposed that an effective PQS, which included a means for the
comprehensive science and risk-based assessment for PACs and which managed new
knowledge in a timely manner, could be a foundational lever to achieve the objective of
reliably producing high quality products. It could also provide a mechanism to realise
the vision laid out in ICH Q10 Annex 1:
“Opportunity to facilitate science based pharmaceutical quality assessment and
optimise science and risk based post-approval change processes to maximise
benefits from innovation and continual improvement” by “demonstrating
effective pharmaceutical quality system and product and process understanding,
including the use of quality risk management principles.” (ICH, 2008)
In order to achieve this, the importance of assessing the PQS of a company for its
effectiveness was highlighted, and this was where pharmaceutical inspectors could play
a key role. This was the primary reason which led to the researcher bringing this topic
for discussion to the PIC/S QRM Expert Circle as it developed its training programmes
for inspectors.
The pharmaceutical industry 1VQ for PAC Initiative was presented to the PIC/S QRM
Expert Circle, in particular the work underway on the development of a standard risk152

based approach, which was intended to be implemented consistently across the
pharmaceutical industry.
The researcher inquired if the PIC/S QRM Expert Circle would be interested in:
1. Reviewing a pilot on a standard risk-based approach for PACs developed and
implemented by companies
2. Engaging in a dialogue on what constitutes an effective PQS and how it could be
assessed during inspections – possibly developing guidance for the
pharmaceutical industry about what attributes constitute an effective PQS for
management of PACs
3. Consider developing guidance for inspectors on how the effectiveness of the
PQS could be assessed during an inspection
The concept of a standard risk-based approach for PACs across the pharmaceutical
industry was supported by the participants, and there was agreement that the PIC/S
QRM Expert Circle would be the right PIC/S group to discuss the risk-based approach
with inspectors, since it was probably the largest and most active forum for GMP
inspectors from PIC/S member countries. It was acknowledged that PQS effectiveness
is a dynamic state - things such as changes in management, loss of key personnel, etc.,
could also affect PQS effectiveness. So, beyond inspections, other mechanisms such as
Quality System Management Review were important to ensure continued PQS
effectiveness. The participants indicated they would consider these suggestions and that
the Coordinating Committee of the Expert Circle would revert to the researcher on the
proposal made in relation to reviewing the pharmaceutical industry’s standard riskbased approach for assessment of PACs, and developing guidance for the
pharmaceutical industry about what constitutes an effective PQS. In addition, the
Coordinating Committee would also consider developing guidance for inspectors on
how the effectiveness of the PQS could be assessed during GMP inspections.
This was a productive discussion and it had an encouraging outcome for the researcher,
with PIC/S acknowledging the need to improve the risk-basis of PACs, and how the
QRM Expert Circle could have a meaningful role to play in this area. The discussion
also demonstrated a high level of openness to evaluating what the Expert Circle might
do to contribute to this topic.
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6.2.3 Understanding the Spirit and Intent of GMP
Requirements on Change Control
Post-meeting, Dr Kevin O’Donnell, Chair of the Expert Circle, suggested exploring
integration of QRM specifically into the change management system, since that PQS
element is core to PAC management. Thus, the researcher commenced a study of GMP
requirements on Change Control, with the objective of understanding the intent and
spirit behind those requirements. In particular, the following documents were explored
for this study:
•

EU GMP Guide, Annex 15

•

ICH Q10: Change Management System

•

ICH Q12: Appendix 2: Principles of Change Management

•

PIC/S GMP Guide on Medicinal Products, Chapter 1, PQS

•

PIC/S GMP Guide on Medicinal Products, Chapter 5, Production

•

PIC/S GMP Guide on Medicinal Products, Chapter 6, QC

•

PIC/S GMP Guide on Medicinal Products, Chapter 7, Outsourced Activities

•

EU GMP Guide Part II (i.e., ICH Q7)

This review also included detailed discussions on Change Control within the 1VQ for
PAC Initiative team. The review and discussions emphasized that the spirit and intent of
these GMP requirements for change control was that - as knowledge increases during
the life of a product, changes are inevitable, so the change control system should ensure
the validated state, and a state of control is maintained even as changes are made.
Control of changes is an important part of KM, and QRM should be used to evaluate the
need, potential impact and effectiveness of a change.
This piece of work led the researcher to further advance the initially developed
considerations on change management, by exploring the development of a checklistbased approach that could aid in distilling the considerations for risk-based change
management into a tangible, actionable, easy-to-implement tool that not only met
documented GMP requirements, but also met their spirit and intent.
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6.2.4 Researcher’s Proposal to the PIC/S QRM
Expert Circle, April 2019
A follow-up discussion with the PIC/S QRM Expert Circle took place at the HPRA
office in Dublin in April 2019. It confirmed that the focus of this research should be on
the integration of QRM into the change management system, with the intent of
supporting continual improvement and innovation, while also ensuring that a state of
control was maintained. At this meeting, the researcher proposed the development of a
document that could be used by the pharmaceutical industry as a tool and a reference,
demonstrating what a good risk-based change management system could look like and
how its effectiveness might be demonstrated during inspections. Figure 6.4 (ICH, 2008)
illustrates the specific areas of focus from the ICH Q10 diagram (highlighted with the
red boxes).

Figure 6.4: Targeted Discussion on Risk-Based Change Management System
with the PIC/S QRM Expert Circle (ICH, 2008)
The discussion was framed in the context of 21st century manufacturing paradigms and
innovative therapies (such as personalised medicines, Advanced Therapy Medicinal
Products (ATMPs)), which require a complete revision of the pharmaceutical industry’s
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traditional manufacturing paradigm. In order to achieve the objective of reliably
producing high quality products, the pharmaceutical industry needs to implement new
knowledge in a timely fashion and continually improve and innovate without
increasing risk to the patient. Manufacturing of the future must become efficient,
flexible and agile, to adapt to rapidly changing demands and meet evolving patient
needs. Meanwhile, improvements need not compromise the quality and availability of
therapies. This implies the use of innovative manufacturing and supply approaches and
cutting-edge technologies. It requires overcoming challenges and barriers to their
implementation. The need to revolutionise the technical sector was recognised almost 2
decades ago by the pharmaceutical industry, ICH and regulatory authorities such as
FDA, when the first therapies based on recombinant monoclonal antibodies were
showing significant benefits for patients. Shortly thereafter, work was started to develop
harmonised guidelines outlining risk- and science-based approaches to product
development and manufacturing. ICH Q8-Q11 were published between 2005 and 2011,
and included new, paradigm-changing concepts such as ‘Quality by Design’ (QbD).
Per the FDA guidance for industry on Quality Systems Approach to Pharmaceutical
cGMP regulations:
“effective change control activities (e.g., quality planning and control of
revisions to specifications, process parameters, procedures) are key components
of any quality system. In this guidance, change is discussed in terms of creating
a regulatory environment that encourages change towards continual
improvement. This means a manufacturer is empowered to make changes
subject to the regulations based on the variability of materials used in
manufacturing and process improvements resulting from knowledge gained
during a product’s lifecycle.” (FDA, 2006)
With all this in mind, a discussion on the ICH Q10 Annex 1 (ICH, 2008) shown below
in Table 6.1 which stated several potential opportunities to enhance regulatory
approaches, took place with the PIC/S QRM Expert Circle.
Table 6.1: ICH Q10 Annex 1 - Potential Opportunities to Enhance Science and
Risk-Based Regulatory Approaches (ICH, 2008)
Scenario

Potential Opportunity

1. Comply with GMPs

Compliance – status quo
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2. Demonstrate effective
pharmaceutical quality system,
including effective use of quality
risk management principles (e.g.,
ICH Q9 and ICH Q10).

Opportunity to:
• increase use of risk-based approaches for
regulatory inspections.

Opportunity to:
• facilitate science based pharmaceutical quality
assessment;
• enable innovative approaches to process
validation;
• establish real-time release mechanisms.
Opportunity to:
• increase use of risk-based approaches for
regulatory inspections;
4. Demonstrate effective
• facilitate science based pharmaceutical quality
pharmaceutical quality system and
assessment;
product and process understanding,
• optimise science and risk based post-approval
including the use of quality risk
change processes to maximise benefits from
management principles (e.g., ICH
innovation and continual improvement;
Q8, ICH Q9 and ICH Q10).
• enable innovative approaches to process
validation;
• establish real-time release mechanisms.
3. Demonstrate product and process
understanding, including effective
use of quality risk management
principles (e.g., ICH Q8 and ICH
Q9).

The discussion reiterated that the intent and spirit of cGMP requirements on change
control must be met.
It was agreed that structured and evidence-based risk reduction could enable faster
implementation of changes that reduced risk to patient safety, product quality and
product availability. The researcher, together with Dr O’Donnell, presented a vision of
what evidence-based risk reduction is and how it could be used within a continual
improvement framework (Ramnarine and O’Donnell, 2018). A structured risk
assessment for each change should enable rigorous assessment, planning, categorisation
and implementation of a change. A science and data-driven basis for the risk assessment
could help assess whether a change might increase risk to product quality and/or patient
safety. Where the risk assessment showed that the change did not increase such risk, it
could and should enable faster implementation and management of the change entirely
within the PQS, thus allowing the timely implementation of new knowledge.
In April 2019, the researcher presented to the Expert Circle, a draft checklist on QRM
application for change management. This checklist had been developed by the
researcher and was further refined with Dr O’Donnell prior to bringing it for discussion
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to the Expert Circle. An overview of the draft checklist is depicted in Figure 6.5,
developed by the researcher and O’Donnell.

Figure 6.5: Structured QRM Application Checklist for Change Management for
PIC/S QRM Expert Circle Discussion
The checklist approach, which was developed essentially to serve as a potential tool and
solution for supporting PAC management that required prior-approval, in accordance
with the vision of ICH Q12 and Annex 1 of ICH Q10, received positive comments from
the Expert Circle; there was a very productive discussion on the contents of the
checklist, and the Expert Circle agreed to review and provide detailed comments on the
checklist in order to continue to develop it further. Agreement was achieved at that
April 2019 meeting that the checklist could become useful guidance for inspectors on
how to assess the effectiveness of risk-based change management activities during
inspections of pharmaceutical companies. The Expert Circle agreed to discuss and
decide on next steps for the checklist. The checklist eventually became one of the
published PAC solutions that is key for implementation of ICH Q10 and ICH Q12, and
is described in Chapter Eight, section 8.4 of this thesis.
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European Commission (EC)
6.3.1 Research-related Contribution to the EC’s
Pharmaceutical Strategy for Europe 2020
In November 2020, the European Commission (EC) published a Pharmaceutical
Strategy for Europe that aimed at:
“creating a future proof regulatory framework and at supporting industry in
promoting research and technologies that actually reach patients in order to
fulfil their therapeutic needs while addressing market failures. It will also take
into account the weaknesses exposed by the coronavirus pandemic and take
appropriate actions to strengthen the system.” (European Commission, 2020)
The strategy was built on four pillars:
1. Ensuring access to affordable medicines for patients
2. Supporting

competitiveness,

innovation

and

sustainability

of

the

pharmaceutical industry
3. Enhancing crisis preparedness and response mechanisms, diversified supply
chains and addressing medicines shortages
4. Ensuring a strong EU voice in the world
One of the elements of the third pillar was a “sound and flexible regulatory system” that
enables regulatory efficiency, simplifies and streamlines procedures, and brings EU
regulatory approval timelines on to par with other parts of the world. A flagship
initiative on regulatory efficiency is revising the EU variations framework to “make the
lifecycle management of medicines more efficient and adapted to digitalization”.
The researcher and Vinther, on behalf of the 1VQ for PAC Initiative, provided specific
feedback to the EC in September 2020 on the Pharmaceutical Strategy for Europe,
specifically on aspects related to PAC management and flexible and efficient regulatory
processes. So, it was encouraging to see the Commission acknowledge the need to
modernise, via a more flexible and efficient regulatory system, and the action to make
legislative and non-legislative updates to the EU variations regulations and processes
called out as a flagship initiative.
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6.3.2 Research-related Contribution to the EC’s
Structured Dialogue on Security of Medicines
Supply Initiative
The COVID-19 crisis highlighted the need for enhanced resilience and security in
medicines supply. Enhanced resilience and supply security are clear objectives of the
EC’s Pharmaceutical Strategy for Europe, adopted in November 2020.
To this end, in February 2021, the EC launched a Structured Dialogue Initiative with the
intent to:
“strengthen the resilience of pharmaceutical supply chains and ensure the
security of supply of medicines, without compromising the affordability of
medicines.” (European Commission, 2021)
Four specific workstreams were initiated – Robust Supply Chain, Critical Medicinal
Products, Vulnerabilities and Innovation – and each was chartered to collect data and
sound evidence, analyse it, share perspectives and produce a report by July 2021 with
concrete measures to strengthen the resilience of pharmaceutical supply chains and
ensure security of medicines supply to patients in Europe. Workstream 3, on
Vulnerabilities, was scoped to identify the most frequent disruption challenges that
threaten medicines supply, drivers of these vulnerabilities at various stages in the supply
chain, and the potential financial impact of addressing those challenges and drivers.
The researcher and Vinther worked with the CQOs sponsoring the 1VQ for PAC
Initiative to identify three Qualified Persons (QPs) from Abbvie, Sanofi and Takeda, to
participate on Workstream 3, on Vulnerabilities, and in doing so, they would contribute
to the discussions related to regulatory requirements, by raising the issues pertaining to
the high level of global regulatory complexity associated with PAC management and
supply. The draft report was submitted to the EC in July 2021. It stated that:
“a vulnerability in the supply of medicines is a risk that might cause challenges
in access to medicines”
and it identified the following four aspects that lead to vulnerabilities:
1. Consolidation of the supply chain and investments in manufacturing capacity
linked to cost pressures
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2. The degree of geographical diversification for certain pharmaceuticals, raw
materials or technologies
3. Regulatory complexity and degree of regulatory convergence
4. Degree of visibility on supply and demand
On the third aspect, related to regulatory complexity, the report states:
“With relevance for all products, there is the need to improve the regulatory
efficiency associated with Post Approval Changes (PACs). PACs are inevitable
and necessary throughout the life of a drug product to implement new
knowledge, maintain a state of control, and drive continual improvement which
serves to enhance product quality and ultimately benefit patients. To better serve
patients, PACs should be managed in a timely manner. However, today many
PACs (including low risk changes) require prior regulatory approval that can
take up to five years before full implementation worldwide. Standardizing
regulatory procedures across the EU and globally, and leveraging a risk-based
approach to post-approval changes, would decrease supply chain
vulnerabilities.”
Though not published yet, Annex B of the report elaborates on the global regulatory
complexity issue, and it includes direct input from the 1VQ for PAC Initiative.
As expected of a ‘wicked problem’ and reaffirmed by the workstream, the report clearly
acknowledges that stakeholders involved in the work had divergent views and position,
and it was not possible to get consensus on all aspects of the report. Nevertheless,
securing general agreement within the drafting group on the above text for the
Vulnerabilities section of the report was a significant achievement for this research
work and the 1VQ for PAC Initiative – as perhaps for the first time, it was agreed that
the issue of regulatory complexity affecting PAC management and continual
improvement needed to be highlighted in an official publication as a contributor to the
problem of supply chain vulnerabilities and ultimately medicines shortages.

World Health Organisation (WHO)
The WHO founded in 1948, is a specialised agency of the United Nations responsible
for international public health. It connects nations, partners and people to promote
health, keep the world safe and serve the vulnerable – so everyone, everywhere can
attain the highest level of health. The World Health Assembly (WHA) is the decision-
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making body of WHO, attended by delegations from all WHO Member States; it
focuses on a specific health agenda prepared by the Executive Board.

6.4.1 WHO’s Reliance Practices
As a general operating principle, the WHO has supported reliance between regulatory
authorities in order to optimise the utilisation of available resources and expertise, and
avoid duplication of efforts, thereby allowing National Regulatory Authorities (NRAs)
to focus their efforts on value-added regulatory activities that cannot be performed by
another authority. The WHO is one of the more advanced agencies in acknowledging
that the complexity of regulatory oversight activities can be addressed “through
innovative and more effective forms of collaboration including reliance”. As a part of a
‘smart regulation’ initiative, it encourages Good Reliance Practices as a component of
Good Regulatory Practices, QAS/16.686 (WHO, 2016b).
In 2020, WHO issued draft working document QAS/20.851 on Good Reliance Practices
that provides guidance, definitions, key concepts, and considerations to guide reliance
activities between NRAs (WHO, 2020). The guidance defines reliance as:
“the act whereby the NRA in one jurisdiction may take into account and give
significant weight to assessments performed by another NRA or trusted
institution, or to any other authoritative information in reaching its own
decision.
The relying authority remains independent, responsible and
accountable regarding the decisions taken, even when it relies on the decisions
and information of others.” (WHO, 2020)
It makes an important distinction between reliance and recognition, whereby
recognition is:
“the acceptance of the regulatory decision of another regulatory authority
obviating the need for additional regulatory assessment in reaching one’s own
decision.”
The WHO’s six key principles that underpin good reliance practices are:
1. Universality (reliance applies to all NRAs irrespective of their levels of maturity
or resources
2. Sovereignty of decision-making (reliance does not imply dependence or giving
up accountability for regulatory decision-making)
3. Transparency (regarding standards, processes and approaches for reliance)
4. Respect of national and regional legal basis
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5. Consistency in application of pre-determined categories for products or
processes, and
6. Competency for critical decision-making
As part of the considerations in implementing reliance, the guidance highlights the role
the pharmaceutical industry must play in strictly adhering to the factors that make
reliance possible, such as when filing applications in multiple countries. Several barriers
were outlined, including a lack of accessible information (such as a company’s
proprietary knowledge being shared across countries), and maintaining confidentiality
of non-public information.
This was the first instance the researcher noted of a regulatory authority clearly
recognising and acknowledging that a “one size fits all” approach is not workable, that a
culture and mindset shift towards innovative and more effective ways of working, based
on trust is essential, and that convergence or harmonisation of requirements or
standards, and information-sharing and dialogue between regulators are important
enablers.

6.4.2 Collaboration Proposal to WHO from the 1VQ
for PAC Initiative
The vision, guidance, principles and considerations laid out in the WHO’s QAS/20.851
publication led the researcher and Vinther to seek a meeting in March 2021 with Dr
Samvel Azatyan (Team Lead Regulatory Convergence and Networks at the WHO),
along with other regulators at the WHO. The meeting was productive, and it resulted in
the researcher and Vinther making a collaboration proposal to the WHO in relation to
PAC management in the context of the WHO’ reliance initiative. Aligned with the
research objectives, the proposal focused on the utilisation of two dimensions - science
and reliance - to reduce regulatory complexity and improve medicines supply for
patients, as depicted in Figure 6.6.
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Figure 6.6: Reducing Global Regulatory Complexity Through Science and
Reliance
The contextual framework for the 1VQ for PAC proposal was getting to an environment
that was closer to real-time implementation of PACs, and it utilised the following three
levers:
1. Timely assessment of PACs by regulatory authorities. This was where each
NRA assesses and makes its decisions on PACs requiring prior-approval within
6 months. This could be made possible by regulatory authorities eliminating
regulatory procedures that extended overall PAC assessment timelines (the
proposal offered that the 1VQ for PAC Initiative could publish data on the
percentage of PACs that were decided on within 6 months across all relevant
countries).
2. Regulatory reliance among the WHO Listed Authorities for individual PACs
that had been assessed in accordance with the WHO guidance QAS/20.851. The
proposal also advocated for consistency in the reporting level and in the
documentation requirements for different types of PACs across the NRAs, using
the WHO guidance as a starting point.
3. Science and risk-based assessment of individual PACs, and the management of
low-risk PACs within an effective PQS without regulatory prior-approval.
Management Review activities at the company and reviews by regulatory
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authorities during inspections were proposed as the means to assess the
effectiveness of the PQS for PAC management.
The WHO was very supportive of the 1VQ for PAC proposal and of the concept of
using increased reliance in the management of PACs by NRAs; this tied in well with the
WHO's published Good Reliance Practices document (WHO, 2020). The WHO stated
that reliance with respect to PACs had been implemented already in several ongoing
initiatives, such as where NRAs were proactively informed of PACs that had been
approved for pre-qualified products (the WHO’s Prequalification Programme relies on
PAC decisions made by what is termed a ‘Stringent Regulatory Authority (SRA)’; this
applies to products originally approved by SRAs who were recognised by the WHO’s
Prequalification Programme). As one of the first steps in for the collaboration with the
1VQ for PAC Initiative, the WHO indicated to the researcher and Vinther that it
intended to map out the existing reliance frameworks for PACs between NRAs in
different regions. The WHO indicated that a situation in which an NRA exercised full
reliance on the PAC assessments by other regulatory authorities when dealing with
PACs itself would allow the best use of resources at that NRA, but it also acknowledged
that this would represent a significant shift in PAC management activities, given most
NRAs at that time performed their own assessment of PACs, and therefore it would take
time to change the mindset and culture. It suggested a pilot project for a defined scope
of products, where willing NRAs could be considered to serve as a test case and to
facilitate a larger roll-out of the proposed approach.
Further definition and scoping for the pilot with the WHO will continue as part of the
1VQ for PAC Initiative.

International Coalition of Medicines
Regulatory Authorities (ICMRA)
ICMRA is a voluntary, executive-level, strategic coordinating, advocacy and leadership
entity of regulatory authorities. ICMRA provides a forum for its member authorities to
work together in order to:
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•

address current and emerging human medicine regulatory and safety challenges
globally, strategically and in an ongoing, transparent, authoritative and
institutional manner

•

provide direction for areas and activities common to many regulatory authorities'
missions

•

identify areas for potential synergies

•

wherever possible, leverage existing initiatives, enablers and resources.

ICMRA provides a global architecture that supports enhanced communication,
information sharing and crisis response among and by its member regulatory
authorities, and it also addresses regulatory science issues. Currently, 35 medicines
regulatory authorities from every region in the world are ICMRA members, with the
WHO as an observer.
As a follow-up to the January 2019 discussion and direction from the FDA, as described
in Chapter Six, section 6.1, the researcher and Vinther continued regular exchanges with
Dr Theresa Mullin, FDA CDER’s Associate Director for Strategic Initiatives. Dr Mullin
had been assigned by Dr Woodcock as the FDA lead to activate discussions and
collaborative solutions among global regulatory authorities in relation to improving
reliance and agility in PAC management. The exchanges between the researcher,
Vinther and Dr Mullin included her seeking, and acquiring, a deeper understanding of
the operational challenges that companies faced when proposing and implementing
PACs, especially those affected by regulatory complexity and long assessment
timelines. She sought specific input from the 1VQ for PAC Initiative on topics such as
establishing a global quality dossier, the use of standard IT platforms for electronic
sharing of information between a company and multiple regulatory authorities, and
between regulatory authorities.
Dr Mullin leveraged the wicked problem and the global regulatory complexity framing
that had been provided by the researcher and Vinther, to establish a case for change in
ICMRA; and in this regard, the researcher’s work was cited in a confidential ICMRA
Reflection Paper on this topic. While the Reflection Paper cannot be disclosed outside
of ICMRA, Dr Mullin shared it with the researcher and Vinther, acknowledging that
this research and the work of the 1VQ for PAC Initiative were foundational for the
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development of the ICMRA paper and in convincing ICMRA of this case for change.
The section below presents the outcome of the work driven by Dr Mullin within
ICMRA.

6.5.1 Influencing ICMRA’s Strategic Initiative Global Pharmaceutical Quality Knowledge
Management System (PQKMS): Enhancing
Regulatory Reliance and Agility
In June 2021, ICMRA announced a global initiative on a Pharmaceutical Quality
Knowledge Management System (PQKMS). It had the objective of improving
efficiencies and agility across regulatory authorities through common procedures,
guidelines, requirements and infrastructure that facilitated reliance and timely sharing of
PAC-related information among regulators (ICMRA, 2021).
This was the first-time regulators had collectively acknowledged the global supply
challenges that pharmaceutical companies faced due to the delayed implementation of
PACs, and they recognised the need for a coordinated Pharmaceutical Quality
Knowledge Management capability that would ensure timely and complete information
access and assessment of pharmaceutical quality management and risk management
capabilities. The following is an excerpt published by ICMRA which demonstrates its
thinking in this area:
“ICMRA recognizes that regulatory authorities can gain efficiencies by
developing common procedures, guidelines, requirements, and interoperable
infrastructure that would facilitate the timely sharing of information among
regulators on changes occurring within the supply chain. This may include
reliance on the assessments of other regulators reviewing those changes.
ICMRA considers that this could lead to more timely availability of medicinal
products for patients by shortening approval timelines.”(ICMRA, 2021)
The desired state envisaged by ICMRA included standards for review among regulators
(“Enabling more extensive mutual reliance among regulators through work to
harmonize specific data expectations for sponsors and standards for review among
regulators, so that regulators can be assured of the comparability of the assessments
and related determinations of other regulatory authorities on whom they intend to
rely”), standardised and structured electronic formats that would facilitate rapid
assessments of PACs, secure and timely sharing of information among regulators,
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harmonisation of submission requirements and data expectations (in a manner that could
eventually support simultaneous PAC submissions to all relevant regulatory
authorities), and increased mutual reliance between regulatory authorities.
True to the nature of a ‘wicked problem’ that requires involvement from multiple
stakeholders to design and implement solutions, ICMRA recognised that this work was
strategic, transformative, that it would take time, and require a multi-stakeholder
approach involving regulators, legislators and the pharmaceutical industry.
In summary, parallel progression of this research and continued exchange with key
regulatory authorities, as described in this chapter, has served to raise awareness of this
wicked problem among the various stakeholder groups, and it has helped advance
discussions

to identify opportunities

for

collaborative solutions

within the

pharmaceutical industry, within the regulatory authorities’ community, and between
regulatory authorities and the pharmaceutical industry.
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Part Four: Unifying the Pharmaceutical
Industry
Part Four provides an overview on how the researcher brought the
pharmaceutical industry together to create deeper awareness and understanding of
current state challenges in assuring a reliable supply of safe, effective, high-quality
medicines for patients due to inadequate continual improvement and innovation.
It discusses how the researcher established a unified One-Voice-of-Quality (1VQ) for
PAC pharmaceutical industry platform for the development of practical solutions that
could be consistently implemented with respect to PAC management (Chapter 7).
This represents an important segment of the body of work undertaken in this research
study.
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The Importance of Bringing the
Pharmaceutical Industry Together
The pharmaceutical industry plays a multi-dimensional role on the broader topic of drug
shortages relating to manufacturing, quality and supply chain issues. Through the course
of this research and, while exploring the position of various regulatory authorities as
described in Chapter Six of this thesis, it became evident that the pharmaceutical
industry had to play a crucial role in the development and implementation of standard
global solutions in this area. As many drug shortages originate in the manufacturing and
supply processes that are within the scope and responsibility of pharmaceutical
companies, many mitigations and controls fall within the remit and responsibility of
these companies. However, for the effective implementation of controls, regulators and
other stakeholders in the supply chain also have a critical role to play.
Patients rightfully expect that medicines are produced and controlled consistently using
modern, or even state-of-the-art technologies, processes, and test methods. This implies
that manufacturing facilities, process controls and analytical test methods must be
continuously improved and updated over a drug’s entire lifecycle, in line with
advancing science and evolving technology. This also aligns with the primary
objectives of ICH Q10 of product realisation, maintaining a state of control and
continual improvement. However, due to the complexity of the regulatory process, it is
common for pharmaceutical companies to ‘lock in’ their manufacturing processes,
equipment and test methods, rather than innovate and continually improve them through
the commercial lifecycle of a product.
There are multiple barriers to innovation during lifecycle management of a product, and
as discussed earlier, one is the complexity of the current PAC management
environment. Most changes in processes, methods, facilities, and equipment apply to
medicines that are distributed globally. Yet regulatory requirements related to PAC
implementation (including the assessment of impact to product quality, safety, and
efficacy) are mainly established on a local or national level. With these requirements
170

varying significantly from country to country in terms of reporting levels, reporting
requirements, documentation needed, and approval timelines, globally applicable PACs
become a logistical challenge that require excessive time and resources to see them to
completion. This discourages innovation as well as increases the risk of drug shortages,
supply mistakes and noncompliance situations.
While drug shortages remain as the underpinning theme for this research, this part of the
study explores the role of the pharmaceutical industry in developing and implementing
solutions to overcome the challenges and complexities associated with driving
innovation and continual improvement. Without this, pharmaceutical companies cannot
make a meaningful impact and contribution towards reducing drug shortages.
While focusing on the role of pharmaceutical companies in this chapter, the researcher
does not intend to underestimate that other stakeholders, including regulators, play in
identifying and working towards meaningful solutions for their sector of activities. As is
true for a ‘wicked problem’, many solutions, even if not jointly designed by the
different stakeholder groups, will require active dialogue, engagement and collaboration
for implementation, if they are to make the much-needed difference for patients.
This chapter focuses on:
•

Pre-PhD research activities that were foundational to the design of this research
study and its hypotheses as described earlier in Chapter Three of this thesis

•

Research focus, where a case for change was made with the CQOs of 20+ global
pharmaceutical companies, and which led to the inception of the 1VQ for PAC
Initiative.

Pre-Research Activities Foundational to
Unifying the Pharmaceutical Industry
Advancing the activities that resulted from the drug shortages work and the PDA
Technical Report 68 on barriers to continual improvement and innovation, the
researcher started a deeper exploration into the hurdles for PACs. The sections below
describe work that is considered foundational to this research component on unifying
the pharmaceutical industry towards common positions that would lead to standardised
solutions further in the research.
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7.1.1 Pharmaceutical Industry Call to Action
As discussed in Chapter One of this thesis, in October 2016, the researcher established
PDA’s PAC iAMSM Task Force and issued a Call to Action (Ramnarine and Vinther,
2016), inviting the pharmaceutical and regulatory community to come together in
tackling the ‘wicked problem’ of drug shortages. The specific focus of this Call to
Action was on overcoming barriers to post-approval control and maintenance of
operations, continual improvement and innovation. This marked the beginning of the
researcher’s work in bringing the pharmaceutical industry together into an awareness,
exploration and engagement-raising dialogue on this topic. The objectives of the PAC
iAMSM Task Force included the following:
•

Bring awareness to current challenges, accelerate the dialogue and enable
stronger collaboration amongst opinion leaders and key stakeholders (within the
pharmaceutical industry, regulatory agencies, and other relevant stakeholders)

•

Foster a science and risk-based approach to PAC management and regulatory
decision-making for global product quality, safety, and efficacy assessments

•

Encourage international convergence or standardisation in PAC management in
a manner that can foster and enable mutual reliance between regulatory
authorities

•

Manage more PACs through the use of an effective PQS without prior
regulatory approval

The Call to Action emphasized the important role that the pharmaceutical industry must
play in bringing about a reform for PAC management, whereby the global
implementation timeline for a PAC can be reduced from years to months. This was
identified as an essential factor that would incentivise pharmaceutical companies to
innovate and continually improve, thereby contributing to improving the availability of
medicines.
The Task Force discussed the importance of developing practical science and risk-based
solutions, including a library of PAC examples, and how application of science and
risk-based approaches could enable better decisions in determining the submission and
approval categories for changes. In addition to developing the solutions and PAC
examples, it was also recognised that they should be standardised in order to truly gain
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value from them. The Call to Action was also a call to the pharmaceutical industry to
come together as one. The expectation was that developing conceptual aspects into
practical real-life implementation examples would bring the industry and regulators to a
more common and aligned understanding of the mutual challenges and opportunities to
collaboratively improve the current state.

7.1.2 Post-Approval Change Innovation for
Availability of Medicines (PAC iAMSM) Survey: Is the
Regulatory Environment Hindering Much-Needed
Innovation in the Pharma Industry?
In 2016, the researcher led the PDA PAC iAMSM Task Force to collect information and
data on PAC management experiences from across the pharmaceutical industry, in order
to determine the extent of the challenge with global PAC management, and the
contributions of the global regulatory complexity towards hindering continual
improvement and innovation. This information was collected by means of a survey; the
researcher led the design of the survey and it was distributed by PDA to its members as
described below. The results of the survey were analysed by the researcher, published in
early 2017 (Ramnarine, Busse, Colao, Edwards, Follman, et al., 2017), and were used
as a trigger by the Task Force to start expanding awareness and initiating dialogue
within the pharmaceutical industry. Simultaneously, while the survey was being carried
out, the Expert Working Group that had been convened by ICH to develop ICH Q12,
Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle
Management, was in the early stages of developing that new guideline.
PAC iAMSM Survey Design
The survey was designed to explore specific aspects related to the volume of PACs
initiated, why PACs were needed, their submission and approval timelines, any impacts
on shortages, innovation and burden. Up until that point, the information related to PAC
management complexity and burden was mainly anecdotal and perception-based, and
the survey was designed to generate qualitative verifiable evidence. The results of the
survey presented below confirmed the perceptions and the unintended implications of
the global regulatory complexity associated with PAC management, potentially
resulting in drug shortages.
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To ensure anonymity, the survey was distributed via survey monkey by PDA to all
companies that had members in PDA. The results were also collected by PDA.
Survey Results
There were 85 respondents to the survey from Quality, Regulatory, Manufacturing,
Technical Operations and Development functions, from Biologics, Small Molecules,
Drug Substance and Drug Product manufacturing companies, both generics and
innovator companies. 51% of the companies marketed greater than 20 products, and
33% marketed greater than 100 products. 38% of respondents reported that they
managed greater than 1000 PACs annually, and 32% reported 50-500 PACs in a year.
This was a significant volume of PACs going through the global regulatory system.
Almost 40% of companies responded that more than 50% of their changes required
submission to regulatory authorities in 25 to 100+ countries, and the changes were not
permitted to be managed only within the company’s PQS. The survey also explored the
reasons for the PACs and found that many of the changes sought by pharmaceutical
companies were intended to improve processes (89%), drive innovation (60%) and
upgrade aging equipment (71%), with many changes considered major or moderate, and
therefore requiring prior-approval.
Respondents almost unanimously (97%) identified the complexity of global regulations
as inhibiting both innovation and technological progress. 76% reported that they
experienced supply disruptions and drug shortages due to prolonged regulatory approval
timelines. Additionally, 65% of companies indicated that they had non-compliance with
product registrations because the current knowledge on a product was not represented in
the product file. In particular it was of concern to the researcher that 87% of participants
reported that they did not proceed with changes due to the regulatory burden. The
survey supported the hypothesis proposed by the researcher that:
global regulatory complexity contributes to the increased burden of PAC
management, increases the barrier for innovation and continual improvement,
and could eventually contribute to drug shortages and supply issues.
Impact of the Survey
The researcher presented the PAC iAMSM survey results at PDA conferences and
workshops in 2017-2018 so that it could be discussed by stakeholders. Arising out of
these discussions, an infographic (Figure 7.1) depicting the complexity of PACs was
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developed by the researcher and Vinther, where approval of every PAC by each
regulatory authority was compared to an analogy where every passenger must inspect a
plane before it takes off (Stauffer, Vinther and Ramnarine, 2017). Obviously, this is not
the case in the aviation industry, but one ponders:
‘if passengers can trust a system that checks all relevant aspects before a
plane’s take-off, why could pharmaceutical regulatory authorities not trust
pharmaceutical companies to manage moderate or minor PACs within the
company’s PQS, without requiring a submission and in several instances, a
prior-approval by each regulatory authority?’
Furthermore, is it possible that all regulatory authorities could employ a consistent
checklist for PAC assessments, which would lead to a situation where, if one regulatory
authority were to approve and confirm acceptance of a PAC, other regulatory authorities
could accept this approval, without requiring their own independent review and
approval? Four years later, this is now being taken up by ICMRA as part of their
strategic PQKMS Initiative, where one of the envisioned capabilities is:
“Enabling more extensive mutual reliance among regulators through work to
harmonize specific data expectations for sponsors and standards for review
among regulators, so that regulators can be assured of the comparability of the
assessments and related determinations of other regulatory authorities on whom
they intend to rely.” (ICMRA, 2021)
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Figure 7.1: Analogy between PAC Approval and an Airplane Check Prior to
Take Off (Stauffer, Vinther and Ramnarine, 2017)

176

7.1.3 PDA PAC iAMSM Workshop, September 2017
In September 2017, the PDA PAC iAMSM Task Force organised its first 2-day
workshop in Washington D.C. Chaired by Ursula Busse, Novartis, and Lisa Skeens,
Pfizer, with the researcher a member of the Workshop Planning Committee. The
workshop provided insights into several international initiatives such as ICH Q12,
touched on practical aspects of PAC implementation, and provided an overview of the
PDA PAC iAMSM Task Force’s work. There was extensive discussion on the lack of a
harmonised global regulatory framework for PACs and how this led to supply chain
complexity, slowed down the pace of manufacturing innovation, and increased the risk
of quality failures. Several global initiatives to address the issue had been launched by
ICH and WHO. Co-sponsored by IFPMA, a trade association operating at a global scale
and PDA, this workshop was attended by 80 participants, and featured active
participation by speakers and panelists from the FDA, the ICH Q12 EWG, IFPMA,
PDA and the pharmaceutical industry.
The workshop provided the case for change, why a global dialogue was essential, what
changes were needed, and it presented some proposed global solutions that were being
informally discussed by the pharmaceutical industry and regulators. It reflected the most
current thinking on the concepts and tools proposed to facilitate PACs and spur
manufacturing innovation, through the in-progress ICH Q12 document and beyond.
The researcher made the case through her presentation that much attention had been
given thus far to the development & technology transfer phases and less so to the
commercial phase of a product’s lifecycle. The commercial phase is where companies
continued to gain extensive product and process knowledge that needs to be captured in
a structured way, making lifecycle management quite dynamic. The researcher provided
insights into why KM and QRM must be an integral part of the product lifecycle. She
laid out the importance of having a lifecycle management strategy that would be
holistic, proactive and global, and she described how an overall product lifecycle could
be managed within the company’s PQS to ensure that all quality requirements were
implemented and maintained according to relevant global and regional regulatory
requirements or commitments. The elements of the lifecycle management strategy as
described in the PDA Points to Consider Paper, Technical Product Lifecycle
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Management: Pharmaceutical Quality System Effectiveness for Managing Postapproval Changes (Ramnarine, Busse, Colao, Edwards, O’Donnell, et al., 2017), were
also presented by the researcher, along with practical examples of product lifecycle
management (PLCM) from Roche, how the company handled this plan within their PQS
to manage the lifecycle of a product, and how the plan was used to determine which
PACs needed to be filed with regulatory authorities. The researcher emphasized that:
1.

A lifecycle management strategy could enable a MAH to manage a product
holistically, prospectively and globally, to accomplish the objectives of ICH
Q10

2.

An effective PQS was essential for establishing and executing the lifecycle
management strategy

3. The lifecycle management strategy could serve as an excellent communication
mechanism to proactively engage regulatory authorities and build trust
4. A

knowledge

and

risk-based

approach

could

expedite

review

and

implementation of planned PACs, and
5. Proactive and timely exchange of knowledge between pharmaceutical
companies and regulatory agencies could reduce PAC notification requirements.
At the workshop, presentations were complemented by interactive case studies, where
participants explored concepts and tools proposed by ICH Q12 to better manage PACs,
by applying the science- and risk-based approaches mentioned by the speakers.
Participants clearly prioritised knowledge management and quality risk management in
their change management system to gain regulatory flexibility, as shown in Figure 7.2
which was compiled from a mentimeter5 pulse survey conducted at the workshop.

5

An interactive, live polling tool to get real-time input from an audience
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Figure 7.2: Mentimeter Pulse Survey on Knowledge Management and QRM as
Key to Enable Regulatory Flexibility
The workshop was highly interactive and showed how ICH Q12 could increase
opportunities to make changes without prior-approval for the benefit of both the
pharmaceutical industry and regulators, if appropriately implemented. It affirmed that
companies should work together to develop and implement solutions; additionally, the
pharmaceutical industry should work in a transparent and proactive manner with
regulators to build trust. Investment in product lifecycle management and PQS
effectiveness should be incentivised. All global efforts combined could foster regulatory
convergence of PAC regulations, encourage adoption of shared principles, and facilitate
continual improvement to spur manufacturing innovation globally.
Towards the end of the workshop, participants shared their views on the impact they
anticipated of the current initiatives with ICH Q12 and WHO on PAC management. In
general, the views about the impact of these initiative on the current situation did not
change from when they were polled on the same question at the beginning of the
workshop - 75% still pointed to a favourable impact, while 25% felt that PAC
management would just be different as a result of these initiatives. It was acknowledged
that, while ICH Q12 would help with some improvements, it would not solve the issue
in non-ICH countries which was where global pharmaceutical companies faced the
majority of their PAC challenges. Participants also highlighted additional critical
success factors for these initiatives - trust, harmonisation, dialogue, courage and
practical examples, as shown in the mentimeter results of Figure 7.3. There emerged
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evidence of a desire to support standardisation across the pharmaceutical industry and
the implementation of shared principles through practical application PAC examples.

Figure 7.3: Mentimeter Pulse Survey on What is Needed in Addition to ICH Q12
and WHO Efforts
The workshop discussions identified the strong link between an effective PQS and
successful product lifecycle management. Particular focus on risk-based change
management emerged as an area to delve further into, with real-life PAC examples.
Overall, the workshop discussions suggested that companies could gain regulatory
flexibility in PAC management if they applied the principles of ICH Q8 – 11. A sound
scientific understanding of products and processes, coupled with consistent application
of QRM, which are embedded in an effective PQS, would provide the basis for ICH
Q12 realisation.
The next section describes the two PDA Points to Consider Papers on Product Lifecycle
Management that resulted from the PDA PAC iAMSM Task Force’s work, with the
researcher being the lead author.

7.1.4 PDA Points to Consider Papers on Product
Lifecycle Management
The discussions and activities of the PDA PAC iAMSM Task Force were published in
two Points to Consider Papers on Technical Product Lifecycle Management, one related
to communication and knowledge exchange between Marketing Authorisation Holders
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and regulatory authorities (Ramnarine, Busse, Colao, Edwards, Jornitz, et al., 2017),
and the other on use of an effective PQS for management of PACs (Ramnarine, Busse,
Colao, Edwards, O’Donnell, et al., 2017). The researcher and Vinther co-led the
development and authorship of both. The work undertaken in their development
resulted in text that was also provided as input to the ICH Q12 Expert Working Group
(EWG) for consideration during the drafting of ICH Q12.
The prior work described above by the researcher led to the development of a formal
research study, which is the focus of this PhD.

Research Focus: Making a Case for Change with
Chief Quality Officers (CQOs), Sept. 2018
The PAC iAMSM Task Force had started as a small team comprised mainly of
volunteers interested in and passionate about improving PAC management. It was
becoming evident to the researcher and Vinther, especially given the feedback from Dr
Woodcock and senior FDA leaders that, the effort needed to be broadened beyond PDA
to the industry level. It also was becoming increasingly important to expand beyond
volunteers from companies to ownership by senior leaders that were directly responsible
for PAC management and the PQS within their companies. Therefore, in August 2018,
the researcher and Vinther along with the PAC iAM SM Task Force members hosted a
workshop where attendees were expanded beyond the Task Force to QMS Heads and
operational Quality and Regulatory Affairs leaders who were directly involved in PAC
management. This workshop became a seeding point for a unified Quality voice on the
topic, and an outcome was that the researcher and Vinther seek endorsement to formally
establish a single voice of Quality for PAC management.
The CQOs are the senior-most Quality leaders in pharmaceutical companies. The CQOs
of the 25 top global pharmaceutical companies regularly meet, at least biannually, for
roundtable discussion on Quality hot topics, organised by PricewaterhouseCoopers
(PwC). This is a closed forum and no agendas or minutes are published from these
sessions due to the nature of confidential company specific information that might come
up. After the August 2018 workshop, which is considered as the first 1VQ for PAC
workshop, the researcher and their co-lead met with the CQOs to gauge their interest
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and to seek sponsorship from these senior-most Quality leaders for a 1VQ for PAC
Initiative. This meeting took place in September 2018 in Washington DC, and the
discussion was framed by the researcher and Vinther as:
“How can One-Voice-Of-Quality foster an environment of continual
improvement while reducing risk to patient?”
The discussion focused on elevating awareness by the CQOs of the global PAC
complexity, which creates a paradox in which continual improvement is desired and
expected, yet it can take years to implement new knowledge into operations.
The CQOs were asked for their level of interest in speaking with one voice to align and
standardise the pharmaceutical industry on a standard, risk-based approach for PACs,
and to define what constitutes an effective PQS for PAC management. Both aspects
could be designed to reduce the number of PACs that were submitted for priorapproval, with more PACs being managed within the PQS only. Development of
practical examples as a means to activate the dialogue within the pharmaceutical
industry and between the pharmaceutical industry and its regulators was also proposed.
The CQOs discussed the importance of finding the right mechanism to present this
problem to regulators, including ‘what’s in it’ for regulatory agencies individually, as
well as collectively, and ultimately for patients. They discussed concerns that regulators
might as a result of this initiative, add more requirements on companies for the
documentation of PACs that would be proposed as no longer needing a prior-approval
submission. The importance of enabling a culture of trust and transparency with
regulators emerged.
The meeting with the CQOs was highly productive, with evidence of a keen interest in
the topic demonstrated. They appreciated and acknowledged that the regulatory
complexity for PACs slowed down continual improvement and innovation, to a point
where it caused additional burden for companies in terms of cost and supply. This was a
significant global problem in their view, and in several cases, could lead to supply
disruptions. Outcomes of the discussion with the CQOs were summarised as follows
and circulated to the attendees (with a request for an update at their next meeting in
April 2019):
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•

Agreement that the current regulatory complexity was increasing with time, and
that a concerted effort would be needed to reduce that complexity and allow for
more improvement and innovation

•

Agreement that this is a ‘wicked problem’ i.e., highly resistant to solutions

•

Endorsement by CQOs of the One-Voice-of-Quality (1VQ) for PAC Initiative
and agreement to speak with a unified voice

•

Agreement that more PACs should be managed within the PQS only rather than
requiring prior-approval by regulatory authorities prior to implementation

•

Agreement to the development of standard and practical solutions with real
examples for:
o Effective PAC management within the PQS
o Structured risk-based approach for PACs

•

Agreement to assign a representative from their respective companies to be
members of the 1VQ for PAC Initiative

•

Agreement to provide specific PAC examples that could be covered solely
within the PQS without requiring prior-approval submissions

All subsequent 1VQ for PAC activities and focus groups were conducted within the
context of this high-level framing endorsed by the CQOs.

1VQ for PAC Focus Group Sessions Summary
The research methodology used to bring the pharmaceutical industry together for Part
Four of this study was through face-to-face and/or virtual (during the COVID-19
pandemic) focus group sessions, hosted at different pharmaceutical companies that are
members of the 1VQ for PAC Initiative or at the PDA headquarters. The scope of work
that was decided on for the 1VQ for PAC Initiative and Focus Groups at the first session
in August 2018, which was subsequently endorsed in September 2018 by the CQOs
sponsoring the initiative included:
•

Raise awareness of global PAC complexity

•

Influence through practical solutions:
o Elevation of the risk appetite for innovation
o Management of more PACs within the PQS only – provide specific
examples
183

•

Align & standardise the industry on:
o What is an effective PQS for PACs?
-

Metrics and attributes capable of distinguishing effective vs
ineffective PQS for PACs

-

How could it be assessed during inspections?

o Standard risk-based approach for PACs
•

Build a culture of transparency & trust with regulators

Figure 7.4 below lists the 1VQ for PAC Initiative member companies that have
participated in one or more of the focus group sessions and/or CQO Forum discussions.

Figure 7.4: 1VQ for PAC Initiative Member Companies
Eight focus group sessions ranging from one to two-and-a-half days in duration, co-led
by the researcher and Vinther, were held between August 2018 through March 2021,
with representatives from 1VQ for PAC Initiative member companies. (Note: 1VQ for
PAC Initiative activities and workshops will continue with the member companies even
after completion of this research study). Following the September 2018 meeting
(described in section 7.2), where the CQOs confirmed their sponsorship of the 1VQ for
PAC Initiative, an additional eleven focus group sessions were held by the researcher
and Vinther with the CQOs sponsoring the initiative and the QMS Heads from these
companies. An overview of the format and approach used to conduct these focus groups
and review of resulting outputs is provided earlier in Chapter Three, section, 3.5 of this
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thesis. A summary of these focus group sessions is provided in Tables 7.1 and 7.2
below.
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Table 7.1: Summary of Focus Group Sessions with 1VQ for PAC Member Companies
Focus
Group #

1

2

Date/Location

1VQ for PAC Member
Companies

27-August-2018
PDA, Bethesda

Amgen, Astellas, Biogen,
Catalent, Emergent
Biosolutions, Intarcia, Johnson
& Johnson, Merck, Novartis,
Roche/Genentech,
Sanofi/Sanofi Pasteur

13-November-2018
PDA, Bethesda

Amgen, Astellas, Astrazeneca,
Bayer, Biogen, Eli Lilly,
Emergent Biosolutions, GSK
Vaccines, Intarcia, Johnson &
Johnson, Merck, Novartis,
Novonordisk,
Roche/Genentech,
Sanofi/Sanofi Pasteur

Key Outcomes
• Decision to create 1VQ on the importance of implementing new
knowledge to continually improve/innovate faster
• Decision to take practical actions to improve handling PACs, by
standardising the approach across industry
• Agreement that the participants would raise awareness about the
unsustainable situation with PACs; generate more dialogue with
regulators as a single Quality voice
• Agreement to define key elements of an effective PQS for PACs and
drive implementation within companies – the importance of being
consistent across the pharmaceutical industry was acknowledged
• Agreement to define, in consultation with regulators, attributes or
measures capable of distinguishing effective vs. ineffective PQS for
PACs, and discussions with regulators for input and alignment
• Agreement to develop a standard risk-based approach for PACs, which
would be applied consistently across the pharmaceutical industry
• Agreement to assess how to engage with PIC/S to pilot the standard
risk-based approach for PACs, with a view to agreeing on what an
effective PQS for PACs could look like, and how it could be assessed
during inspections
• Obtained endorsement from 1st CQO discussion 27-Sept-2018 (DC)
• Agreement on the ambition - at least 50% reduction of prior-approval
PACs by end 2021
• Agreement on attributes to demonstrate effectiveness of PQS for PACs
Foundational Attributes (across all PACs)
o Company is cGMP compliant
o Company demonstrates right quality culture (e.g., no recurring
issues)
o Company demonstrates a robust quality risk management
programme
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Focus
Group #

Date/Location

1VQ for PAC Member
Companies

Key Outcomes

•

•

3

27-March-2019
PDA, Bethesda

Amgen, Astrazeneca, Bayer,
Biogen, Catalent, Eli Lilly,
Emergent Biosolutions, GSK
Vaccines, Intarcia, Johnson &
Johnson, Merck, Novonordisk,

•
•

o Company resources proactively allocated to continual
improvement activities
o PACs initiated by proactive continual improvement projects (as
part of the company’s Quality Plan)
o New knowledge (complaints, operations, Annual Product
Review (APR)/ Product Quality Review (PQR), etc.) integrated
into PACs
o Company inspection or audit findings related to management of
PACs
Metrics/Attributes for Individual PACs
o Formal risk management performed for each PAC
o Adherence to implementation timelines for PAC
o PAC and CAPA Effectiveness
o PACs with unintended risk or consequence (deviations)
o No unacceptable risks introduced as a result of PAC
Agreement to develop 4 specific PAC examples
o Excipient supplier name or address change - with no change in
manufacturing site, equipment, material, process, or material
grade or specification
o Drug product batch size increase – with no change in
equipment
o New technology – rapid microbiology method
o New technology for indirect product quality testing such as
environmental monitoring
Obtained support and sponsorship from QMS Head Forum, 6-Mar-2019
(London)
Finalised 1VQ for PAC Concept Paper
Agreement to deliver the following from the 1VQ for PAC Concept
Paper
o Define and demonstrate effectiveness of the PQS for
management of PACs - so that more changes can be managed
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Focus
Group #

Date/Location

1VQ for PAC Member
Companies

Key Outcomes

Roche/Genentech,
Sanofi/Sanofi Pasteur

•

•
•
•

•

4

19-20-Jun-2019
GSK, Rockville

Amgen, Astrazeneca, Biogen,
Eli Lilly, Emergent
Biosolutions, GSK Vaccines,
Intarcia, Johnson & Johnson,
Merck, Novartis,
Roche/Genentech,
Sanofi/Sanofi Pasteur

•

in the PQS or via notification pathways, instead of priorapprovals
o Standard risk-based assessment of PACs incorporating latest
product and process knowledge
o Pilot proposed solutions with a limited number of companies.
Seek input from regulatory agencies on outcomes
Agreement to develop 3 additional PAC examples
o Implementation of a new reference standard
o Extension of DP shelf life
o Compendial changes
Agreement to develop general PAC framework for a new technology
implementation (as a notification instead of prior-approval submission)
Obtained endorsement for Concept Paper at 2nd CQO Forum, 4-Apr2019
Established sub-teams to work on the deliverables
o Sub-team 1: Effectively Managing PACs in the PQS
o Sub-team 2: Standard Risk-based approach for individual
PACs
Decided on specific outputs for each sub-team
o Sub-team 1: A document that would be written at the level and
format of ICH Q10 and ICH Q12 describing the ‘what’ and
not the ‘how’ for effective management of PACs in the PQS.
The team determined that it would be written as though it
could be an Annex 3 to ICH Q10, specifying what should be
in the PQS to effectively manage PACs (especially for
changes that could be downgraded from prior-approval
submissions)
o Sub-team 2: A document that would describe a standard riskbased approach to manage individual PACs (applying ICH Q9
and Q12 principles)
Developed standard template for PAC examples
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Focus
Group #

Date/Location

1VQ for PAC Member
Companies

Key Outcomes
• Decided on highlights for next updates to CQO Forum 19-Sept-2019,
and QMS Heads Forum 24-25-Sept-2019

5

6

7

15-16-October-2019
Biogen, Raleigh

Amgen, Astrazeneca, Biogen,
Eli Lilly, Emergent
Biosolutions, GSK Vaccines,
Intarcia, Johnson & Johnson,
Merck, Novartis,
Roche/Genentech,
Sanofi/Sanofi Pasteur

26-27-February-2020
Merck, Philadelphia

Amgen, Astrazeneca, Biogen,
Catalent, CSL Behring, Eli
Lilly, Emergent Biosolutions,
GSK Vaccines, Intarcia,
Johnson & Johnson, Merck,
Roche/Genentech,
Sanofi/Sanofi Pasteur, PDA

30-31-July-2020
Virtual

Amgen, Astrazeneca, Biogen,
Catalent, CSL Behring,
Emergent Biosolutions, GSK
Vaccines, Intarcia, Johnson &
Johnson, Merck, Novartis,
Roche/Genentech,

• Finalised solutions from sub-teams 1 and 2 for Effective PQS for PACs
and Risk-Based Change Management
• Initiated Communication & Implementation Planning
• Continued development of PAC examples
• Finalised 1VQ for PAC Solution paper – Effective PQS for PACs
including risk-based decision tree
• Developed 1VQ for PAC Implementation Plan outline for
o PIC/S Recommendation Paper
o 1VQ for PAC Solution Paper
o 1VQ for PAC Examples
• Continued development of 1VQ for PAC Communication Plan
• Agreement to develop 1VQ for PAC position papers for the following
PAC examples
o Automated colony counter
o Drug product scale change
o Compendial excipient update
o Drug product shelf-life change
o Analytical instrument model change
o Reference standard update
o Analytical new technology
• Discussed COVID-19 impact and experiences and what to retain postpandemic
• Further development of Management Review 1VQ for PAC position
paper
• Refinement of the 1VQ for PAC message to continue increasing
awareness of the problem and expand involvement from companies and
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Focus
Group #

8

Date/Location

29-30-March-2021
Virtual

1VQ for PAC Member
Companies

Key Outcomes

Sanofi/Sanofi Pasteur, PDA

regulatory authorities that had not yet engaged in the effort
• Agreement that all companies would complete a maturity assessment
against
the
PIC/S
Recommendation
Paper
How
to
Evaluate/Demonstrate the Effectiveness of a Pharmaceutical Quality
System in Relation to Risk-Based Change Management
• Development of a standard approach to assess maturity gaps against the
published draft PIC/S Recommendation Paper

ADMA Bio, Amgen,
Astrazeneca, Biogen, Catalent,
CSL Behring, Emergent
Biosolutions, GSK Vaccines,
Intarcia, Johnson & Johnson,
Merck, Novartis,
Roche/Genentech,
Sanofi/Sanofi Pasteur, PDA

• Aligned on 2021 objectives & key activities including publications (see
section 7.4)
• Refined 1VQ for PAC messaging and communication deck
• Discussed status of PAC examples in progress and agreed on next PAC
examples
• Dialogue on implementation of ICH Q12 and 1VQ for PAC solutions
within companies
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Table 7.2: Summary of Focus Group Sessions with 1VQ for PAC Sponsoring CQOs and QMS Heads
Date

March-2019

April-2019

Focus Group
Attendees

QMS Heads Focus Group
Session #1

CQOs Focus Group
Session #1,

Key Outcomes
• Awareness of wicked problem of continual improvement, innovation and drug
shortages. The significance of the problem and the need for practical solutions was
confirmed.
• Provided update on decision from CQOs of 25+ global pharma companies to sponsor
the 1VQ for PAC Initiative
• Obtained commitment from QMS Heads for the 1VQ for PAC Initiative and to
implement resulting solutions within their companies for the following:
o How to demonstrate effective management of PACs in the PQS so that more
changes can be managed in the PQS or via notification pathways, instead of priorapprovals
o How to perform standard risk-based assessment of individual PACs that
incorporates latest product and process knowledge
• QMS Heads committed to partnering with Regulatory Affairs Heads within their
respective company to realise the vision of ICH Q9, Q10 and Q12
• QMS Heads committed to share approaches and examples from their companies on how
to demonstrate an effective PQS to reduce regulatory burden for PACs
• CQOs discussed the wicked problem of continual improvement, innovation and drug
shortages as a follow up to their September 2018 meeting. The significance of the
problem and the need for practical solutions was confirmed.
• Appreciated the terminology ‘wicked problem’ as it is indeed ‘highly resistant to
solutions’
• CQOs agreed to sponsor the 1VQ for PAC Concept Paper and approved it with the
following. Published paper incorporated these edits
o Add text regarding regulatory agencies already having company specific
information indicating the effectiveness of a PQS such as inspection reports,
PACMPs, and various reports and information exchanged between the agency and
the company
o Add text specific to state that downgrading a change from prior-approval can
either be notification or annual report
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Date

Focus Group
Attendees

September-2019

CQOs Focus Group
Session #2

September-2019

QMS Heads Focus Group

Key Outcomes
• CQOs were pleased with progress and agreed to continue their support and allocate
senior level resources from their companies
• Asked that dialogue should continue with regulatory agencies across the world and with
PIC/S
• Asked team to consider more data that objectively shows the magnitude of the problem
in a way that can be used in a tangible, constructive way. Examples - like 8,000 priorapproval submissions in one year from one company, > 99 % of changes approved, 80
% of RA team working on PACs
• Discussed that PAC assessments generate significant revenue for regulatory agencies.
Reducing PACs requiring prior-approval would reduce this revenue. Potential to
consider an alternative fee structure where individual PAC assessments aren’t revenue
drivers.
• Encouraged expansion of the initiative to more companies including CDMOs
• Supported develop of practical PAC examples that should be downgraded from priorapproval to notification or annual report. But asked to be cautious not to generate more
reporting or complexity
• Asked how CQOs could play a role in advancing this topic. Public and company
internal support both were noted as essential.
• CQOs continued to strongly sponsor and support the 1VQ on PAC Initiative (“We are
all in”)
• Pleased that the CQO-endorsed 1VQ for PAC Concept Paper was published, as well as
the progress on the Effective PQS, Risk-Based approach solutions (decision tree) and
PAC examples. Asked for development of more PAC examples.
• Informed of the PIC/S Recommendation Paper and its expectations
• Appreciated the importance of speaking with One Voice and standardised approach to
PAC management across the industry
• Asked researcher for communication materials to share within their companies
• Discussed the paradox of regulatory agencies expecting innovation and continual
improvement on the one hand and having rigid regulatory framework that doesn’t apply
a science and risk-based approach on the other hand
• Asked researcher for a common storyboard and case for change as communication
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Date

Focus Group
Attendees

Key Outcomes

Session #2
•
•
•
•
•
•
•
•
•
•
•
•
March-2020

QMS Heads Focus Group
Session #3

•
•
•

•
April-2020

CQOs Focus Group
Session #3

material
Discussed value gain from science and risk-based approach to PAC management
Developed a common implementation plan framing to be used by all companies
Discussed opportunities to pilot solutions within companies
Discussed influencing plan, targeting conferences attended by regulators too
Discussed importance of involving Regulatory Affairs within companies for
implementation
Agreed on the need to get input from both reviewers and inspectors on the 1VQ for PAC
solutions and PAC examples
Discussed how to influence solutions and examples being included in the ICH Q12
training package
Aligned on the industry position paper approach for simple PACs that could be
downgraded
Discussed PAC examples that should be downgraded
Aligned that no pilot was needed for 1VQ for PAC solutions. Companies would simply
implement the published 1VQ for PAC examples position papers
Acknowledged the need to continue to raise awareness of the global complexity
Many companies informed that they had initiated exchange between their Quality and
Regulatory Affairs functions for implementation
Emphasized the need for a joint meeting between CQOs and Regulatory Affairs Heads
Action: Continued PIC/S engagement; engage reviewers on published 1VQ for PAC
Additional request made by researcher to QMS Heads:
o Raise awareness and advocacy for 1VQ for PAC through their interactions
o Drive implementation of 1VQ for PAC solutions in their companies
o Provide input on 1VQ for PAC communication messages
o Provide PAC examples that are currently prior-approval, but should not be
Continued strong sponsorship and willingness from CQOs to show public support for
1VQ for PAC
o CQOs agreed to have their names and their companies added as endorsing
companies to 1VQ for PAC publications
o Asked that the 1VQ for PAC solutions paper be made stronger and relevant for
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Date

Focus Group
Attendees

September-2020

QMS Head Focus Group
Session #4

September-2020

CQOs Focus Group
Session #4

November-2020

CQOs and Regulatory
Heads Joint session

Key Outcomes
COVID-19 challenges
• Agreed that meeting with FDA (CDER, CBER) along with Regulatory Heads would be
useful. Asked that other regulatory authorities be invited
o Followed-up with FDA and other regulatory authorities was that such a meeting
would be challenging to organise due to pandemic priorities
• Agreed to a joint CQO-Regulatory Heads
• Additional requests made to CQOs:
o Support implementation of 1VQ for PAC solutions in their companies
o Provide input on 1VQ for PAC communication messages
o Provide PAC examples that are currently prior-approval, but should not be
• Key communication messages were discussed
• Reviewed and sought feedback on the 1VQ Management Review checklist position
paper
• Sought support to complete the PIC/S Recommendation Paper maturity assessment for
their companies
• Sought feedback on communication slides and key 1VQ for PAC messages
• Updates shared on 1VQ for PAC activities and deliverables
• CQOs continued to sponsor the 1VQ for PAC Initiative; emphasized the CQOs role
regarding regulatory flexibility solutions
• Continued raising awareness about 1) the PAC complexity and 2) the CQOs solution to
manage more PACs in the PQS only
• Key communication messages were discussed; recommended adding communications
experts
• Updated the communication slides and further clarified the messages
• Agreed to a joint focus group session between CQOs and Heads of Regulatory Affairs
• Reviewed and provided feedback on the 1VQ Management Review checklist position
paper
• Agreed to complete the PIC/S Recommendation Paper maturity assessment for their
companies
• First joint session between the senior-most leaders for Quality and Regulatory Affairs
within companies
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Date

Focus Group
Attendees

March-2021

CQOs Focus Group
Session #5

March-2021

CQOs Focus Group
Session with Dr Theresa
Mullin (CDER)

Key Outcomes
• Quality and Regulatory Heads aligned on the objectives and scope of 1VQ for PAC
Initiative
• Agreed to work together on 1) implementation in their respective companies and 2)
outreach to regulators
• Discussed that biggest challenge with global regulatory complexity comes from nonICH countries; agreed to leverage Regulatory functions in country Affiliates and
influence through WHO too
• Agreed on the importance of continuing to raise awareness of this wicked problem and
emphasising the science and risk-based approach
• Discussed learnings and improvements from COVID-19 that should be retained post
pandemic e.g., electronic documents
• Asked for communication material for companies to engage Affiliate Regulatory
functions
• CQOs continues to actively sponsor the 1VQ on PAC Initiative and were happy with
progress
• CQOs supported having a workshop with FDA (and potentially other agencies) once
feasible
• The objectives of 1VQ for PAC Initiative for 2021 were agreed to (as described in
section 7.4). It was suggested to engage more agencies like China, Russia and non-ICH
countries. CQOs agreed to provide their top 3-5 countries to engage with
• Agreed to establish a small 1VQ on PAC Initiative governance group with the
researcher, co-lead and 2-3 CQOs
• Provided a draft for input from CQOs on the roles of the QMS Heads and the CMC RA
Heads in context of transforming PAC management.
• Clarified the specific role of the CQOs in driving simplification of the PAC complexity
by offering the 1VQ for PAC solutions to manage more PACs in the PQS only
• First direct session organised by researcher and Vinther between CQOs and Dr Theresa
Mullin, FDA
• The CQOs shared examples of challenges with the multi-year approvals and global
complexity of PACs
• Dr Mullin shared her views especially that we are at the beginning of risk-based
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Date

Focus Group
Attendees

Key Outcomes
management of PACs
• She was very supportive of a system-based global approach to PAC management
• She stated that COVID-19 disruption had reinforced the need for change and more
regulatory reliance - it would take time though
• She shared that FDA and other agencies were working actively on more regulatory
reliance.
That
required
better data
standards and standardised
data
sharing through technology solutions
• CQOs actively supported more regulatory reliance but reiterated that the pharmaceutical
industry’s work was mostly related to regulatory flexibility
• FDA was interested in doing pilots and examples with the CQO group
• CQOs confirmed that in general PACs were the same globally, but the approval timeline
and reporting requirements differ from country to country
• Discussed that a simplified PAC global framework must keep the patient in mind and at
the centre. They stated that one of the lessons learned from the pandemic was more
willingness to use a risk-based approach to PAC management
• The CQOs also noted the role they have as owners of the PQS and decision makers on
all quality matters at the company. Therefore, they asked to be heard more and be
involved in PAC simplification work particularly related to defining an effective PQS
for managing PACs
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In addition to using the focus group sessions as summarised in Tables 7.1 and 7.2 to
seek input, gain alignment and secure implementation commitment from the 1VQ for
PAC member companies, the researcher also utilised them as working sessions to
design, iterate, influence direction, and finalise practical solutions that are expected to
drive meaningful impact and shifts in accelerating continual improvement and
innovation in the pharmaceutical industry.
The next section describes the 2021 workplan for the 1VQ for PAC Initiative that will
continue beyond this research.

2021 1VQ for PAC Work Plan
The objectives for 2021, as endorsed by the CQO in March 2021, were centred on
demonstrating a real reduction in PAC complexity from the application of the 1VQ for
PAC solutions. This would be accomplished through 3 sub-elements:
•

Improve awareness
CQOs accountable for PQS and owning ‘effective PQS for PAC’
solution, including the science & risk-based approach
Publish PAC problem & 1VQ for PAC solution, practical examples

•

Increase engagement
Workshop and meetings with regulatory authorities and pharmaceutical
companies
At least one regulatory authority and company 1VQ for PAC joint pilot
Involve more regulatory authorities (e.g., China, Russia, non-ICH
countries) and companies

•

Enable implementation
Initiate implementation of 1VQ for PAC solutions in companies

The 1VQ for PAC Initiative aligned on these objectives for 2021, and the member
companies reiterated that implementation would require joint collaboration between
Quality and Regulatory. It was agreed that company internal training materials for
implementation of 1VQ for PAC solutions would be developed by the companies, and
shared within the 1VQ for PAC community. The next part of this thesis elaborates on
the practical solutions resulting from the work described thus far in this thesis.
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Part Five: Practical Science and RiskBased Solutions
Part Five focuses on practical, standard, global solutions that facilitate effective
delivery of medicines to patients. These solutions are a result of ongoing collaborative
work within the pharmaceutical industry through the 1VQ for PAC Initiative, with
ongoing input from regulators. The solutions are based on the current and latest thinking
and concepts on product lifecycle management and PAC management, as laid out in
ICH Q12, Technical and Regulatory Considerations for Pharmaceutical Product
Lifecycle Management (ICH, 2019), and are provided below in Chapter 8.
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Standard Solutions for the
Pharmaceutical Sector
The term ‘pharmaceutical sector’ is intended to encompass pharmaceutical companies
and regulatory authorities, two key stakeholders and contributors to this research study
and its outcomes. It also includes academic groups such as the PRST at the
Technological University, Dublin, where direct collaborations with the pharmaceutical
industry and its regulators have led to patient-focused advancements since its inception
in 2005. An overview image of this landscape is provided in Chapter Two, Figure 2.4 of
this thesis. Pharmaceutical companies and regulatory authorities are distinct entities
with clear separation and independence of roles in relation to serving patients and public
health needs. However, they are not mutually exclusive, and there is a definite
interconnectedness between them when it comes to the design, implementation and
value realisation from solutions resulting from this body of work.
As described in Chapter Seven of this thesis, in response to FDA’s suggestion, the
researcher, with Vinther, brought the pharmaceutical industry together through the
CQO-sponsored 1VQ for PAC Initiative to develop and propose standard solutions to
improve PAC management and advance innovation in the pharmaceutical industry. The
body of work undertaken via the 1VQ for PAC Initiative focus group sessions also
formed the basis for bringing in regulators to discuss their perspectives, collect their
input, and verify relevant applicability and usefulness of the solutions for regulatory
authorities too.
This chapter reviews the 1VQ for PAC Concept Paper that was developed under the
researcher’s leadership, and represents the commitment of Senior Quality Leaders as the
unified voice of the pharmaceutical industry. It also describes the four resulting
solutions and practical application PAC examples that have been published.
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Review of the 1VQ for PAC Concept Paper Solving the Global Continual Improvement and
Innovation Challenge: How an Effective
Pharmaceutical Quality System Can Transform PostApproval Change Management
In the first step towards developing a 1VQ for PAC Concept Paper, Solving the Global
Continual Improvement and Innovation Challenge: How an Effective Pharmaceutical
Quality System Can Transform Post Approval Change Management (Vinther and
Ramnarine, 2019a), the researcher started by reviewing the intent of the original ICH
Q10 Concept Paper (ICH, 2005b), approved in November 2005.
The ICH Q10 Concept Paper proposed that the ICH Q10 guideline would provide a
framework for a modern and internationally harmonised quality system for
pharmaceutical manufacturing that would build upon the cGMPs, and facilitate
continual improvement while ensuring product realisation and maintenance of a state of
control. In the Concept Paper, the PQS was envisioned as encouraging a science and
risk-based approach to quality decisions, facilitating innovation and continual
improvement throughout the product lifecycle. It was envisioned that ICH Q10 would,
when implemented, provide a mechanism for assuring that there would be no
unintended consequences of continual improvement, and demonstrating commitment
from both the pharmaceutical industry and regulators to utilising robust quality systems,
activating innovation, and assuring the consistent global availability of medicines (ICH,
2005b).
A review of the Concept Paper and ICH Q10, together with the feedback from FDA
discussions presented in Chapter Six of this thesis reiterated for the researcher that the
reason the anticipated benefits had yet to be realised might be because there was no
guidance available on what the practical application of utilising the PQS and a science
and risk-based approach should entail. There also was no practical definition on how to
demonstrate effective management of PACs within the PQS. All of this resulted in,
albeit unintended, a high burden of cost, resources and effort for both companies and
regulators in implementing improvements and innovation through PACs. This research
set about to address these issues, by developing practical guidance, standard solutions
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and proposed examples of how to demonstrate effective management of PACs within
the PQS.
Hence, the 1VQ for PAC Concept Paper, utilising the approach, outline, sections and
flow similar to ICH Concept Papers, focused on designing and implementing standard
solutions for the pharmaceutical industry in these areas. The solutions specifically
targeted utilisation of an enhanced science and risk-based approach within the construct
of an effective PQS to achieve timely and faster implementation of new knowledge
gained and innovation by making PACs. By consistent and global implementation of
these solutions it was envisaged pharmaceutical companies would have common
standardised ways to demonstrate to regulators that they were utilising the latest product
and process knowledge and had a robust PQS to manage changes and continual
improvement. The intended outcome was that regulators could trust the concerned
companies to manage certain PACs solely within their PQSs without additional
regulatory approval.
The 1VQ for PAC Concept Paper described the perceived problem from a
pharmaceutical company’s perspective and how this led to a global complexity that
impacted product availability for patients. The primary premise was that a company’s
latest product and process knowledge, and the strength of its PQS, were not factored
into the regulatory assessment and decision-making on individual PACs. This meant
that even changes that could be well-justified for a simple regulatory notification or
management solely within the PQS (based on the change being low risk, and the
strength of the PQS in effectively managing such low-risk changes), still had to be
submitted to each relevant regulatory authority for prior-approval. This resulted in
delayed improvements and innovation, sometimes at the cost of increasing risk to
product quality and availability for patients. One example (among others) from the
researcher’s direct experience is related to replacing visual colony counting test
methods (with manual result reporting) with a rapid micro automated colony counter
system for routine water monitoring, environmental monitoring and even in-process and
drug substance product related testing. The automated method and technology provided
shorter assay times, earlier detection of micro colonies over the human eye, faster time
to results and reduced review times (counts the same colonies in half the time of the
traditional method) that enabled faster response to contamination events, did not impact
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the ability to detect slow-growing organisms, improved data integrity with automated
and validated result interface with the Lab Information Management System (LIMS),
eliminated manual (human) plate counting and manual data entry into LIMS – yet this
technology has not been widely implemented across the pharmaceutical industry to the
extent it can and should be because of the global PAC complexity of introducing such a
change.
The strategic importance of this topic was the implementation of the vision laid out in
the ICH Q10 Concept Paper, and as clearly articulated in ICH Q10 Annex 1. The
aspiration of the 1VQ for PAC Initiative was:
“increased innovation and faster implementation of new knowledge through a
transformational shift in PAC implementation timelines with at least 50%
reduction in prior- approval PACs.”
The standard solutions that the 1VQ for PAC Concept Paper committed to delivering
were as follows:
1. Define and demonstrate effective management of PACs in the PQS, so that more
changes could be managed within the PQS instead of via prior-approvals
2. Develop a standard risk-based assessment of PACs incorporating the latest
product and process knowledge
3. Pilot the proposed solutions
The 1VQ for PAC Concept Paper was sent to FDA for their feedback which was
substantive particularly in relation to industry proposing how to demonstrate
effectiveness of the PQS for PAC management, improving evaluation of this PQS
effectiveness during inspections, and the need to engage with other regulatory
authorities beyond FDA. The researcher and Vinther adjudicated all received FDA
comments, accepting most, and revised the Concept Paper accordingly. The revised
paper was extensively reviewed by approximately 400+ people across the 1VQ for PAC
member companies, including their PQS/QMS Heads, comments were collated and
adjudicated by the researcher and Vinther, before it was finalised and approved by the
CQOs. It was published in September 2019 in the peer-reviewed PDA Journal (Vinther
and Ramnarine, 2019a).
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The subsequent sections in this chapter describe the standard solutions that were
developed as per the scope of the approved 1VQ for PAC Concept Paper.

Solution 1: Industry 1VQ for PAC - Effective
Management of Post-Approval Changes in the
Pharmaceutical Quality System
Through the first two 1VQ for PAC Focus Group sessions, described in Chapter Seven
of this thesis, the specific elements of the PQS that are essential in the proactive and
effective management of PACs were identified. The starting point for the PQS
discussions were ICH Q10 and the published PDA Points to Consider paper, Technical
Product Lifecyle Management: Pharmaceutical Quality System Effectiveness for
Managing Post-Approval Changes (Ramnarine, Busse, Colao, Edwards, O’Donnell, et
al., 2017). The focus group discussions also explored attributes and metrics that could
demonstrate effective use of the PQS for PAC management. This in turn could allow
faster implementation of changes that improve quality, ensure a sustainable supply of
medicines and enable innovation, all based on the latest product and process knowledge.
Initially, one might think that the Change Management system might be the only PQS
element that is relevant and applicable for PAC management. However, the finding that
emerged through the focus groups sessions was that, in addition to change management,
there were other proactive and reactive components of the PQS that were important for
demonstrating effective management of PACs within the PQS. In fact, it became
apparent that the systems framework of the ICH Q10 PQS model, with the four PQS
elements (Management Review, PPPQMS, CAPA, and Change Management) and the
two enablers (QRM and KM), were all essential for effective management of PACs.
This was because:
•

Typically, these PQS elements and enablers were the first points to capture the
triggers or signals that indicated a change or a corrective or preventive action
might be needed

•

Then the PQS provided the processes and framework for responding to the
triggers, managing the resulting actions

•

Finally, the PQS verified them for effectiveness
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These interdependencies are depicted in Figures 8.1 which builds upon the ICH Q10
diagram to propose mechanisms to support PAC regulatory filing assessments. Then
Figure 8.2 gives details of how this support can be generated, relating it back to PQS.
Both figures were developed and published by the researcher in May 2020 (Ramnarine
et al., 2020). By applying these, the PQS could help determine the regulatory filing
approach for a PAC.
ICH Q10 Pharmaceutical Quality System

Utilize ICH Q10 principles in the PQS to:

GMP
Pharmaceutical
Development

Technology
Transfer

Commercial
Manufacturing

Product
Discontinuation

Investigational Products

Management Responsibilities

Respond

Process Performance & Product Quality Monitoring Systems (PPPQMS)
PQS
CAPA System
Element
Change Management System
s
Management Review
Enablers

Knowledge Management
Quality Risk Management

Management
Responsibilities
PQS Elements
Enablers

Capture
Triggers/
Signals

Verify
Effective
ness

Support PAC Regulatory Filing
Assessment

GMP

Figure 8.1: Utilising ICH Q10 for Effective Management of PACs (Ramnarine et
al., 2020)
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Pharmaceutical Quality System (PQS)
Capture Triggers/Signals

Respond

Deviations, Nonconformances
Complaints, Changes, Adverse
Events, Failures, Rejects, Recalls
Audits, inspections

Allocate resources & priorities

Trends from PPPQMS, APR

Assess, plan, execute change

Verify CAPA Effectiveness

Operations & Management
reviews

Assess, plan, execute, CAPA

Verify effectiveness during
PPPQMS

New knowledge
Proactive QRM
Reactive QRM

Verify Effectiveness
Product quality, safety,
availability,
PQS Effectiveness Review
Verify Change Effectiveness

Assess and manage risks for
change or CAPA based on
current knowledge

Document New Knowledge
Perform Risk Review

Emerging industry & tech trends
New regulations

Support PAC Regulatory Filing Assessment
Management Responsibilities
PQS Elements
Enablers

Figure 8.2: Maintaining a State of Control, Facilitating Continual Improvement
and Effective Management of PACs in the PQS (Ramnarine et al., 2020)
This 1VQ for PAC solution (shown in the figures above) described the role of the PQS
in extending beyond GMP compliance, and functioning as a holistic system, which if
utilised appropriately, could enable regulatory flexibility for faster and more timely
PAC management. This solution built on ICH Q10, and further defined specific details
on how each of the four PQS elements and the two enablers could be used to
demonstrate effective decision-making and management of PACs. It provided specific
guidance on practical utilisation of the PQS, which, as highlighted in feedback from
FDA and the focus groups, had been missing.
Companies could directly adopt and implement within their current PQS the details for
the PQS elements and enablers specifically for PAC management, as defined in this
solution. This would not only allow a company to strengthen its PQS, but consistent
implementation of this solution could also standardise the pharmaceutical industry.
Regulators would then see companies using the same attributes of the PQS to
implement PACs faster, and demonstrate that they were able to do this well within the
framework of an effective PQS.
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Solution 2: Industry 1VQ for PAC - Risk-Based
Assessment of Individual PACs
While pharmaceutical companies and regulatory authorities have worked tirelessly over
the past decade to improve implementation of the principles and concepts of QRM as
described in ICH Q9, Quality Risk Management, at the time of writing this thesis, the
vision of risk-based decision-making has yet to be widely realised in the pharmaceutical
environment. The science and data-basis for QRM application and risk-based decisionmaking considering balanced risk-benefit assessments remains weak, both in the
pharmaceutical industry and in regulatory authority processes, as demonstrated by the
following:
•

Risk assessments are performed by companies, but they are not always updated
with the latest product and process knowledge

•

Risk-based decisions are made by regulators, but they are typically based on a
generic risk understanding, not on the totality of a company’s specific product
knowledge and its latest risk controls

•

Risk-benefit assessments for PACs are not performed well, especially in context
of the expected improvements relative to the potential risks they might present
and their associated mitigations to further improve the risk-benefit balance

•

Additionally, effectiveness of the PQS in identifying and managing risks in a
timely manner is not visible to regulators in the right context, and therefore, it is
not considered in regulatory decision-making

•

Finally, even though the risks remain the same, different decisions are made by
regulatory authorities in different countries for the same risks

The result of this weak risk-based application is that decisions are based on potential
‘worst-case’ or generic risk scenarios, instead of being based on the extent of product
and process knowledge that is in place. For example, a regulatory submission to
introduce a Process Analytical Technology (PAT) application in order to significantly
enhance process monitoring capabilities will usually be assigned the highest level of
regulatory assessment possible, e.g., via a Type II variation in the EU, regardless of how
much prior knowledge and process understanding the applicant has. The extent of
regulatory assessment and questioning that accompanies such applications, regardless of
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where the applicant is starting from in terms of process understanding and product
knowledge, and the unpredictability as to approval timelines, have led many companies
to simply not seek to register their PAT applications at all. The unfortunate net effect of
this is that the use of such advanced technologies in product quality decision-making
does not get realised, and offline, traditional and older batch monitoring methods
remain in place. This hinders continual improvement and innovation, that ultimately
results in delayed benefits for patients.
It is the researcher’s opinion that the application of an enhanced science and risk-based
approach at an individual PAC level is essential if one is to realise the ICH Q10 Annex
1 vision, where more knowledge and better risk controls should enable more regulatory
flexibility and faster implementation of PACs.
Science knows no country or regional borders – to quote Dr Louis Pasteur:
“Science knows no country, because knowledge belongs to humanity, and is the
torch which illuminates the world. Science is the highest personification of the
nation because that nation will remain the first which carries the furthest the
works of thought and intelligence.”
A standard science and data-based risk assessment, founded on the latest product and
process knowledge, could be expected to enable alignment between a pharmaceutical
company and regulators, and among regulators on the categorisation and decisionmaking for PACs. The researcher contends that an enhanced and fully transparent
science and risk-based approach is essential and would also build trust between
companies and regulatory authorities. It could accomplish this as follows:
•

A pharmaceutical company would perform a risk assessment for a proposed
PAC using the latest product & process knowledge; this would be documented
in the company’s PQS

•

The proposed change category would be based on the PAC risk level, the
company’s proposed risk controls, and the effectiveness of the company’s PQS

•

The company’s PAC risk assessment, based on the latest knowledge, would be
made transparent to regulators to enable a level 1 calibration & alignment
between the company and the regulatory assessor on the risk level, change
category, and implementation timelines for the PAC; the risk assessments for
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any PAC’s that were not submitted for prior-approval would also be available
for review during inspections
•

The company’s PAC risk assessment would also enable a level 2 calibration and
alignment between regulatory assessors from different countries on the risk
level, change category, and implementation timelines for the PAC

Figure 8.3, developed by the researcher, illustrates on the left-hand side how, in the
current state, and regardless of the level of specific product and process knowledge, a
PAC is categorised, assessed and handled. The desired future state, depicted on the
right-hand side of Figure 8.3, is that the same PAC (e.g., change in a starting raw
material that can impact a Critical Quality Attribute (CQA)), could result in different
regulator decisions for different companies, based on the level of knowledge, risk and
the strength of the company’s PQS at each company.

Figure 8.3: Illustrative Example on Utilisation of Knowledge and Risk to
Provide Appropriate Flexibility in PAC Management
The researcher noted that there was a difference between basic QRM and an enhanced
QRM application, with the latter presenting the possibility of unlocking the regulatory
flexibility potential as envisioned in ICH Q10 Annex 1. Figure 8.4, also developed by
the researcher, describes the current state for PAC management and the distinction
between basic and enhanced QRM application for assessing an individual PAC.
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Figure 8.4: Basic vs. Enhanced Risk Management Application for PACs
The objectives for this second 1VQ for PAC solution were:
•

A standard, objective, science and risk-based approach for PAC assessment that
utilised the latest and specific product and process knowledge, and

•

Facilitating a process whereby the same PAC decision outcomes are made by
the company and all relevant regulatory authorities

The approach the researcher facilitated in the focus groups to develop solution 2 was to:
1. Expand on the ICH Q12 decision tree (ICH, 2019) (shown in Figure 8.5), and
2. Integrate the risk-based approach into the change management process
This would allow the PAC categorisation to be based on the company’s risk assessment
of the change considering the latest product and process knowledge, and not only on the
different national and regional requirements. This would also mean that the same PAC
could have different categorisation depending on the knowledge and risk assessment
outcomes, as illustrated above in Figure 8.4.
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Figure 8.5: ICH Q12 Decision Tree for Identification of ECs and Associated
Reporting Categories for Manufacturing Process Parameters (ICH, 2019)
The ICH Q12 decision tree guides the identification of Established Conditions (EC) and
determination of reporting categories. It classifies parameters as ECs or not. Changes to
a parameter that is not an EC, does not need to be reported to regulatory authorities.
Where a change is made to an EC, a risk assessment for the change would determine the
level of risk to product quality associated with the change. Changes to ECs that present
a high risk would need to be reported to regulatory authorities for prior-approval, while
changes that present moderate or low risk could be handled as a notification.
Starting with this ICH Q12 decision tree, the 1VQ for PAC focus group sessions led to
expanding upon it and integrating it into each of the steps of the change management
process. This enhanced risk-based approach for assessment of a PAC and determination
of the regulatory reporting category was the second 1VQ for PAC solution; this was
published along with Solution 1 in the 1VQ for PAC Solutions Paper in May 2020
(Ramnarine et al., 2020).
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The risk-based decision-making process underpinning Solution 2 was as follows:
•

During a Change Proposal step, a high-level assessment would determine
whether there are any potential impacts to the Quality, Safety or Efficacy (QSE)
of the product, or if there any legal or regulatory impacts. If this initial
assessment determined there was no QSE or legal or regulatory impact of the
change, no further risk assessment would be needed, the change could be
managed solely within the company’s change management system, and not
require any regulatory submission. However, if there was a potential QSE or
legal or regulatory impact, a more detailed risk assessment would be needed.

•

During the Change Evaluation step, a detailed risk assessment would be
performed to assess, based on the latest product and process knowledge, any
potential direct or indirect risks to the identity, strength, quality, purity or
potency of the product. A list of example risk questions was provided in the
published paper to aid with this detailed risk assessment. Integrating the ICH
Q12 decision tree, high risk changes to an EC would be categorised as priorapproval, and moderate or low risk changes would be categorised as
notifications. Changes to non-ECs would require no regulatory reporting.

•

During the Change Implementation, Change Review and Change Closure steps,
the risk controls identified through the risk assessment would be implemented
through a change implementation plan, residual risks would be assessed for
acceptance or further mitigation, and change effectiveness would be evaluated
prior to and post-change closure.

Development of this solution involving the risk-based assessments, categorisation and
management steps for PACs as depicted in Figure 8.6 below, was led by the researcher:
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Step 1 – Change Proposal

PAC

Change Mgmt.(CM)
System

High Level Impact Assessment of Change
NO
• Is there a potential impact to Quality, Safety
Efficacy (QSE) ?
• What might go wrong that may affect
QSE?
• Is there a potential legal / regulatory impact ?1

No impact on QSE AND
no legal / regulatory impact

Q9,
Q12

Step 2 – Change Evaluation
YES or MAYBE

(likely impact to ECs)

Q9

Assessment of risks to QSE
(based on current knowledge & Control Strategy)

Risk Assessment of
Change
(QRM tool/extent may vary)
MODERATE / LOW

HIGH

Q12

Assignment of regulatory reporting category :
• What is the legal / regulatory impact (e.g. to ECs )?
• Document justification for proposed reporting category

Step 3 – Change Implementation

Low/Moderate risk
Notification1

High risk
Prior-Approval

No submission/reporting required
Document with rationale within the
CM system and implement change

Change Implementation plan
(including risk controls identified)

Q9
Step 4 – Change Review & Closure

Change Review & Closure
(incl. Risk Review & Change Effectiveness)

1

Q9, Q10

Ongoing
Review/Monitoring
June 2019
(through PQS post change closure)

per local regulations

Figure 8.6: Risk-Based Assessment and Determination of Regulatory
Reporting Category for a PAC (Ramnarine et al., 2020)
The step-wise details provided in this 1VQ for PAC solution, if accepted by regulators,
would allow companies to know exactly how to apply the concepts of ICH Q9, Q10 and
Q12 in a practical and tangible manner, in order to gain the regulatory flexibility and
speed of implementation for PACs that, based on product and process knowledge and
risk controls, could be managed solely within the PQS or as a notification, without
requiring regulatory prior-approval. The company could also use the same risk-based
approach for a PAC for all regulatory authorities.

Solution 3: PIC/S Recommendation Paper How to Evaluate and Demonstrate the Effectiveness
of a Pharmaceutical Quality System in Relation to
Risk-Based Change Management
As described in Chapter Six, section 6.2 of this thesis, the researcher’s discussion with,
and her proposal to the PIC/S QRM Expert Circle in 2018, resulted in the development
of a practical PIC/S guidance document, for both inspectors and companies, on
assessing and demonstrating the effectiveness of a company’s PQS in relation to riskbased change management (PIC/S, 2019). The guidance contained a comprehensive
checklist that was essentially a tool which gave precise considerations for each of the
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key steps of the change management process – change proposal, change assessment,
change planning and implementation, change review, and change closure. For each step,
it provided a guide on key questions to ask, actions to take, and assessments to make in
order to reach relevant decisions. The use of such a clear, practical tool would yield
value for both company and inspectors. The benefits of demonstrating the effectiveness
of the PQS with regard to risk-based change management would include the timely
management of risks to product quality and patient safety, better quality and
manufacturing performance, and opportunities for continual improvement and
innovation, as envisioned by ICH Q10 Annex 1.
As described in Chapter Six of this thesis, the researcher worked directly with the PIC/S
QRM Expert Circle for the development of the paper. The researcher also served as the
conduit to the 1VQ for PAC Initiative, gathering input through the focus groups, and
providing to the PIC/S QRM Expert Circle all throughout the paper’s development. It
was published in November 2019 as a draft Recommendation Paper (PIC/S, 2019) with
the intent of having inspectors use it through May 2020, and provide feedback that
would be used to finalise the Recommendation Paper.
If a company were to implement the 1VQ for PAC solutions 1 and 2, as described in
sections 8.2 and 8.3, it would be able to provide evidence of an effective science and
risk-based change management system as described in the PIC/S Recommendation
Paper.
At the 6th focus group session, as described in Chapter Seven of this thesis, the member
companies of the 1VQ for PAC Initiative decided to implement the PIC/S
Recommendation Paper. In order to do so, it was necessary to first assess their maturity
relative to the PIC/S Recommendation Paper; the next section describes this maturity or
gap assessment developed by the researcher and completed by the 1VQ for PAC
member companies.
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8.4.1 Maturity or Gap Assessment Completed by
1VQ for PAC Companies Against the PIC/S
Recommendation Paper and Feedback Provided to
PIC/S
Prior to implementation of the PIC/S Recommendation Paper, How to Evaluate and
Demonstrate the Effectiveness of a Company’s Pharmaceutical Quality System (PIC/S,
2019), the researcher proposed that the 1VQ for PAC member companies complete a
maturity assessment of their company’s change management system against the paper,
and also provide relevant feedback to PIC/S prior to finalisation of the paper.
The researcher designed a maturity or gap assessment survey that companies responded
to anonymously, communicating the maturity level of their change management system
relative to the expectations in the PIC/S Recommendation Paper. The survey questions
were developed during the 6th focus group session along with the following maturity
scale, which would be used to assess the change management system.

To ensure anonymity and confidentiality of the companies completing the survey, the
researcher distributed the survey via PDA to the member companies in October 2020
and received the results in November 2020; the results were collated and analysed by
the researcher. This also allowed for benchmarking among the 1VQ for PAC member
companies, it provided a macro view of the consolidated change management maturity
of those companies, and it helped identify potential improvement opportunities both at a
company level and an industry level.
Survey Results (shared with 1VQ for PAC member companies in November 2020)
The survey results were consolidated and shared by the researcher to the 1VQ for PAC
member companies. The survey indicated, overall, that the change management system
for most companies fell in the maturity range of 2-3, i.e., partially to fully compliant
with the PIC/S Recommendation Paper ’s expectations. Only 15-20% of the companies
reported exceeding the expectations (maturity level 4), or being at the stage of
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predictive change management (maturity level 5); however, even these were only for
some, and not all steps. The survey gave participating companies a view into what
aspects of their change management systems were mature and where further effort was
needed.
The lowest maturity score was related to change risk assessments – 25% of the
companies were at a maturity level of 4, and only 1 (out of 22 companies) was at a
maturity level of 5 in terms of performing science and knowledge-based risk
assessments for changes, and their utilisation for appropriate categorisation of changes.
Only 20% of the companies reported a maturity level of 4 in regards to using the
outcomes of a change risk assessment to drive change planning, prioritisation,
implementation and associated timelines. An opportunity for improvement was also
identified with respect to the timeliness of implementing identified risk control
measures. Additionally, it was found that evaluation of unintended consequences of
risks introduced as a result of the change, or evaluation of residual risk and level of
acceptability, was also not mature. The survey results indicated that risk assessments for
changes were the weakest link in the change management systems across the companies
that responded, and also for the overall pharmaceutical industry. If companies are to
gain the benefits of regulatory flexibility for PACs based on science and risk-based
application as envisioned by ICH Q8, Q9, Q10, Q11 and Q12, the results of the survey
clearly suggested that efforts must be made to improve the use of QRM and KM for
proposed changes.

8.4.2 1VQ for PAC Comments to PIC/S on the PICS/S
Recommendation Paper
The PIC/S Recommendation Paper was published in November 2019 as a draft for a
period of a year, to collect feedback on its use prior to finalisation of the document.
Therefore, in addition to assessing maturity of their change management systems, the
1VQ for PAC member companies used the survey results to identify revision
suggestions to PIC/S.
No major concerns were identified by the companies that completed the survey, and
they classified their comments as high, medium or low in terms of importance, as listed
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below in Table 8.1. For sections of the PIC/S Paper not listed in the table below, there
were no comments provided.
Table 8.1: Feedback to PIC/S QRM Expert Circle on PIC/S Recommendation
Paper
Section of
PIC/S Paper

Comments with Rationale

Importance

Please clarify that the intent is not to verify every single
change against this checklist, but to use the
Recommendation Paper to assess effectiveness of the High
Change Management System as a whole by ensuring that
the risk-based decision making for changes is appropriate
Recommend adding a statement that the rigor of the riskbased application should be commensurate with the
criticality, complexity and impact of the change. This
would explicitly clarify that simpler approaches such as a High
documented risk-based decision rationale can be adequate
for simpler changes that should not require use of detailed
risk-assessment tools

3.4

3.5

st

5.1, 1 bullet,
and addition of
a sub-bullet

5.1, 2nd bullet

5.1, 6th bullet

5.2, 1st, 2nd and
3rd paragraphs

• Suggest updating to “….Common lifecycle factors that
trigger change include, but are not limited to:”
• Suggest updating the 6th sub-bullet under the 1st bullet to
“….management review, new or updated regulations….”. Low
Though this is not intended to be an exhaustive list,
changes in regulations are an important one to call out
Update to “The objectives, scope, description of current
state (before the change) and future state (after the
implementation), expected outcomes and anticipated
High
benefits of the proposed change are documented. It is
important to document current vs. expected future state in
the change proposal
The requirement to document rationale for rejected
changes in the statement “For rejected/voided change
proposals, the system ensures that the rationales for those
rejections are documented, and that continued risks are
adequately managed” is an overkill for ALL changes.
Propose that a clarification be added to require High
documentation of rationale for rejections only for
compliance/quality/safety/patient impact driven changes.
Rejection of a change for edits/corrections is not the same
as voiding a change; therefore, suggest addition of the term
‘voided” to make this clear.
• Revise the statement to “However, an impact assessment
is often not as comprehensive as a risk assessment for in
High
assessing risks of the proposed change.
• Revise the statement to “Therefore, an appropriate
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structured risk assessment for the change should be
performed, and where possible, changes should reduce
product quality risks and/or patient safety hazards.
• Please add a statement after the above statement "The
rigor and approach/ tool selected for the risk assessment
may vary depending on the complexity, criticality and
impact of the change."
• Update the statement to “….knowledge-based risk
assessments are performed and documented for changes,
taking into account the points below (as relevant to the
criticality and risk associated with the change):”
• These updates will avoid creating an undue expectation
of a detailed structured risk assessment for ALL changes.
There is definitely value in doing so for complex
changes, but this would be overly burdensome for
simple, straightforward changes and will only
overcomplicate the change control process.

st

5.3, 1 bullet

5.3, 2nd bullet,
and 5.4 1st and
3rd bullets

5.3, 3rd bullet

5.3, 4th bullet

5.4, 1st bullet

Update to “The scope, criticality, outcomes of risk
assessments and the assigned risk levels drive….”. This
revision accommodates simple changes that may not have
detailed risk assessments
Would be useful to acknowledge by adding a note that
change effectiveness can be by means of other parts of the
Quality System, such as Quality Systems Management
Review (QSMR), Annual Product Review (APR),
Continuous Process Verification (CPV), complaint
monitoring. If the effectiveness review indicates a negative
impact on product quality, actions are assigned as required
by the relevant process. This would also help provide a
clear distinction between change effectiveness and change
acceptance criteria. Acceptance criteria can mean that the
deliverables to implement the change were completed as
expected;
effectiveness
looks
at
long
term
positive/negative effects and this can be verified through
other parts of the PQS
Update to “Potential risks with the current state….”. Not
all changes are a result of compliance/quality/safety/patient
issues and may not present any risks to quality, safety or
compliance, yet need to be documented in the change
control process.
Update to “Interim controls (short-term measures) as
needed, are identified and implemented in a timely
manner…..” This would be an overkill for changes that are
not a result of compliance/quality/safety/patient issues.
Update the statement to “Whenever possible and
appropriate, quantitative data are leveraged….” This
clarification allows exclusion of simple changes where it is
not necessary or value-added to gather quantitative data,
even if it is possible

217

High

Medium

High

High

Additional
comment to
support
implementation

• Further guidance or implementation materials on how to
execute risk assessment for a “critical” change would be
helpful. Clear definitions and expectations would aid in
understanding the tool.
High
• Further clarity on when a “formal structured risk
assessment” should be performed, could also be useful
for implementation

On behalf of the 1VQ for PAC Initiative, the researcher sent a letter to Dr Kevin
O’Donnell, Chair of the PIC/S QRM Expert Circle on 19-November-2020, providing
comments for consideration in finalising the PIC/S Recommendation Paper. All
comments were considered by the Expert Circle and most accepted either directly or per
intent behind the comment.
The 1VQ for PAC Initiative reiterated support for the PIC/S Paper as practical guidance
that can be used by inspectors and companies alike to assess and/or demonstrate the
effectiveness of a company’s change management system, and agreed that it would be
of fundamental importance in realisation of the ICH Q10 Annex 1 vision.
Furthermore, the researcher proposed a collaboration between the 1VQ for PAC
member companies and the PIC/S QRM Expert Circle in developing further
implementation and training materials to jointly advance the respective implementation
of the PIC/S Recommendation Paper by the industry and inspectors. Thus far, there has
been no formal response from PIC/S on the researcher’s collaboration proposal likely
because their focus was on finalising and publishing the paper.

Solution 4: Industry 1VQ for PAC - Management
Review of PACs Guide
Though many companies have Management Review processes and practices in place for
their overall PQS, the 1VQ for PAC focus group sessions highlighted that they did not
adequately cover an assessment of how effective the PQS was in specifically managing
PACs. Current Management Review processes did not have the objective of gaining
regulatory flexibility to downgrade PACs from requiring regulatory prior-approval to
being managed solely within the PQS.
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Towards this end, the researcher, Vinther and Fanzia Mohammed (QMS Head, Roche),
developed a draft guide for Management Review of PACs as the fourth 1VQ for PAC
solution. Similar to the other 1VQ for PAC solutions, this was intended to provide a
practical guide to companies identifying important aspects to include in their
Management Review activities, in order to evaluate and demonstrate the effectiveness
of their PQS for managing PACs. The fundamental premise of this guide was based on
the ICH Q10 expectation that:
“Senior management should be responsible for pharmaceutical quality system
governance through management review to ensure its continuing suitability and
effectiveness.” (ICH, 2008)
This requires senior management to establish an effective PQS including appropriate
decision-making processes, and to monitor its effectiveness.
The draft was sent out to the 1VQ for PAC member companies as a pre-read in advance
of the 7th focus group session. Attendees were asked to come prepared with feedback on
the content of the document and on the examples provided of Management Review
performance indicators.
During the 7th focus group, a session was held on the content of the draft guide, each of
the performance indicators and their intent. Comments were received on the draft and
specifically on the performance indicators. The guide needed to be as clear and practical
as possible, to allow consistent interpretation. Key themes that emerged from the
session included:
•

refining the intent and clarity of the guide including aligning on terms such as
‘new knowledge’

•

clarifying why and how Management Review for the overall PQS might not
sufficiently assess the effectiveness of the PQS specifically for PAC
management, and the ability to gain regulatory flexibility in downgrading
changes

•

reducing the number of performance indicators to the 1-2 most meaningful ones

•

identifying metrics that might already be collected as part of monitoring the
overall PQS effectiveness, to minimise or avoid an overlap or redundancy in
effort
219

•

understanding the amount of manual effort that might be needed to implement
the performance indicators, as if they were too resource or time-intensive, there
was a possibility that companies might not implement them

•

stressing the importance of the right foundational quality culture, as absent this,
the value derived from the guide, or any of the performance indicators, would be
limited

Based on the feedback received from the focus group session, the draft guide was
updated, and it subsequently went through multiple rounds of reviews and updates,
including review by the 1VQ for PAC member companies, their QMS Heads and CQOs
before it was published.
Having discussed the four standard solutions that were developed for science and riskbased assessment of PACs and how to demonstrate effectiveness of the PQS for
managing PACs, the next section of this chapter will focus on case studies where the
standard solutions 1 and 2 described above were applied to specific PAC examples.

Application Case Studies: 1VQ for PAC Example
Position Papers
An important aspect of the 1VQ for PAC solutions is that they describe how the 1VQ for
PAC solutions 1 (Effective Management of PACs in the PQS) and 2 (Risk-based
Assessment of Individual PACs) could be applied to specific individual PAC examples,
whereby a company could demonstrate sufficient evidence to support downgrading the
PAC from a prior-approval submission to a notification. Towards this objective, the
1VQ for PAC member companies were asked to provide a list of examples that would
benefit from a downgrade. A total of 66 examples were submitted during the second
focus group session.
Through the subsequent focus group sessions, participants voted on the list of 66
examples and selected those that would either be quick-wins or would bring broad and
large benefits to the industry through their downgrading to notifications for faster
implementation. The following 13 PAC examples were selected to develop 1VQ for
PAC industry position papers on:
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1. Administrative changes to excipient suppliers (e.g., name change, address
change)
2. Drug substance or drug product shelf-life extensions
3. Changes to analytical equipment or instrument that are deemed equivalent to
what was already registered
4. Replacement of identification testing of liquid drug substance with visual
verification
5. Changes in the size of thermal shipping solution used for transport of product
6. Addition of a testing lab at an existing testing site
7. Changes that bring additional restrictions compared to registered conditions
8. Reference standard changes
9. Drug product batch or scale change with no change to equipment materials of
construction or technology
10. Automated colony counter for water, environmental monitoring or product
testing
11. Compendial excipient changes
12. Manufacturing equipment or line changes
13. Replacement of Active Pharmaceutical Ingredient (API) suppliers
The intent was to develop each example utilising the published 1VQ for PAC solutions
and to describe the controls that should be implemented within the PQS in a manner that
reduced risks to product quality and patient safety, such that the change could be
implemented in a timely manner within the PQS, without requiring regulatory priorapproval. These PAC examples also demonstrate application of the ICH Q9, ICH Q10
Annex 1 and ICH Q12 concepts that are expected to enable regulatory flexibility
through the application of science and risk-based approaches within the framework of
an effective PQS.
The first three PAC examples have been developed by members from the 1VQ for PAC
team (including the researcher), and are published; the next five have undergone peer
review, been endorsed by the CQOs and are being prepared for publication, the next
two are in development, and work on the last three hasn’t been initiated yet. The intent
is to continue to add to this list in order to construct a library of PAC examples; this
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work will continue with the 1VQ for PAC member companies even post-completion of
this research.

8.6.1 1VQ for PAC Position Paper - Managing
Excipient Supplier Name and Address Changes in
the Pharmaceutical Quality System
The first 1VQ for PAC example position paper describes how and why simple name and
address changes for excipient suppliers can be downgraded from being prior-approval
changes to being managed within the PQS only.
Co-authored by the researcher, the first PAC example selected was administrative
changes such as to the name or address of an excipient supplier. It was surprising to the
researcher that when the 1VQ for PAC team prioritised the list of 66 examples, this
example surfaced as one of the first to develop because one would have assumed that
such simple PACs would be easy to make. It became apparent through the focus group
discussion

that

several

companies

particularly

those

involved

in

generics

manufacturing, had a high volume of such changes to name and address of excipient
suppliers, and they generated high non-value-added workload for their Regulatory
Affairs functions. There was unanimous agreement across the member companies that
these PACs should not require any regulatory submission in any country. This PAC
example was considered a ‘quick win’, in that if regulators accepted such changes to be
ones that could be managed only within the company’s PQS, there would be a
significant reduction in the effort and lead times that companies encountered through
having to file such simple administrative changes for prior-approval in several
countries, even though such changes had no impact to product quality and/or patient
safety. Most regulatory authorities around the world recognised that these changes
could be managed solely within a company’s PQS and not require regulatory
submissions - but the ones that do require submission for approval generated work for
both the companies and regulators that could be easily eliminated without any adverse
impact to patients or product. Given that these changes are entirely administrative and,
in many cases, retrospective, the 1VQ for PAC member companies took the position that
they would stop submitting such changes for prior-approval in the limited number of
countries where this practice remained. The position paper was published in 2020
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(Rolke et al., 2020) and describes the rationale for why companies should be able to
manage these simple changes to an excipient supplier’s name and address within their
PQSs only.

8.6.2 1VQ for PAC Position Paper: Changes to
Analytical Equipment or Instrumentation That Are
Deemed Equivalent
The second 1VQ for PAC example position paper applies the 1VQ for PAC solutions to
an analytical equipment or instrument PAC and describes how a risk-based assessment
and specific PQS controls can be used to downgrade the change.
This was the second PAC example selected to develop a position paper on; it was coauthored by the researcher and published in the December 2020 peer-reviewed Journal
of Validation Technology (Rolke and Ramnarine, 2020).
The primary premise for this example was that changes deemed ‘like for like’, or
equivalent, could be downgraded from being prior-approval submissions to being
managed only within the PQS, because they presented no added risks to product quality
and/or patient safety, and the regulatory risk of such changes was minimal. The paper
describes the term ‘like for like’ as one where:
“replacement, retirement or decommissioning does not cause any change in
analytical methodology, method principles, method parameters and method
validation as defined by ICH Q2(R1), analytical specifications, or system
suitability, and/or where full method re-validation is not required, and
equivalency has been demonstrated.”
In other words, the change is such that it could be managed solely within an effective
PQS, without needing additional regulatory approval. The paper further asserted that
such changes should not be assessed as regulatory impacting only because the filed
dossier included details such as part, model or version numbers, equipment brand
names, etc., which when changed typically trigger an update to the filing – there is no
regulatory requirement after all to provide such details in the dossier. A revision to the
dossier to update or remove such details could be done at a future opportunity when a
regulatory impacting revision is needed to the filing.
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Experiences shared by the 1VQ for PAC member companies during the focus group
sessions indicated that such changes to analytical equipment or instrumentation were
common across all companies, and represented significant non-value-added resource
and effort from QC and regulatory functions. The current state resulted in the continued
use of outdated or unreliable equipment models, parts or software by QC laboratories,
even when the vendor could no longer repair or replace them, and even when better or
newer replacements were available. This invariably resulted in deviations, unreliable
results or data integrity concerns, in addition to unnecessary investigations, rework or
retesting – all of which could be entirely avoided if the equipment, parts or software
could be simply replaced with the latest or better versions.
The position paper articulated a sound science and risk-based rationale, and a list of
relevant controls that, when documented and demonstrated within the company’s PQS,
should allow companies to implement these simple ‘like for like’ (or equivalent)
changes to analytical equipment in an expeditious manner without regulatory approval.

8.6.3 1VQ for PAC Position Paper: Shelf-Life
Extensions for Pharmaceutical Products
The third 1VQ for PAC position paper describes how shelf-life extension PACs for
pharmaceutical products can be downgraded from prior-approval submissions to
notifications.
This third 1VQ for PAC position paper was published in the December 2020 peerreviewed Journal of Validation Technology (Egal and Lombardi, 2020). The researcher
did not co-author it, but was active in its development, and drove all the reviews and
endorsement (by 1VQ for PAC member companies and their QMS Heads and CQOs),
and publication steps.
The paper explained that the initial product shelf-life, usually based on limited stability
data, is approved as part of the product registration filing. As ongoing stability
monitoring provides further supporting data, companies typically extend the approved
shelf-life post-authorisation via PAC submissions. In most countries this change is
handled as a regulatory prior-approval submission or notification. The paper identified
60 countries where shelf-life extensions must be filed as a major or minor variation,
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each requiring regulatory approval. Only the US allowed shelf-life changes to be
submitted via a lower notification reporting category, accompanied by an approved
stability protocol for shelf-life extensions; India was the only other country allowing for
a simple notification of shelf-life changes.
The paper provided 3 case studies on the current state and the proposed future state of
faster implementation that could be achieved through application of the 1VQ for PAC
solutions described in sections 8.2 through 8.4. This downgrading of the change is
dependent on a company’s ability to demonstrate that all underlying risk controls that
mitigate potential risks of a product failing its shelf-life specifications were adequate,
and that the company had an effective quality system. The paper provided a listing of
controls in addition to stability data that would be important in supporting product shelflife extensions. In the event such controls and supporting data could not be
demonstrated, the company would be required to file the change as a prior-approval
submission, meaning that the product shelf-life could not be extended until approved by
all relevant regulatory authorities – this could take several years. Therefore, it would be
to a company’s advantage to implement the 1VQ for PAC solutions and follow this
position paper for immediate implementation of shelf-life extensions.
This chapter described all the solutions that resulted from this research study including
application position papers for specific PAC examples. The next part of the thesis
summarises the outcomes, impacts and conclusions of this research study, and identifies
opportunities for future research.
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Part Six: Outcomes and Impact,
Conclusions, and Opportunities for Future
Research
Part Six brings the research study to a close with a review of the outputs,
outcomes, and impact of this research. Though this research started pre-pandemic, this
concluding section of this report articulates key learnings and opportunities that the
pandemic

has

brought

forward

or

underscored.

Part

Six

concludes

with

recommendations for potential opportunities and focus areas for future research. It
includes the following:
•

Outputs, outcomes and impacts of this research study (Chapter 9).

•

Research

conclusions,

and

pandemic

observations,

opportunities for future research (Chapter 10).
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learnings

and

Outputs, Outcomes and Impacts of
Research Study
This chapter describes the outputs, outcomes, and impacts from this research study. It is
noteworthy that, as true of all ‘wicked problems’, while some near-term impacts can be
known and other longer-term ones can be anticipated, realising the bottom-line value to
patients and public health will be a multi-year, multi-phased, multi-pronged journey.
This concept is further elaborated upon in this chapter and also in the next Chapter Ten
in the context of post-pandemic and future research considerations.
The University College Dublin’s (UCD) Research Impact toolkit illustrated in Figure
9.1 below is being used as a framework to lay out the outputs, outcomes and impacts of
this research study (UCD, no date).

Figure 9.1: UCD’s Research Impact Toolkit (UCD, no date)
As described in Chapter Three of this thesis, this research used a mixed methods
approach involving focused group sessions with targeted stakeholder groups, KOLs,
and decision makers within the pharmaceutical sector. The body of work (both indevelopment and outputs) from this research was disseminated by the researcher
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through a variety of methods and channels, including peer-reviewed publications,
presentations, focus group sessions, direct dialogue, surveys, podcasts, social media
articles and blogs, and formal or informal interviews with stakeholders and KOLs.
These methods and channels are summarised in table format in Table 9.1.
Table 9.1: Methods and Channels the Researcher used for Research
Dissemination
Methods of research dissemination
(how)

Count

Total Papers

Channels (with whom research
was disseminated)

14

Total Papers (as lead author)

10

Peer-reviewed papers (in journals)

11

1VQ for PAC Industry Position
Papers (published)

6

1VQ for PAC Industry Position
Papers (in peer review)
Proposals to Regulatory Authorities (FDA,
PIC/S, WHO)

5
3

•
•
•
•

Surveys

2

Technical Report

1

Commentary

2

•

Focus Groups

18

•

Industry One-Voice-of Quality
Focus Group Sessions

8

•

CQOs Focus Group Sessions

6

QMS Heads Focus Group Sessions

4

•
•
•

Conference presentations

10+

Panelist

8+

Podcasts and Webinars

3

Social media posts (1500-2000 hits per
post)

5+

Guest Academic Lectures (TU Dublin)

2

Advisory Board presentations

2

Industry 1VQ for PAC Forums
CQO Forum
QMS Heads Forum
PDA (PAC iAMSM Task Force,
conferences, workshops,
Advisory Board, Board of
Directors)
PIC/S QRM Expert Circle
Coordinating Committee
PIC/S Inspectors’ Training
Events on QRM
Closed Discussion Sessions with
Regulators (PIC/S, FDA, WHO)
TU Dublin PRST lectures
IVT Network
Interviews and Discussion
Sessions (regulatory authorities,
industry leaders, KOLs and
SMEs)

Key Research Themes
The resulting outcomes and impacts of the research study can be grouped under several
themes. These themes, though distinct, are not mutually exclusive and, therefore, the
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related outputs and resulting impacts may deliver value across more than one theme.
The four major themes for the outputs, outcomes and impacts of this study are as
follows:
1. Global recognition by regulators (for the first time) of the problem of PAC
management
2. Influencing the development of regulatory guidances with respect to PAC
management
3. Unifying the pharmaceutical industry (for the first time) on the topic of PAC
management
4. Practical application of ICH Q9, Q10 Annex 1 and ICH Q12 by development of
standard solutions and position papers for selected PACs, incorporating
evidence-based QRM
Each of these themes, their specific outputs resulting from this research study and their
associated outcomes and impact, as currently known and anticipated, are discussed
below.

9.1.1 Key Research Impact Theme 1: Global
recognition by regulators of the PAC management
problem and its impact
Before any problem can be solved, recognition that a problem exists and can be
sufficiently described, is essential. This may not be easy for complex problems, but
through the body of work leading up to this research, and even as it proceeded towards
defining and scoping the problem, it became evident how much more challenging
alignment of a problem definition across the involved stakeholders was for this
research, arguably on account of it being a ‘wicked problem’. This research served to
validate one of the typical characteristics of a ‘wicked problem’ – that the ‘wicked
problem’ of drug shortages even in its relation to PAC management, continual
improvement and innovation, is unique and difficult to clearly define where
stakeholders may agree on the nature of the problem and on the importance of
addressing it, but they may each view the problem, and therefore its possible solutions,
differently, from their own angle.
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A key outcome for this research was a graphic representation of the global problem
(Figure 9.2) which made it irrefutable for the pharmaceutical industry and regulators
alike that:
1. this is indeed a problem,
2. it is a global problem, and
3. its solutions need to be global.

Figure 9.2: Impact of Various Options to Reduce Global PAC Complexity
This graphic became the basis to drive numerous discussions with stakeholders and
KOLs across the pharmaceutical sector. It became the basis for the development of the
1VQ for PAC Concept Paper (Vinther and Ramnarine, 2019b), which aligned the
senior-most Quality leaders from 30 global pharma companies and gained their
commitment to develop and implement standard solutions across the industry. It is also
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noteworthy that this graphic helped elevate the recognition of the problem across ICH
and non-ICH countries. It has been cited in presentations, including a confidential
reflection paper used to align regulators which was shared with the researcher, the ICH
Management Committee, ICMRA and PIC/S.

9.1.2 Key Research Impact Theme 2: Influencing
regulatory activities and development of
regulatory guidance related to PAC management
This was the first time the problem of global regulatory complexity and its impact on
slow PAC management, was elevated to the level of a global unifying call to action for
standard solutions, both within the worldwide industry and regulator communities, with
the following occurring:
1. PIC/S and the global inspector community recognising and activating to develop
a solution to assess and demonstrate an effective PQS to support PAC
management and other areas
2. ICMRA activating a coordinated pharmaceutical knowledge management
strategy to enhance regulatory reliance and agility (ICMRA, 2021)
3. the WHO accepting the researcher’s

6

proposal to collaborate with

pharmaceutical companies and work further towards reliance through pilots on
specific PACs applying the 1VQ for PAC solutions
The contribution of this research study to the recently finalised and published PIC/S
Recommendation Paper (PIC/S, 2021) and the researcher’s leadership all through its
development, pilot and finalisation were acknowledged by the PIC/S Chair, Dr Anne
Hayes, when the paper came into force on July 15, 2021 by a personal email to the
researcher which stated:
“I know that you’ve contributed significantly to the development of this PIC/S
Recommendation and I just wanted to say ‘thank you’ for your great work on
this.”

6

Co-developed with Vinther
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The PIC/S QRM Expert Circle Chair, Dr Kevin O’Donnell also recognised the
researcher’s contributions in a letter sent to the researcher on 13-July-2021, specifically
stating:
“Your presentation at the PIC/S Quality Risk Management (QRM) Expert Circle
meeting in Taiwan in September 2018, in relation to risk-based change
management, continual improvement, post-approval change management and
drug shortages, was absolutely fundamental in driving the development of the
paper, as from that presentation and discussion came the agreement and the
impetus to develop the paper. The paper, however, would not have come to
fruition without your continued involvement in it following that meeting in
Taiwan.”
The published 1VQ for PAC standard solutions paper (Ramnarine et al., 2020),
endorsed by CQOs from 25+ pharma companies, was another output that has led to
regulators such as WHO, PIC/S and FDA being willing to enter into direction-setting
discussions and possible case study application pilots with the senior-most industry
Quality leaders. This has the potential to drive unprecedented collaborations in this area
of work between the pharmaceutical industry and regulatory authorities at a global scale
to drive better science and risk-based decision making both by companies and
regulators based on latest product and process knowledge. It also has the potential to
further facilitate regulatory reliance opportunities using actual case studies from
companies that can enable risk-based decision-making alignment between countries. It
is anticipated that the science and reliance basis will be highly impactful levers, as
elaborated further in Chapter Ten, section 10.3 of this thesis, to accelerate
implementation of PACs, thereby speeding up continual improvement and innovation in
the pharmaceutical industry for the ultimate impact to patients – the on-time and reliable
availability of medicines for patients anywhere in the world.

9.1.3 Key Research Impact Theme 3: Unifying the
Pharmaceutical Industry on PAC Management
The 1VQ for PAC focus group sessions co-led by the researcher with pharmaceutical
companies and their Senior Quality Leaders (CQOs and QMS Heads) led to unifying 30
global companies for the first time, resulting in:
•

The creation of a new stakeholder community of Senior Quality Leaders – this
group is setting the strategic direction for the pharmaceutical industry on
reducing regulatory complexity through improved science, QRM and an
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effective PQS. They are owners of their company’s PQS and are accountable
for all product quality and cGMP compliance decisions. Therefore, this
stakeholder community has the potential to set the direction on broader and
other impactful Quality topics. They can be key in shifting the operational
direction of the industry from rule-based to risk-based to evidence-based and
risk-informed decision-making.
•

Unified industry standard solutions and commitment from their senior-most
Quality leaders to implement practical solutions for PAC management. This will
enable building more trust of the industry by regulators, leveraging the strength
of an effective and mature PQS and the role of Quality in timely and fast
decision-making, such that greater regulatory flexibility becomes possible.
These standard solutions align with other sectors such as the medical device
industry, which relies on standards, such as ISO to inform and drive decision
making, while continuing to innovate and improve.

•

Transformation of PAC management through improved science and risk-based
decision making and an effective PQS, such that more changes can be managed
only within the PQS and fewer PACs need to be submitted to regulatory
authorities for approvals. This would be highly impactful in accelerating
continual improvement and innovation in the pharmaceutical industry, via the
faster implementation of changes, while significantly reducing the resource,
effort and lead time burden on both industry and regulators. The regulatory
oversight for the changes shifts from the assessors reviewing and providing
prior-approval for certain PACs to the inspectors during inspections verifying
the effectiveness of the PQS in adequately managing PACs, facilitates a more
timely implementation of changes which allows the industry to continuously
improve and innovate faster.

9.1.4 Key Research Impact Theme 4: Practical
application of ICH Q9, Q10, Annex 1, and ICH Q12
case studies for PACs
The body of work from the 1VQ of PAC focus groups led, for the first time, to practical
application information including specific PAC example position papers on ‘how to’
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implement the high-level concepts and requirements from ICH and other regulatory
guidances. This, along with the commitment from CQOs to implement these concepts
within their companies, will facilitate implementation of the standard solutions,
increased acceptance by regulators given consistent application, collective learnings,
collaboration with regulators, and evolution based on shared experiences and learnings.
These PAC example position papers provide practical application case studies of Lipa’s
Risk Knowledge Infinity (RKI) Cycle for product lifecycle management, as published
in 2020 and 2021, and shown in Figure 9.3 below (Lipa, O’Donnell and Greene, 2020;
Lipa et al., 2021).

Figure 9.3: The RKI Cycle as Applied to ICH Q10 (Lipa, O’Donnell and Greene,
2020)
Gaining regulatory flexibility can be co-related to increased product and process
knowledge, leading to better risk controls and thereby lowering product quality and/or
patient safety risks. The published PAC example position papers described in Chapter
Eight, section 8.6 of this thesis, are also case studies that demonstrate application of the
RKI cycle (as described by Lipa and illustrated via various case studies (Lipa et al.,
2021)); this is because increasing knowledge and decreasing risk should make these
PAC examples viable candidates for:
•

Downgrading to a lower change category, thereby allowing greater regulatory
flexibility as envisioned by ICH Q10 Annex 1
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•

Gaining trust from regulators on managing more PACs within an effective PQS,
(demonstrated via the 1VQ for PAC solutions (Ramnarine et al., 2020) and the
PIC/S Recommendation Paper (PIC/S, 2021))

•

Shifting from rule-based or compliance-based decision-making to risk-based
decision-making, and further improving towards evidence-based and riskinformed decision-making

•

Faster implementation of PACs, thereby accelerating continual improvement
and innovation

•

Ultimately leading to the on-time and reliable availability of medicines for
patients anywhere and everywhere in the world

All of these outputs, outcomes and impacts signify the value that can be delivered nearterm and longer-term towards the 21st century vision of:
“a maximally efficient, agile, flexible manufacturing sector that reliably
produces high-quality drug products without extensive regulatory oversight.”
(FDA, 2004)

Summary of Research Study Outputs, Outcomes
and Impacts
Table 9.2 provides a summary of the four key research impact themes mapped out for
outputs, outcomes and impacts per Figure 9.1. It should be noted that several outputs
and impacts are not exclusive to only one research impact theme, as they are expected
to deliver value across multiple themes.
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Table 9.2: Mapping Key Research Themes to Outputs, Outcomes, and Impacts
Key Research
Impact Themes
1. Global recognition
by regulators (for
the first time) of the
problem of PAC
management

Outputs | Products of research
•

•

•
•
•

Industry Concept Paper: 1VQ
on PACs (requested by FDA
CDER Head and Acting
Commissioner Dr Janet
Woodcock and FDA senior
staff)
A graphical depiction of the
global problem (Figures 1.1
and 1.2 cited in papers and
presentations by regulators
and KOLs)
Survey: Impact of global
complexity for PACs
Various publications and
presentations on problem and
solutions
Social media posts and
podcasts addressing problem
and disseminating solutions
for PAC management

Outcomes | Awareness and use of
outputs
• ICMRA and ICH Management
Committee Reflection Papers cited
research content and graphics –
signals unprecedented recognition
by regulators of the global PAC
problem and its impacts
• Increased dialogue on regulatory
reliance. ICMRA Reflection Paper
and ICMRA’s coordinated
pharmaceutical quality knowledge
management strategy to enhance
regulatory reliance and agility is
evidence of authorities coming
together to evaluate possible
solutions
• EC’s 2021 ‘Structured Dialogue on
Security of Medicines Supply
Initiative’ recognised need for
standardising regulatory procedures
for PAC management across EU
and globally
• WHO’ interest in collaboration and
pilot with the CQOs
• Shift from a problem to a solutions
mindset – based on science and risk
• Acknowledgement that public
health is a global matter, and PAC
management cannot be addressed at
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Impacts | Consequences of
people using outputs (planned or
anticipated)
•

•
•
•

•

•

A unified pharmaceutical
industry (~30 top global
pharma companies coming
together) for the first time to
propose solutions for better
science and risk-based
decisions
A public health issue being
addressed as a global matter
Faster global approval of PACs
(from years to months)
Regulatory authorities
collaborating to design and
implement solutions to
facilitate faster PAC approvals
Better use of regulatory
authority resources – due to
fewer PACs needing approvals
(can allow focus shift to other
important issues)
Impact of future research to be
determined with continued
focus on 1) faster approval
timelines for more PACs by
more regulatory agencies and 2)
fewer PACs requiring preapprovals

Key Research
Impact Themes

2. Influencing
regulatory activities
and development of
regulatory
guidances related to
PAC management

Outputs | Products of research

•

•

•

•
•

•

Presentation and proposal to
PIC/S QRM Expert Circle on
PQS Effectiveness and riskbased PAC management
1VQ for PAC Solutions paper
– how to perform risk-based
PAC assessment and
demonstrate effective PQS for
PACs
Practical PAC management
example case studies
published – case studies that
companies can implement as
is
Proposal to WHO for
collaboration and pilot
High level concepts and text
content for ICH Q12
(specifically Product
Lifecycle Management Plan,
Change Management and
PQS sections)
Submission of consolidated
industry 1VQ for PAC
Initiative feedback to FDA on
ICH Q12 guidance and
European Commission’s
Strategy for Timely Patient
Access to Affordable

Outcomes | Awareness and use of
outputs
fragmented local or regional levels
• Clear approach on ‘how to’ apply
practical, science and risk-based
PAC management with case study
examples
• PIC/S guidance developed (in
collaboration with researcher) and
published on ‘how to demonstrate
effectiveness of the change
management system’
• Active input, endorsement and
adoption of the PIC/S guidance on
risk-based change management by
the top 25+ global pharma
companies
• Industry’s assessment of its
maturity, gaps and remediation
against the 1VQ for PAC PQS
solution paper and the PIC/S
guidance
• ICMRA Reflection Paper and
ICMRA’s published coordinated
pharmaceutical quality knowledge
management strategy to enhance
regulatory reliance and agility

Impacts | Consequences of
people using outputs (planned or
anticipated)
•

•
•
•
•

•

•
•
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Implementation of the practical
1VQ for PAC solutions and
PIC/S guidance will facilitate
regulatory flexibility for PACs,
per ICH Q10 Annex 1
Better science and risk-based
change management decisions
and processes
Improved PQS maturity for
faster PAC implementation
Implementation of ICH Q10
Annex 1 by regulatory
authorities
Consistency during inspections
in evaluation of companies’
change management processes
(PIC/S, 2021)
Potential to drive more
collaboration
(regulatory authority
regulatory authority and
regulatory authority
industry)
Potential to increase mutual
reliance between regulatory
agencies
On-time and reliable
availability of medicines for
patients anywhere and

Key Research
Impact Themes

Outputs | Products of research

Outcomes | Awareness and use of
outputs

Impacts | Consequences of
people using outputs (planned or
anticipated)

Medicines

3. Unifying the
pharmaceutical
industry (for the
first time) on PAC
management

•
•

•

Published 1VQ for PAC
Industry Concept Paper
Published 1VQ for PAC
standard global solutions:
1. Risk-based decision
tree for PACs
2. How to demonstrate an
effective PQS for PACs
Various publications and
presentations (summarised in
Figure 1.10)

everywhere in the world

• Endorsement and commitment by
the CQOs of 30 global pharma
companies (first time senior-most
Quality leaders speaking with one
voice and willing to have their
names and company names listed on
published papers) to solve this
global PAC problem with
standardised and practical global
solutions
• Created a new stakeholder
community of Senior Quality
Leaders that are now mapping a
more strategic direction for the
industry on not just the ‘what’ but
also the ‘how’ in relation to science
and risk-based Quality decision
making and PQS topics
• Unified communication, messaging
and exchange between industry
Quality leaders and regulators
• Standardised and practical solutions
that, for the first time, address how
PACs can achieve faster approvals
in both ICH and non-ICH countries
• Facilitate regulatory flexibility per
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•

•

•

•
•
•
•

Mechanisms whereby
companies can routinely request
regulatory flexibility based on
product and process knowledge,
risk-basis and an effective PQS
Faster global approval of PACs
(from years to months) with
more consistent risk-based
decisions across countries
More PACs managed only in
the PQS; greater trust in
industry, leveraging the role of
Quality (e.g. QP and QA) for
quality decisions)
Increased science basis and
more regulatory reliance and
collaboration
Accelerate innovation and
continual improvement in the
pharma industry
Less burden (resources, effort
and time) on companies and
regulatory authorities for PACs
The CQOs stakeholder group
can be key in shifting the
industry from rule-based to

Key Research
Impact Themes

4. Practical
application of ICH
Q9, Q10 Annex 1
and ICH Q12 case
studies for PACs

Outputs | Products of research

•

•
•

•
•

ICH and other regulatory
guidances have provided the
‘what’ concept and
requirements that companies
must follow. This is the first
time detailed practical
application information was
made available on ‘how to’
implement those concepts at
an operational level
Published 1VQ for PAC
solutions paper - this directly
supports ICH Q10
Published specific PAC
example case studies
illustrating application of the
solutions
1VQ for PAC website
Various publications and
presentations (summarised in
Figure 10.1)

Outcomes | Awareness and use of
outputs

Impacts | Consequences of
people using outputs (planned or
anticipated)

ICH Q9 and Q10 Annex 1, when
risk and evidence-basis is presented
by companies

risk-based to evidence-based
and risk-informed decisions
On-time and reliable
availability of medicines for
patients anywhere and
everywhere in the world
Increased number of science
and risk-based decisions by
both companies and regulators
for PACs
Consistent and standardised
global practices across industry
and regulatory authorities for
specific types of PACs
Implementation of ICH Q10
Annex 1 by regulatory
authorities with regard to
regulatory flexibility for PACs
based on demonstrated PQS
effectiveness
Additional guidance and
collaboration from regulatory
authorities (via ICMRA) in
relation to PAC management
On-time and reliable
availability of medicines for
patients anywhere and
everywhere in the world

• Rediscovery and increased focus on
ICH Q10 Annex 1 – raising
accountability of both industry and
regulatory authorities to implement
• 1VQ for PAC becoming a unified
voice on PQS and Quality at a
broader level for greater impact – as
evidenced by published industry
position papers and case studies
• Recognition by regulators and
industry that the latest product and
process knowledge is not being
implemented as fast as necessary
• PAC case studies demonstrating
o evidence-based QRM and the
Risk Knowledge Infinity (RKI)
cycle for product lifecycle
management
o step-wise approach companies
can use to accelerate
implementation of new product
and process knowledge
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•

•

•

•

•

•

This chapter summarised the outcomes and impact of this research study designed and
conducted in a pre-pandemic context. The next chapter draws on some of the insights
and learning acquired from the COVID-19 pandemic, and expands on future research
opportunities that could extend from this research study and its conclusions.
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Research Conclusions and Opportunities
for Future Research
This chapter draws conclusions on the research study. As stated in Chapter One, section
1.3 of this thesis, the overarching goal of this research study was to accelerate
continual improvement and innovation, and reduce global complexity through
science and risk-based transformation of PAC management– so that the
pharmaceutical sector can ensure the uninterrupted delivery of safe, effective highquality medicines to patients.
This research was conducted at an opportune time, when there was a heightened focus,
momentum and interaction across key stakeholders - regulatory authorities,
pharmaceutical industry, policy makers, patients, governments - towards the objectives
of reducing global drug shortages, improving product lifecycle management, and
advancing innovation to address unmet medical needs. This research study resulted in
practical science and risk-based solutions that, if implemented by pharmaceutical
companies and regulators, could meaningfully contribute towards addressing the
‘wicked problem’ of drug shortages, by facilitating faster continual improvement and
innovation for medicinal products throughout their commercial life. This would be
based on implementation of new knowledge gained closer to real-time, instead of taking
years.
The final stages of this research occurred during the course of the global COVID-19
pandemic. This was entirely unanticipated in the initial research plan, and while the
research plan evolved during the course of this study, it was decided not to extend the
research to delve deeply into pandemic-related changes and post-pandemic learnings.
This was primarily because the pandemic is still ongoing and the regulatory authorities,
pharmaceutical industry, healthcare sector and policies are continuing to evolve.
Nevertheless, in this concluding chapter, in addition to the research conclusions and
considerations for future research, the researcher has highlighted aspects of the COVID19 pandemic that are pertinent to this research and which are anticipated to alter the
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future state of PAC management, product lifecycle management, and ultimately, the
pace of continual improvement and innovation at a global level in the pharmaceutical
sector. These are therefore, also expected to inform and influence future research into
these topics.

Some COVID-19 Pandemic Observations:
Increased Focus on Public Health
The COVID-19 pandemic started in the small Wuhan region in China towards the end
of 2019, but ballooned to a global scale at an unprecedented pace in a matter of weeks;
it has had a global public health impact of a magnitude that no single country had
anticipated or was even remotely prepared for. As each country worked hard and fast to
contain, control and manage the pandemic at a national level, it quickly became
apparent that all countries were facing similar daunting challenges, and many of the
mitigating actions taken at a national level could have been (but were not), proactively
and quickly leveraged across countries. Each country struggled to adapt their practices,
processes, and policies, and to implement pandemic control measures based on their
individual experiences and learnings. Though similar lessons were being learned across
countries, with some being fairly basic and obvious, such as the importance of masks,
social distancing and hygienic practices, it was interesting and intriguing to note that
each country became more inward-focused. The lessons learned in one country did not
necessarily and adequately translate to lessons adopted in others, as quickly as they
could and should have. Similar to the topic of this research, where solving a global
problem at a global level should be intuitive and primary, all action has tended to be at
smaller, national (not even regional) levels with a ‘country-first’ mindset. One wonders
whether this might be because these problems and their solutions are simply too huge,
too ‘wicked’, to tackle at a global scale.
The pandemic has underscored the fact that diseases know no borders, patient and
public health needs largely do not vary by country, and therefore, solutions must be
global in nature. The pandemic forced the pharmaceutical industry, regulatory
authorities, supply chains, distribution networks, governments, policy makers, societies
and communities as a whole to flex and adapt in a manner and at a scope that had not
been envisaged or planned for. Though pharmaceutical companies and regulators have
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always had the primary objective of serving patients, with the COVID-19 pandemic, the
need to be unequivocally patient-centric, emerged as the singular unambiguous
objective.
The worldwide outbreak of COVID-19 highlighted that the current regulatory
frameworks both at national and global levels were not designed for, or capable of,
managing through a pandemic. Managing drug shortages had already been a global
challenge pre-pandemic; the pandemic further exacerbated this challenge, threatened the
availability of critical medicines including those needed for COVID-19 patients, and it
impacted people’s lives in a manner and scale that the world had never experienced
before.
Pharmaceutical companies and regulatory agencies across the world realised that
standard ways of working were not effective, or even possible, in several regards due to
pandemic-imposed restrictions. Business continuity mode in significant facets of the
pharmaceutical, regulatory and healthcare sectors had to be activated, and greater
flexibility in making, assessing, and releasing products, and administering patient care,
became essential. Greater flexibility was afforded by regulatory agencies to
manufacturers and marketing authorisation holders without compromising the safety,
quality and efficacy standards for medicines in order to mitigate drug shortages. Public
health was elevated to a more prominent, front-and centre-stage as the world raced to
overcome the catastrophic impact of a virus that had shutdown countries and economies
globally within weeks. Even so, providing medicines to patients was not something that
could be deferred, delayed or shut down – the public health crisis caused by the
pandemic had to be dealt with swiftly.

10.1.1 Regulatory Flexibility to Mitigate COVID-19
Related Public Health Consequences
Ensuring the availability of critical medicines became a public health priority during the
pandemic. Within a month after the COVID-19 outbreak was declared a global
pandemic on March 11, 2020 by the WHO (Cucinotta and Vanelli, 2020), the EMA,
together with the Heads of Medicines Agencies (HMA) and the European Commission
(EC), published an important Questions and Answers paper on 10-April-2020, on
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Regulatory Expectations for Medicinal Products for Human Use During the COVID-19
Pandemic (EMA, HMA and EC, 2020). This notice to stakeholders granted immediate
regulatory flexibility to mitigate drug shortage and supply continuity risks due to supply
chain or manufacturing disruptions that were a consequence of the extenuating COVID19 constraints. The Q&A document was revised on 17-April-2020 and 26-May-2020, in
order to introduce additional flexibilities.
Some areas of regulatory flexibility granted to manage through the COVID-19
challenges and restrictions on a temporary basis included:
•

Companies being able to utilise new manufacturing sites and quality control
labs, or alternative suppliers for starting materials, reagents, intermediates,
active substances, or finished product, even when these were not specified in the
marketing authorisation. This could be done under an Exceptional Change
Management Process (ECMP) where such changes were necessary to mitigate
drug shortages and supply disruption.

•

Potential to postpone renewal of marketing authorisation license when warranted
due to COVID-19 constraints.

•

Extension of GMP certificates and authorisations to manufacture or import
products through the end of 2021 without on-site inspections and on the basis of
a distant assessment.

•

Acceptance of remote batch certifications and remote audits of active ingredient
manufactured by a Qualified Person (QP).

•

Flexibility in labelling and packaging requirements to facilitate movement of
medicinal products within the EU.

•

Flexibility in allowing limited prospective qualification for new manufacturing
equipment and facilities, or concurrent validation of manufacturing processes for
COVID-19 crucial medicines. This required the application of formal QRM to
determine scope of desired flexibility, assure product quality, and it required
documentation of all relevant decisions within the PQS and approved by
authorised personnel, including the Quality Unit and QP.

In May 2020, to further expand on the Questions and Answers paper, the Co-ordination
EU’s Group for Mutual Recognition and Decentralised Procedures - Human (CMDh)
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provided practical guidance on handling and expediting certain regulatory processes
during the COVID-19 crisis (CMDh, 2020). The EMA also published initiatives for
acceleration of development support and evaluation procedures for COVID-19
treatments and vaccines (EMA, 2020).
In the US, the FDA, under section 564 of the Federal Food, Drug, and Cosmetic Act,
activated its 2017 guidance for Emergency Use Authorization (EUA) of Medical
Products and Related Authorities (FDA, 2017). An EUA is a mechanism to facilitate the
availability and use of medical countermeasures, including vaccines, during public
health emergencies, such as the COVID-19 pandemic. Under an EUA, FDA can
authorise use of unapproved medical products or unapproved uses of approved medical
products during public health emergencies, to diagnose, treat, or prevent serious or lifethreatening diseases or conditions caused by chemical, biological, radiological, and
nuclear threat agents, including infectious diseases when certain statutory criteria are
met, or when there are no adequate, approved, and available alternatives. To manage the
COVID-19 public health emergency, FDA granted EUAs for several treatments,
diagnostic tests and vaccines for the duration of the pandemic.
The flexibility and accelerated timelines for marketing authorisations, post-authorisation
or emergency use authorisation applications were targeted to resolve shortages or
availability issues for critical products that were directly intended for COVID-19 use, or
for expediting the development and evaluation of treatments and vaccines for COVID19. The primary focus of all these regulatory efforts was to efficiently manage a public
health crisis. They were exactly in the direction of swift and much-needed science and
risk-based decision-making, also aligning with the insights and outcomes that emerged
from this research study.
Since the regulatory flexibility and accelerated timelines offered by the ECMP during
the pandemic were most relevant for this research, in the context of PAC management,
the researcher contends that this approach and its intended application could continue to
yield valuable benefits even post-pandemic. The ECMP allowed MAHs to implement
changes very quickly, by notifying the relevant competent authority within 48 hours of
making the change, and without waiting for prior-approval by the regulatory authority.
It also required the EU competent authorities to respond back to the MAH within 2
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working days and, if they did not raise any objections within the 2 working days, the
ECMP application would be considered as accepted (CMDh, 2020; EMA, HMA and
EC, 2020).
However, it was made clear that this regulatory flexibility via the ECMP was narrowly
restricted:
1. It could ONLY be applied to medicines that were considered crucial for the
treatment of COVID-19 patients, and
2. It could ONLY be used to implement changes to manufacturing sites, QC
laboratories or suppliers for starting materials, reagents, intermediates, active
substances, or finished products that were specifically for COVID-19 treatments.
All other non-COVID-19 related crucial medicines and all other types of post-approval
changes (e.g., changes to specifications) were excluded from the ECMP flexibility.

10.1.2 Unprecedented Speed of Innovation and
Collaboration from Pharmaceutical Companies
In parallel to the prompt actions from regulatory authorities, COVID-19 propelled the
pharmaceutical industry into a broad range of undertakings as well, and at extraordinary
speed - from testing and investigating existing medicines as potential treatment options
against COVID-19, through rapid clinical trials, and highly accelerated development of
novel treatments and preventive vaccines. The standards of care for treatment of
COVID-19 hospitalised patients in many countries involved Gilead's antiviral product,
Veklury (remdesivir) and the corticosteroid dexamethasone. The FDA granted EUAs
for several treatments - convalescent plasma to treat hospitalised COVID-19 patients,
Eli Lilly’s monoclonal antibodies (bamlanivimab, bamlanivimab+etesevimab), and
Regeneron’s antibody cocktail (casirivimab and imdevimab), to treat mild to moderate
COVID-19, and Eli Lilly's Olumiant (baricitinib) in combination with remdesivir for the
treatment of hospitalised COVID-19 patients requiring supplemental oxygen. Per
GlobalData, an intelligence gathering resource for the pharmaceutical sector, as of
March 2021, a record-breaking 1600+ novel or repurposed drugs were in the global
pipeline for COVID-19 treatment, and while 62% of them were in the discovery or preclinical stages, 4500+ clinical trials had been initiated and were in progress globally.
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The authorised or approved COVID-19 vaccines included Pfizer and BioNTech's
Comirnaty (BNT162b2), Moderna's mRNA-1273, AstraZeneca's AZD1222, and
Johnson & Johnson’s single-dose adenoviral vector vaccine (JNJ-78436735).
Additionally, the Russian vaccine, Sputnik V, was made available in several countries,
and vaccines from Chinese manufacturers, Sinovac, Sinopharm, and CanSino were
authorised in China and several other countries. Vaccine efficacies upwards of 90%, as
seen with the mRNA vaccines, were not typical. Yet, as vaccines and treatments were
brought to market with extraordinary effort and unmatched speed, the virus, not
unexpectedly, has continued to mutate fast, and at accelerating level. New viral variants
continued to emerge even as countries urgently worked towards increasing vaccination
rates. Several companies, including Moderna and Pfizer, initiated a new wave of
development for vaccines and vaccine boosters against the newly emerging SARSCoV-2 viral variants, soon after their vaccines against the original viral strain had been
commercialised.
Vaccines are highly complex biologics to develop, manufacture and supply. Typical
development, manufacturing and approval has historically taken 3-5 years and often
longer. Having multiple vaccines developed, tested through global clinical trials, and
approved in multiple countries in less than a year, with two of them based on a new
mRNA technology not approved before, was ground-breaking and pioneering! It is a
clear demonstration that this speed of innovation and change is not only needed, it is
indeed possible.
The challenges with manufacturing enough doses and making them available globally to
treat and vaccinate patients also spurred an exceptional wave of unusual strategic
partnerships, agreements and collaborations between pharmaceutical companies – some
examples being Roche collaborating with Regeneron to manufacture their antibody
cocktail, Novartis producing Pfizer/BioNTech’s vaccine to boost global supply, and
also manufacturing the mRNA bulk drug for CureVac’s COVID-19 vaccine candidate,
Merck producing Johnson & Johnson’s COVID-19 vaccine, and Sanofi and
GlaxoSmithKline partnering to develop a vaccine. Competition became secondary to
collaboration in the service of public health, as pharmaceutical companies and
regulators spared no effort or resources in the race to deal with the COVID-19
pandemic. Such collaborations were previously more an exception and driven by mutual
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benefits to the collaborating companies; but with the pandemic they became the norm,
driven by a common, unifying purpose of supplying vaccines and treatments to patients
in order to alleviate a public health crisis.

Learnings from the COVID-19 Crisis
The COVID-19 crisis forced new ways in the application of science and risk-based
decision-making by both regulatory authorities and pharmaceutical companies. In this
regard, it led to an increased utilisation of the PQS to manage and document changes
and decisions, and an increased reliance on the Quality Unit (including the QP) and on
QRM to ensure that the granted flexibility and the expedited change processes did not
compromise product quality and/or patient safety in any unacceptable way. Without this
paradigm shift in operations across the global pharmaceutical sector, public health
would have been significantly and unavoidably impacted well beyond that directly
resulting from COVID-19 infections, in that patient access to life-saving crucial
medicines would have been compromised even more severely.
These provisions may seem new, but their underlying reliance on the PQS, the Quality
Unit and QRM and KM to support them reflects what has long been in existence to
provide a balanced framework and structure for science and risk-based decisionmaking, while ensuring that product quality, safety and efficacy remained
uncompromised. This was how the ICH Q9, Q10, and Q12 guidances had envisioned
their objectives and concepts to be realised. However as acknowledged by both industry
and regulatory authorities, practical guidance is needed to implement the concepts and
principles in the ICH guidances. This is where unified practical solutions such as those
resulting from this research are necessary.
Speed and flexibility are paramount in accomplishing the primary objective of making
safe, effective, high-quality products available for patients during the pandemic. During
the pandemic, regulators were able to mobilise, debate, align and make important
decisions within a matter of weeks on the optimal and appropriate course of actions to
prevent a potential public health crisis resulting from drug shortages. Companies were
able to innovate and bring products to market faster than ever before. To quote Malcolm
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Gladwell, a global thought leader and author on innovation, history, management and
leadership:
“A sense of urgency and social risk-taking, beyond operational risk-taking is
essential.”
The urgency of the COVID-19 crisis enabled a different risk-benefit view. The swift
actions taken by regulators and companies to overcome manufacturing and supply
disruptions, were exemplary and laudable (clearly demonstrating that it could be done
when needed), but it also raised some obvious, thought-provoking questions and lessons
from the pandemic that the pharmaceutical and regulatory sectors should consider going
forward:
•

Why did it take a significant crisis like COVID-19 to realise the regulatory
flexibility and speed that had already been envisioned for over a decade via ICH
Q10 and Q9?

•

Why was the applicability of the flexibilities introduced in 2020, which relied
heavily on science and risk-based decision-making, strictly limited to medicines
considered crucial for COVID-19 treatment?

•

Why were these provisions for regulatory speed and flexibility made for only
temporary use?

•

What would it take for these new concepts and ways of working to become the
new and better normal, post-pandemic, in order to reduce drug shortages and
accelerate continual improvement and innovation?

•

How can trust and an extraordinary level of cooperation among stakeholders
continue to be made stronger at a global scale?

•

How can scientific advancement, the heightened commitment and common
unifying purpose of serving public health, be retained regardless of a pandemic
or crisis?

•

How can we achieve faster coordination, assimilation, and execution across the
globe, instead of countries striving for self-sufficiency and becoming more
inward- focused, when solving a global problem?

These and many other questions will continue to arise and persist into the postpandemic era. It will be essential to use the lessons from this pandemic to prevent and
be better prepared for another such pandemic. The past 18 months of the pandemic have
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truly tested the pharmaceutical, regulatory and healthcare sectors, as well as
governments, societies, countries and communities. Albert Tate, a visionary leader,
author and founding pastor of one of the fastest multi-ethnic churches in the US raised a
profound question:
“What if the COVID-19 pandemic wasn’t the test? What if it was the lesson and
the test is yet to come on whether or not we will keep these lessons?”
Building in resilience and a more effective response system to a public health crisis has
to be made a priority not only to meet the needs during a crisis, but even outside of it.

Research Value and Future Research
Considerations
The ‘wicked’ problem of drug shortages and the challenges with slow continual
improvement and innovation cannot be resolved overnight through a single set of
solutions or by a few stakeholders. As characteristic of a ‘wicked problem’, there is no
way to measure the goodness or effectiveness of any proposed solution. Furthermore,
per the ‘no stopping rule’, no solution to a ‘wicked’ problem is definitive or final, and
solutions cannot be deemed as either good or bad – they simply make the situation
better or worse.
The body of work undertaken in this research study was broad, transparent, inclusive,
and resulted in the development of several practical science and risk-based standard
solutions for both pharmaceutical companies and regulatory authorities that, if
implemented across the sector, would deliver regulatory flexibility to enable fast and
close to real-time implementation of new knowledge gained through routine operations
during the commercial life of a product. The desired objective of the research was a
transformational shift where at least 50% of PACs had the potential of being managed
within a company’s PQS without the need for regulatory prior-approval, whilst still
acknowledging that regulatory oversight for those changes was entirely possible, via the
inspection and surveillance activities of regulatory authorities.
There are various possible pathways to reduce the global complexity associated with
management of PACs. As an illustration developed by the researcher and Vinther, a
scenario based on a company making 100 prior-approval PACs globally every month,
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and where worldwide approval took an average of 3 years for each PAC was
considered. In this scenario, at any given time the company would be managing 3600
open PACs awaiting regulatory authority approvals. This is a conservative assumption;
for global companies, this number is typically much larger. The researcher proposed as
shown in Figure 6.1 in Chapter Six of this thesis, two overarching pathways to reduce
the global complexity for the faster implementation of these PACs:
1. Increase the use of science and risk basis within the framework of an effective
PQS – by implementing the standard solutions described in Chapter Eight of this
thesis

2. Increase regulatory reliance – whereby, if one regulatory authority has assessed
a PAC or a company’s PQS, other regulatory authorities could rely on and
accept their conclusions of acceptance or rejection
Building on these pathways, three different mechanisms have been proposed through
this research which could assist in reducing complexity and achieving the desired
transformation:
1. Mechanism 1 – Reduced approval timelines
2. Mechanism 2 – Regulatory reliance
3. Mechanism 3 – Regulatory flexibility to manage more PACs in the PQS
Figure 10.1 below depicts how these three different mechanisms to reduce complexity
could contribute towards achieving the desired transformation; each of these
mechanisms is further described following the figure.
Open PACs if….

3600
Approved in
6 months

Regulatory
Reliance

Worldwide

10 HAs rely on
each other

50% in PQS

80% in PQS

only (no prior
approval)

only (no prior
approval)

1800

600

Approved in
6 months &
Regulatory
Reliance &
50 % in PQS

Approved in
6 months &
Regulatory
Reliance &
80 % in PQS

720
360

V

1 ice

of

Q uality

V

1 ice

of

Q uality

30

12

Figure 10.1: Impact of Various Mechanisms to Reduce Global PAC Complexity
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The value delivered by each of the three mechanisms or a combination of them as
shown in this figure could be described as follows:
•

Mechanism 1 - Reduced approval timelines: The first mechanism in the figure
(bar 2) reflects a reduction in the average time from 3 years to 6 months between
first country to last country approval. As depicted, this would reduce the number
of concurrently open PACs to 600 (an 83% reduction).

•

Mechanism 2 – Regulatory reliance: With this second mechanism of
regulatory reliance, if regulatory authorities relied more on each other’s
regulatory assessments of PAC submissions and inspection of their PQSs, doing
so would further reduce number of open PACs (bar 3). Assuming 10 regulatory
authorities practiced such mutual reliance in this area, this would reduce the
number of open PACs down to 360 (a 90% reduction).

•

Mechanism 3 – Regulatory flexibility to manage more PACs within the PQS
only: This third mechanism is the ability to manage and implement more
changes within the PQS only, or via a lower change category of regulatory
notification, without requiring prior-approval from regulatory authorities, as
described in ICH Q10, Annex 1. The fourth and fifth bars in the figure show the
reduction that could be achieved if 50% and 80% of the current prior-approval
PACs were managed within the PQS only, without having to go through the
prior-approval process before implementation. This would reduce the number of
open PACs to 1,800 and 720 respectively from the original 3600.

•

Combination of Mechanisms: Finally, the last bars in the figure show
examples of the extent of reduction that is possible through a combination of all
3 mechanisms – reduced approval times, regulatory reliance, and regulatory
flexibility per ICH Q10, Annex 1 to handle more changes without priorapproval. This would reduce the number of open PACs to 30 and 12 respectively
for the two scenarios, achieving reductions of more than 99% in each case.

Application of all 3 mechanisms individually or in combination, would substantially
reduce the overall number of open PACs at any given time and it would lower the
extent of global complexity that currently affects PAC management. There has been a
recent increase in more NRAs acknowledging the benefits and value of work and
resource sharing, and reliance on scientific assessments carried out by other regulatory
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authorities. The mutual recognition agreements between EMA and other regulatory
authorities like the FDA to rely on each other’s GMP inspection system and share
information on inspections and quality defects, is an example of this (EMA, 2017).
Such reliance can vary by country and be complete, partial (where an NRA still reviews
an application but the review is abbreviated or less stringent), or unilateral (where a
country decides to rely on the work of another specific trusted NRA). However, as of
now, there are very few instances (such as within EU countries,) of mutual reliance for
PACs.
This research work has studied and explored ways to reduce the global complexity
associated with PAC management; it has developed practical solutions and tools that
facilitate regulatory flexibility in this area through enhanced science and risk-based
approaches that are grounded in latest product and process knowledge, and where the
role of an effective PQS is maximised. The practical solutions presented in this research
would allow pharmaceutical companies and regulatory authorities to implement and
gain advantage from the application of these possible levers.
PACs are inevitable and essential for maintaining a state of control and for driving
continual improvement, as expected by ICH Q10. It is important to make the point that
the goal is not simply to reduce the number of PACs, but to facilitate knowledge-led
continual improvement when manufacturing and supplying medicines. Reducing the
number of PACs that require regulatory approval prior to their implementation, such
that the time it takes to implement them is significantly shortened, will drive continual
improvement and innovation forward, and at an accelerated pace. This will serve the
interests of all stakeholders, but especially patients. Achieving such a transformation via
the faster implementation of PACs through unified practical solutions is entirely
possible, as concluded by this research, and demonstrated by the rapid action-taking and
decision-making during the pandemic by both industry and regulatory authorities. An
overall framework for doing so has already been laid out in the ICH guidances - this
research work focused on developing practical solutions that would enable those
guidances to be implemented and for their vision to be realised. These solutions will
enable the faster implementation of new product and process knowledge, thereby
advancing continual improvement and innovation, for the ultimate benefit of patients.
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If companies and regulators were to implement the solutions presented in this research,
then the number of open PACs at any given point in time for a company could be a
useful measure of how successful a company has been in the timely management and
implementation of new knowledge gained during the commercial life of its products,
and in advancing continual improvement and innovation through effective and timely
PAC management. It would represent the strength of effectiveness of the company’s
PQS, including its science and risk-based decision-making. Finally, it would also be a
useful indicator of the level of trust and regulatory flexibility earned by the company
from regulatory authorities.
Future research areas that could be considered include the following:
•

Development of new systems thinking-based solutions including policy and
legislation changes: A deeper exploration into the social, cultural, behavioural
and heuristics-related complexity of the problem, through the perspective of
stakeholders beyond pharmaceutical companies and regulatory authorities, could
lead to the development of additional solutions. Exploring policies at local or
regional levels, identifying policies that would be beneficial at global levels, and
researching mechanisms to influence and advance such policy development,
would contribute further towards meaningful change and impact.
Calnan in 2014 had identified that a shift from compliance-based quality to
excellence-based quality performance, needed a holistic approach to quality and
improvement, beyond application of a static set of procedures and GMP-led
systems to Total Quality Management (TQM)-based practices (Calnan, 2014).
This study affirmed systems thinking, as described in Chapter Three, section
3.2.1 of this thesis, as the holistic means to address this complex problem.
Additional interconnected solutions need to be designed and implemented within
and across interdependent stakeholder groups. This research study established a
new stakeholder group of the CQOs as the senior-most Quality leaders and
decision-makers for the pharmaceutical industry. PIC/S is facilitating
harmonisation and unification of the global regulatory inspector community.
ICMRA is starting to unify the global assessor community on this topic through
its PQKMS strategic initiative, described in Chapter Six, section 6.5 of this
thesis.
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There is unprecedented opportunity for these three stakeholder groups to come
together in applying systems thinking to collectively co-develop standard
solutions that will serve the needs of both their individual subsystems and the
interfacing, interconnected and interdependent aspects of other subsystems they
co-exist with.
•

Progress in innovation and continual improvement: by exploring how the
solutions resulting from this research have impacted the various characteristics
of this ‘wicked problem’ (described in Chapter Four of this thesis). As
characteristic of a ‘wicked problem’, solutions are neither good nor bad – they
simply make the situation better or worse. One of the considerations for future
research would be exploring whether the solutions resulting from this research
have made the current state of continual improvement, innovation and global
complexity better or worse, or whether the solutions here have led to any
unforeseen consequences.

•

Post-pandemic state: Learnings that have and are continuing to emerge from
the COVID-19 pandemic will provide rich and broad grounds for future research
to answer the questions the researcher raised in section 10.2:
o Why did it take a significant crisis such as COVID-19 to realise the
regulatory flexibility and speed that had already been accessible and
envisioned for over 15+ years via ICH Q10 and Q9?
o Why was the applicability of these flexibilities limited to medicines
crucial for COVID-19 treatments?
o Why were these provisions for regulatory speed and flexibility made
only temporary?
o What would it take for these new concepts and ways of working to
become the new and better normal, post-pandemic, in order to reduce
drug shortages and accelerate continual improvement and innovation?
o How can trust and an extraordinary level of cooperation among
stakeholders continue to be made stronger at a global scale?
o How can scientific advancement, the heightened commitment and
common unifying purpose of serving public health, be retained
regardless of a pandemic or crisis?
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o How can we achieve faster coordination, assimilation, and execution
across the globe, instead of countries striving for self-sufficiency and
becoming more inward-focused in solving a global problem that afflicted
every nation?
•

Advancing regulatory reliance: While this research has identified regulatory
reliance as an essential component in resolving the ‘wicked problem’ of drug
shortages, exploring the current state of regulatory reliance or mechanisms, and
bringing regulatory authorities together to advance global regulatory reliance
could be a valuable topic for future research. Particular focus on non-ICH
regions or countries, their regulatory systems, infrastructure, challenges and
opportunities, could further expand understanding of the problem and the
possibilities for other potential solutions.
At the time of this thesis submission, a new Ph.D. research study at PRST in TU
Dublin has been approved for V. Sachdeva; titled ‘Facilitating reliance
approaches through collaborative registration procedure (CRP): How
National Medicines Regulatory Authorities (NMRAs) can expedite
Marketing Authorisation and Post-approval Changes (PACs) to ensure
timely and uninterrupted supply of the medicinal products.’
This future research study intends to further facilitate a reduction in PAC
implementation timelines by:
o Influencing greater harmonisation and coordination of actions from
individual countries by working with NMRAs that are in the most mature
cohort and facilitating the sharing of good practices
o Providing capability and maturity building supporting materials
(training, case studies, reference examples) for NMRAs and by
encouraging more convergence regarding the management of the PAC
process through global regulatory bodies such as PIC/S

Innovation is necessary not only for new medicines but also for medicines that are
already on the market and will remain so for years, maybe decades.
The three years of this research study, preceded by almost five years of pre-research
foundational work, and now being followed on by the future research referred to above,
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underlines the importance, need and value of continual improvement and innovation for
patients and public health. As long as patients are waiting for their medicines, we
cannot be good enough or fast enough – the journey of doing more and better must
continue.

Additional Post-Research Reflections
At the conclusion of this research study, as the researcher circled back to the approved
2005 Business Plan for ICH Q10 and the envisioned benefits, she and Vinther sent a
short survey to the 30 CQOs on 1-Sept-2021, 13 years after the PQS model in ICH Q10
was published, asking the following question:
Since 2008, on a scale of 1-5, how much do you think each of the potential benefits
(A through E below) envisioned for ICH 10 have materialised in your daily
operations in your current and/or previous companies?
1 = Things have become significantly worse or complex
2 = Things have become slightly worse or complex
3 = No change
4 = Things have improved slightly (less complex)
5 = Things have improved significantly (less complex)
Table 10.1 below provides an average of the 10 CQOs that responded:
Table 10.1: Survey of CQOs on the Extent of ICH Q10 Benefits Realisation
Score Range

Average Score

2-4
2-4

3.44
3.11

1-3

2.44

2-3

2.33

2-4

2.78

Envisioned Benefit
Improved process performance
A reduction in the costs of internal failures (rejects,
reworks, reprocessing and investigations) as the
quality system guideline drives improvement
A reduction in the costs of holding duplicate stock
and operating multiple processes as improvements
and changes are made more effectively across all
regions
A reduction in the costs of preparing / reviewing
certain regulatory submissions
Enhanced assurance of consistent availability to the
patient
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The responses from these Senior Quality Leaders were disappointing in that they
indicated ICH Q10 has not had much positive impact at all – the responses were mostly
that it had made no change, and in several instances had made the situation slightly
worse or more complex. Some comments provided below convey further context behind
these scores:
•
•

•
•
•
•
•

“I think higher expectations have not driven better process design beyond what
we should have been doing in the first place – CPV maybe tells you when things
aren’t right but that’s after the fact.”
“I see no change in failures due to Q10 as we always strive to get to root cause
and decent CAPAs so have reduced deviations because of good investigations.
QRM is an added workload to little impact from what I have seen. What you
don’t know you still don’t know.”
“Supply chain complexity driven by different regulators has only made things
worse.”
“Our world has got more complex and Q10 didn’t help for anything.”
“While the PQS is helpful, the complexity of the regulatory framework has
actually prevented the last three potential benefits”.
“The fact that I have to respond as I do is disappointing.”
“The consensus is that ICH Q10 did not have a significant impact on daily
operations at our company as we already had a strong PQS. Since the
introduction of Q10 in 2008, we have undergone several Enterprise initiatives
which were focused on driving further standardization across the breadth of the
company’s Business Segments including medical device, pharmaceutical and
consumer health. While we have implemented many changes since the
introduction of Q10 in 2008, none of these changes were specifically driven by
or linked to Q10. With regard to regulatory submissions, ICH Q8(R2), Q9, Q11
and now Q12 have had more impact. Although aligned with these other ICH
guidance documents, ICH Q10 has not significantly impacted the regulatory
submission process. Q10 does provide benefit in terms of globally harmonized
definitions and expectations when working with 3rd parties.”

This led the researcher to a useful post-research reflection, linking the nature and
complexity of a ‘wicked problem’, the body of work and outcomes from this research
study, the unexpected insights from the COVID-19 pandemic – that standard solutions
developed and implemented in a collaborative, unified manner within and across
interdependent stakeholder groups, has likely been the missing component for
realisation of the desired state and benefits envisioned by ICH Q10, Q9 and now ICH
Q12. Solving a ‘wicked problem’ requires systems thinking, as uncovered by this
research study. Harmonising on concepts and high-level approaches is an important
step, but it might only be the first step in the journey to the desired state – standard
solutions are necessary. ISO standards and standard ISO certifications provide a useful
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paradigm that the pharmaceutical sector might need to consider. Time and the extent of
consistent and unified adoption will tell how the solutions resulting from this research
study influence the achievement of the potential benefits envisioned above, whether or
not they accelerate the pace of continual improvement and innovation in the
pharmaceutical sector, and whether or not this ultimately leads to a marked reduction in
drug shortages. This research study’s recognition that the pharmaceutical, regulatory,
healthcare, legislative and governmental sectors must operate as a dynamic adaptive
‘living system’ to open up numerous opportunities for these stakeholders to rise above
their organisational boundaries, limitations and assumptions and create new pathways
for interacting and collaborating, ways that will transform their service of public health.
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Appendices
Appendix I: Researcher’s Prior Experience
Appendix I summarises the researcher’s professional career experience in the
pharmaceutical industry, her role and involvement in establishing a QRM programme at
the company of employment Roche/Genentech, her activities in advancing risk-based
application both for the company and broader for the pharmaceutical industry, and how
these led to her extensive industry work and the current research study into Drug
Shortages and PAC Management. Drug shortages and integration of QRM into the PQS,
are the specific areas of the researcher’s risk-based application experience discussed in
this appendix.

Significant Publications Underpinning this Research
It is useful to follow the researcher’s journey by reviewing the timeline of significant
publications underpinning this research. Figure 2.2 in Chapter Two (Literature Review)
provides a timeline-based overview of key publications relevant to this research;
highlights from the researcher’s career, leadership and publication experience starting in
2003 till date, are mapped against it. The figure is organised to show on the left side, the
guidelines that informed this research. These are mainly the ICH guidelines – ICH Q8
(R2), Q9, Q10 and Q11, and the PIC/S Recommendation Paper on demonstrating
effectiveness of risk-based change management (PIC/S, 2019). The far right of the
figure highlighted the researcher’s key leadership and publications experience that are
relevant for this research. Chapter Two discussed the specifics of the ICH guidelines
that underpinned this research.

Researcher’s Career Experience Informing this Research, Prior
Registration Research Work
Figure 2.2 in Chapter Two laid out the researcher’s career experience, and her
leadership and influencing experience in the pharmaceutical industry, with regulators,
and via the PDA. This section gives a high-level review of the researcher’s career prior
to registration for this Ph.D. Following this, specific details relating to QRM, drug
shortages, and PACs will be discussed.
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The researcher’s career commenced with QRM practical implementation experience in
2003, with foundational QRM concepts for medical device combination products first,
and then for pharmaceutical and biotechnological products. QMS and QRM application
for medical devices based on ISO concepts, started in 1996 with the publication of the
first ISO 13485 standard, Medical Devices (intended for the design, production,
installation and servicing of medical devices and related services), latest revision being
ISO 13485:2016 (ISO, 2016); and in 2000, the first ISO 14971 standard, Medical
Devices – Application of Risk Management to Medical Devices (that specifies the
terminology, principles and a process for risk management of medical devices through
all phases of a device’s lifecycle), latest revision being ISO 14971:2019 (ISO, 2019).
Due to these ISO standards, the medical device industry has a longer history and higher
maturity with QMS and QRM integration into device lifecycle management, than the
pharmaceutical or biotechnology industry, which did not have the ICH Q9 and ICH Q10
guidance until 2005 and 2008, respectively. Hence, gaining operational experience with
device combination products was very beneficial, as it afforded the researcher with a
knowledge of device Quality System Regulations and integrated QRM application into
device lifecycle management, as expected by ISO 13485 and ISO 14971.
This foundational experience in device QRM and device QMS was then expanded in
2005 when the researcher made a career change towards pharmaceutical and
biotechnological products. This was also when ICH Q9 was published followed by ICH
Q10, a few years later in 2008. During her role in the Corporate Quality System and
Support function at Genentech, the researcher gained experience with design and
implementation of a PQS per ICH Q10 expectations. This was followed by gaining
practical experience on QRM application per ICH Q9 for pharmaceutical and
biotechnology products and processes - first as the Global Head of Quality Risk
Management for Genentech starting in 2008, and then for Roche through 2012, the
researcher was responsible for the design, deployment, and governance of a harmonised
QRM programme (global standards, business processes, global tools including an IT
tool, templates and role-based QRM training) across both companies. In addition, the
researcher acted extensively as a QRM facilitator and trainer, led complex crossfunctional, cross-site risk assessments, led complex network-wide QRM strategies for
products, processes and systems, including risk-based regulatory filings, and led the
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integration of QRM into end-to-end product management and into the PQS, within the
Roche/Genentech organisation.
The researcher has been a member of PDA since 2002, and has actively volunteered for
a range of technical, quality and regulatory topics. While she was leading QRM
implementation at Roche/Genentech, in December 2008, PDA established an initiative
known as the Paradigm Change in Manufacturing Operations (PCMO ®). The goal of
this initiative was to establish 'best practice' documents and/or training events that
would assist pharmaceutical manufacturers in implementing ICH Q8, Q9, and Q10
guidelines. The strategic objectives of PCMO were as follows:
•

Enable an innovative environment for continual improvement of products and
systems,

•

Integrate science and technology into manufacturing practice,

•

Enhance manufacturing process robustness, risk-based decision making and
knowledge management, and

•

Foster communication among industry and regulators.

The researcher was invited to lead the QRM workstream under the scope of the PCMO®
programme. This involved leading a Task Force for the development of the parent
Technical Report 54 and sub-teams that developed QRM application case studies.
In parallel, during this part of her career journey, the researcher became increasingly
involved in QRM interactions and dialogue within the larger pharmaceutical industry
through training programmes, workshops, conferences, and interactions with regulators
across different regulatory authorities including the FDA, EMA, HPRA and Health
Canada, among others.
These external interactions beyond her role at Roche/Genentech, allowed the researcher
to broaden her pharmaceutical industry leadership and influence of QRM practices
including training regulatory authorities (FDA, EMA, Health Canada, PIC/S) on QRM
applications, and how to review or inspect risk-based applications. Figure 2.3 in Chapter
Two highlights key aspects of the researcher’s experience with training programmes,
workshops, and influencing the pharmaceutical industry and regulators on QRM
implementation and applications.
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In 2012, the researcher changed roles and assumed responsibilities as the Head of
Global Biologics QC, Roche/Genentech, with a further specialised broadening in 2018
as the Global Head of Analytical Science and Technology for both Biologics and Small
Molecules. In these roles, the researcher’s focus was analytical control systems lifecycle
management and product lifecycle management. Relevant to this research, the
researcher integrated QRM application into the lifecycle management decisions for
product analytical control systems. It became adequately evident during this part of her
work that the restricted ability to make PACs to analytical methods, specifications and
product controls (due to the significant global complexity), even when latest product
and process knowledge indicated a need for change, could indirectly contribute to drug
shortages, as described in PDA Technical Report 68. During this period drug shortages
were rapidly becoming an increasing global concern both for regulators and
pharmaceutical companies.
Therefore, compelled by the need and importance of reducing drug shortages, one of the
areas of risk-based application that the researcher expanded her work into starting in
2012 through 2015, was risk-based prevention and management of drug shortages.
Extensive discussions within the pharmaceutical industry and with regulators,
particularly EMA and FDA, and her real-time experience with long lead times for
global implementation of PACs for analytical methods/technologies, directed the
researcher’s exploration into the global complexities of PAC management, and how
extended approval timelines for a change might contribute to worsening the global drug
shortages problem.
In 2012 the researcher took on leadership for the development of Technical Report 68
on a Risk-Based Approach for Prevention and Management of Drug Shortages. This
report provides practical application, a Risk Triage model and templates for both
proactively preventing and responding to drug shortages, as described in Chapter Five,
section 5.3.4 (Ramnarine et al., 2014). In addition, the researcher functioned as the PDA
co-lead on EMA’s Inter-association Task Force that was established as a result of
European Commission’s Call to Action in 2012 (European Commission, 2012). During
this time, the researcher also led drug shortage workshops, training sessions, and
delivered several relevant presentations; a list of all these are given in Figures 2.2 and
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2.3. This body of work on drug shortages and the EMA Inter-Association Drug
Shortages Task Force, is described in further detail in Chapter Five.
Once the final report and recommendations from the EMA Drug Shortages InterAssociation Task Force was completed and submitted to the EMA, the researcher
directed her focus to one of the potential factors that had started to surface during the
course of her work on drug shortages – the enormous global complexity of PAC
management. In 2015, the researcher proposed to PDA the importance and need of
initiating dialogue with the pharmaceutical industry and regulators on the challenges
with PAC Management.
The PDA Board of Directors approved the establishment of a Post-Approval Change:
Innovation for Availability of Medicines (PAC iAMSM) Task Force in 2016 with the
researcher as a co-lead. This Task Force brought together leaders from different
pharmaceutical companies, and their work led to the development of several articles,
presentations and papers which are discussed previously in Chapter Seven, section 7.1
of this thesis; these papers also became sources of input to the ICH Q12 EWG as they
developed the content for ICH Q12.
During the course of this work and through a meeting with Dr Janet Woodcock
described in Chapter One, the PAC iAMSM Task Force’s work was expanded in 2018 to
become a platform to enable and establish a unified pharmaceutical industry position on
Quality topics relevant to PAC Management – this became the 1VQ for PAC Initiative
under the co-leadership of the researcher and is described in detail in Chapter Seven of
this thesis. A high-level overview of the PAC iAMSM Task Force and the initial 1VQ for
PAC activities is presented in a diagram developed by the researcher shown in Figure
AI-1 below.
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Better define problem and impact

Engage Industry Leaders and Regulators

Global implications of current
barriers & complexity needs to
be better articulated

Raise awareness
Need dialog at a global level
Why and how to accelerate
innovation and continuous
improvement

ICH Q12 EWG
One Voice of Quality
Drug Shortage Solution Efforts
PIC/S QRM Working Group

PAC iAMSM

Provide examples

Design practical solutions
Risk-based assessment of PACs
Effective PQS measures for
PACs
Technical Report

Training and implementation of solutions
Training partner for ICH and WHO
Pilot and implement PAC iAMSM
solutions

PACMP examples
Continuous improvement
examples

Figure AI-1: Researcher’s Scope of Work for PAC Management
Beyond active leadership on the topics of QRM, Drug Shortages and PAC
Management, the researcher has served on the PDA’s Board of Directors since 2014, is
currently the Secretary of the PDA Board Executive Committee, and was on PDA’s
Regulatory Affairs and Quality Advisory Board (RAQAB) from 2013 through 2019.
Her collective global pharmaceutical industry experience and thought leadership over
16+ years prior to registration in this PhD research programme, forms a strong basis for
this research study. The researcher pre-registration body of work for QRM, drug
shortages and PAC management became a relevant basis as she continued this research
study with a deeper academically structured focus. The researcher is keenly driven not
only by her interest in these topics, but more importantly her passion for making a
difference for patients and public health - by advancing the pharmaceutical industry and
enabling opportunities for collaborations with regulatory authorities to develop and
implement joint solutions that will contribute towards solving complex problems
through practical application of science and risk-based approaches.
The following sub-sections provide a breakdown with further details on the researcher’s
prior-registration QRM, drug shortages and PAC management experience.

Researcher’s QRM Experience
From 2012-2017, the researcher co-led PDA’s QRM Interest Group (QRM IG) which
grew in membership during the course of her leadership term to greater than 600
members. The QRM IG became one of PDA’s most active IGs for grass-roots
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exchange, dialogue, collective learning and exchange across companies, sharing
practices on QRM programme design and implementations within companies, and
therefore overall contributing to elevating the industry’s maturity in QRM use and
practice. The researcher’s QRM -related leadership experience is listed in Table AI-1.
Table AI-1: QRM-Related PDA Leadership Experience
•

PDA Task Force Leader for Technical Report 54: Implementation of Quality Risk
Management for Commercial and Biotech Manufacturing Operations, 2009-2012.

•

Lead PDA’s Paradigm Change in Manufacturing Operations (PCMO) Risk-based
Manufacturing Task Force, 2010-2012.

•

Co-chair of PDA Quality Risk Management Interest Group, 2012-2017.

The researcher ensured that Technical Report 54 “Implementation of Quality Risk
Management for Pharmaceutical and Biotechnology Manufacturing Operations”,
which was the first Technical Report to be published in March 2012, under PDA’s
PCMO initiative (Ramnarine et al., 2012), was developed such that it was practical
and could be applied by all companies regardless of their size or infrastructure. This
technical report was also the basis for the subsequent series of technical reports on
QRM application case studies as depicted in Figure AI-2.

PDA TR 54
Implementation of QRM for
Pharmaceutical & Biotech.
Manufacturing Operations

PDA TR 54-2

PDA TR 54-3

PDA TR 54-4

PDA TR 68

Case Studies for
Packaging and Labeling

Case Studies for Drug Product
(liquids and solids)

Case Studies for Biotechnology
Manufacturing Operations

Risk Based Approach Preventing
& Managing Drug Shortages

Regular 2-day PDA training workshops for TR54 series and related QRM topics
Special Focus: Prevention of Drug Shortages (PDA Task Force started activities in 2012)
2013: Drug Shortages
Presentations and discussions at
PDA FDA Joint Conference

2014: Drug Shortages
Presentations and discussions at
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Figure AI-2: QRM Related Technical Reports
In addition to the technical reports, the researcher was also actively involved in a
benchmarking survey on the pharmaceutical industry’s QRM maturity (Waldron,
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Ramnarine and Hartman, 2017), led by Dr Kelly Waldron and supported by the
researcher (in her capacity as the PDA QRM IG Leader). Details of the researcher’s
QRM publication experience resulting from the leadership of PDA Quality Risk
Management Technical Report 54 Task Force and the QRM IG is listed in Table AI-2.
Table AI-2: QRM Publications
1.

A. Mire-Sluis, E, Ramnarine, J. Siemiatkoski et.al., Practical Applications of Quality Risk
Management, BioProcess International, March 2010.

2.

E. Ramnarine, J. Hartman, L. Huffman et. al. Implementation of Quality Risk Management for
Pharmaceutical and Biotech Manufacturing Operations, PDA Technical Report 54, 2012.

3.

E. Ramnarine, Understanding Problems of Subjectivity and Uncertainty in Quality Risk
Management, Quality Risk Management in the GMP Environment – Ten Years Since the
Finalisation of ICH Q9 – A Critical Review 2005-2015, The Journal of Validation Technology –
10 Year Anniversary Special Edition, December 21, 2015, 43-50.

4.

K. Waldron, E. Ramnarine. J. Hartman, 2016/2016 Quality Risk Management Benchmarking
Survey, PDA Journal of Pharmaceutical Science and Technology, 71 (2017): 330-345.

In addition to the activities discussed above, the researcher developed and delivered
several QRM training and workshop sessions for the pharmaceutical industry and
regulators as part of PDA and beyond PDA. Given the pharmaceutical industry’s lower
QRM maturity, the researcher set in motion with PDA Training and Research Institute
(TRI), another activity related to the development and implementation of PDA’s Rolebased modular QRM Training and Certification Programme. The researcher led the
conceptual creation of this modular role-based certification program, which is further
helping raise industry’s application and maturity with quality risk management. The
researcher’s experience in designing and delivering quality risk management training
sessions and workshops is listed in Table AI-3, with the ones highlighted in blue, being
training programmes and workshops provided to regulators.
Table AI-3: QRM Training and Workshop Experience
•

E. Ramnarine as Head of Genentech-Roche Global Quality Risk Management, established Genentech
& Roche’s QRM program, 2009-2012.

•

E. Ramnarine as Head of Genentech-Roche Global Quality Risk Management, QRM Training for
Investigators, 2009.

•

E. Ramnarine, Risk Assessment Fish Bowl, WCBP CMC Strategy Forum, Practical Applications of
Quality Risk Management, July 27-28 2009, NIH Bethesda. On Planning Committee for the 2-day
Forum (125 regulators from 33 global regulatory authorities).

•

E. Ramnarine, V. Davoust, Quality Risk Management in Manufacturing, PDA Training and
Workshop, May 6-7, 2011, London.
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•

E. Ramnarine, The Benefit of QRM Methodology Case Study: Integrating Quality Risk
Management During Technology Transfer, PDA Training and Workshop, May 6-7, 2011, London

•

E. Ramnarine, Integration of Quality Risk Management into The Quality System, PDA Training
and Workshop, May 6-7, 2011, London.

•

E. Ramnarine as Head of Genentech-Roche Global Quality Risk Management, Auditing QRM
Training for Auditors, 2011.

•

E. Ramnarine as Head of Genentech-Roche Global Quality Risk Management, Modular Role-Based
QRM Training Program for QRM Facilitators, QRM Lead, Decision Makers and QRM
Participants/Subject Matter Experts (includes modules on QRM process steps and different QRM
tools), 2008-2012.

•

E. Ramnarine, K. Terry, A. Mire-Sluis, D. Weese, K. Murray, S. Reich, R. Spohn, FDA 2-day QRM
Workshop, January 20-21, 2011, NIH Bethesda (trained 50+ regulators).

•

E. Ramnarine, K. Terry, A. Mire-Sluis, D. Weese, K. Murray, S. Reich, R. Spohn, Health Canada 2day QRM Training, June 16-17, 2011, Ottawa (trained 70+ regulators).

•

E. Ramnarine, K. Terry, L. Richter, R. Spohn, Advanced FDA 2-day QRM Workshop, November
3-4, 2011, NIH Bethesda (trained 100+ regulators).

•

E. Ramnarine, J. Hartman, Implementation of Quality Risk Management for Pharmaceutical and
Biotech Manufacturing Operations, PDA TR54 Training (2-day), April 2012. Delivered multiple
training sessions (trained 100+ attendees).

•

E. Ramnarine, Understanding Risk Management Fundamentals for Data Integrity – Why Does
it Matter? 2015 Data Integrity Training Workshops with FDA and CFDA, August 28-September 4,
2015, Beijing, Nanjing, Hangzhou (trained 350+ attendees from China industry and CFDA).

•

E. Ramnarine, Practical Application of Quality Risk Management for Data Integrity, 2015 Data
Integrity Training Workshops with FDA and CFDA, August 28-September 4, 2015, Beijing, Nanging,
Hangzhou (trained 350+ attendees from China industry and CFDA).

•

E. Ramnarine, Understanding the Problems of Subjectivity and Uncertainty in QRM – Issues to
Consider, PIC/S QRM Expert Circle Training, Use of Advanced QRM by Regulatory Agencies, Sept
26-28, 2015, London (trained 75+ regulators from 15 countries).

•

E. Ramnarine, Understanding the Problems of Subjectivity and Uncertainty in QRM – Issues to
Consider, US PIC/S QRM Training Event, October 5-7, 2015, Los Angeles. (trained 80 regulators
from 15 countries).

•

E. Ramnarine, Understanding the Problems of Subjectivity and Uncertainty in QRM – Issues to
Consider, PIC/S QRM Training Workshop, September 11-13, 2018, Taipei (trained 68 regulators
from 16 countries).

•

E. Ramnarine, S. Ko, Gain Proficiency in Quality Risk Management: PDA’s New Role-based
QRM Certificate Program Offers Courses for all Levels of QRM Involvement, October 2017.
https://www.pda.org/pda-europe/news-archive/full-story/2017/10/03/gain-proficiency-in-quality-riskmanagement. Led the design, development and implementation of the role-based modular training
and Certificate Program.

•

E. Ramnarine, G. Claycamp, A. McFarland, Quality Risk Management: Risk Control and Riskbased Decision-Making Training as part of PDA’s QRM Certificate Program, December 2017.
Delivered multiple training sessions.

In addition to the training and workshop activities listed above, the researcher also gave
QRM presentations at various conferences as listed in Table AI-4.
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Table AI-4: QRM Presentation Experience
•

E. Ramnarine, A Harmonized Risk-based Validation Approach for Manufacturing and
Computer Systems, 2009 Annual PDA Conference, April 20-22, 2009, Las Vegas.

•

E. Ramnarine, Integration of Quality Risk Management into the Quality System –
Operationalizing QRM, 2009 PDA/FDA Joint Regulatory Conference, September 2009,
Washington DC.

•

J. Edwards, E. Ramnarine, B. Rellahan (FDA), N. Waites (FDA), Implementation of Quality Risk
Management – Challenges and Considerations for Biopharmaceuticals, WCBP CMC Strategy
Forum, January 25-27, 2010, Bethesda.

•

E. Ramnarine, Practical Applications of Quality Risk Management as an ‘Enabler’ of the
Quality System, GMP by the Sea, August 16-18, 2010, Savannah.

•

E. Ramnarine, Quality Risk Management in Manufacturing, 2010 PDA/FDA Joint Regulatory
Conference, September 15, 2010, Washington DC.

•

E. Ramnarine, Quality Risk Management in Manufacturing, 2011 PDA/FDA Joint Regulatory
Conference, September 19-21, 2011, Washington DC.

•

E. Ramnarine, Implementation of Quality Risk Management at Roche, PDA West Coast
Professional Dinner Meeting Series, September 29, 2011, San Francisco.

•

E. Ramnarine, Practical Implementation of Quality Risk Management, 2011 Annual ISPE
Conference, October 5, 2011, Boston.

•

E. Ramnarine, Quality Risk Management in Technical Research and Development, ISPE QRM
Working Group, August 19, 2013, Washington DC.

•

E. Ramnarine, Hammer or Screwdriver? Practical Applications of QRM Tools and The
Formality Spectrum, PDA/FDA ICH Q10 Workshop on Quality Risk Management, November 3-5,
2015, Maryland.

•

E. Ramnarine, Integration of QRM Into The Quality System, FDA Quality Systems Work Group,
December 11, 2015, FDA Bethesda.

Researcher’s Drug Shortage Experience
In 2012, the researcher focused on the topic of drug shortages as EMA and FDA
heightened their attention to this growing global concern. This focus was in particular
on practical risk-based applications such that the risk and/or impact of drug shortages
could be proactively assessed, and the risk control actions needed to prevent, or
mitigations needed to respond to drug shortages, were commensurate with the level of
risk.
In 2012, PDA established a Drug Shortage Task Force as part of the PCMO
programme under the leadership of the researcher, who led it through 2015 as noted in
Table 1. This was a continuation of PDA’s Technical Report No. 54 series of
documents on quality risk management application case studies. The Drug Shortage
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Task Force published PDA Technical Report 68 (Ramnarine et al., 2014), as described
in Chapter Five, section 5.3.4 of this thesis.
Table AI-5 lists the researcher’s Task Force leadership experience related to Drug
Shortages.
Table AI-5: Drug Shortages Task Force Leadership Experience
•

PDA Task Force Leader for Technical Report 68: Risk-based Approach for Prevention and
Management of Drug Shortages, 2012-2014.

•

PDA Co-Lead for EMA Inter-association Task Force on Drug Shortages. Led the development of
PDA’s risk-based approach, tools and templates for drug shortage prevention and response plan.
2013-2015.

Drug shortages related publications during the course of the researcher’s leadership of
the PDA Drug Shortage Task Force and being on the EMA Inter-association Task Force
are provided in Table AI-6.
Table AI-6: Drug Shortages Publications
•

E. Ramnarine, S. Rönninger, A. Vinther, Preventing and Managing Drug Shortages, PDA Letter,
April, 2014, 36-39.

•

E. Ramnarine, A. Vinther et.al. Risk-Based Approach for Prevention and Management of Drug
Shortages, PDA Technical Report 68, 2014

•

Prevention of Drug Shortages Based on Quality and Manufacturing Issues, Interim Report to
EMA on a Collaborative Contribution to the EMA and their Inspectors Working Group (EMA-IWG),
November 18, 2014. Report authored by ISPE, PDA, EFPIA, EGA, AESGP and PPTA. [PDA
Authors E. Ramanarine, A. Vinther].

•

E. Ramnarine, M. Jornitz, M. A. Long, K. O'Donnell (HPRA), S. Rönninger, C. Smalley, A. Vinther,
Risk-based Approach for Prevention and Management of Drug Shortages, PDA Technical
Report 68, 2014.
o

Included in European Medicines Agency’s (EMA) Final Report on a Collaborative
Contribution to the EMA and their Inspectors Working Group (EMA-IWG) on Prevention
of Drug Shortages based on Quality and Manufacturing Issues, 23, December 2014, 9-11.
https://www.pda.org/docs/default-source/website-document-library/scientific-andregulatory-affairs/drug-shortage/interrupted-supply-inter-association-summary-final-report2014.pdf?sfvrsn=4

In addition to leading the PDA Task Forces, the researcher chaired a workshop on drug
shortages in 2014 and delivered several training programmes as listed in Table AI-7,
while also representing PDA in the Inter-Association Task Force that was established in
2013 at the request of EMA. An overview of PDA’s 2014 drug shortages workshop, and
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the body of work related to EMA’s Inter-Association Task Force is provided in Chapter
Five, section 5.3.
Table AI-7: Drug Shortages Workshop and Training Experience
•

PDA Drug Shortages Workshop, September 10-11, 2014. Workshop Chair.

•

E. Ramnarine, A. Vinther, S. Rönninger, Risk-based Prevention and Management of Drug
Shortages, PDA TR68 Training (1-day), July 2015. Delivered multiple training sessions (trained
40+ attendees).

•

E. Ramnarine, A. Vinther, S. Rönninger, G. Roessling, PDA’s Risk-based Prevention and
Management of Drug Shortages, EMA Drug Shortage Workshop, October 9, 2015, London.

The researcher further delivered several presentations on risk-based application for drug
shortages at various conferences and discussion forums involving pharmaceutical
companies and regulators. This body of work is listed in Table AI-8
Table AI-8: Drug Shortages Presentation Experience
•

E. Ramnarine, Risk and Knowledge Management Leading to Robust Manufacturing Process
Control, 2012 PDA/FDA Joint Regulatory Conference, September 10-12, 2012, Baltimore

•

E. Ramnarine, Risk-based Approach to Manage Drug Shortages, PDA/FDA Joint Regulatory
Conference, Sept 2013, Washington DC.

•

A. Vinther, E. Ramnarine, PDA Risk-based Approach to Prevent and Manage Drug Shortages,
EMA Drug Shortage Meeting with Interested Parties, November 26, 2013, London.

•

A. Vinther, E. Ramnarine, PDA Risk-based Approach to Prevent and Manage Drug Shortages,
EMA Drug Shortage Meeting, January 27, 2014. London.

•

E. Ramnarine, PDA Risk-based Approach to Manage Drug Shortages. Inter-Association Drug
Shortage Prevention Initiative with EMA, ISPE Annual European Conference, April 29-30
2014, Frankfurt.

•

E. Ramnarine, Preventing and Managing Drug Shortages, 2014 PDA/FDA Joint Regulatory
Conference, September 8, 2014, Washington DC.

•

E. Ramnarine, A. Vinther, S. Rönninger, G. Roessling, PDA’s Risk-based Prevention of Drug
Shortages Update, EMA Drug Shortages Inter-Association Task Force Meeting, September 22,
2014, Brussels.

•

E. Ramnarine, A. Vinther, S. Rönninger, G. Roessling, PDA’s Risk-based Prevention of Drug
Shortages Update, EMA Meeting, October 2, 2014, London.

•

E. Ramnarine, TR68: Risk-based Prevention and Management of Drug Shortages. How
Companies Can Implement a Practical Approach, PDA Midwest Chapter, March 15, 2015.

•

E. Ramnarine, TR68: Risk-based Prevention and Management of Drug Shortages. How
Companies Can Implement a Practical Approach, 2015 Annual PDA Conference, March 16-18,
2015, Las Vegas.

•

E. Ramnarine, Technical Report 68: Risk-based Approach for Prevention and Management of
Drug Shortages, 2015 PDA/FDA Joint Regulatory Conference, September 28-30, 2015,
Washington DC.

•

E. Ramnarine, Post Approval Change and Knowledge Management. Where are We? Results
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from the PAC iAM Task Force Survey, 2017 PDA Annual Meeting, April 3-5, 2017 Anaheim.
•

E. Ramnarine, S. Rönninger, Managing Single- and Multi-Source Supply Chain Challenges. A
Practical Tool for Prevention and Management of Drug Shortages, 2nd Annual PDA Europe
Conference, June 13-14, 2017, Berlin.

Researcher’s PAC Management Experience
As described in Chapter One, the causes of drug shortages are complex and multifactorial, with one of the many causes being manufacturing and quality issues (Birgli®,
2013). As part of this research and work on drug shortages, and development of
Technical Report 68: Risk-Based Prevention and Management of Drug Shortages, the
researcher started exploring the topic of long PAC timelines across many regulatory
authorities that need to approve a change before it can be implemented (Ramnarine et
al., 2014). The researcher initiated a discussion on how drug shortages could potentially
be reduced through expedited PAC management.
PAC management remained the current focus of the researcher’s work that started in
2016, and extended into this doctoral research. This research is intended to study
solutions that could transform PAC management even with the currently highly diverse
and complex global regulatory landscape, in order to ensure timely availability of muchneeded medicines for patients. Figure AI-3 provides an overarching summary of the
researcher’s prior scope of work with PDA for PAC management, and her direct
involvement and influencing efforts for PAC management activities.
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Figure AI-3: Researcher’s Involvement (Direct and Influencing) in PAC
Management
Table AI-9 lists the researcher’s PAC management leadership experience.
Table AI-9: PAC Management Industry Task Force Leadership Experience
•

PDA Co-Lead for Post Approval Change Innovation for Availability of Medicine (PAC iAM SM)
Task Force, 2016-2018.

•

Co-Lead for Industry One-Voice-of-Quality (1VQ) on Post-Approval Change Management, 2018Present

Details of the activities including workshops and focus groups conducted as part of the
researcher’s PAC leadership are the subject of this research and described in this thesis.
The researcher’s key presentations on PAC management prior to initiating this research
study are listed in Table AI-10.
Table AI-10: PAC Management Presentation Experience
•

M. James, E. Ramnarine, A. Vinther, Lifecycle Management, PDA and GSK Input to ICH Q12
Lifecycle Strategy, November 25, 2015 & May 4, 2016.

•

E. Ramnarine, A. Vinther, U. Busse, Post Approval Changes: The Need and Concept of Global
Change Protocols, Presentation to the PDA Manufacturing Science and Operations Program, June
22, 2016.

•

E. Ramnarine, Analytical Control System Lifecycle Management, 1st Annual PDA Europe
Conference, June 28-29, 2016, Berlin

•

E. Ramnarine, A. Vinther, M. Seymour, D. Baker, FDANews Webinar – PDA’s Post Approval
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Change: Innovation for Availability of Medicines Program, February 8, 2017.
http://info.fdanews.com/pdas-post-approval-change-innovation; https://www.pda.org/docs/defaultsource/website-document-library/workshops/2017/pac-iam/fda-news-webinar.pdf
•

E. Ramnarine, A. Vinther, M. Seymour, Q1 Productions Webinar - Lifecycle Management:
Update and Insights on Post Approval Changes and PAC iAM Activities, July 25, 2017.

•

E. Ramnarine, Product Lifecycle Management, PDA PAC iAM Workshop, September 13-14, 2017,
Washington DC.

•

E. Ramnarine, Post Approval Change and Product Lifecycle Management, PDA West Coast
Chapter Meeting, February 22, 2018.

•

E. Ramnarine, Risk-based Post Approval Change and Lifecycle Management, ECA Quality Risk
Management Summit, June 20-21, 2018, Lisbon.

•

E. Ramnarine, U. Busse, ICH Q12 and Post Approval Change: PDA Innovation for Availability
of Medicines, 3rd Annual PDA Europe Conference, June, 2018, Berlin.

•

E. Ramnarine, How Can We Foster an Environment With An Incentive For Industry To
Continually Improve And Reduce Risk To Patient? PIC/S QRM Expert Circle Meeting,
September 13, 2018, Taiwan.

The researcher’s prior work on the topics of QRM, drug shortages, and PAC
management, activated extensive dialogue in the pharmaceutical industry on these
topics, and has helped pharmaceutical companies come together in sharing their
experiences, learnings and working together to move forward in their risk-based
application maturity. It also helped increased awareness of regulators to the global
complexities associated with the diverse regulatory expectations across different
regulatory authorities. This in turn advanced the dialogue between the pharmaceutical
industry and regulators through different forums on understanding mutual challenges
and a recognition and appreciation that no single stakeholder group can solve these
complex problems of drug shortages and PACs on their own.
The researcher’s prior work described in this Appendix I laid important groundwork for
this PhD research study.
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Appendix II: Index to Study-related Publications, Proposals to
Regulatory Authorities and Key Presentations
This appendix provides a compilation of peer-reviewed and other publications,
proposals to regulatory authorities and key presentations associated with this research
study summarised in Figure 1.10 in Chapter One (Research Introduction and Context)
and referenced in various chapters of the main thesis. The following table is an index to
the main study outputs and prior publications that formed the preliminary basis for this
research.
Description

† = Lead author

|

* = Peer-reviewed

# of
pages

Prior-Publications Forming Preliminary Basis for Research
1

2
3

4

5

6

7

Paper†*: Ramnarine, E., Jornitz, M., Long, M., O’Donnell, K.,
Roenninger, S., Smalley, C., & Vinther, A. (2014). PDA
Technical Report No. 68, Risk-Based Approach for Prevention
and Management of Drug Shortages (Vol. 1, Issue 68)
Paper†: Ramnarine, E., Roenninger, S., & Vinther, A. (2014).
Preventing and Managing Drug Shortages. PDA Letter, 4, pp
36–39
Paper†: Ramnarine, E., & Vinther, A. (2016). PDA Program to
Address Post-Approval Hurdles: A Call to Action. PDA Letter,
9, pp 34–35
Paper†*: Ramnarine, E., Busse, U., et. al. (2017) “PDA PAC
iAMSM 2017 Survey on Post-Approval Change: Is the
Regulatory Environment Hindering Much-Needed Innovation in
the Pharma Industry?” PDA Journal of Pharmaceutical Science
and Technology, 71 (5), pp 421-427. doi:
https://doi.org/10.5731/pdajpst.2017.008219
Paper†*: Ramnarine, E., Busse, U., et. al. (2017) “PDA Points to
Consider: Technical Product Lifecycle Management:
Communication and Knowledge Exchange Between Marketing
Authorization Holders and Health Authorities” PDA Journal of
Pharmaceutical Science and Technology, 71 (2), pp 163–169.
doi: https://doi.org/10.5731/pdajpst.2016.007492
Paper†*: Ramnarine, E., Busse, U., et. al. (2017) “PDA Points to
Consider: Technical Product Lifecycle Management.
Pharmaceutical Quality System Effectiveness for Managing
Post-Approval Changes. PDA Journal of Pharmaceutical
Science and Technology, 71 (3), pp 252–258. doi:
https://doi.org/10.5731/pdajpst.2017.007575
Paper: Vinther, A., Ramnarine, E., & O’Donnell, K. (2017).
PQS, An Effective Lever for Managing Post-Approval Changes.
PDA Letter, 9, pp 42, 44.
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54

4
2

9

9

9

2

8

Paper†*: Ramnarine, E., & O’Donnell, K. (2018). Demonstrating
Pharmaceutical Quality System Effectiveness and Driving
Continual Improvement: Evidence-based Risk Reduction. PDA
Journal of Pharmaceutical Science and Technology, 72 (3), pp
338–345. Doi: https://doi.org/10.5731/pdajpst.2017.008524

10

Publications During Research Study
9

10

11

12

13

14

15

Paper†*: Ramnarine, E., Vinther, A., Greene, A., & O’Donnell,
K. (2019). “Continual Improvement While Maintaining A State
of Control: A Concealed Paradox or a Mutual Interdependence?”
Journal of Validation Technology (JVT), Journal of GXP
Compliance (GXP), 23(6).
Paper†*: Vinther, A., Ramnarine, E. (2019) “Solving the Global
Continual Improvement and Innovation Challenge: How an
Effective Pharmaceutical Quality System Can Transform PostApproval Change Management. Industry One-Voice-of-Quality
(1VQ) Concept Paper,” PDA Journal of Pharmaceutical Science
and Technology, 73 (5), pp 517-521. doi:
https://doi.org/10.5731/pdajpst.2019.010827
Paper†*: Ramnarine, E., Vinther, A. et.al. (2020) “Industry OneVoice-of-Quality (1VQ) Solutions: Effective Management of
Post Approval Changes in the Pharmaceutical Quality System
(PQS) – Through Enhanced Science and Risk-Based
Approaches.,” PDA Journal of Pharmaceutical Science and
Technology, 74 (4), pp 456-467. doi:
https://doi.org/10.5731/pdajpst.2020.011734
Paper*: Rolke, R., Ramnarine, E. et. al. (2020) “One-Voice-ofQuality (1VQ) Industry Position Paper: Managing Excipient
Supplier Name and Address Changes in the Pharmaceutical
Quality System,” PDA Journal of Pharmaceutical Science and
Technology, 74 (2), pp 286-288. doi:
https://doi.org/10.5731/pdajpst.2019.011239
Paper†*: Rolke, R., Ramnarine, E. (2020) “One-Voice-ofQuality (1VQ) Industry Position Paper: Changes to Analytical
Equipment/Instrumentation that are Deemed Equivalent,”
Journal of Validation Technology (JVT), 26 (6).
Paper*: Lombardi, K., Egal, N. (2020) “One-Voice-of-Quality
(1VQ) Industry Position Paper: Shelf-Life Extensions for
Pharmaceutical Products,” Journal of Validation Technology
(JVT), 26 (6).
Paper*: Vinther, A., Mohammed, F., Ramnarine, E. (2021)
“Industry One-Voice-of-Quality (1VQ) Solutions: Management
Review (MR) of Post Approval Changes (PAC) Guide” PDA
Journal of Pharmaceutical Science and Technology. doi:
https://doi.org/10.5731/pdajpst.2021.012627

12

7

14

5

8

11

10

Proposals to Regulatory Authorities
16
17

Initial Presentation to PIC/S† – September 2018
Proposal to FDA – January 2019
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15
27

18
19
20
21
22

Proposal to PIC/S† – April 2019
Follow-up Proposal to PIC/S† – June 2020
Feedback to PIC/S on the Draft PIC/S Recommendation Paper †
– November 2020
Letter from PIC/S QRM Expert Circle Chair Acknowledging
Researcher’s Contribution – July 2021
Proposal to WHO – April 2021

1
2
4
2
7

Key Presentations
23
24
25

Facilitating Continual Improvement, Innovation and Reduced
Drug Shortages – Through Enhances Science and Risk-Based
Post Approval Change Management – 2020 Annual PDA
Conference
Effective Management of Post-Approval Changes in the
Pharmaceutical Quality System – 2020 PDA Europe Conference
Standard 1VQ Communication Deck – April 2021

22
20
18

Details of 1VQ for PAC Focus Group Sessions
26
27

Details of 1VQ for PAC Focus Groups 1- 8
Details of 1VQ for PAC Focus Group Sessions with Chief
Quality Officers and QMS Heads

48
20

Drug Shortage Notification Requirements in
Legislation and GMPs
28

Relevant Requirements from the EU Directives, EU GMPs and
US FDASIA Laws
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